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Glucose is an essential metabolic substrate of all mammalian cells being the major 
carbohydrate presented to the cell for energy production and also many other anabolic 
requirements. Hypoglycemia is a disorder where the glucose serum concentration  is  
usually low. The organism usually keeps the glucose serum concentration in a range of 
70 to 110 mL/dL of blood. In hypoglycemia the glucose concentration normally remains 
lower than 50 mL/dL of blood. This book provides an abundance of information for all  
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Hypoglycemia is a disorder where the glucose serum concentration is usually low. The 
organism usually keeps the serum glucose concentration in a range of 70 to 110 mL/dL 
of blood. In hypoglycemia the glucose concentration remains normally lower than 50 
mL/dL of blood.  
Glucose is an essential metabolic substrate of all mammalian cells being the major 
carbohydrate presented to the cell for energy production and also many other anabolic 
requirements. 
This book comprehensively reviews and compiles information on hypoglycemia in 15 
chapters which cover occurrence, damages, treatments and preventions, and relevant 
discussions about the occurrence of hypoglycemia in neonates, drug-induced and 
caused by infections in animals. 
This book is written by an international group of authors from America, Europe, Asia 
and Africa. The editor has tried to arrange the book chapters in an issue order to make 
it easier for the readers to find what they need. However, the reader can still find 
different  approaches on the same issue in the same Section. 
Section A, which includes chapters 1-4, mainly presents therapy. It includes some 
treatment methods and their applications. 
Section B, which includes chapters 5-7, mainly deals with the occurrence of 
hypoglycemia in neonates. It shows different approaches to the same issue. 
Section C, which includes chapters 8-9, covers hypoglycemia associated with drugs. 
Section D, which includes chapters 10-12, covers hypoglycemia caused by some kinds 
of cancer. 
Section E, which includes chapter 13, deals with hypoglycemia caused by septicemia 
in animals. It shows that the hypoglycemia may be a parameter that could be analyzed 
for detection of Leptospire infection in pigs. 
The scientists selected to publish in this book were invited because of their recognized 
expertise and important contributions in their respective fields of research. Without 
X Preface 
 
these scientists and their dedication and enthusiasm, the publication of this book 
would not have been possible. I recognize and am very grateful for their efforts and 
the attempt to decrease the suffering of many people afflicted with this disorder.  
Hopefully, this book will be of help to many scientists, doctors, pharmacists, chemicals 
and other experts in a variety of disciplines, both academic and industrial. In addition 
to supporting research and development, this book should also be suitable for 
teaching. 
Finally, I would like to thank my daughter Maria Eduarda and my wife Fernanda for 
their patience. I extend my apologies for many hours spent on the preparation of my 
chapter and the editing of this book, which kept me away from them. 
 
Prof. Dr. Everlon Cid Rigobelo 
Laboratory of Microbiology & Hygiene, 
Campus Experimental de Dracena 
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A New Therapy of Type 2  
Diabetes: DPP-4 Inhibitors 
Tatjana Ábel 
National Health Center 
Hungary 
1. Introduction  
Type 2 diabetes is a progressive disease which is significantly spreading all over the world. 
It is characterized by developing insulin resistance, impairment of the pancreatic beta cells 
and an impaired suppression of glucagon production of the pancreatic alpha cells (Figure 1) 
(DeFronzo 2009). When choosing a therapy for it, several aspects should be taken into 
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Fig. 1. Type 2 diabetes features 
how long has his/her diabetes been known; were there any side effects caused by his/her 
previous antidiabetic medication, and are there any complications present (e.g. 
nephropathy). A good glycemic control reduces the rates of diabetes-associated 
microvascular and possibly macrovascular complications. Reduction of the associated risk 
 1 
A New Therapy of Type 2  
Diabetes: DPP-4 Inhibitors 
Tatjana Ábel 
National Health Center 
Hungary 
1. Introduction  
Type 2 diabetes is a progressive disease which is significantly spreading all over the world. 
It is characterized by developing insulin resistance, impairment of the pancreatic beta cells 
and an impaired suppression of glucagon production of the pancreatic alpha cells (Figure 1) 
(DeFronzo 2009). When choosing a therapy for it, several aspects should be taken into 













Development of macrovascular complication
Development of microvascular complication
Insulin level
 
Fig. 1. Type 2 diabetes features 
how long has his/her diabetes been known; were there any side effects caused by his/her 
previous antidiabetic medication, and are there any complications present (e.g. 
nephropathy). A good glycemic control reduces the rates of diabetes-associated 
microvascular and possibly macrovascular complications. Reduction of the associated risk 
 
Hypoglycemia – Causes and Occurrences 
 
4 
factors, including those related to excessive weight, high blood pressure and dyslipidemia 
are also necessary to meaningfully decrease cardiovascular risk. Agents that can improve 
glycemia with weight neutrality could offer an additional benefit to overweight patients 
with type 2 diabetes. Many new drugs are currently in development for the treatment of 
diabetes, including products with a new mechanism of action such as dipeptidyl peptidase-
4 (DPP-4) inhibitors.  
2. Mechanisms of DPP-4 inhibitor action 
Up to now the treatment of type 2 diabetes has been limited primarily to elevation of insulin 
production, increase of insulin sensitivity, reduction of glucose absorption and replacement 
of insulin. In the recent years, however, DPP-4 inhibitors (gliptins) emerged. These belong to 
a novel group of medicines which exert their action by increasing incretin levels (Drucker, 
Sherman et al. 2010). Incretins include glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) which are produced in the intestine and 
contribute to the physiological regulation of glucose homeostasis (Thornberry and Gallwitz 
2009) (Figure 2). Active endogenous GLP-1 and GIP concentrations increase two- to 
threefold following a meal. Active GLP-1 and GIP increase the production and release of 
insulin by pancreatic beta cells. Approximately 60% of the postprandial insulin release is 
promoted by these two hormones. In addition, GLP-1 also reduces the secretion of glucagon 
by pancreatic alpha cells, resulting in a decreased hepatic glucose production. These effects 
are glucose-dependent; GLP-1 stimulates insulin secretion and reduces glucagon production 
only at a higher blood glucose level. However, the effects of GLP-1 and GIP last only for a 












































DPP-4 = dipeptidyl peptidase-4; GI = gastrointestinal; GIP = glucose-dependent insulinotropic 
polypeptide; GLP-1 = glucagon-like peptide-1; 
Fig. 2. Mechanisms of DPP-4 inhibitor action. 
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The promising therapeutic potential of GLP-1 as a pharmacologycal tool for treating type 2 
diabetes has been discovered in the 1990s. By inhibiting DPP-4, the gliptins increase insulin 
production and release as well as reduce glucagon levels in a glucose-dependent way, 
resulting in a decrease of fasting and postprandial glycemia, as well as HbA1c levels 
(Nauck, Vilsboll et al. 2009). Further, it has the ability to restore the blunted first phase 
insulin secretion in type 2 diabetes. Also in this respect, their mechanism of action differs 
from that of the sulfonylureas which stimulate insulin secretion also at low levels of blood 
glucose and may lead to hypoglycemia.  
Fix combinations of sitagliptin and then vildagliptin with metformin have also been 
launched; these affect pathogenic factors of type 2 diabetes at more target points: they 
reduce the extent of insulin resistance, regulate insulin secretion in a glucose-dependent 
way, reduce glucagon secretion and also decrease hepatic glucose production (Nauck, 
Vilsboll et al. 2009). Their effects are additive, levels of active GLP-1 are increased not only 
by DPP-4 inhibitors but by metformin as well (Cho and Kieffer 2011).  
3. Clinical and experimental evidence with the DPP-4 inhibitors 
The oral antidiabetic drugs (OADs) used before the emergence of DPP-4 inhibitors may 
cause significant side effects including e.g. gastrointestinal symptoms, weight gain, cardiac 
heart failure, myocardial infarction, bone fractures and hypoglycemia and they do not 
reverse the progressive decline in beta cell function. Among others this led to the 
development of newer OADs, the DPP-4 inhibitors.  
As a first step, according to the consensus statement of the European Diabetes Association for 
the Study of Diabetes (EASD) and the American Diabetes Association (ADA), in patients with 
no metabolic upset, lifestyle changes and metformin are recommended (Nathan, Buse et al. 
2009). If no sufficient metabolic control can be attained by this way (HbA1c > 7%), or the 
patient should not receive metformin (it is not tolerated or it is contraindicated), addition of an 
oral antidiabetic of second choice is recommended. Although DPP-4 inhibitors are mentioned 
as second-line drugs among the less validated therapies, this seems to have to be changed due 
to the increasing amount of study results published in relation to them.  
The use of sitagliptin, the first oral DPP-4 inhibitor was approved by the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) in 2006 and in 2007 
respectively (Gerich 2010). Sitagliptin can be given in monotherapy or in combination with 
metformin, sulfonylurea, thiazolidinediones, or as a triple combination with metformin and 
sulfonylurea or metformin and thiazolidinediones both in the USA and Europe. In the recent 
years a fix combination of sitagliptin/metformin has also been available. Concomitant 
administration of sitagliptin with insulin has been approved by FDA and EMA in 2010. 
Saxagliptin can be used in combination with other OADs (metformin, sulfonylurea, 
thiazolidinediones) both in the USA and in Europe in 2007 (Gerich 2010).  
Marketing of vildagliptin was not approved by the FDA due to dermal lesions and renal 
impairment observed in animal studies. In Europe, based on the approval of EMA in 2008, 
vildagliptin can be given with metformin, sulfonylurea or thiazolidinediones. A fix 
combination of vildagliptin/metformin has also been marketed.  
3.1 Clinical efficacy 
As far the results have shown no difference between DPP-4 inhibitors in the reduction of 
HbA1c values. Both in monotherapy and in combination (with metformin, sulfonylurea, 
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thiazolidinediones, or insulin) they effectively reduce HbA1c levels (by 0.6% to 1.1%) 
(Ahrén 2011). This effect has proven to be dependent of diabetes duration and baseline 
HbA1c values as well. Greater reductions in HbA1c are seen in subjects with higher baseline 
levels and they are more effective in patients with shorter diabetes duration (< 3 years). A 
survey summarized the results of 18 publications and 3 presentations where elderly (≥ 65 
years) patients with type 2 diabetes received DPP-4 inhibitor (sitagliptin, saxagliptin, 
vildagliptin, or alogliptin) treatment in monotherapy or in combination (metformin, 
glimepiride, glibenclamide, thiazolidinediones or insulin) (Schwartz 2010). No significant 
difference was found in the HbA1c level reducing effect of DPP-4 therapy in elderly and in 
younger patients.  
Although the DPP-4 inhibitors differ from each other in several aspects, it is not known yet 
whether this means any substantial difference in their e.g. long-term efficacy (Table 1).  
 
 
Inhibitor               Metabolism                         Elimination route Dosing DPP-4 selectivity DPP-4 inhibition* 
Sitagliptin not appreciably metabolized renal (~ 80% unchanged
as parent)                            100mg qd high max ~ 97%; > 80% 24 h postdose
Vildagliptin hydrolyzed to inactive metabolite renal (22% as parent,  
(P450 enzyme independent)                55% as primary metabolite)         50mg bid moderate max ~ 95%; > 80% 12 h postdose
Saxagliptin hepatically metabolized to renal (12-29% as parent,
active metabolite (via P450 3A4/5)             21-52% as metabolite)                5mg qd moderate max ~ 80%; ~ 70% 24 h postdose
 
Table 1. Characteristics of DPP-4 inhibitors. 
3.2 Hypoglycemia 
Intensive glucose control increases the risk of developing hypoglycemia. In the Diabetes 
Control and Complications Trial (DCCT) the rate of severe hypoglycemia was 65% and 35% in 
the arms of intensive and conventional insulin therapy respectively (Keen 1994; The Diabetes 
Control and Complications Trial Research Group 1997). In the UK Diabetes Prospective Study 
the episodes of major hypoglycemia occurred in 0.7%, 1.4% and 1.8% in the groups receiving 
conventional, glibenclamide and insulin treatment respectively (Gore, McGuire 2009). Some 
epidemiological studies and minor prospective studies found that hypoglycemia increased 
cardiovascular risk (Desouza, Bolli et al. 2010). Its occurrence and a severe, even fatal outcome 
are not rare in patients with type 2 diabetes, primarily during the administration of insulin 
therapy and use of medicines which stimulate insulin secretion (sulfonylurea). Far from 
enough importance seems to have been attributed to hypoglycemia in the practice, although it 
increases the risk of accidents in certain situations, it impairs cognitive function, it may cause 
hemorrhage at the fundus and in the vitreous body, but it may also play a role in the 
development of tachycardia, hypertension and arrhythmia (Desouza, Bolli et al. 2010). 
Therefore it represents a not negligible risk for morbidity and mortality.  
Hypoglycemia is a potential side effect of OAD, primarily sulfonylurea, therapy. As 
compared to metformin, sulfonylurea therapy represents an approximately threefold risk. In 
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contrast, there has been a very low occurrence of hypoglycemia, nearly identical with that of 
placebo, during DPP-4 inhibitor monotherapy or its combination with metformin of 
thiazolidinedione (Blonde 2009). No differences were found in the risk of developing 
hypoglycemia between each DPP-4 inhibitor treatments (Tahrani, Piya et al. 2010) (Table 2). 
 
 
DPP - 4 inhibitors Study Any hypoglycemia
(number)
investigational drug / comparator
Sitagliptin Scott, R., Loeys, T. et al. (2008)                                                        1 / 1    
Scott, R., Wu, M. et al. (2007)                                                        12 / 21
Goldstein, B. J., Feinglos, M. N. et al. (2007)                                 1 / 1
Charbonnel, B., Karasik, A. et al. (2006)                                        6 / 5
Vildagliptin Schweizer, A., Couturier, A. et al. (2007)                                        2 / 1
Bolli, G., Dotta, F. et al. (2008)                                                        1 / 0 
Bosi, E., Camisasca, R. P. et al. (2007)                                              1 / 1
Rosenstock, J., Baron, M. A. et al. (2007)                                        1 / 0           
Saxagliptin Rosenstock, J., Sankoh, S. et al. (2008)                                            0 / 0
 
Table 2. Occurrence of hypoglycemia during DPP-4 therapy. 
While the DPP-4 inhibitors and the GLP-1 increase insulin production in a glucose-dependent 
way, in contrast with them the sulfonylureas exert their effect via the ATP-dependent 
potassium channel, even at low levels of blood glucose, and therefore they make patients 
susceptible to hypoglycemia. Thus the incidence of hypoglycemia increases when DPP-4 
inhibitors are combined with sulfonylurea. This has also been demonstrated in a metaanalysis 
of studies with a great number of subjects (n=10246), where sitagliptin monotherapy or its 
combination (with metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin or 
metformin + rosiglitazone) was compared with placebo or other OAD (metformin, 
pioglitazone, sulfonylurea, sulfonylurea + metformin or metformin + rosiglitazone) treatment 
in patients with type 2 diabetes (Williams-Herman, Engel et al. 2010). A lower incidence of 
hypoglycemia (5.2%) was found in the group of sitagliptin therapy as compared to the control 
group (12.1%) that could be attributed primarily to sulfonylurea therapy.  
3.3 Body weight 
There is no increase of body weight during treatment with DPP-4 inhibitors, and even a 
reduction of it is possible during a combined therapy with metformin (Monami, Iacomelli et 
al. 2010). 
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contrast, there has been a very low occurrence of hypoglycemia, nearly identical with that of 
placebo, during DPP-4 inhibitor monotherapy or its combination with metformin of 
thiazolidinedione (Blonde 2009). No differences were found in the risk of developing 
hypoglycemia between each DPP-4 inhibitor treatments (Tahrani, Piya et al. 2010) (Table 2). 
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The safety and tolerability of sitagliptin was investigated in patients with type 2 diabetes, 
who were on a stable dose of metformin for at least 8 weeks and were randomised in 
double–blind manner to receive either sitagliptin 100mg q.d. (n= 588) or glipizide 
5mg/day (up-titrated, to a maximum dose of 20mg/day, based upon prespecified 
glycemic criteria) (n= 584) (Seck, Nauck et al. 2010). The analysis showed that the addition 
of sitagliptin to ongoing metformin monotherapy was associated with weight loss (-1.6 
kg) compared with weight gain (+ 0.7 kg) with glipizide. In addition patients treated with 
sitagliptin compared with those treated with glipizide had a lower incidence of 
hypoglycemia (5% vs 34%).  
The body weight neutral effect of DPP-4 inhibitors may prevail through several mechanisms 
which include the following (Foley and Jordan 2010): 
 After a meal that is rich in fat, DPP-4 inhibitor treatment reduces the level of 
chylomicron apoB-48 and so it hinders intestinal triglyceride absorption.  
 Postprandial catecholamine (norepinephrine) levels increase upon the administration of 
DPP-4 inhibitors, resulting in an increased lipolysis in the adipose tissue and fatty acid 
oxidation in the musculature.  
3.4 Cardiovascular effects 
Although it summarized the results of studies with non-cardiovascular endpoints, a 
metaanalysis investigating the safety of sitagliptin (100mg/day) showed no substantial 
differences as compared to the control group in relation to coronary artery disease (0.2 vs. 
0.4 event per 100 patient-years), myocardial ischemia (0.0 vs. 0.2 event per 100 patient-years) 
and acute myocardial infarction (0.1 vs. 0.2 event per 100 patient-years) respectively 
(Williams-Herman, Engel et al. 2010).  
A post hoc metaanalysis of saxagliptin’s effect on major cardiovascular events (CV death, 
non-fatal MI, non-fatal stroke) showed no increase of CV risk in the treated patients (Wolf, 
Friedrich et al. 2009).  
Recently, a large outcome trial with sitagliptin (A randomized placebo controlled clinical 
Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with 
type 2 diabetes mellitus and inadequate glycaemic control on mono or dual combination 
oral antihyperglycaemic therapy, TECOS) and with saxagliptin (Saxagliptin Assessment of 
Vascular Outcomes Recorded in patients with diabetes mellitus, SAVOR-TIMI 53) has been 
started.  
GLP-1 receptors can be found in cardiac muscle cells and vascular endothelial cells as well 
(Nauck and Smith 2009; Nikolaidis, Mankad et al. 2004). The beneficial effect of GLP-1 has 
been demonstrated also in coronary ischemia and left ventricular failure both in animal 
experiments and in human studies (Nikolaidis, Mankad et al. 2004; Bose, Mocanu et al. 2005; 
Nikolaidis, Elahi et al. 2004). In rats, myocardial necrosis developed in a smaller area when 
they received GLP-1 infusion (Bose, Mocanu et al. 2005). Following intravenous infusion of 
GLP-1, less wall motion disorder and better left ventricular function developed in patients 
with and without type 2 diabetes who had undergone angioplasty after acute myocardial 
infarction (Nikolaidis, Mankad et al. 2004).  
Based on these, a beneficial effect of DPP-4 inhibitors on cardiovascular disease may be 
presumed, however further long-term clinical studies with a high number of patients are 
required for an exact elucidation.   
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3.5 Other side effects and potential for drug-drug interactions 
Based on the results so far, DPP-4 inhibitors seem to have no group-specific side effects 
(Nauck and Smith 2009; Hollander and Kushner 2010). An occurrence of slightly increased 
upper respiratory symptoms was not confirmed by a metaanalysis investigating the safety 
of sitagliptin therapy on a high number of subjects (29 placebo-controlled and 11 active 
comparison studies) (Williams-Herman, Round et al. 2008). Also a similar result was 
obtained in a study investigating the safety of vildagliptin (Ligueros-Saylan, Schweizer et al. 
2010).  
DPP-4 inhibitors are eliminated mostly through the kidneys, so that the question has 
emerged whether they can be used in patients with impaired renal function (Table 1). The 
results so far show that sitagliptin was tolerated well also in patients with mild, moderate 
and severe renal failure (including those on dialysis) (Bergman, Cote et al. 2007). Currently 
DPP-4 inhibitors are approved in patients with mild renal impairment (creatinine clearance 
[CCr] ≥ 50 mL/min) both in Europe and in the USA. However, in patients with moderately 
(CCr ≥30 to < 50 mL/min) and severely (CCr < 30 mL/min) impaired renal function / end 
stage renal disease (ESRD) in Europe it is not approved, while in the USA sitagliptin and 
saxagliptin can be given in a reduced dose (Deacon 2011).  
In patients with mild and moderate liver disease, of the DPP-4 inhibitors solely sitagliptin 
has been approved with no restrictions. Monitoring of transaminase levels is required before 
and during saxagliptin therapy (Deacon 2011). If transaminase levels exceed three times the 
upper limit of normal, the therapy should be discontinued. At present, vildagliptin should 
not be given to patients with mild to moderate hepatic impairment. Neither DPP-4 inhibitor 
is approved in patients with severely impaired hepatic function.  
Results show that DPP-4 inhibitors cause no more interactions with other OADs (metformin, 
pioglitazone, glyburide) or simvastatin. Only saxagliptin is metabolized via the CYP3A4/5 
system; therefore a reduction of saxagliptin dose (2.5mg qd) is recommended when it is 
administered concomitantly with a strong CYP3A4/5 inhibitor (e.g. ketoconazole) (Table 1).  
3.6 ß-cell funcion 
Typically, islet function has already declined by approximately 50% by the time patients 
are diagnosed with type 2 diabetes mellitus (Wajchenberg 2007). Reduced pancreatic beta 
cell mass, largely because of accelerated apoptosis, seems to account for, at least in part, 
the impaired islet cell function (Butler, Janson et al. 2003). In vitro, neither sulfonylureas, 
nor metformin protect beta cell from apoptosis (Maedler, Carr et al. 2005; Kefas, Cai et al. 
2004) . 
Studies in diabetic animals showed beneficial effects of GLP-1 on pancreatic beta cells 
(Farilla, Hui et al. 2002; Mu, Petrov et al. 2009; Gallwitz and Häring 2010) (Figure 3). GLP-1 
stimulates beta cell proliferation and differentiation while it hinders beta cell apoptosis both 
in vitro and in animal studies. DPP-4 inhibitors increased the number of insulin-positive 
beta-cells in islets and the beta to alpha cell ratio in different diabetic animals was 
normalized. 
The effects of sitagliptin vs. sulfonylurea therapy were compared in mice with type 2 
diabetes (Mu, Petrov et al. 2009). Sitagliptin treatment was found to have repaired the 
amount of beta and alpha cells and also alpha/beta cell rate to a significantly greater degree 
as compared to glipizide therapy. The effect of sitagliptin therapy (50mg/day) on beta cell 
function in patients with type 2 diabetes (n=28) taking metformin was analyzed in a double-
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blind randomized placebo-controlled study (Brazg, Xu et al. 2007). Beta cell function was 
determined with the ‘C-peptide minimal model’ by measuring blood glucose and C-peptide 
levels for 5 hours after a standardized breakfast. Sitagliptin therapy was found to have 
significantly improved beta cell function in comparison to the placebo group. In addition 
sitagliptin and vildagliptin significantly improved HOMA-B value and it also reduced the 













Fig. 3. Effects of GLP-1 on beta cell. 
Thus, DPP-4 therapy can delay or prevent the progression of type 2 diabetes, but further 
studies are required in order to obtain a more exact knowledge relating to its effect on beta 
cells, as well as its mechanism of action.  
4. Conclusion 
Large intervention studies demonstrated that antihyperglycemic therapy with treatment 
goals aiming at normoglycemia can reduce the risk or the progression of microvascular as 
well as macrovascular risk.  
Sulfonylureas, glinides and insulin therapy are associated with an increased risk for 
hypoglycemia and are also associated with weight gain. The novel incretin based therapies 
with DPP-4 inhibitors, both in monotherapy and in combination therapy, can effectively 
reduce fasting and postprandial blood glucose levels and also HbA1c value. When 
administered concomitantly with metformin, their GLP-1-increasing effects are additive. 
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Based on studies and clinical experience so far, they can be tolerated very well, and they 
cause no increase of body weight, hypoglycemia and gastrointestinal side effects and the 
potential, based on animal and in vitro studies, for preservation or enhancement of beta cell 
function. Their administration is particularly beneficial in overweight patients who 
represent the majority of patients with type 2 diabetes, as well as in elderly patients and in 
diabetics who are susceptible to hypoglycemia. At present, there seems to be little to 
distinguish between the different inhibitors in terms of their efficacy as antidiabetic agents 
and their safety. Long-term accumulated clinical experience will reveal whether compound-
related characteristics lead to any clinically relevant differences. 
In the future further gliptins (alogliptin, linagliptin, denagliptin) may be marketed, with 
which Phase III studies are in progress or the results have already been published.  
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1. Introduction 
Diabetes mellitus is a chronic debilitating disease affecting over 23 million children and 
adults in the United States. Many of the ill effects of this disease lie in part with uncontrolled 
glucose levels in the body. Hypoglycemia increases the risk of cardiovascular and 
cerebrovascular events, progression of dementia, injurious falls, emergency department 
visits, and hospitalizations (Desouza, 2003; Leese, 2003; Schwartz, 2008; Whitmer, 2009).  
Hypoglycemia-associated autonomic failure is another major complication that diabetic 
individuals go through when their glucose levels are not properly regulated. In this 
complication, antecedent hypoglycemia causes both defective glucose counter-regulation and 
hypoglycemia unawareness (by reducing autonomic and neurogenic symptom response) thus 
making it difficult for patients to properly sense a hypoglycemic event and thus cause further 
complications in the future (Cranston, 1994; Cryer, 2004; Dagogo-Jack, 1994, Fanelli, 1994). 
Hyperglycemia is associated with secondary damage to many organ systems especially the 
kidneys, eyes, nerves and blood vessels. Hyperglycemia is associated with both macro- and 
microvascular complications. The macrovascular complications include increased risk of 
myocardial infarction as well as stroke, cerebrovascular disease, and coronary artery disease 
(Kannel, 1979; Lehto et al., 1996). On the microvascular level, hyperglycemia is associated 
with vascular damage, leakage, and edema. Such inflammation can lead to occlusion and 
ischemia as well as nerve damage (Kannel, 1979).  
Since the Diabetes Complications and Control Trial (DCCT) established hemoglobin A1C as 
the gold standard of glycemic control there has been a lot of research on other factors that 
might better predict the risk of diabetic complications. One such factor has been glycemic 
variability. Large changes in glycemic levels lead to production of reactive oxygen species 
(ROS), which in turn accelerate the micro- and macrovascular complications of diabetes. It is 
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also possible that neglecting these variations in glycemic control could lead to 
misinterpretation of the risk of diabetic complications even if the mean A1C levels fall 
within the normal accepted range (Hirsch & Brownlee, 2005). 
However, for a variety of reasons ranging from biomedical to psychosocial it is difficult to 
achieve optimal glycemic control (Amir et al., 1990). Continuous glucose monitoring (CGM) 
provides a useful method to help monitor glucose values and to provide useful feedback to 
more effectively control glycemic levels (Klonoff, 2005). In a multicenter clinical trial 
studying two groups, one using CGM and the other using self-glucose monitoring it was 
found that there was a significant improvement in hemoglobin A1C in patients using CGM 
as compared to patients using self-monitored finger stick glucose measurements after a 26 
week trial (Tamborlane et al., 2008). 
To further study some of these observations, in our study we used CGM over a 72 hour 
period to examine 84 male patients who had been diagnosed with either Type I or II 
diabetes. Our goal was to characterize the time the patient spent in a hypo-, hyper-, and eu-
glycemic state with respect to age and the treatment type the patient received (oral 
medication vs. insulin). 
2. Methods 
Eighty-four treated adult male diabetic patients (18 oral treatment, 51 insulin only, and 15 
both oral and insulin) were studied. All patients had attended a comprehensive diabetes 
clinic on a regular basis and had received diabetes education including diet, exercise and 
self-monitoring of blood glucose (SMBG) instructions.  
Assessment of clinical data included age, sex distribution, and duration of diabetes, body 
mass index, diabetic complication (i.e. Diabetic neuropathy, retinopathy, nephropathy, 
cardiovascular disease and peripheral vascular disease). Pertinent laboratory data included 
HbAlC, plasma glucose, creatinine, liver function tests, lipid levels and microalbuminuria. 
The patient’s home medications were also reviewed for potential effect on glucose 
homeostasis.  
A CGMS sensor was inserted and calibrated according to the Minimed Medtronic 
procedure. Patients were instructed to continue with their regular lifestyle, to keep a food 
diary and to record event markers into the monitor e.g. insulin administration, exercise, 
SMBG and hypoglycemic episode. After 72 hours, the monitor was removed and the data 
were downloaded using Minimed Solutions Software version 2.0b. 
2.1 Statistical analyses 
Standard procedures were used to calculate the means, SD, SEM, hyperglycemia frequency 
and correlation coefficients. SMBG glucose values were paired with corresponding CGMS 
glucose values for linear regression analyses. Blood glucose concentration >140 mg/dL for 
at least 30 minutes indicated hyperglycemia. Hyperglycemic prevalence was calculated as 
the percentage of a specified time period spent during hyperglycemia. Changes in blood 
glucose > 100mg/dL within a 60-min period were defined as rapid glucose excursions.  
3. Results  
During the 3-day evaluation, 84 men provided a continuous measure of blood glucose levels 
using a CGM device4. The participants mean age was = 66.17 (± 11.36) years, with N=36 
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subjects younger than 65 and N= 48 subjects 65 and older. Of the 84 patients, 18 were on oral 
medications alone, 51 were on insulin alone, while 15 were on both. Table 1 provides 
demographic information including age, BMI, systolic blood pressure and HbA1C.  The 
correlations among BMI, systolic BP, hemoglobin A1C and age are presented in Table 2. The 
analysis of the glycemic levels were divided into 3 time periods: 6 am – 6 pm (daytime), 6 
pm – midnight (evening), and midnight – 6 am (early morning). 
 
Age x̄  = 66.17 ± 11.36 
BMI x̄ =  30.3 ±  5.86 
Systolic Blood Pressure x̄ = 135.04 ± 18.9 
HbA1C x̄ = 7.76 ± 1.62 
Table 1. Demographics (N = 84) 
 
 Age BMI HbA1c Systolic BP 
Age 1 -0.15 -0.41* 0.32* 
BMI -0.15 1 -0.11 -0.06 
HbA1c -0.41* -0.11 1 -0.15 
Systolic BP 0.32* -0.06 -0.15 1 
*p <.05; **p < .01  
Table 2. Zero order correlations    
Overall, a greater percentage of time was spent in hyperglycemia during the day (57.86% ± 
14.59) than at night (16.11% ± 10.40), t(83) = 16.50, p <0.01. The analysis of hypoglycemic and 
euglycemic states showed no statistically significant difference (multiple regression 
analysis) between time intervals when comparing the association with age, BMI, treatment, 
HbA1c, or any other predictive variables.  Also no significant findings were seen in the 
evening hours (6 pm to midnight) when examining the same variables for either age or 
treatment type for any glycemic state. 
The effects of Age Grouping (<65 and ≥65) on the percentage time that subjects were in the 
hyperglycemic state during the early morning was evaluated with multiple regression 
analyses using covariates (BMI, systolic blood pressure, and hemoglobin A1C) that were 
found to be statistically significantly related to hyperglycemic events. The model outlined in 
Table 3 included BMI entered on the first step, systolic blood pressure entered on the second 
step and HemoglobinA1c (HbA1C) entered on the third step. The same analysis was done 
for the daytime interval. Increasing values of HbA1C were associated with a significantly 
greater percentage of time in the hyperglycemic state, as expected, but only during the early 
morning hours. 
However, BMI and systolic blood pressure were not significant predictors of percentage 
time in the hyperglycemic state. On the other hand, subjects older than 65 years exhibited a 
significantly greater percentage of time in the hyperglycemic state for the daytime interval 
and a lower percentage of time in the hyperglycemic state for the early morning interval. 
The opposite pattern was found for subjects younger than 65. That is subjects younger than 
65 spent a greater percentage of time in hyperglycemia during the early morning interval 
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and a lower percentage of time in hyperglycemia during the daytime interval. The 
difference between the age groups for the percent time hyperglycemic during the day was 
significant, p = 0.02 while a borderline difference was evident during the early morning, p = 
0.06. These effects are displayed in Figure 1 and Table 3. In addition, Figure 2 displays the 
percentage of time in the hyperglycemic state as a function of age for the early morning 
period (A) and for the daytime (B). The distinctive positive and negative effects of increasing 
age has a beneficial effect (lower percentage time in hyperglycemia) during early morning 
and a detrimental effect (higher percentage time in hyperglycemia) during the day. 
Although these effects were not significant, the results are of interest due to the fact that 
clinical evidence of hyperglycemic patterns can help physicians better control glycemic 
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Multiple linear regressions (Table 4) examine the effects of diabetes treatment type on the 
percentage of time that subjects were in the hyperglycemic state. The groups were analyzed 
based on treatment modality (oral, insulin, or both). To further clarify the analyses only 
those receiving either insulin or oral medication were examined. The results indicated that 
during the early morning period, those taking oral medication exclusively exhibited a lower 
percentage of time in the hyperglycemic state (p = < 0.06). These effects are displayed in 
Figure 3. Similar findings were not found in the other two time periods. 
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Finally to test the hypothesis that age and type of treatment may have interacting effects 
with respect to percentage time in the hyperglycemic state a third multiple regression was 
constructed (Table 5). The Interaction was not significant for either the early morning 
interval or for the daytime interval. Apparently, age and type of treatment have relatively 
independent influences on the percentage of time in the hyperglycemic state. 
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Beta = Standardized Beta; Medication Type:  Oral =1, Insulin =2 
*p< .05; **p<.01 
Table 5. Multiple Linear Regressions – Relationship Between the Interaction of Age X 
Medication Type (Oral, Insulin) and % Time Hyperglycemic 
4. Conclusion   
Results from this study demonstrate that both increasing age and the exclusive use of oral 
anti-hyperglycemic medications are associated with a lower percent of time spent in 
hyperglycemia during the early morning. On the other hand, as age increases, the opposite 
effect is exhibited during the daytime interval, namely a higher percent of time in the 
hyperglycemic state. In search for an explanation for these findings there is evidence from 
the animal literature that in older rats, glucose utilization by the brain, using 
autoradiography, tended to increase more slowly in the morning and decrease faster in the 
afternoon and evening (Wise et al., 1988). That is, glucose utilization is overall less effective 
during the day for older rats leading to elevated levels of blood glucose and possibly 
hyperglycemia during the day. Thus, glucose levels in older human subjects (≥65 years) 
compared to younger subjects (<65 years) appear to display a similar pattern as those found 
in the older rats. If the interspecies mechanism is similar, this would give some explanation 
to the pattern of increased percentage of diurnal hyperglycemia found in the older subjects 
with diabetes. 
There was no interaction between age of patient and type of medication administered. 
Therefore, our findings showing that older people and people taking only oral medication 
exhibit less time spent in hyperglycemia during the early morning are two completely 
independent predictors of hyperglycemic episodes and do not influence each other.  
Secondly, elevated HbA1c levels correlated with the percent time spent in a hyperglycemic 
state primarily during the early morning time interval. A study of Type II diabetics revealed 
that non-euglycemic states in the morning (pre-breakfast) and at night (bedtime) correlated 
with increased HbA1c levels. Therefore, patients whose glucose levels were not regulated 
well in the morning or late night tended to have poorer overall glycemic control as 
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measured by HbA1c. Perhaps the reason why the strongest association with HbA1c was 
“exerted” during the night (between the bedtime and pre-breakfast measurements) was due 
to the inability to effectively respond to extreme glucose values while asleep. Thus in the 
absence of an insulin injection (or comparable treatment) to correct for the elevated blood 
glucose levels, these patients may have an overall higher HbA1c. This indicates the 
importance of normalizing glucose levels overnight so as to avoid hyper and hypoglycemic 
states.  
Future studies are needed to help account for the mechanisms behind both the age and 
percent time spent in hyperglycemia as well as the use of oral medication and percent time 
spent in hyperglycemia. Cortisol, for example, has been shown to promote the release of 
large amounts of glucose into the bloodstream as well as to block the absorption of insulin 
and it was shown that cortisol increases with age (Larsson et al., 2009).  Therefore it would 
be beneficial to look further into this relationship as a means of explaining some of our 
results. It was also shown that the amount of REM sleep is reduced by about half in late life. 
This loss of REM sleep has been correlated with elevated cortisol levels throughout the day 
(Van Cauter et al., 2000). Increased cortisol elevates insulin resistance thereby promoting 
hyperglycemic episodes that may be reflected in older subjects with presumptive sleep 
difficulties. 
Among the limitations of the present study is the absence of female subjects.  Also many of 
the Type II diabetics recruited for this study were found to be taking insulin with or without 
oral medication. This led to treatment overlap between the diabetic types making it difficult 
to justify analysis based on type of diabetes, so instead the treatment modality was 
compared. This analytic strategy resulted in the elimination of 15 patients due to their 
treatment plan using both insulin and oral medications.  
In summary, this continuous glucose monitoring study presents some novel observations 
into the relationship between hyperglycemia, advancing age and treatment type.  While 
hypoglycemic episodes may also cause life-threatening situations, prolonged 
hyperglycemic episodes throughout the night, while asleep, will promote life-threatening 
sequellae and reduced quality of life.  Although the complications of hyperglycemia may 
not be as instantaneously debilitating or as acute as hypoglycemia, more research is 
needed to prevent these episodes (Greene et al., 1992; Morello, 2007; Resnikoff et al., 2004). 
By understanding the pathophysiology behind circadian fluctuations of hyperglycemic 
episodes, physicians may be better able to help patients reduce the frequency and 
duration of these occurrences and thus reduce the complications that are associated with 
them. 
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1. Introduction 
Epidemiological evidence indicates that postprandial hyperglycemia is an independent risk 
factor for cardiovascular disease (Bonora & Muggeo, 2001). Improving postprandial 
glycemic control is considered a target for decreasing the morbidity and mortality due to 
cardiovascular disease in prediabetic and diabetic individuals. Recently, clinical trials such 
as the STOP-NIDDM Trial and Victory Study demonstrated that -glucosidase inhibitors 
(GIs) reduced the progression from impaired glucose tolerance (IGT) to type 2 diabetes 
(Chiasson et al., 2002, 2003; Kawamori et al., 2009). Therefore, considerable attention has 
been paid to GIs as preventive and therapeutic agents for type 2 diabetes and its 
complications. Some food consumed on a daily basis also contains GIs and may therefore 
be effective for attenuating increase in postprandial blood glucose levels. Therefore, 
introducing GIs into the diet may prevent diabetes. 
In Asian countries, mulberry leaves are a known traditional medicine for preventing 
diabetes. According to a prior study, mulberry leaves have a potent GI activity because of 
1-deoxynojirimycin (DNJ), a glucose analog. In this chapter, we describe a method for 
determining DNJ in mulberry leaves; we also describe development of food-grade DNJ-
enriched mulberry leaf extract (ME). Furthermore, we review the efficacy of this extract for 
postprandial glycemic control through human trials aimed at investigating use of mulberry 
leaves as food to prevent diabetes. 
2. Development of ME 
2.1 Diabetes mellitus 
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels. 
Type 2 diabetes, defined as noninsulin-dependent diabetes mellitus (NIDDM), is the most 
common form that affects 90–95 percent of all adults who develop diabetes. Type 2 diabetes 
is a lifestyle disease caused by reduced insulin production or impaired insulin response in 
target organs. It is associated with genetic background, obesity, unhealthy dietary habits, 
and physical inactivity. Hyperglycemia-induced oxidative stress causes serious diabetic 
complications such as diabetic retinopathy, nephropathy, and neuropathy, leading to 
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decreased quality of life. The International Diabetes Federation (IDF) estimates that 285 
million people around the world have diabetes; this total is expected to rise to 438 million 
within 20 years. Each year, a further 7 million people develop diabetes (IDF Diabetes Atlas 
fourth edition committee, 2009). 
Type 2 diabetes increases morbidity and mortality as a result of serious macrovascular 
complications such as cardiovascular disease (Krolewski et al., 1987; Kannel & McGee, 
1979). Recent epidemiological studies suggest that postprandial hyperglycemia is an 
independent risk factor for cardiovascular disease that has a greater effect on the 
development of this disease than fasting hyperglycemia (Ceriello, 1998; Hanefeld et al., 
1996). Therefore, postprandial glycemic control is essential for effective reduction in the risk 
of cardiovascular disease. Carbohydrates comprise about 50% of our daily intake of calories. 
Carbohydrates ingested as food are digested to disaccharides by salivary and pancreatic 
amylases. The disaccharides are then hydrolyzed to monosaccharides by -glucoside at the 
small intestine brush border and absorbed into the blood. -Glucosidase is involved in this 
final step of carbohydrate digestion prior to absorption.GIs retard the digestion and 
absorption of carbohydrates in the small intestinal lumen and therefore reduce the increase 
in blood glucose concentrations after a carbohydrate load. Acarbose, miglitol, and voglibose 
are -glucosidase inhibitory agents used widely in clinical practice. These GIs decrease 
both postprandial hyperglycemia and hyperinsulinemia but do not induce hypoglycemia 
and have a good safety profile, although their gastrointestinal adverse effects may limit 
long-term compliance to therapy. Long-term intervention trials of GIs in patients with type 
2 diabetes and IGT have been conducted. Recent placebo-controlled, prospective trials, 
including the STOP-NIDDM Trial and Victory Study, demonstrated that GI intake before 
each meal reduces the risk of type 2 diabetes in patients with IGT (Chiasson et al., 2002, 
2003; Kawamori et al., 2009). Therefore, improvement in postprandial hyperglycemia by GI 
leads to prevention of diabetes and provides the basis for studies on the use of naturally 
occurringGIs in plant foods. 
2.2 Mulberry 
Mulberry is a tree belonging to the genus Morus of the family Moraceae (Fig. 1). It is 
distributed over a wide area of tropical, subtropical, and temperate zones in Asia, Europe, 
North America, South America, and Africa. There are at least 24 species of mulberry with 
more than 100 known cultivars (Koidzumi, 1917). Historically, the trees have been planted 
for sericulture in east, central, and southern Asia. On the basis of folklore remedies, the 
leaves have also been used as a Chinese herbal tea, especially for diabetes. In the modern 
era, health benefits from mulberry products have been verified scientifically, with mulberry 
shown to have potent -glucosidase inhibitory activity mainly because of azasugars. This 
has led to proposals that dietary mulberry intake is beneficial for attenuating postprandial 
hyperglycemia, thereby preventing diabetes. Several animal studies have been conducted to 
date. Nojima and co-workers showed that administration of mulberry leaf extract restored 
impaired glucose metabolism and hyperglycemic conditions in streptozotocin-induced 
diabetic mice (Nojima et al., 1998; Kimura et al., 1995). At present, various mulberry food 
products, including teas, powders, and tablets, are commercially available in Japan and 
many other countries. Although these products have apparent antidiabetic effects, their 
efficacy in humans requires further study. 
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2.3 Azasugars in mulberry 
Azasugars are alkaloids that mimic the structures of monosaccharides. In azasugars, the 
oxygen atom in the ring of these sugars is replaced by nitrogen. The first azasugar, the 
antibiotic nojirimycin, was discovered in 1966 in Streptomyces microorganisms (Inoue et al., 
1966). Since then, more than 100 azasugars have been isolated from plants and 
microorganisms. DNJ is a 5-amino-1,5-dideoxy-D-glucopyranose or D-glucose analog (Fig. 
2). Initially, DNJ was chemically synthesized by reduction of nojirimycin (Inoue et al., 1967) ; 
later, naturally occurring DNJ was isolated from the roots of mulberry trees and called 
moranoline (Yagi et al., 1976). DNJ has also been produced by microorganisms such as 
Bacillus and Streptomyces (Schmidt et al., 1979; Murao & Miyata, 1980; Ezure et al., 1985). 
Mulberry leaves are relatively rich in azasugars such as DNJ, fagomine, N-methyl-DNJ, and 
2-O-R-D-galactopyranosyl-DNJ. DNJ is the dominant alkaloid, accounting for 50% of 
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Fig. 2. Chemical structure of DNJ and glucose 
Azasugars have -glucosidase inhibitory properties because of their ability to competitively 
bind to the active sites of glucosidases by mimicking the corresponding natural substrates 
(Fig. 3). The GI clinical agents described above are all azasugars developed from natural 
occurring azasugars (Junge et al., 1996). Among the naturally occurring azasugars, DNJ 
shows potent -glucosidase inhibitory activity. Consequently, miglitol was developed as a 
lead compound from DNJ.  
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Based on this background, the relationship between the concentration of DNJ and the 
antidiabetic effect of mulberry food has attracted considerable attention. For this reason, 















Fig. 3. Possible mechanism of DNJ in the digestive tract 
2.4 Methods for determining DNJ in mulberry 
Determination of DNJ levels in mulberry has been difficult because of the high polarity of 
DNJ and the absence of a chromophore in the molecule. Therefore, DNJ is too hydrophilic to 
be retained by widely used reverse-phase chromatography columns, and it cannot be 
detected with common ultraviolet or fluorescence detectors. Ligand-exchange and 
aminopropyl columns are commonly used for HPLC determination of relatively polar 
compounds such as carbohydrates and water-soluble vitamins (Sharpless et al., 2000). 
However, even these columns do not achieve reasonable retention of DNJ, and for this 
reason, several other methods have been developed for determining DNJ in mulberry.  
Kimura et al. reported a method that used hydrophilic interaction liquid chromatography 
(HILIC) coupled with an evaporative light-scattering detector (ELSD) (Kimura et al., 2004); 
This method is known as the HILIC-ELSD method. HILIC has been developed as an 
efficient tool for analyzing highly hydrophilic compounds, and its analytical application to 
carbohydrates (Alpert et al., 1994) and peptides (Alpert et al., 1990) has been reported. The 
retention ability of the HILIC column basically depends on the hydrophilicity of the 
analytes, and if the compound has amino groups, its retention time is increased (Tolstikov & 
Fiehn, 2002). Therefore, a HILIC column is preferable for efficient separation of azasugars. 
ELSD is the universal detector that responds to nonvolatile compounds and directly detects 
analytes lacking chromophores.  
Kim et al. (2003) reported the procedures for deriving DNJ using 9-
fluorenylmethoxycarbonyl chloride, which targets secondary amino groups in DNJ, 
followed by reverse-phase HPLC using a fluorescence detector. 
Furthermore, several other methods, such as HILIC-MS/MS (Nakagawa et al., 2010) and 
anion-exchange chromatography with pulsed amperometric detection methods (Yoshihashi 
et al., 2010), have been developed for measuring DNJ levels. 
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2.5 Development of ME  
Since the putative effective dose of more than 10 mg DNJ per individual weighing 60 kg 
cannot be generally provided by commercially available mulberry leaf products because of 
their low DNJ content, the development of DNJ-enriched products is highly desired. 
Therefore, to produce nutraceutical ME, the concentrations of DNJ in mulberry leaves from 
different cultivars, harvest seasons, and leaf locations were examined. DNJ concentrations 
differed according to cultivars, with M. alba L. var. Tsuruta and Hayatesakari having a high 
DNJ content. The harvest season and region of mulberry leaves were also closely related to 
the DNJ content, with young mulberry leaves from the top part of the branches in the 
summer having the highest DNJ concentration. After optimization of harvesting and 
processing, ME was produced containing 1.5 % DNJ. This powder contained DNJ at 
concentrations approximately 15 times higher than general mulberry products (Figs. 4, 5; 












Fig. 4. Improved production process for DNJ-enriched mulberry extract (ME) (modified 
from Ref. Kimura, 2010; used with permission) 
Young mulberry leaves from the top part of the branches in August contained the highest 
amount of DNJ. For harvesting, a method involving a plucking machine was considered an 
effective way for collecting young leaves. For blanching, steam treatment was used to 
prevent leaching of DNJ. For the drying process, hot air was employed, and the dried leaves 
were then disintegrated and added to a mixture of ethanol and water (20:80, v:v). After 
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Fig. 5. DNJ concentrations in mulberry products produced by different processes (modified 
from Ref. Kimura, 2010; used with permission) 
In the traditional process, widely cultivated leaves (M. alba L. var. Kairyou nezumigaeshi) 
were collected from whole branches and dried using hot air. In the improved process, the 
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DNJ content in the extract (M. alba L. var. Kairyou nezumigaeshi) was 15 times higher than 
that in the traditional mulberry product. If mulberry leaves containing high levels of DNJ 
(e.g., M. alba L. var. Tsuruta) were used, products with considerably greater DNJ 
concentrations could be produced. 
3. Evaluation of ME 
3.1 In vitro -glucosidase inhibitory activity 
The rat intestinal -glucosidase inhibitory activity of ME was measured with p-nitrophenyl-
-D-glucopyranoside as the substrate (Yamaki & Mori, 2006). ME showed potent -
glucosidase inhibitory activity, which was approximately the same as the activity of the DNJ 
content in ME. This implied that the -glucosidase inhibitory activity of ME was  
attributable to DNJ. 
3.2 Single oral administration test 
ME showed potent in vitro -glucosidase inhibitory activity. Human intervention trials with 
ME were conducted. To clarify the effect of improving postprandial hyperglycemia and the 
efficacious dose of ME, single oral administration tests were performed. 
3.2.1 Sucrose tolerance test in healthy subjects 
Twenty-four healthy volunteers were randomly divided into four groups of six individuals. 
After fasting overnight, the individuals in each group received either 0 (placebo), 0.4, 0.8, or 
1.2 g ME (corresponding to 0, 6, 12, or 18 mg DNJ, respectively), followed by 50 g sucrose 
dissolved in 100 mL water. Blood samples were collected before and 30, 60, 90, 120, 150, and 
180 min after DNJ or sucrose administration. Plasma glucose and insulin levels were then 
measured. The results showed that oral administration of 0.8 and 1.2 g ME significantly 
suppressed the elevation of postprandial blood glucose and secretion of insulin (Kimura et 
al., 2007). 
3.2.2 Carbohydrate tolerance test in subjects with borderline diabetes 
To examine the diabetes preventative effect of ME in a practical daily meal, a carbohydrate 
tolerance test was performed in subjects with borderline diabetes. The study design was a 
randomized, double-blind, four-period, crossover trial. Twelve volunteers with impaired 
glucose metabolism [fasting plasma glucose (FPG) in the range of 100–140 mg/dL] were 
enrolled in the study. In each trial, all the subjects consumed 200 g boiled white rice 15 min 
after ME ingestion. Blood samples were drawn before ME ingestion and 30, 60, 90, and 120 
min after starting the meal. Plasma glucose, plasma insulin, and other biochemical 
parameters were then measured. Similar to the study described above, administration of 0.8 
and 1.2 g ME caused significant suppression and peak time delay of postprandial blood  
glucose and secretion of insulin (Fig. 6; Asai et al., 2011). 
3.3 Long-term supplementation trial 
Elevation of postprandial blood glucose levels and secretion of insulin were suppressed 
significantly at a dose of more than 0.8 g ME. To assess the safety and effects of long-term 
ingestion, a long-term supplementation trial was then conducted. 
 


















































































After fasting for 12 h, the subjects with borderline diabetes were orally administered either 0 (placebo), 
0.4, 0.8, or 1.2 g ME (0, 6, 12, or 18 mg DNJ, respectively), followed by 200 g boiled rice. Blood samples 
were collected prior to intake and 30, 60, 90, and 120 min after rice intake. The plasma glucose and 
insulin levels were then determined. Data represent the mean ± S.E.M. (n = 10). *P < 0.05 vs. placebo. 
Fig. 6. Effects of a single oral administration of ME on plasma glucose (A) and insulin (B) 
levels (from Ref. Asai et al., 2011; used with permission) 
3.3.1 Thirty-eight–day supplementation trial in healthy subjects 
Twelve healthy volunteers were enrolled in the study. Based on the results of the above 
described single oral administration test, the ME dose was set at 1.2 g before every meal. 
The subjects were randomly divided into two groups; they received either 0 (placebo) or 1.2 
g ME before every meal for 38 days (0 or 3.6 g/day, corresponding to 0 and 54 mg DNJ/day, 
respectively). Fasting blood samples were collected on days 0, 24, and 38 of ME powder 
administration. Blood biochemical parameters such as FPG, insulin, glycated hemoglobin 
(HbA1c), triglyceride (TG), total cholesterol (Tcho), HDL cholesterol (HDL-C), adiponectin, 
high-molecular-weight adiponectin (HMW adiponectin), and lipoprotein lipase (LPL) were 
measured. The results showed no significant differences in any of the biochemical 
parameters between the placebo group and the group ingesting the test food either before, 
during, or after the study. The daily intake of the ME powder did not cause hypoglycemia 
or abnormal lipid profiles (i.e., high cholesterol). According to previous reports, long-term 
ingestion of GI (acarbose, tochi extract) reduced FAG, HbA1C, TG, and Tcho levels in the 
subjects (Fujita et al., 2003; Hillerbrand et al., 1979), changes which may contribute to 
diabetes prevention and improvement. The results of our study showed no such effects, 
which could be attributable to the short administration period. The major side effects of GI 
involve the gastrointestinal system (Harano et al., 2002). However, no subjects in our study 
complained of negative gastrointestinal system-related side effects such as abdominal 
distension, abdominal pain, retching, or flatulence (Kimura et al., 2008). 
3.3.2 Twelve-week supplementation trial in subjects with borderline diabetes 
Next, we conducted a 12-week randomized, double-blind, placebo-controlled trial, followed 
by a 4-week posttreatment observation in subjects with borderline diabetes. Seventy-six 
subjects with FPG in the range of 110–140 mg/dL were recruited and randomized to receive 
either mulberry leaf extract or placebo. During the 12-week trial, ME (18 mg DNJ) or 
 
Hypoglycemia – Causes and Occurrences 
 
30
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After fasting for 12 h, the subjects with borderline diabetes were orally administered either 0 (placebo), 
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3.3.1 Thirty-eight–day supplementation trial in healthy subjects 
Twelve healthy volunteers were enrolled in the study. Based on the results of the above 
described single oral administration test, the ME dose was set at 1.2 g before every meal. 
The subjects were randomly divided into two groups; they received either 0 (placebo) or 1.2 
g ME before every meal for 38 days (0 or 3.6 g/day, corresponding to 0 and 54 mg DNJ/day, 
respectively). Fasting blood samples were collected on days 0, 24, and 38 of ME powder 
administration. Blood biochemical parameters such as FPG, insulin, glycated hemoglobin 
(HbA1c), triglyceride (TG), total cholesterol (Tcho), HDL cholesterol (HDL-C), adiponectin, 
high-molecular-weight adiponectin (HMW adiponectin), and lipoprotein lipase (LPL) were 
measured. The results showed no significant differences in any of the biochemical 
parameters between the placebo group and the group ingesting the test food either before, 
during, or after the study. The daily intake of the ME powder did not cause hypoglycemia 
or abnormal lipid profiles (i.e., high cholesterol). According to previous reports, long-term 
ingestion of GI (acarbose, tochi extract) reduced FAG, HbA1C, TG, and Tcho levels in the 
subjects (Fujita et al., 2003; Hillerbrand et al., 1979), changes which may contribute to 
diabetes prevention and improvement. The results of our study showed no such effects, 
which could be attributable to the short administration period. The major side effects of GI 
involve the gastrointestinal system (Harano et al., 2002). However, no subjects in our study 
complained of negative gastrointestinal system-related side effects such as abdominal 
distension, abdominal pain, retching, or flatulence (Kimura et al., 2008). 
3.3.2 Twelve-week supplementation trial in subjects with borderline diabetes 
Next, we conducted a 12-week randomized, double-blind, placebo-controlled trial, followed 
by a 4-week posttreatment observation in subjects with borderline diabetes. Seventy-six 
subjects with FPG in the range of 110–140 mg/dL were recruited and randomized to receive 
either mulberry leaf extract or placebo. During the 12-week trial, ME (18 mg DNJ) or 
 
Hypoglycemia – Causes and Occurrences 
 
32
identical placebo capsules were taken three times a day before meals. Anthropometric data 
and blood samples were collected from the subjects after they had fasted overnight every 4 
weeks of the supplementation period (week 0, 4, 8, and 12) and 4 weeks after withdrawal of 
the supplementation (week 16). Adverse effects were assessed by interview and self-reports. 
Blood biochemical parameters such as FPG, insulin, HbA1c, glycated albumin (GA), 1,5-
































Changes in the concentration of 1,5AG during the 12-week supplementation with either ME (18 mg 
DNJ, thrice daily) or placebo followed by a 4-week observation without supplementation 
Data are expressed as the mean ± S.E.M. (n = 33 in the extract group, n = 32 in the placebo group). *P < 
0.05 vs. placebo. 
Fig. 7. Effects of 12-week supplementation of ME on plasma 1,5AG levels (modified from 
Ref. Asai et al., 2011; used with permission) 
The results showed that there were no significant differences between the ME and placebo 
groups in baseline values or values during the study for the glycemic control parameters 
(FPG, insulin, HbA1c, GA), anthropometric measurements, or serum lipid profiles. Among 
the glycemic control parameters, there were significant differences between the two groups 
with regard to the change in serum 1,5AG concentration over the study period. The 1,5AG 
concentration of the ME group increased gradually from baseline through to weeks 4, 8, and 
12 and was higher than that in the placebo group at weeks 4, 8 and 12. The increase in 1,5AG 
concentration in the ME group returned to the baseline level after the 4-week posttreatment 
observation period (i.e., at week 16) (Fig. 7). The serum 1,5AG concentration is maintained at 
a constant level under euglycemic conditions; however, it decreases as a result of 
competitive inhibition of renal tubular reabsorption caused by glycosuria under 
hyperglycemic conditions (Akanuma et al., 1988; Yamanouchi et al., 1990). Serum 1,5AG 
concentrations therefore sensitively respond to blood glucose fluctuations within a few days 
(Yamanouchi et al., 1992, 1996; Dungan et al., 206). Hence, the increased 1,5AG 
concentration we observed may reflect a continuous reduction in postprandial 
hyperglycemic spikes over the 12-week supplementation period. The increase in the 1,5AG 
concentration returned to baseline levels after the 4-week withdrawal of ME 
supplementation. On the other hand, no significant differences in FPG, HbA1c, or GA 
concentrations were observed between the groups. While the 1,5AG concentration 
 
Development of Mulberry Leaf Extract for Suppressing Postprandial Blood Glucose Elevation 
 
33 
responded to glycemic fluctuations within a few days, the HbA1c and GA concentrations 
reflected time-averaged glycemia in the previous 2–3 months and 2–3 weeks, respectively. 
In contrast to this result, meta-analysis of GI drug trials in patients with type 2 diabetes 
showed that FPG and HbA1c concentrations were reduced by acarbose and miglitol (Van 
Der Laar et al., 2005). Because the subjects in these trials had diabetes, their baseline HbA1c 
and FPG concentrations were considerably higher than those of subjects in the present trial. 
Moreover, these earlier trials were conducted for considerably longer durations. 
Gastrointestinal symptoms such as abdominal distension, diarrhea, and flatulence are the 
most frequent adverse effects of GI agents. No such adverse effects were observed through 
the study period (Asai et al., 2011). 
4. Conclusion 
Increasing evidence strongly supports the efficiency of interventions such as diet and 
exercise for preventing or delaying the onset of diabetes in prediabetic individuals. 
Pharmacological approaches are another effective strategy for achieving these objectives.  
Mulberry leaves have been used in folk medicine for treating diabetes since ancient times. 
Three decades ago, DNJ, a potent GI, was found in mulberry leaves. Since this discovery, 
DNJ has been considered to be responsible for the antidiabetic effect of mulberry leaves. 
However, there is only limited information on the efficacy and effective dose of DNJ in 
humans. Recently, food-grade mulberry leaf extract with a defined DNJ concentration 
(1.5%) has been developed. Human studies involving ingestion of the extract prior to meals 
showed suppression of postprandial hyperglycemia and hyperinsulinemia. In addition, 
studies on long-term supplementation of the extract at reasonable doses showed an 
improvement in postprandial glycemic control. Hypoglycemia; abnormal lipid profiles; 
gastrointestinal system-related side effects such as abdominal distension, abdominal pain, 
retching, or flatulence; or any other adverse effects have also not been observed. Therefore, 
DNJ in mulberry leaves appears to be a promising therapy for preventing or delaying the 
onset of diabetes, especially in prediabetic or mildly diabetic individuals. 
As described above, we have gathered favorable evidence for the efficacy of ME. However, 
in terms of safety, there is insufficient evidence because of a lack of history of mulberry as a 
food for humans. Further safety evaluation on the absorption, distribution, metabolism, and 
excretion of mulberry DNJ is therefore required before the plant can be deployed as a 
functional food. 
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These are times when health awareness has become part of everyday life to an extent that 
may have never been true before. We see health related articles and advertisement 
numerous times every day on newspapers, TV programs, and of course the internet and all 
related forms of novel electronic media. We are told repeatedly what is best for us, what we 
should or should not do, why we have been wrong in the past and how we can improve in 
the future. Unfortunately, these messages often comes to us in a very confusing and 
inconsistent manner, making it very hard to filter out what is backed by sound, proven 
scientific principles, and what is just the “in” new trend that may fade away in a few weeks 
or months. Among the many messages that are more systematically thrown at us, however, 
is that we should definitely try to incorporate at least some form of exercise in our daily 
routine. This is nothing new in general, as going back in history, looking at most ancient 
civilizations, from the Chinese to the Romans or Greeks, they all seemed to value and 
implement forms of structured physical exercise. And in fact in our society, if one were to 
ask anybody, even people who are not health professionals, whether they think that exercise 
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them”. And common sense indicate that would be right. Now, if you were to ask why 
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effects are, but we still not know in detail why they occur.  
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the underlying mechanisms, a lot of positive health effects are associated with regular 
exercise, and are especially important for patients with T1DM (Berenson et al. 1998; Hannon 
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vascular-related diseases, protecting against both micro- and macro-vascular complications 
such as diabetic retinopathy, nephropathy, neuropathy, and cardio- and cerebro-vascular 
diseases (Anonymous 1993b; Anonymous 2002; Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study 
Research Group. 2005; Hambrecht et al. 2000; The Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Research Group 2000; 
White et al. 2001). Exercise also improves insulin sensitivity (Pedersen et al. 1980), helps to 
control body weight, and exerts positive intracellular molecular effects such as activation of 
the peroxisome proliferator-activated receptors (PPARs) target genes, coding for anti-
inflammatory cytokines and other novel protective candidate targets, and enhancing cellular 
metabolism and insulin sensing pathways (Nieman et al. 2005b; Smith & Muscat 2005; 
Teran-Garcia et al. 2005). In children, there is also the added issue of regulation of 
physiological growth and development. It is therefore in fact now very well established that 
during their schools years, children must perform multiple bouts of moderate to vigorous 
exercise every day, in order to achieve proper development of their musculoskeletal and 
cardiovascular systems, as well as an appropriate psychomotor and behavioral equilibrium. 
Different authors have suggested different amounts of minimum necessary duration of 
daily physical activity, but in general the recommendation of at least 60 minutes of exercise 
per day is considered appropriate, and supported by a recent revision of several hundred 
scientific articles published on the topic (Strong et al. 2005). 
As we stated above, despite this broad consensus on the vague concept that “exercise is 
good”, many of the detailed biochemical mechanisms by which exercise actually induces its 
health effects remain incompletely elucidated. This is due in part to the simple fact that the 
number of interwoven mechanisms that are trigger by exercise is enormous, and probably 
included several additional still un-identified components. Among the most typical 
responses to exercise are those aimed at maintaining constant circulating level of glucose, 
and at making sure that sufficient amounts of energy substrates, such as glucose and lipids, 
are made available to the exercising muscle, whose metabolic need may have increased by 
several fold. These responses are collectively defined as counterregulatory responses, and 
include secretion of hormones such as catecholamines, cortisol, glucagon, growth hormone 
(GH), with stimulation of both hepatic glycogenolysis and gluconeogenesis, as well as 
lipolysis. In addition to its glucoregulatory effects, GH is also part of the GH insulin-like 
growth factor I (GHIGF-I) axis (Nemet et al. 2002), which modulates growth and 
development, and ins therefore especially relevant for subjects of pediatric age. Another 
series of adaptive response to exercise includes the production of reactive oxygen species, 
(ROS), the causing agents of oxidative stress, that can be acutely increased by strenuous 
exercise, as well as mitigated by appropriate antioxidant mechanisms (Nikolaidis et al. 2007; 
Urso & Clarkson 2003). Also, exercise can exert a strong effect on immunologic and 
inflammatory status, by inducing substantial changes in circulating concentrations of 
leukocytes (WBC), as well as their level of secretion of cytokines, chemokines, colony-
stimulating factors, adhesion molecules and other inflammatory markers (Cryer 1993; 
Galassetti et al. 2006a). Inflammatory and oxidative stress pathways, as well as other critical 
homeostatic pathways, are also stimulated  by exercise at the level of gene expression; in fact 
hundreds of genes in all subtypes of WBCs (Nemet et al. 2004), skeletal muscle (Nieman et al. 
2005a) and other tissues undergo either up-or down-regulation, as well as post-translational 
epigenetic regulation especially during physical exertions of considerable intensity (Cooper 
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et al. 2004). This chapter is focused on hypoglycemia and exercise, and therefore, among the 
many adaptive response listed above, counterregulatory functions are the most relevant. 
However, this broader context of multiple, simultaneous and coordinated adaptive response 
to exercise had been presented to make the point that hypoglycemic counterregulation does 
not occur as an isolated set of events, but together with the stimulation or suppression of 
numerous other systems with which it interacts and by which it can be regulated. Along this 
line of thought, it is important to remember that in diabetes management, one must 
constantly evaluate the reciprocal balance of all components of glycemic responses;  as 
specifically related to exercise, it is necessary to determine if all physiological exercise 
response are preserved, and if alterations are present, whether these are permanent or 
reversible, and what factors may have affected them (Cooper et al. 2007).  It is in fact now 
amply established that many components the comprehensive exercise response to exercise 
may indeed become altered. Several glucoregulatory responses to exercise can become 
attenuated permanently (for instance when diabetic autonomic neuropathy develops, 
typically after years of poor glycemic control), or acutely and reversibly, which may occur 
even in well controlled patients, in whom diabetic tissue complications have not yet 
developed.  
In this chapter we will therefore review in detail the key known physiologic molecular 
mechanisms that during exercise maintain glucose homeostasis, and how their potential 
alterations in T1DM may result in increased incidence of hypoglycemia both during the 
performance of physical activity, in the first several hours after exercise cessation, and 
during the following night or even several days. 
2. Glucose homeostasis during exercise of varying intensity in type 1 diabtes  
The concentration of glucose in plasma is one of the most tightly controlled variables in 
overall human homeostasis. The range of values within which plasma glucose levels 
physiologically fluctuate is in fact very narrow, and any changes below or above this range 
are rapidly corrected by a series of extremely effective adaptive mechanisms. A number of 
sensors for glucose concentrations are in fact located at critical sites, both within the central 
nervous system (hypothalamus)(Biggers et al. 1989) and in peripheral tissues (walls of the 
portal vein to detect differences in arterial vs. venous blood, pancreatic islets to directly 
affect beta- and alpha cells’ output of insulin an glucagon, respectively, etc.)(Cherrington 
1994; Donovan et al. 1994; Hamilton-Wessler et al. 1994; Pagliassotti et al. 1991). As soon as 
changes in glucose levels are perceived, corrective actions are immediately undertaken. 
With increasing glucose concentration insulin is released and counterregulatory hormone 
secretion is suppressed. I glucose levels are dropping, hormones such as cortisol, glucagon, 
epinephrine, norepinephrine and growth hormone are released, rapidly activating 
glycogenolysis an gluconeogenesis in the liver and, to a lesser extent, in other tissues such as 
the kidney and some areas of the gut. Exercise imposes an additional layer of stress upon 
these mechanisms, by causing very rapid changes in the skeletal muscle requirement of 
energy substrates (both carbohydrates and lipids) paralleled by acute increases in insulin 
sensitivity.  
As in T1DM the very hallmark of the disease is an impairment of insulin availability, not 
surprisingly, in these patients major disruptions of this complex equilibrium are often 
present. The number of possible events that may occur during exercise in T1DM is actually 
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very broad, but fundamentally most glycemic alterations derive from the combination, in 
variable proportions, of two main homeostatic situations. First, T1DM patients are often 
unable to avoid hypoglycemia during exercise performance of in the hours following 
exercise cessation. This seems to happen more often if the exercise challenge was moderate 
in intensity but long in duration. Second, at the opposite end of the glycemic spectrum, 
when patients perfume very intense, albeit brief exercise formats, they can experience acute 
hyperglycemia, typically beginning during exercise and further increasing afterwards.  
A healthy person of average body size, in resting conditions and at least 2-3 hours after the 
last meal, (i.e. not actively absorbing carbohydrates), “burns” every minute about 2 mg of 
glucose per Kg of body weight. This is referred to as glucose rate of disposal, or glucose Rd, 
and is a measure of all the glucose that at any given time is taken up cumulatively by all 
cells in the body. In these conditions, the movement of glucose into human cells is mediated 
by baseline systemic insulin concentration ranging between ~ 5 and 10 �U/ml.   
If glucose were gradually take up from the bloodstream without replacement, glycemia 
would  progressively decreases over  time;  this is prevented, however, by endogenous 
glucose sources, which simultaneously release into the bloodstream an amount of glucose 
exactly matching the amount that is being taken up. This occurs via breakdown of existing 
glycogen stores (glycogenolysis) and de novo synthesis of glucose molecules 
(gluconeogenesis). Interestingly, while the body’s greatest glycogen stores are contained in 
the skeletal muscle, muscle glycogen cannot be used to sustain systemic glycemia, as muscle 
does not express glucose-6-phospahtae, an enzyme necessary to “free” glucose molecules 
before they are released into the bloodstream. Muscle glycogen can therefore only be used 
for energy production within the muscle cell. For exercise to be sustained for prolonged 
periods of time, it must be at a “sub-maximal” level, i.e. at a workload below the anaerobic 
(or lactate) threshold (normally occurring at 50-60% of individual maximal aerobic capacity). 
With this type of exercise, glucose Rd typically increases by two- or three- fold, due to the 
increased metabolic needs of contracting skeletal muscle. This increase in uptake, however, 
results in only minimal or no decrease in glycemia by the combined effects of two key 
mechanisms: a) a quick compensatory increase in endogenous glucose production, and b) a 
parallel decrease in the amount of insulin secreted by the pancreatic beta cells, which is 
induce by an acute increase in autonomic nervous system efferent stimulation of the 
pancreas through alpha-adrenergic fibers. This reduction in insulin levels is critical, because 
during exercise not only insulin sensitivity is markedly enhanced, resulting in increased 
glucose disposal for the same concentration of insulin, but the is also a simultaneous 
activation of non-insulin dependent glucose transport across the sarcolemmal membrane, 
mediated by the increase intracellular calcium release associated with exercise. As a result, if 
baseline insulin levels do not decrease, the amount of glucose transported into the skeletal 
muscle cells would actually be excessive, and glycemia in the bloodstream would drop.  
It is then evident how this situation can become problematic in T1DM subjects, who can’t 
any longer regulate endogenous insulin release. Preventing the onset of hypoglycemia  
during exercise then becomes a matter of how accurately patients can reproduce the 
physiological profile of insulin secretion. If they are using an insulin-infusion pump, they 
can try and decrease, or even completely stop insulin infusion (many prefer to do so even if 
this may result in mild hyperglycemia). Conversely, subjects who administer insulin via 
multiple insulin injections cannot reduce their baseline insulin level, and may find 
themselves in a state of relative hyperinsulinemia. In fact, sometimes even the opposite may 
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occur, i.e. they may experience an acute increase in insulin release. This may happen if the 
last insulin injection before exercise was performed close to a muscle mass likely to be 
mobilized during exercise, such as the side of the thigh; part of the injected fluid, in fact, 
may occasionally be trapped in a subcutaneous pocket, and be acutely released into the 
bloodstream when exercise in started, which is practically equivalent to a small additional 
insulin shot. The added amount of insulin will then not only cause an exaggerated uptake of 
glucose by the skeletal muscle, but will also suppress endogenous glucose production. 
These two effects combined markedly enhance the likelihood of the development of an 
acute hypoglycemic episode.  
Conversely, if the type of exercise is very intense, i.e. well above the anaerobic threshold and 
closer to individual maximal aerobic capacity, a series of drastically different adaptive event 
are likely to take place. This type of exercise can only be sustained for a much shorter time - 
rarely more than 20 to 30 min-, and induces a very strong whole-body  activation of 
adrenergic efferents. The main purpose of this response is to generate a sufficiently strong 
up-regulation of cardiovascular function to match the now extremely increased systemic 
metabolic needs. The increase in endogenous glucose production resulting from this level of 
adrenergic activation actually exceeds required by peripheral tissues, resulting in a state 
transient hyperglycemia of moderate magnitude (typically under 140 mg/dl), which 
spontaneously subsides shortly after exercise ends, in response to a prompt insulin response 
(in fact, in the immediate post-exercise state the combination of this insulin secretion with 
increased insulin sensitivity often induce brief, mild hypoglycemia). In T1DM the initial 
hypoglycemic response is similar, but at exercise cessation, as the diabetic cannot produce 
the expected insulin response, the magnitude of hyperglycemia often continues to increase, 
sometimes up to very elevated levels.  
Exercise in real life is almost never exclusively moderate and prolonged, or brief and 
intense, but most commonly a combination of the two in various proportions. The actual 
glycemic fluctuations that can be experience in the presence of any given specific exercise 
format, therefore, could fall anywhere across this broad range. In fact, moderate and intense 
exercise, performed within the same exercise session, could exert opposite hypo- and hyper-
glycemic effects that could, to some effect, cancel each other out.  Used in a controlled 
manner, this principle could conceptually result in optimal glycemic control without 
additional interventions, and its use has indeed be explored in a series of  controlled studies 
on a group of diabetic Australian youth (Bussau et al. 2007a).  
3. Altered counterregulatory mechanisms in t1dm 
Unfortunately even in T1DM patients who manage to administer themselves an ideal 
amount of exogenous insulin, and indeed reproduce as closely as possible the physiological 
profile of endogenous insulin secretion, a variable degree of counterregulatory impairment 
may still occur, although the underlying mechanisms to date are not understood in full 
(Tansey et al. 2006a). Evidence derived from several studies indicates that the exercise 
response of major counterregulatory hormones is in general decreased in T1DM when 
compared to healthy controls (Galassetti et al. 2006b; Tansey et al. 2006b; Wanke et al. 1996).  
The issue of counterregulation is very complex, and extends to a number of conditions other 
than exercise. Of these, the best studied is hypoglycemia itself. The possible blunting of 
counterregulatory response to exercise, in fact, is very similar to what occurs when 
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in intensity but long in duration. Second, at the opposite end of the glycemic spectrum, 
when patients perfume very intense, albeit brief exercise formats, they can experience acute 
hyperglycemia, typically beginning during exercise and further increasing afterwards.  
A healthy person of average body size, in resting conditions and at least 2-3 hours after the 
last meal, (i.e. not actively absorbing carbohydrates), “burns” every minute about 2 mg of 
glucose per Kg of body weight. This is referred to as glucose rate of disposal, or glucose Rd, 
and is a measure of all the glucose that at any given time is taken up cumulatively by all 
cells in the body. In these conditions, the movement of glucose into human cells is mediated 
by baseline systemic insulin concentration ranging between ~ 5 and 10 �U/ml.   
If glucose were gradually take up from the bloodstream without replacement, glycemia 
would  progressively decreases over  time;  this is prevented, however, by endogenous 
glucose sources, which simultaneously release into the bloodstream an amount of glucose 
exactly matching the amount that is being taken up. This occurs via breakdown of existing 
glycogen stores (glycogenolysis) and de novo synthesis of glucose molecules 
(gluconeogenesis). Interestingly, while the body’s greatest glycogen stores are contained in 
the skeletal muscle, muscle glycogen cannot be used to sustain systemic glycemia, as muscle 
does not express glucose-6-phospahtae, an enzyme necessary to “free” glucose molecules 
before they are released into the bloodstream. Muscle glycogen can therefore only be used 
for energy production within the muscle cell. For exercise to be sustained for prolonged 
periods of time, it must be at a “sub-maximal” level, i.e. at a workload below the anaerobic 
(or lactate) threshold (normally occurring at 50-60% of individual maximal aerobic capacity). 
With this type of exercise, glucose Rd typically increases by two- or three- fold, due to the 
increased metabolic needs of contracting skeletal muscle. This increase in uptake, however, 
results in only minimal or no decrease in glycemia by the combined effects of two key 
mechanisms: a) a quick compensatory increase in endogenous glucose production, and b) a 
parallel decrease in the amount of insulin secreted by the pancreatic beta cells, which is 
induce by an acute increase in autonomic nervous system efferent stimulation of the 
pancreas through alpha-adrenergic fibers. This reduction in insulin levels is critical, because 
during exercise not only insulin sensitivity is markedly enhanced, resulting in increased 
glucose disposal for the same concentration of insulin, but the is also a simultaneous 
activation of non-insulin dependent glucose transport across the sarcolemmal membrane, 
mediated by the increase intracellular calcium release associated with exercise. As a result, if 
baseline insulin levels do not decrease, the amount of glucose transported into the skeletal 
muscle cells would actually be excessive, and glycemia in the bloodstream would drop.  
It is then evident how this situation can become problematic in T1DM subjects, who can’t 
any longer regulate endogenous insulin release. Preventing the onset of hypoglycemia  
during exercise then becomes a matter of how accurately patients can reproduce the 
physiological profile of insulin secretion. If they are using an insulin-infusion pump, they 
can try and decrease, or even completely stop insulin infusion (many prefer to do so even if 
this may result in mild hyperglycemia). Conversely, subjects who administer insulin via 
multiple insulin injections cannot reduce their baseline insulin level, and may find 
themselves in a state of relative hyperinsulinemia. In fact, sometimes even the opposite may 
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occur, i.e. they may experience an acute increase in insulin release. This may happen if the 
last insulin injection before exercise was performed close to a muscle mass likely to be 
mobilized during exercise, such as the side of the thigh; part of the injected fluid, in fact, 
may occasionally be trapped in a subcutaneous pocket, and be acutely released into the 
bloodstream when exercise in started, which is practically equivalent to a small additional 
insulin shot. The added amount of insulin will then not only cause an exaggerated uptake of 
glucose by the skeletal muscle, but will also suppress endogenous glucose production. 
These two effects combined markedly enhance the likelihood of the development of an 
acute hypoglycemic episode.  
Conversely, if the type of exercise is very intense, i.e. well above the anaerobic threshold and 
closer to individual maximal aerobic capacity, a series of drastically different adaptive event 
are likely to take place. This type of exercise can only be sustained for a much shorter time - 
rarely more than 20 to 30 min-, and induces a very strong whole-body  activation of 
adrenergic efferents. The main purpose of this response is to generate a sufficiently strong 
up-regulation of cardiovascular function to match the now extremely increased systemic 
metabolic needs. The increase in endogenous glucose production resulting from this level of 
adrenergic activation actually exceeds required by peripheral tissues, resulting in a state 
transient hyperglycemia of moderate magnitude (typically under 140 mg/dl), which 
spontaneously subsides shortly after exercise ends, in response to a prompt insulin response 
(in fact, in the immediate post-exercise state the combination of this insulin secretion with 
increased insulin sensitivity often induce brief, mild hypoglycemia). In T1DM the initial 
hypoglycemic response is similar, but at exercise cessation, as the diabetic cannot produce 
the expected insulin response, the magnitude of hyperglycemia often continues to increase, 
sometimes up to very elevated levels.  
Exercise in real life is almost never exclusively moderate and prolonged, or brief and 
intense, but most commonly a combination of the two in various proportions. The actual 
glycemic fluctuations that can be experience in the presence of any given specific exercise 
format, therefore, could fall anywhere across this broad range. In fact, moderate and intense 
exercise, performed within the same exercise session, could exert opposite hypo- and hyper-
glycemic effects that could, to some effect, cancel each other out.  Used in a controlled 
manner, this principle could conceptually result in optimal glycemic control without 
additional interventions, and its use has indeed be explored in a series of  controlled studies 
on a group of diabetic Australian youth (Bussau et al. 2007a).  
3. Altered counterregulatory mechanisms in t1dm 
Unfortunately even in T1DM patients who manage to administer themselves an ideal 
amount of exogenous insulin, and indeed reproduce as closely as possible the physiological 
profile of endogenous insulin secretion, a variable degree of counterregulatory impairment 
may still occur, although the underlying mechanisms to date are not understood in full 
(Tansey et al. 2006a). Evidence derived from several studies indicates that the exercise 
response of major counterregulatory hormones is in general decreased in T1DM when 
compared to healthy controls (Galassetti et al. 2006b; Tansey et al. 2006b; Wanke et al. 1996).  
The issue of counterregulation is very complex, and extends to a number of conditions other 
than exercise. Of these, the best studied is hypoglycemia itself. The possible blunting of 
counterregulatory response to exercise, in fact, is very similar to what occurs when 
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counterregulatory responses to hypoglycemia (occurring independent of exercise) become 
impaired (Bjorgaas et al. 1997; Hoffman et al. 1991), (the response to hypoglycemia also 
include associated neurogenic symptoms-hunger, sense of anxiety, sweating, palpitations) 
caused by the sympathoadrenal effects of epinephrine (Hoffman et al. 1991).  
This parallelism between altered adaptation to exercise and hypoglycemia is important, as 
most involved hormones and autonomic pathways are shared by the two conditions. A 
notable exception, however, is glucagon. Patients with T1DM, in fact, within the first two 
years after having been diagnosed with the disease, become completely unable to secrete 
glucagon during a hypoglycemic episode (this was demonstrated by Dr. Gerich and co-
authors in a classic study appeared in the journal Science in 1973, (Gerich et al. 1973) and 
confirmed in numerous subsequent studies in both adult and pediatric patients, in which 
hypoglycemia of varying depth, duration and onset kinetics was induced,  always with 
glucagon concentrations remaining unchanged as compared to baseline values (Ross et al. 
2005). Interestingly, it appears that pancreatic α-cells in these patients are not unable to 
secrete glucagon (in fact basal levels are normal), but rather are incapable of increasing 
glucagon secretion when hypoglycemia is induced artificially via elevated levels of 
exogenous insulin, which is by far the most common way in which hypoglycemia occurs in 
T1DM. In animal models of T1DM, however, it was observed that if hypoglycemia was 
induced by other means, (i.e. via administration of agents such as AICAR and phlorizin, 
(Banarer et al. 2002; McCrimmon et al. 2002),  the glucagon response was restored. Similarly, 
and pertinent to the focus of this chapter, the �-cells of patients with T1DM retain the full 
ability to secrete glucagon in response to other stimuli, including physical exercise (Marliss 
& Vranic 2002). 
Before we further advance in our discussion of altered adaptive mechanisms to exercise, we 
should now clearly delineate the distinction between those alterations in counterregulatory 
responses to exercise in diabetes that are permanent (irreversible) and those that are 
transient (reversible). This is not just and academic distinction, but has a series of obvious 
practical implications that affect the way a patient may approach exercise. Permanently lost 
responses, in fact will require alternative ways to substitute lost mechanisms; dealing with 
reversible alterations, on the other hand, will instead imply focusing on prevention of the 
causes inducing the temporary impairment.  
The two counterregulatory hormones that are commonly defined as the “first line” 
intervention against hypoglycemia are epinephrine and glucagon; quantitatively, they 
account for large majority of counterregulatory function during the first hour or so 
hypoglycemia or exercise have started. In T1DM, with long lasting, poorly controlled 
diabetes, the characteristic tissue complications of the disease start appearing, including 
diabetic neuropathy. As part of this condition, the catecholamine response to stress is 
gradually attenuated until, in the most advanced stages of the disease, may become 
completely suppressed (Cryer et al. 2003) (it should be noted that these complications are not 
a mandatory part of being diabetic, but can be virtually completely prevented with 
continuous optimal glycemic control) (Karavanaki & Baum 2003).  
If autonomic neuropathy becomes established, however, it is typically irreversible. This 
means that among other related alterations, the epinephrine response to stress is lost;  this 
essentially leaves the burden of counterregulation at the beginning of a stress event to 
glucagon alone. If the stress is a hypoglycemic episode, however, as stated above the 
glucagon response is lost, and very little resistance is offered against the rapid onset of 
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hypoglycemic episode. May of these patients in fact suffer form repeated severe 
hypoglycemia, often leading to serious accidents if occurring during driving or the 
operation of heavy machinery, with sometimes catastrophic consequences. If the stress is 
exercise, on the other hand, the glucagon response is still preserved, producing at least some 
of the expected counterregulation. This, at least, provided that one of the mechanisms 
inducing temporary blunting of counterregulatory response is not also present.    
Independent of the presence of autonomic dysfunction, in fact, all major counterregulatory 
responses to stress may undergo a variable degree of reversible attenuation. In general, this 
occurs according to this general paradigm: a certain stimulus occurs, that is able to blunt the 
activity of the hypothalamus-pituitary-adrenal axis (that coordinates counterregulation), 
and for the following hours to days, if counterregulation is needed in response to an episode 




   Prior Blunting Stimulus     →       ↓ Responses to Subsequent Stress  
 
 
The best studied set of blunting stimulus/subsequent stress if repeated hypoglycemia, in 
which indeed hypoglycemia acts as both prior stimulus and subsequent stress. Therefore in 
this case the above paradigm can be re-written as: 
 
 
   Prior Hypoglycemia     →      ↓ Responses to Subsequent Hypoglycemia 
 
 
The scenario is unfortunately very common in T1DM, in which, even after a long period of 
optimal glycemic control, a hypoglycemic episode may be triggered by excessive insulin 
administration, insufficient carbohydrate ingestion, acute increase in insulin sensitivity, etc.  
Once this first episode occurs (during which counterregulatory responses may be normal)       
For a number of hours to days the subject will be more susceptible to developing an additional 
hypoglycemic episode. This condition is now describe as Hypoglycemia-Associated 
Autonomic Failure (HAAF), and often results in more and more episodes of hypoglycemia, in 
which each episode acts as the blunting stimulus for the next, de facto starting a vicious cycle 
out of which it is very difficult for the patients to break. Paradoxically, this happens most 
commonly in those patients who put the greatest effort into tightly controlling their glycemia. 
By testing glycemia many times a day, and aggressively adjusting their insulin administration 
regimen in order to prevent any possible hyperglycemic episode, they in fact often 
inadvertently expose themselves repeatedly to situations of relative hyperinsulinemia, 
favoring the onset of hypoglycemia of variable depth and duration. It is unfortunately well 
documented that in these patients the incidence of hypoglycemic episodes is markedly higher 
that in patients with worse glycemic control(Amiel et al. 1987; Simonson et al. 1985). Now, as 
stated above, both hypoglycemia and exercise elicit similar responses; a logical development of 
this axiom should therefore be that these two situations could also reciprocally act as blunting 
stimuli. For instance, if an episode of hypoglycemia preceded an exercise challenge, the above 
paradigm could be hypothetically become: 
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secrete glucagon (in fact basal levels are normal), but rather are incapable of increasing 
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T1DM. In animal models of T1DM, however, it was observed that if hypoglycemia was 
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and pertinent to the focus of this chapter, the �-cells of patients with T1DM retain the full 
ability to secrete glucagon in response to other stimuli, including physical exercise (Marliss 
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transient (reversible). This is not just and academic distinction, but has a series of obvious 
practical implications that affect the way a patient may approach exercise. Permanently lost 
responses, in fact will require alternative ways to substitute lost mechanisms; dealing with 
reversible alterations, on the other hand, will instead imply focusing on prevention of the 
causes inducing the temporary impairment.  
The two counterregulatory hormones that are commonly defined as the “first line” 
intervention against hypoglycemia are epinephrine and glucagon; quantitatively, they 
account for large majority of counterregulatory function during the first hour or so 
hypoglycemia or exercise have started. In T1DM, with long lasting, poorly controlled 
diabetes, the characteristic tissue complications of the disease start appearing, including 
diabetic neuropathy. As part of this condition, the catecholamine response to stress is 
gradually attenuated until, in the most advanced stages of the disease, may become 
completely suppressed (Cryer et al. 2003) (it should be noted that these complications are not 
a mandatory part of being diabetic, but can be virtually completely prevented with 
continuous optimal glycemic control) (Karavanaki & Baum 2003).  
If autonomic neuropathy becomes established, however, it is typically irreversible. This 
means that among other related alterations, the epinephrine response to stress is lost;  this 
essentially leaves the burden of counterregulation at the beginning of a stress event to 
glucagon alone. If the stress is a hypoglycemic episode, however, as stated above the 
glucagon response is lost, and very little resistance is offered against the rapid onset of 
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hypoglycemic episode. May of these patients in fact suffer form repeated severe 
hypoglycemia, often leading to serious accidents if occurring during driving or the 
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inducing temporary blunting of counterregulatory response is not also present.    
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and for the following hours to days, if counterregulation is needed in response to an episode 
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      Prior Hypoglycemia      →       ↓ Responses to Subsequent Exercise 
 
 
As it turns out, this was directly demonstrated in a recent study on sixteen young adults 
with T1DM (eight males and eight females) (Galassetti et al. 2003). These subjects 
participated in an experimental protocol that included biking on a stationary cycle for one 
hour and a half. If this exercise challenge was performed after several days of very tight 
glycemic control, i.e. with no episodes of hypoglycemia occurring, all response to exercise 
(including the expected increase in glucagon and epinephrine, cortisol, GH, endogenous 
glucose production and mobilization of free fatty acids), were the same as measured in age-
matched, healthy control subjects. If, however, prolonged hypoglycemia was artificially 
induced on the day before the exercise challenge (four hours of glycemia at ~ 50 mg/dl, 
divided in two 2-hour blocks, morning and afternoon), the glucagon response to exercise 
was abolished, the epinephrine response was reduced by 50%, and other counterregulatory 
hormones, as well as tracer-determined endogenous glucose production and lipolysis, were 
all significantly reduced by 40-60%. Interestingly, while healthy subjects, unlike T1DM, 
\don’t ever experience hypoglycemia of this depth in normal life, when exposed to the same 
experimental protocol they displayed an identical pattern of blunted exercise responses 
(Davis et al. 2000b). An important notion to keep in mind is also that this blunting effect is 
not an all-or-nothing phenomenon, but occurs in a dose-dependent fashion with respect to 
the depth of the antecedent hypoglycemic episode. This was well exemplified in a separate 
set of experiments, similar to those described above, in which again a group of patients with 
T1DM performed a standard 90 min cycling exercise after having been exposed to 
hypoglycemia for four hours on the previous day. This time, however, each subjects 
performed the study several times, with several weeks between study visits, and each time 
was exposed to hypoglycemia of different depth (50 mg/dl, 60 mg/dl, 7- mg/dl or no 
hypoglycemia). Not surprisingly, the deeper the antecedent hypoglycemia, the more 
blunted were the responses to subsequent exercise. Considering the glucagon response,  for 
instance, the milder prior hypoglycemia (70 mg/dl) induced a suppression of ~ 35%, prior 
hypoglycemia of 60 mg/dl a suppression of ~ 60%, and prior hypoglycemia of 50 mg/dL an 
almost complete suppression of > 95% (Galassetti et al. 2001a).  A progressively smaller 
blunting effect on subsequent exercise responses, in addition to a smaller prior stimulus, can 
be observed as time passes after t he blunting has occurred. In the studies, reported above, 
prior hypoglycemia occurred ~18-20 before the exercise challenge during which blunted 
responses were measured. To date no definitive data have been published reporting the 
exact duration of this blunting effects; however, general consensus exists that within a few 
days to a week following the antecedent stimulus, provided that no additional blunting 
stimuli occur, the full ability to mount physiological counterregulatory responses is re-
gained. Preventing these recurrent blunting stimuli, however, is no minor challenge in 
every-day diabetes management. Recurrent, often profound episodes of hypoglycemia are 
unfortunately very common, and this paradoxically seems to occur even more often in 
subjects who are very aggressive in their attempts to obtain close to perfect glycemic control 
(Anonymous 1993a). A final piece of the puzzled is generated by the fact that exercise itself 
may act as an antecedent blunting stimulus. Going back to our initial paradigm, we can then 
derive two more combinations:  
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    Prior Exercise           →         ↓ Responses to Subsequent Exercise 
 
Both these possibilities have been documented to actually occur. An exercise bout 
performed in the morning, for instance, was shown to reduces a wide range of adaptive 
response to a second bout of exercise performed in the afternoon of the same day (while 
counterregulatory responses were attenuated, in this study hypoglycemia was not actually 
allowed to occur, to prevent its confounding effect on data interpretation) (Galassetti et al. 
2001a). Further, in at least one study prior exercise of different intensity was shown to 
reduce next-day responses to hypoglycemia, again in a dose dependent manner (Sandoval et 
al. 2004). While a somewhat similar protocol form a different laboratory failed to reproduced 
the same effect (McGregor et al. 2001), possibly due to differences in the intensity of the 
exercise format used during experiments, an increased incidence of hypoglycemia in the 
hours following exercise is commonly reported by T1DM patients. This is especially true if 
exercise was of long duration and/or high intensity, after which insulin sensitivity is 
markedly increased and redistribution of circulating carbohydrate is shifted toward 
preferential replenishment muscle glycogen stores, that become depleted during the 
exercise activity (Borghouts & Keizer 2000).  
Further, counterregulatory responses to hypoglycemia, even in standard physiological 
conditions, become attenuated  during sleep (Jones et al. 1998);  therefore, not surprisingly, a 
second peak of incidence of hypoglycemia has been described occurs during the nights that 
follow intense physical activity (Anonymous 2007; Kaufman et al. 2002; Tsalikian et al. 2005a), 
with the highest incidence occurring between midnight and 4 am. (McMahon et al. 2007).  
A separate of issues to be taken into consideration is that male and female patients may 
responds differently to the same blunting stimulus. Gender differences, often very 
pronounced, are very common in many aspects of human physiology, and the coordinated 
adaptive response to stress is no exception(Diamond et al. 1993). In particular, the hormonal 
response to stresses activating the hypothalamo-pituitary-adrenal axis are in general much 
more pronounced in males than in females. This is true for hypoglycemia as well as exercise 
which, as we stated in detail above, share many of their adaptive responses. This concept 
was recently confirmed in group of young healthy adults of both genders, who performed 
90 minutes of submaximal cycling exercise. In this group, all hormonal and metabolic 
responses to the exercise challenge were significantly lower, after normalization for 
individual exercise intensity, in women as compared to men (Davis et al. 2000a). When a 
blunting stimulus occurs prior to exercise or hypoglycemia, the extent of the blunting on 
counterregulatory responses is much greater in men (who had a greater response to begin 
with, and in whom some of the counterregulatory hormones can be suppressed by 80-95%), 
while in women a much milder, 20-40% blunting occurs (Galassetti et al. 2001b). Therefore, 
in a blunted state responses in males and females become much more similar. In T1DM, the 
same pattern is preserved, with men displaying greater responses to exercise than women in 
conditions of standard glycemic control, and again greater blunting of responses after 
appropriate stimulus in male patients(Galassetti et al. 2004).   
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while in women a much milder, 20-40% blunting occurs (Galassetti et al. 2001b). Therefore, 
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Fig. 1. Schematic representation of counterregulatory events occurring during exercise in 
healthy subjects and in patients with type 1 diabetes. Counterregulatory responses, 
including increased secretion of glucagon, epinephrine, norepinephrine, cortisol and growth 
hormone, display a typical amplitude, exemplified on the left hand-side panel by a 100% 
response (this general concept can in fact be extrapolated to a number of additional 
responses not directly related to glucose homeostasis, such as production of the appropriate 
balance of pro- and anti-inflammatory mediators, or of growth factors; the physiological, 
full manifestation f the possible, expected health of exercise only occurs when these 
responses are 100% activated). In the right hand-side panel, conversely, is exemplified the 
presence of multiple, simultaneous failures of sever involved counterregulatory hormones. 
Depending of the degree of suppression of these responses, a variable impairment will also 
occur in endogenous glucose production, which these hormones regulate, and therefore 
glucose availability will become acutely inadequate to match the increase metabolic needs of 
the exercising muscle, resulting in the likely onset of a hypoglycemic episode. 
Translated in practical terms, this complex interaction between exercise and hypoglycemia 
means that the more frequent the hypoglycemia, the more likely that subsequent slight 
hyperinsulinemia (or bouts of exercise) will result in additional hypoglycemia, and so on 
(Tsalikian et al. 2005b). Due to the variety and instability of these several factors, exercise-
associated hypoglycemia is often difficult to manage clinically. One of the most basic 
approaches is trying to optimize circulating insulin. Patients on an insulin pump can reduce 
the basal infusion rate, in the attempt to reproduce the physiological 40-50% insulin drop 
occurring in non-diabetic subjects (many T1DM subjects in fact are even more aggressive 
than that, and completely stop insulin infusion. Absolute recommendation as to the 
magnitude and duration of insulin reduction/suspension are impossible to generate, as 
every subjects will react differently, and within the same subject, different strategies will 
have to be implemented for exercise of different duration and intensity. Further, none of the 
currently available sets of practical guidelines incorporates the effects of prior stimuli 
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described above. Therefore, often, even in the same subjects exercising in seemingly identical 
conditions in two different days, in one occasion glycemic control may be perfect, and in the 
next hypoglycemia may occur. A combination of insulin reduction and ingestion of 
carbohydrate snacks may be the best overall approach, but again the exact type and amount of 
ingested carbohydrate, as well as the fractioning and timing of the ingestion, is the objects of 
considerable controversy, and personal, careful experience seems to still yield the best results. 
Carbohydrate ingestion is the only tool available for patients utilizing multiple insulin 
injection, who derive their basal insulin rate from long-acting insulin preparation, and for 
whom therefore rapid reduction in insulin concentrations during exercise is not possible. 
Finally, as briefly mentioned above, a new approach has been proposed recently by members 
of the research group lead by Dr TW Jones, who have attempted to use the intrinsic 
characteristics of exercise itself to counterbalance its hypoglycemic effects. The principle is 
simple: to utilize the hyperglycemic effect of brief, intense exercise, to offset the opposite effect 
of prolonged, moderate exercise.  In two studies performed in well controlled T1DM subjects, 
these authors have introduced a very brief (only 10 seconds) all-out sprint either before or at 
the end of a prolonged, moderate exercise session. When the sprint was performed before the 
training session, it decrease the magnitude of glycemic decline only for the first 45 min after 
exercise; when it was performed at the end, it reduced glycemic decline for several hours after 
exercise (Bussau et al. 2007b; Guelfi et al. 2007). The beauty of this approach, if its broader 
applicability to diabetes management will be confirmed by larger follow-up studies, is that it 
utilizes only physiological tools, it takes very little time and is easily implemetable any time 
exercise is performed. More in-depth description of hypoglycemic prevention techniques, in 
relation to physical exercise, can be found in several excellent recent publications, such as the 
Clinical Practice Consensus Guidelines of the International Society for Pediatric and 
Adolescent Diabetes (Robertson K et al. 2009).  
4. Conclusion 
Recent research advances, summarizing the efforts of a large number of laboratories across 
the globe, demonstrate the high (sometimes incomprehensibly so) complexity of the many 
interwoven molecular mechanisms that translate exercise into a long-term positive health 
status. Most likely, our still incomplete understanding of these many mechanisms derives 
from the fact that they are often activated simultaneously, can partially replace each other in 
function, and can markedly influence the reciprocal effects. Complex as they may be, some 
of them have been relatively well elucidated in physiological conditions. Specific alterations 
in some of these mechanisms, however, appear to be present in subjects with T1DM, 
potentially reducing the overall benefits of exercise. Among these, alterations in the 
mechanisms regulating the glycemic homeostasis are especially important, as this alteration 
may result in exercise-associated hypoglycemia, one of the acute complications of diabetes 
that patients fear the most. Exercise-associated hypoglycemia may be caused by permanent 
counterregulatory impairment, as can be seen for instance in the failure to secrete 
catecholamines when diabetic autonomic neuropathy has become established. More 
commonly, however, it is observed as the result of acute and reversible blunting of adaptive 
responses, caused by the occurrence of some prior events, such as prior hypoglycemia, 
intense exercise or even intense emotional stress. The latter category of events is therefore 
preventable with the avoidance of these prior stimuli, rendering the control of 
hypoglycemia, or the identification of the most appropriate exercise formats, a priority in 
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every-day diabetes management. The issue of optimization of exercise regimens is indeed 
not a simple one, as many different formats (with varying type of activity, duration, intensity 
and repetition patterns) may not be similarly applicable to all subjects. Finally, it is absolutely 
necessary to gain a definitive, thorough understanding of all molecular complexities 
underlying exercise adaptations; in no other way will we be able to conclusively provide the 
conceptual foundation on which evidence-based exercise guidelines can be systemically 
developed. As a very final thought, I would like to address here a question that is very often 
asked after I give a talk on some of the topics discussed above. Considering that the multiple 
possible alterations in the exercise response that are observed in patients with T1DM, and their 
implications regarding the overall health effects of exercise in general and on increased 
incidence of hypoglycemia in particular, I am in fact often asked something along the lines of: 
“Should then T1DM patients avoid exercise?”. I would like to make absolutely clear that the 
answer is no, they should not avoid exercise. In fact, with all the limitations related to their 
altered metabolism, they should still try to exercise as much as possible. The possibility that in 
several situations the potential health effects of exercise may be somewhat reduced, does not 
take away from the fact that some beneficial effects are still there, and these normally by far 
outweigh the decision of not exercising. It is up to us, who work in this field, to keep 
elucidating all possible ways in which the discrepancy between possible and actually achieved 
beneficial effects of exercise in these patients can be gradually narrowed and hopefully, in the 
not too distant future, completely eliminated.  
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1. Introduction 
Glucose is the predominant  source of energy  for the fetal and neonatal brain. During the 
process of  adaptation from a continuous supply of glucose in-utero to an intermittent supply 
after birth, the neonate is prone to periods  of low blood glucose. Transient mild decreases in 
blood glucose levels are a common  feature of perinatal adaptation. This period is 
characterized by  an up-regulation of hormonal and metabolic pathways of  gluconeogenesis, 
hepatic glycogenolysis and ketogenesis. However, in some neonates, these may be delayed 
and hypoglycemia may get prolonged or severe. Persistent, recurrent or severe hypoglycemia 
may cause irreversible injury to the developing brain. Hence, the  neonatologist needs to  be 
proactive in suspecting, diagnosing and  treating hypoglycemia in the newborn.  
The normal range of blood glucose is different for each newborn and depends upon birth-
weight, gestational age, body stores, feeding status, availability of energy sources as well as 
the presence or absence of disease. Population based meta-analyses have revealed that the 
blood glucose levels rise with increasing post natal age. Although, there are controversies 
surrounding the definition, a blood glucose <40 mg/dL is considered as the operational 
threshold to treat hypoglycemia in  all neonates in first few days of life,  irrespective of 
gestation. Hypoglycemia  is the most common metabolic disorder in the neonatal intensive 
care unit. The reported  incidence of hypoglycemia varies with the definition, population, 
glucose measurement technique and feeding schedule. Preterm infants and those with 
intrauterine growth retardation are at a high risk of developing hypoglycemia in the first 
week of life because of lack of sufficient glycogen and fat stores, which are normally 
accumulated in the third trimester.  In some preterm infants, developmental delays in the 
postnatal up-regulation of enzymes of glucose homeostasis may persist even at the time of 
discharge from hospital. Large for gestational age infants and infants of diabetic mothers are 
the other important high risk groups because of relative hyperinsulinemia. A proportion of 
small for gestational age infants also have high insulin levels which contribute to 
hypoglycemia and can persist for few weeks  to months. Recently, late preterm (340/7 to 
366/7weeks) infants have been identified as another important group prone to 
hypoglycemia. In addition, any sick newborn warrants screening for low blood glucose. 
Term healthy infants without any risk factors need not be monitored routinely. All 
asymptomatic, at-risk neonates should be screened at two hours after birth and surveillance 
should be continued 4-6 hourly thereafter, until feedings are well established and glucose 
values have normalized; which may take 48-72 hours. Monitoring before 2 hours may be 
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postnatal up-regulation of enzymes of glucose homeostasis may persist even at the time of 
discharge from hospital. Large for gestational age infants and infants of diabetic mothers are 
the other important high risk groups because of relative hyperinsulinemia. A proportion of 
small for gestational age infants also have high insulin levels which contribute to 
hypoglycemia and can persist for few weeks  to months. Recently, late preterm (340/7 to 
366/7weeks) infants have been identified as another important group prone to 
hypoglycemia. In addition, any sick newborn warrants screening for low blood glucose. 
Term healthy infants without any risk factors need not be monitored routinely. All 
asymptomatic, at-risk neonates should be screened at two hours after birth and surveillance 
should be continued 4-6 hourly thereafter, until feedings are well established and glucose 
values have normalized; which may take 48-72 hours. Monitoring before 2 hours may be 
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required if mother has been starving or vomiting. The maximum risk for hypoglycemia is in 
first 24 hours  but usually persists till 72 hours.  
The prevention of hypoglycemic brain injury requires early detection in infants considered 
'at risk' and appropriate timely intervention. Detection and treatment of hypoglycemia 
requires accurate, rapid  and reliable measurement of blood glucose. This is usually done on 
the bedside by glucose reagent strips. If the values are low, a blood sample is sent to the 
laboratory for confirmation by glucose oxidase or glucose electrode method. The treatment 
should be given on the basis of screening test and not await laboratory results. Most of the 
point-of-care strip based glucometers are however unsuitable for neonates because they 
were primarily developed to measure higher blood glucose levels in diabetic patients. Their 
accuracy in low blood glucose ranges is not good. Current blood gas machines incorporate a 
glucose sensor which is more accurate  but may require a larger blood volume. Treatment of 
hypoglycemia should be based upon 'operational thresholds' and clinical assessment. 
Symptomatic  hypoglycemia with  neurological signs requires more urgent treatment by 
intravenous route, as compared to  the 'asymptomatic' baby, irrespective of blood  glucose 
value. Supervised and measured volume milk feeding may be an initial treatment option for 
asymptomatic hypoglycemia in healthy infants. However, symptomatic hypoglycemia 
should always be treated with a continuous infusion of parenteral dextrose. Intravenous  
dextrose infusion should be started in babies with asymptomatic hypoglycemia if  the blood 
glucose is <25 mg/dL, blood glucose remains below 40 mg/dL despite one attempt of 
feeding milk, enteral feeding is contraindicated or if the baby becomes symptomatic. If there 
is no contraindication to feeding, oral feeds of breast or formula milk should be continued 
along with and their proportion increased as the intravenous infusion is tapered. Oral 
feeding ensures a more stable glycemic control.  
Symptomatic hypoglycemia, especially if manifesting as seizures, is associated with 
abnormal neurodevelopmental outcomes  in 50% of infants. Moderate asymptomatic 
hypoglycemia persisting for 3 to 5 days is also associated with 30% to 40%  incidence of 
neurodevelopmental sequelae. Neuroimaging in infants with severe hypoglycemia shows  
involvement of the occipital lobes in 82%. Occipital brain injury can cause visual 
impairment, epilepsy and  long-term disability. Cortical visual deficits are seen in a 
significant proportion of infants with recurrent hypoglycemia and correlate significantly 
with low mesial occipital apparent diffusion coefficient values on diffusion weighted MRI. 
All infants  with hypoglycemia should be followed up for neurodevelopmental sequelae. 
Refractory or persistent hypoglycemia should be suspected and investigated if the glucose 
infusion requirement is >12 mg/kg/min or the hypoglycemia persists >5-7 days, 
respectively. Hyperinsulinemic hypoglycemia is the most important cause of severe and 
persistent hypoglycemia after initial few days. The  risk  for brain injury and subsequent 
neurodevelopment handicap is significantly greater with hyperinsulinemic hypoglycemia. 
Hyperinsulinemic hypoglycemia may persist for many  weeks to months  and then remit 
spontaneously, particularly in growth retarded and  stressed neonates. In such infants, the 
hypoglycemia  nearly always responds to medications like  diazoxide. Several forms of 
congenital hyperinsulinism also present with hypoglycemia in neonates that does not remit. 
Depending on the type of genetic mutation, hypoglycemia in these infants with congenital 
hyperinsulinism may be controlled medically or may require surgery. The extent of surgery 
required in infants with ATP-dependent potassium channel mutations unresponsive to 
diazoxide is dependent upon whether the histological subtype is focal or diffuse. Advances 
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in molecular genetics, positron emission tomography scanning and minimally invasive  
surgery have completely changed the clinical approach to these infants. 
Certain clinical practices can help prevent the occurrence of hypoglycemia. These include 
support and promotion of  early exclusive breastfeeds within first hour of life in all healthy 
newborns. Delayed initiation of breast feeds is an important risk factor for hypoglycemia. 
Maintenance of thermoneutral environment in small infants helps prevent hypoglycemia 
and skin to skin contact with mother should be encouraged as a strategy for temperature 
maintenance. Oral dextrose solutions should not be used as a substitute for breast milk. 
Plain dextrose feeding can induce vomiting and will cause increased insulin secretion, 
decreased glucagon, delayed gluconeogenesis and rebound hypoglycemia. In infants 
receiving intravenous infusions, it should be ensured that there is no interruption in the 
glucose infusion by maintaining a good intravenous access and  using  a syringe infusion 
pump to deliver at a steady rate. 
In this chapter, we discuss the controversies behind the definition of hypoglycemia, glucose 
metabolism in fetal and neonatal brain, biochemical derangements during hypoglycemia, 
clinical correlates and pathological manifestations of hypoglycemia, management issues and 
the rare entity of persistent hypoglycemia of infancy.  
2. Definition 
The literal meaning of hypoglycemia is low level of glucose in blood. The ‘low level’ is 
however difficult to define in neonates due to the several reasons. First, their nervous system 
does not have sufficient maturity and capacity to manifest the signs and symptoms of 
hypoglycemia in a consistent fashion, below the ‘low level’ of blood glucose. The ‘critical limit’ 
of blood glucose required for normal integrity of neonatal brain function is currently not fully 
understood. Secondly, the ‘low blood glucose’ levels often occur in association with other 
biological insults. In presence of these insults, the ‘low blood glucose level’ limits are likely to 
be higher as compared to isolated cases of hypoglycemia. These insults e.g. hypoxemia, 
ischemia, asphyxia, acidosis etc. might have a role in potentiating hypoglycemic brain injury in 
the vulnerable sick newborn (Volpe, 2008). Hence, the ‘normal’ range of blood glucose is 
different for each newborn and depends upon birth-weight, gestational age, body stores, 
feeding status, availability of energy sources as well as the presence or absence of disease. 
2.1 Clinical definition  
In early nineteenth century, clinical manifestations (lethargy, tremor, sweating, cyanosis, 
jitteriness, hypotonia, coma, and seizures) were recognized as the only responses to 
hypoglycemia. Working definition of hypoglycemia was the ‘low blood glucose levels’ at 
which the clinical manifestations were noticed (Hartmann et al., 1960; Brown & Wallis 1963; 
Cornblath et al., 2000). These clinical manifestations are however nonspecific and can occur 
with many other neonatal illnesses e.g. sepsis, hypothermia, hypoxic-ischemic brain injury 
etc. Certain signs like jitteriness can be present even in normal healthy neonates. Therefore 
clinically significant hypoglycemia is diagnosed if Whipple’s triad (Whipple & Frantz 1935) 
is present. Whipple’s triad is defined as: (a) the presence of characteristic clinical 
manifestations, (b) clinical manifestations occurring in presence of low plasma glucose 
concentrations, and (c) the clinical signs resolve within minutes to hours, after normalization 
of blood glucose. It is possible to make clinical diagnosis confidently when all three 
requirements are met.  
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required if mother has been starving or vomiting. The maximum risk for hypoglycemia is in 
first 24 hours  but usually persists till 72 hours.  
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significant proportion of infants with recurrent hypoglycemia and correlate significantly 
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Refractory or persistent hypoglycemia should be suspected and investigated if the glucose 
infusion requirement is >12 mg/kg/min or the hypoglycemia persists >5-7 days, 
respectively. Hyperinsulinemic hypoglycemia is the most important cause of severe and 
persistent hypoglycemia after initial few days. The  risk  for brain injury and subsequent 
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hypoglycemia  nearly always responds to medications like  diazoxide. Several forms of 
congenital hyperinsulinism also present with hypoglycemia in neonates that does not remit. 
Depending on the type of genetic mutation, hypoglycemia in these infants with congenital 
hyperinsulinism may be controlled medically or may require surgery. The extent of surgery 
required in infants with ATP-dependent potassium channel mutations unresponsive to 
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in molecular genetics, positron emission tomography scanning and minimally invasive  
surgery have completely changed the clinical approach to these infants. 
Certain clinical practices can help prevent the occurrence of hypoglycemia. These include 
support and promotion of  early exclusive breastfeeds within first hour of life in all healthy 
newborns. Delayed initiation of breast feeds is an important risk factor for hypoglycemia. 
Maintenance of thermoneutral environment in small infants helps prevent hypoglycemia 
and skin to skin contact with mother should be encouraged as a strategy for temperature 
maintenance. Oral dextrose solutions should not be used as a substitute for breast milk. 
Plain dextrose feeding can induce vomiting and will cause increased insulin secretion, 
decreased glucagon, delayed gluconeogenesis and rebound hypoglycemia. In infants 
receiving intravenous infusions, it should be ensured that there is no interruption in the 
glucose infusion by maintaining a good intravenous access and  using  a syringe infusion 
pump to deliver at a steady rate. 
In this chapter, we discuss the controversies behind the definition of hypoglycemia, glucose 
metabolism in fetal and neonatal brain, biochemical derangements during hypoglycemia, 
clinical correlates and pathological manifestations of hypoglycemia, management issues and 
the rare entity of persistent hypoglycemia of infancy.  
2. Definition 
The literal meaning of hypoglycemia is low level of glucose in blood. The ‘low level’ is 
however difficult to define in neonates due to the several reasons. First, their nervous system 
does not have sufficient maturity and capacity to manifest the signs and symptoms of 
hypoglycemia in a consistent fashion, below the ‘low level’ of blood glucose. The ‘critical limit’ 
of blood glucose required for normal integrity of neonatal brain function is currently not fully 
understood. Secondly, the ‘low blood glucose’ levels often occur in association with other 
biological insults. In presence of these insults, the ‘low blood glucose level’ limits are likely to 
be higher as compared to isolated cases of hypoglycemia. These insults e.g. hypoxemia, 
ischemia, asphyxia, acidosis etc. might have a role in potentiating hypoglycemic brain injury in 
the vulnerable sick newborn (Volpe, 2008). Hence, the ‘normal’ range of blood glucose is 
different for each newborn and depends upon birth-weight, gestational age, body stores, 
feeding status, availability of energy sources as well as the presence or absence of disease. 
2.1 Clinical definition  
In early nineteenth century, clinical manifestations (lethargy, tremor, sweating, cyanosis, 
jitteriness, hypotonia, coma, and seizures) were recognized as the only responses to 
hypoglycemia. Working definition of hypoglycemia was the ‘low blood glucose levels’ at 
which the clinical manifestations were noticed (Hartmann et al., 1960; Brown & Wallis 1963; 
Cornblath et al., 2000). These clinical manifestations are however nonspecific and can occur 
with many other neonatal illnesses e.g. sepsis, hypothermia, hypoxic-ischemic brain injury 
etc. Certain signs like jitteriness can be present even in normal healthy neonates. Therefore 
clinically significant hypoglycemia is diagnosed if Whipple’s triad (Whipple & Frantz 1935) 
is present. Whipple’s triad is defined as: (a) the presence of characteristic clinical 
manifestations, (b) clinical manifestations occurring in presence of low plasma glucose 
concentrations, and (c) the clinical signs resolve within minutes to hours, after normalization 
of blood glucose. It is possible to make clinical diagnosis confidently when all three 
requirements are met.  
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However, there are several limitations with this clinical definition. The levels of blood 
glucose at which clinical manifestations appear may be different from the levels at which 
biochemical injury occurs leading to long term neurological sequelae. This clinical definition 
does not take into account clinically asymptomatic neonates who have ‘low blood glucose’ 
i.e. “asymptomatic hypoglycemia”. Asymptomatic hypoglycemia can also cause 
hypoglycemic brain injury (Griffiths, 1968; Griffiths & Bryant, 1971; Lucas et al., 1988). The 
presence or absence of such signs cannot be used reliably to discriminate between normal 
and low blood glucose levels. Nevertheless presence of clinical signs of encephalopathy 
such as decreased level of consciousness or seizures should alert the physician for 
possibility of cerebral fuel deficiency. 
2.2 Metabolic definition 
Low blood glucose concentrations stimulate counter-regulatory hormonal response in order 
to increase the blood glucose. With the decrease in blood glucose levels, plasma insulin 
levels decrease and plasma glucagon levels increase (Sperling et al., 1974). There is increase 
in serum levels of cortisol, epinephrine, and growth hormone levels as well. The 
concentration of alternative brain fuels e.g. lactate and ketone bodies also increase in 
presence of low blood glucose (Persson et al., 1972; Adam et al., 1975; Vannucci et al., 1981). 
The concentration of blood glucose at which counter-regulatory hormonal response is 
elicited, may be utilized to define ‘acceptable’ lower limit of blood glucose. However, there 
is little information available for the thresholds levels of blood glucose in neonates for the 
counter-regulatory hormonal stress response, autonomic and neuroglycopenic signs, as well 
as impaired cognitive function; which have been described in adults (Mitrakou et al., 1991; 
Ward Platt & Deshpande, 2005). Additionally, preterm neonates are unable to mount a 
mature counter-regulatory response to low blood glucose levels, making this judgment 
unsuitable for this population (Hawdon et al., 1992). 
2.3 Neurophysiological definition 
With fall in blood glucose levels, there may be changes in neurophysiological functions, 
which can be recorded in form of evoked potentials. Few authors have attempted to 
measure neurophysiological changes in response to neuroglycopenia. Koh et al. described 
abnormalities of brain-stem auditory or somatosensory evoked potentials in some children 
having blood glucose less than 2.6 mmol/L (Koh et al., 1988). None of the children with 
blood glucose concentrations of ≥2.6 mmol/L showed changes in neurophysiological 
functions. The authors suggested that 2.6 mmol/L of blood glucose may be taken as a safe 
threshold in neonates and children. However, there were only five term neonates included 
in this study. The concentrations of alternative fuels were not measured consistently during 
this study. Moreover, researchers failed to reproduce distinct threshold to diagnose 
hypoglycemia on the basis of evoked potentials in both term and preterm babies (Pryds et 
al., 1988; Cowett et al., 1997).  
Positron emission tomography has been utilized to study changes in cerebral blood flow 
during hypoglycemia among preterm newborn infants (Koh et al., 1988; Pryds et al., 1988). 
However, resolution of these abnormalities in response to glucose administration needs to 
be documented to attribute these abnormalities to significant hypoglycemia. Pryds et al. 
compared hypoglycemic infants (N=13, mean birth weight - 1,500 g) and normoglycemic 
controls (N=12, mean birth weight - 1,310 g) for the cerebral blood flow and plasma 
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epinephrine and norepinephrine responses. Hypoglycemia was defined as a blood glucose 
less than 30 mg/dL. Cerebral blood flow and plasma epinephrine concentrations were 
increased among hypoglycemic infants. There was no difference in norepinephrine levels. 
Among hypoglycemic neonates, cerebral flow decreased by 11% after correction of blood 
glucose. The data suggests that counter-regulatory mechanisms are stimulated below blood 
glucose values of less than 30 to 45 mg/dL (Pryds et al., 1990). 
2.4 Neurodevelopmental approach to define hypoglycemia 
Clinical risk of hypoglycemia can be correlated with neurodevelopmental outcome. In a 
follow-up study of 661 infants weighing less than 1850 g at birth, Lucas et al identified a 
significantly strong association between the number of days (≥5d) on which blood glucose 
concentrations of <2.6 mmol/L(<47 mg/dL)  were found and lower Bayley developmental 
scores at 18 months of age (Lucas et al., 1988). The major limitations of this study were non-
standardized monitoring of blood glucose, and effect of unidentified confounders with the 
result that the ‘safe’ plasma glucose concentrations still cannot be reliably extrapolated. The 
low plasma glucose concentrations may have been a proxy for extreme illness because such 
protracted hypoglycemia lasting for 5 days is rare. At 8 years, however, this association was 
not sustained, and another study in a different large cohort has also failed to replicate this 
finding (Cornblath & Schwartz, 1999; Williams, 2005). 
2.5 Statistical definition 
Conventionally, hypoglycemia is defined by a value lying outside the ‘normality 
distribution of the range of values obtained in a healthy population’. ‘Low’ is arbitrarily 
defined as a value, 2-standard deviations (SD), below the mean of the population. The major 
caveat is this approach is that the blood glucose concentrations in a cohort of normal 
population represent a continuum, and it is not possible to pick a single value that could 
represent a threshold of abnormality. Those ‘minus 2-SD’ cutoff value would vary with the 
gestational age, postnatal age, type of feeding and physiological state e.g. post or pre-feed 
(Srinivasan et al., 1986; Hawdon et al., 1992; de Rooy & Hawdon, 2002). Moreover, this 
‘statistical’ abnormality cannot be taken as ‘biological’ abnormality. Technical issues, 
including discrepancy between values obtained from whole blood and plasma, and the low 
sensitivity of reagent strip for hypoglycemic range of blood glucose, are also deterrent for 
such an approach. This may partly explain the lack of consensus between physicians and 
standard texts in the field. A major criticism of the ‘normal range’ approach to deriving a 
treatment yardstick is that it does not consider the complexities of the metabolic milieu, the 
availability of alternative substrates and  the clinical condition of the baby (Koh et al., 1988; 
Williams, 1997; Williams, 2005).  
2.6 Operational thresh-holds 
Cornblath et al have suggested a pragmatic way to give cut-off values of blood glucose on 
which the action should be taken (Cornblath et al., 2000). An "operational threshold '' is not 
diagnostic of a disease, but an indication for action. These recommendations are 
conservative approximations of designating the lower level of normoglycemia that one can 
safely tolerate in specific infants, at specific ages and under established conditions. It is 
difficult to define significant hypoglycemia by a single cut-off value that can be applied 
universally. Rather, it is characterized by a value(s) that is unique to each individual and 
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epinephrine and norepinephrine responses. Hypoglycemia was defined as a blood glucose 
less than 30 mg/dL. Cerebral blood flow and plasma epinephrine concentrations were 
increased among hypoglycemic infants. There was no difference in norepinephrine levels. 
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glucose values of less than 30 to 45 mg/dL (Pryds et al., 1990). 
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significantly strong association between the number of days (≥5d) on which blood glucose 
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‘statistical’ abnormality cannot be taken as ‘biological’ abnormality. Technical issues, 
including discrepancy between values obtained from whole blood and plasma, and the low 
sensitivity of reagent strip for hypoglycemic range of blood glucose, are also deterrent for 
such an approach. This may partly explain the lack of consensus between physicians and 
standard texts in the field. A major criticism of the ‘normal range’ approach to deriving a 
treatment yardstick is that it does not consider the complexities of the metabolic milieu, the 
availability of alternative substrates and  the clinical condition of the baby (Koh et al., 1988; 
Williams, 1997; Williams, 2005).  
2.6 Operational thresh-holds 
Cornblath et al have suggested a pragmatic way to give cut-off values of blood glucose on 
which the action should be taken (Cornblath et al., 2000). An "operational threshold '' is not 
diagnostic of a disease, but an indication for action. These recommendations are 
conservative approximations of designating the lower level of normoglycemia that one can 
safely tolerate in specific infants, at specific ages and under established conditions. It is 
difficult to define significant hypoglycemia by a single cut-off value that can be applied 
universally. Rather, it is characterized by a value(s) that is unique to each individual and 
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varies with both their state of physiologic maturity and the influence of pathology. It can be 
defined as the concentration of glucose in the blood or plasma at which the individual 
demonstrates a unique response to the abnormal milieu caused by the inadequate delivery 
of glucose to a target organ (for example, the brain).  
The operational thresholds may not be applicable to breastfed infants as they have higher 
concentrations of ketone bodies than formula-fed infants despite having lower blood 
glucose concentrations (Hawdon et al., 1992; Swenne et al., 1994). The production of ketone 
bodies among breastfed infants is directly proportional to postnatal weight loss. These data 
suggest that the provision of alternate fuels constitutes a normal adaptive response to 
transiently low nutrient intake during the establishment of breastfeeding. These infants may 
well tolerate lower plasma glucose levels without any significant clinical manifestations or 
sequelae. However any symptomatic infant with clinical signs consistent with low blood 
glucose concentration should be treated if the blood glucose  levels are <45 mg/dL (2.5 
mmol/L). Operational thresh-holds are different among neonates, who are at risk of 
hypoglycemia as a result of alteration in maternal metabolism, intrinsic neonatal problems, 
or anticipated or perceived endocrine or metabolic disorders.  If the plasma glucose 
concentration is less than 36 mg/dL (2.0 mmol/L), a close surveillance should be 
maintained, and intervention is recommended if plasma glucose remains below this level, if 
the level does not increase after a feed, or if abnormal clinical signs develop. At very low 
glucose concentrations (<20–25 mg/dL, 1.1–1.4 mmol/L), intravenous glucose infusion 
aimed at raising the plasma glucose levels above 45 mg/dL (2.5 mmol/L) is indicated. The 
higher therapeutic goal is chosen to include a significant margin of safety in the absence of 
any data evaluating the correlation between glucose levels in this range and long-term 
outcome in full-term infants. The operational thresh-hold suggested for the infants on 
parenteral nutrition is 45 mg/dL (Cornblath et al., 2000).  
It is clear from the above discussion that it is very difficult to give a single value to define 
hypoglycemia. The approach for the diagnosis and treatment of hypoglycemia should take 
into account the gestational age as well as sickness level of the baby. 
3. Fetal glucose metabolism and metabolic adaptation at birth 
In the in-utero life, the fetus is dependent largely on maternal circulation for transplacental 
transfer of nutrients including glucose. However fetus is capable of endogenous glucose 
production during placental insufficiency and maternal starvation (Hay & Sparks, 1985). 
The fetal blood glucose concentrations are lower than but close to those of mother (Bozzetti 
et al., 1988). Glucose crosses the placenta by facilitated diffusion along a concentration 
gradient. Human liver contains glycogenic enzymes as early as 8 weeks of gestation, and 
glycogen deposition begins in early pregnancy. Hepatic glycogen content increases from 
only 3.4 mg/g at 8 weeks of age to 50 mg/g by term (Capkova & Jirasek, 1968; Williams, 
2005). In humans, the enzymes for gluconeogenesis develop by 2 months of gestational age. 
However under normal physiological circumstances, the gluconeogenesis is not expressed 
in-utero (Kalhan et al., 1979). Only 40-50% of the maternal glucose taken up by the placenta 
is transferred to the fetus and rest is utilized by the placenta, which converts it to lactate. 
This lactate is released into the fetal and maternal circulation in a ratio of 1:3. Fetal lactate 
uptake is about half of the fetal glucose uptake and provides a major substrate for both 
oxidative and non-oxidative (such as glycogen synthesis) fetal metabolism. Glucose, 
however, remains the principal energy substrate for the human fetus under physiological 
conditions (Williams, 2005).  
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The blood glucose concentration in the umbilical venous blood is 80-90% of that in the 
maternal venous blood at the time of birth. Clamping of the umbilical cord causes rapid 
decrease in neonatal glucose concentration, reaching a nadir by 1 h of age and then 
increasing to stabilize by 3 h of age even in the absence of any exogenous nutritional intake 
(Fig. 1) (Srinivasan et al., 1986; Heck & Erenberg, 1987). The cascade of events in successful 
adaptation to extrauterine life includes metabolic changes such as hepatic glycogenolysis, 
lipolysis, fatty acid -oxidation with generation of ketone bodies, and proteolysis that 
generates lactate and other substrates for gluconeogenesis. 
These changes in glucose concentration are modified by a number of factors, including prior 
fetal glucose homeostasis influenced by antepartum and peripartum events, umbilical 
concentrations of glucose, plasma insulin concentrations, and the onset of neonatal glucose 
production from glycogenolysis and gluconeogenesis. There is considerable variability in 
glucose concentrations during this early postnatal period, both within individual neonates 
and among groups of neonates of different gestational ages and growth patterns. During 
this period, plasma insulin levels fall and plasma glucagon levels markedly rise from the 
baseline levels (Bloom & Johnston, 1972; Sperling et al., 1974). The stress of the birth process 
causes catecholamine surge. Growth hormone concentration also increases markedly after 
birth. However its physiological significance is not clear. The initial glucagon surge with 
low insulin/glucagon molar ratio is the key hormonal adaptation in the newborn infant 
(Ward Platt & Deshpande, 2005). 
 
 
Fig. 1. Profile of blood glucose concentrations in the immediate postnatal period (Srinivasan 
et al., 1986) 
Ketone bodies and lactate serve as alternative fuels with glucose-sparing effects, and are 
important in maintaining cerebral energy supply. Oxidative metabolism of glucose in fasting 
human newborns can only supply 70% of the estimated energy needs of the brain (Denne & 
Kalhan, 1986). Alternative energy substrates such as ketone bodies and lactate are required 
during fasting for energy production in brain. The capability of newborn brain to utilize 
ketone bodies  is about 5-40 fold greater than that of infant or adult brain (Persson et al., 1972). 
Even in regularly fed newborn infants, ketogenesis and ketone body consumption provide 
around 12% of the cerebral oxygen consumption in neonates after a 6-h fast (Hawdon et al., 
1992; Ward Platt & Deshpande, 2005). Lactate appears to be an important energy substrate for 
the infant in the immediate postnatal life. It is metabolized via oxidation by lactate 
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varies with both their state of physiologic maturity and the influence of pathology. It can be 
defined as the concentration of glucose in the blood or plasma at which the individual 
demonstrates a unique response to the abnormal milieu caused by the inadequate delivery 
of glucose to a target organ (for example, the brain).  
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transiently low nutrient intake during the establishment of breastfeeding. These infants may 
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concentration is less than 36 mg/dL (2.0 mmol/L), a close surveillance should be 
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uptake is about half of the fetal glucose uptake and provides a major substrate for both 
oxidative and non-oxidative (such as glycogen synthesis) fetal metabolism. Glucose, 
however, remains the principal energy substrate for the human fetus under physiological 
conditions (Williams, 2005).  
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dehydrogenase in the brain. Although the lactate pool is small (2.4 mM), the concentrations 
tend to be higher in the crucial first 2-3 postnatal hours (Kalhan et al., 2001).  
In the post-natal life, blood glucose concentrations depend upon the feeding practices. 
Postnatal age and blood glucose concentrations are positively correlated, with the lowest 
values usually found on day-1 of life (Hawdon et al., 1992; Ward Platt & Deshpande, 2005). 
The rate of glucose production in the human neonate during the first few postnatal days is 
estimated to be 4-6 mg/kg/min. Approximately one-third of glucose is produced by 
glycogenolysis (Shelley & Neligan, 1966). Gluconeogenesis is important for continued 
glucose supply at this time. The activity of cytosolic phosphoenolpyruvate carboxykinase 
(PEPCK), which is responsible for gluconeogenesis, markedly increases after birth. Its 
secretion is stimulated by a fall in the plasma insulin/glucagon molar ratio. The 
concentrations of gluconeogenic precursors such as alanine and lactate are higher in term 
neonates as compared to older children or adults (Stanley et al., 1979; Hawdon et al., 1992). 
It may be due to slow postnatal maturation of PEPCK enzyme, or may be due to catabolic 
status of the neonate. Gluconeogenesis starts as early as 2 h after birth in the term human 
neonate (Kalhan et al., 1980). Long-chain fatty acids are required for the postnatal induction 
of enzymes of mitochondrial fatty acid -oxidation (Pegorier et al., 1998). Owing to the 
limited capacity for hepatic ketogenesis in the immediate postnatal life, newborn infants 
have low plasma ketone body concentrations despite adequate levels of precursor free fatty 
acids (FFAs) in the first 8 h after birth (Stanley et al., 1979). From 12 h of age onwards, 
healthy term infants have high ketone body turnover rates (12-22 mmoL/kg/min) (Hawdon 
et al., 1992). The vigorous ketogenesis appears to be an integral part of extrauterine 
metabolic adaptation in the term human neonates. 
Among preterm neonates, blood glucose levels have a greater fall after birth as compared to 
term infants. Circulating levels of gluconeogenic substrates are higher in preterm infants 
(Hawdon et al., 1992). However, the activity of microsomal glucose-6-phosphatase (the final 
enzyme of glycogenolysis and gluconeogenesis) in preterm infants is extremely low as 
compared to term infants (Hume & Burchell, 1993). In contrast to these findings, Sunehag et 
al. showed that preterm infants (25-26 weeks gestation) can have glucose production rates 
similar to the term neonates (Sunehag et al., 1993; Ward Platt & Deshpande, 2005). Similar 
observations were reported in preterm infants of 26-31 weeks gestational age. Preterm 
infants, however, cannot mount mature counter-regulatory ketogenic responses to low 
blood glucose levels in the first week after birth. The preterm infants demonstrate a positive 
relationship between blood ketone body concentrations and the volume of enteral feed 
(Hawdon et al., 1992). This immaturity of counter-regulatory ketogenesis is shown to persist 
during first 8 postnatal weeks. It may persist even till 2-6 months of postmenstrual age. 
Preterm neonates have a higher basal insulin secretion (plasma immunoreactive insulin 
concentrations at low blood glucose levels) as compared to term infants or children. The 
basal insulin concentrations have been shown to decrease with increasing maturity, 
however, they remained persistently high in the longitudinal evaluation of metabolic 
counter-regulation in preterm infants (Ward Platt & Deshpande, 2005). 
4. Glucose metabolism and brain 
Glucose and oxygen are the principle substances required for energy production in brain. To 
understand the injury caused by hypoglycemia it is essential to understand the metabolism 
of glucose in human brain. 
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4.1 Glucose uptake  
Glucose supply to the brain is regulated by the plasma glucose concentration and mediated 
through a process of facilitated diffusion utilizing glucose transporter 1 (GLUT1) and 
glucose transporter 3 (GLUT3) proteins. This transport is not energy dependent. The levels 
of these proteins are relatively low in immature neonates and are a limiting step for glucose 
transfer and utilization (Koh et al. 1988; Cornblath et al., 2000; Volpe, 2008). GLUT1 is 
expressed in the blood-brain barrier endothelial cells, astrocytes, oligodendrocytes and 
choroid plexus while GLUT3 is expressed primarily in neurons and their synaptic 
membranes (Mantych et al., 1993; Kalhan et al., 2001). The brain glucose transporter is 
concentrated in capillaries and the concentration increases with maturity. The limiting factor 
for the passage of glucose to the brain tissue is the concentration of glucose transporters 
rather than the affinity of the receptors. The number of available endothelial receptors in 
human premature neonates is one third to half as compared to the adult brain (Powers et al., 
1998; Volpe, 2008).  
4.2 Glucose utilization in brain 
Glucose is acted upon by hexokinase to form glucose-6-phosphate. It may be utilized via 
glycolytic pathway to produce energy (ATP), Hexose mono-phosphate (HMP) shunt to 
produce reducing equivalents or conversion to glycogen. Glycogen thus formed is stored in 
astrocytes and is used for energy production later on during periods of low blood glucose 
levels. Reducing equivalents from HMP shunt are required for lipid synthesis and nucleic 
acid synthesis. Glucose utilization is highest in brainstem gray matter structures, declining 
in a caudal to rostral manner, to the cerebral cortex. Cerebral glucose utilization in the 
human studies was found to be highest in the sensorimotor cerebral cortex, thalamus, mid-
brain-brainstem, and the cerebellar vermis. By 3 months of age, glucose metabolic activity in 
the human infants had increased in the parietal, temporal, and occipital cortices and in the 
basal ganglia. Subsequently it increased in frontal and various association regions of 
cerebral cortex by 8 months. Little further change was observed between 8 and 18 months of 
postnatal age (Vannucci & Vannucci, 2000). Glucose acts as a primary metabolic fuel in the 
mature and immature brain. The studies in the newborn dogs indicate that glucose 
consumption accounts for 95% of the cerebral energy supply (Volpe, 2008). If the glucose 
supply to the brain is limited, alternative substances such as lactate and ketone bodies can 
be utilized to protect the brain functions and structure. Ketone bodies can be taken up by 
carrier mediated transport system, converted to acetyl CoA and metabolized to produce 
energy. Ketone bodies account for approximately 12% of total cerebral oxygen consumption 
after 6-hr fasting in newborns. However, availability of ketone bodies in such circumstances 
depends on the liver’s capacity to deliver them in blood. The role of exogenous ketone 
bodies as a source of energy in settings of hypoglycemia is yet to be explored (Plecko et al., 
2002). Lactate uptake from the blood also increases during periods of low blood glucose 
levels and it gets oxidized to pyruate by lactate dehydrogenase. The activity of lactate 
dehydrogenase in perinatal animal models is higher than adults (Lehrer et al., 1970; Wilson, 
1972; Nehlig & Pereira de Vasconcelos, 1993). The association of increased lactate utilization 
and relative sparing of neonatal brain is strong but the exact role is yet to be explored. It is 
argued that the lactate utilization in perinatal animal could be an adaptive response to 
increased lactate levels in blood in perinatal period to avoid lactic acidemia (Volpe, 2008). 
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5. Biochemical alterations during hypoglycemia 
In the event of low blood glucose, certain biochemical changes occur in the neonatal brain. 
With continuing hypoglycemia, changes secondary to hypoxia, ischemia and seizures may 
add to the insult. These combined effects are of major concern as it increases the chances of 
brain injury even if individual insults are not of sufficient magnitude to cause injury by 
themselves (Volpe, 2008). 
5.1 Initial changes 
The initial response to the low blood glucose levels is an increase in cerebral blood flow so 
as to increase glucose supply to brain. This effect has been shown in adult models (Siesjo, 
1988), neonatal animal models (Anwar & Vannucci, 1988; Mujsce et al., 1989), and human 
infants (Pryds et al., 1988, 1990; Pryds, 1991; Skov & Pryds, 1992). In human infants, a sharp 
increase in cerebral blood flow has been observed below a blood glucose of 30 mg/dL 
(Pryds et al., 1990). Initial biochemical changes include metabolic attempts to preserve 
cerebral energy status by utilizing alternatives to glucose. Glycogenolysis starts to provide 
glucose to brain tissue. Researchers have noticed that initially there is not much change in 
cerebral oxygen consumption. This discrepancy between falling blood glucose levels and 
relatively preserved oxygen utilization in initial phases of hypoglycemia implies that 
alternative substrates like lactate and ketone bodies might be sufficient to meet cerebral 
energy needs (Norberg & Siesio, 1976; Ghajar et al., 1982). Amino acids may be other 
alternative substrates as a sharp decrease in brain concentrations of most amino acids occurs 
along with increase in brain ammonia levels (Volpe, 2008).  
There is dissociation between cerebral energy metabolism and brain functions during 
hypoglycemia. The changes in level of consciousness (from alert state to depressed state) 
and from normal EEG to slowing can occur with relatively little change in levels of ATP in 
various regions of brain (Siesjo, 1988; Vannucci et al., 1981; Vannucci & Vannucci, 2000; 
Volpe, 2008). This phenomenon can be attributed partially to metabolic changes happening 
during early periods of hypoglycemia. The concentration of ammonia goes up as the levels 
of amino acids decrease so as to preserve ATP production. The level of ammonia production 
is considered sufficient to produce stupor in adult hypoglycemic animals. Mature rats, who 
were made hypoglycemic, displayed impaired acetylcholine synthesis in early phase of 
hypoglycemia (Gibson & Blass, 1976; Ghajar et al., 1982). Only modest hypoglycemia was 
able to decrease acetylcholine levels by 20-45%. Moreover there was 40-60% decrease in 
synthesis of this neurotransmitter in cortex and striatum (Ghajar et al., 1982). The likely 
mechanism for the dissociation between cerebral energy metabolism and brain functions 
during hypoglycemia, is decrease in acetyl-coA concentration secondary to low blood 
glucose and hence glycolysis (Volpe, 2008). However in newborn animal models, 
hypoglycemia severe enough to deplete glucose from brain is accompanied by some 
preservation of glycolytic intermediates such as pyruate and lactate; and almost complete 
preservation of ATP levels. Newborn animal models showed resistance to neurological 
deterioration even at plasma glucose levels of 15 mg/dL when maintained for a period of 2 
hours (Vannucci & Vannucci, 1978). In newborn dog, the EEG slowing was observed only 
below 20 mg/dL (Vannucci et al., 1981). There are various reasons for the relative resistance 
of newborn brain towards neuronal injury to hypoglycemia. These include lower cerebral 
energy requirements, marked increase in cerebral blood flow in early phases of 
hypoglycemia, increased capacity of neonatal brain to utilize lactate as an alternative brain 
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fuel and relatively less effect on cardiovascular system as compared to adults due to 
abundant endogenous carbohydrate stores (Volpe, 2008).  
5.2 Later changes 
If hypoglycemia continues, generation of fatty acids increases due to phospholipid 
degradation, to provide additional source of energy. However, this energy source is not 
sufficient to provide for the deficit of high energy phosphate compounds and prevent 
clinical and EEG deterioration (Ghajar et al., 1982; Siesjo, 1988). In advanced phases of 
hypoglycemia, there are changes in intracellular Ca++ and extracellular K+ concentration 
(Agardh et al., 1981; Wieloch et al., 1984; Siesjo, 1988). The neuron loses its ability to 
maintain normal ionic gradients. The failure of energy dependent Na+/K+ ATPase is the 
likely reason responsible for these changes. With energy failure, Na+ accumulates 
intracellularly and K+ accumulates in extracellular space leading to sustained membrane 
depolarization. Increase in intracellular Na+ would lead to activation of Na+/Ca2+ exchange 
system and intracellular accumulation of Ca2+ ions. There is also failure of energy dependent 
Ca2+ transport across the cell membrane, which again leads to intracellular accumulation of 
Ca2+ ions. The increased concentration of cytosolic Ca2+ ions leads to phospholipase 
activation and cellular injury. This explanation is supported by the observed corresponding 
decline in phospholipid concentration and increase in fatty acid levels with increase in 
intracellular Ca2+. Additionally, the increase in cytosolic calcium concentration causes 
increase in release of excitatory amino acids (e.g. aspartate and glutamate) from synaptic 
nerve endings and reduced uptake secondary to failure of glutamate transport. Antagonists 
of N-Methyl-D-Aspartate type of glutamate receptors have been shown to attenuate 
neuronal injury in cultured neurons and in vivo models (Wieloch, 1985; Volpe, 2008). The 
excess cytosolic Ca2+ also leads to increase in reactive oxygen and nitrogen species. These 
free radical species result in DNA damage and as a consequence DNA repair enzyme, poly 
(ADP-ribose) polymerase-1 (PARP). Excessive activation of PARP, leads to apoptosis. PARP 
inhibitors have been shown to protect neurons from hypoglycemic injury in in- vivo and in- 
vitro models (Suh et al., 2003; Volpe, 2008).  
6. Pathological changes in hypoglycemic brain injury 
It is difficult to define exact neuropathology in newborns suffering from hypoglycemia as it 
almost always coexists with other morbidities. However the literature suggests that the 
topography of the hypoglycemic brain injury is peculiar and is different from that of 
hypoxic ischemic brain injury. Adolescent monkeys when exposed to blood glucose of <20 
mg/dL for more than 2 hours showed neuronal injury predominantly in the regions of 
parieto-occipital cortex. Less commonly involved regions were hippocampus, caudate 
nucleus, and putamen. The injury was most severe in regions contiguous to cerebrospinal 
fluid such as superficial cerebral cortical layers (Agardh et al., 1980; Auer et al., 1984, 1985; 
Kalimo et al., 1985; Siesjo, 1988). Similar topographical distribution of neuropathology was 
observed in premature infants using autopsy studies, computed tomography, magnetic 
resonance imaging and single photon emission computed tomography blood flow scans 
(Anderson et al., 1967; Spar et al., 1994; Chiu et al., 1998; Volpe, 2008). The hypoglycemic 
brain injury primarily involves neurons but glia are also affected (Anderson et al., 1967). 
Studies of oligodendrocyte precursor cells and cerebellar slice cultures showed that 
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fuel and relatively less effect on cardiovascular system as compared to adults due to 
abundant endogenous carbohydrate stores (Volpe, 2008).  
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decline in phospholipid concentration and increase in fatty acid levels with increase in 
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hypoglycemia induces apoptotic cell death and inhibits differentiation and myelination (Yan 
& Rivkees 2006). Additionally hypoglycemia alone if not severe enough to cause neuronal 
injury, may contribute to the injury caused by other insults. The sequelae of hypoglycemic 
brain injury include microcephaly, widened sulci and atrophic gyri, diminished cerebral 
white matter and dilated lateral ventricles. The pathological effects of marginal 
hypoglycemia with or without other concomitant insults are not known.  
7. Clinical profile 
Hypoglycemia is a concomitant finding in variety of neonatal disorders. The incidence of 
hypoglycemia depends upon the proportion of term and preterm in a given population, 
type of milk feeding, the pattern of feeding, screening timings and methods, temperature, 
sickness level and definition used for the diagnosis of hypoglycemia. In a large series of 661 
preterm neonates with birth weight <1850 g, 10% had at least one value of blood glucose 
<0.6mmol/L (<10mg/dL approximately), 28% had at least one value <1.6mmol/L 
(<30mg/dL approximately), and 66% had at least one value of blood glucose <2.6 mmol/L 
(<45mg/dL approximately) (Lucas, Morley et al. 1988). Among breastfed healthy term 
neonates, approximately 17% of the neonates had plasma glucose value of <2.16mmol/L 
(<40 mg/dL) at 3 hours of postnatal life. Ten percent of neonates had similar values at 72 
hours of life (Diwakar & Sasidhar, 2002).  
The clinical manifestations of hypoglycemia are largely related to central nervous system. 
Common clinical signs include jitteriness, irritability, varying degree of altered 
consciousness, seizures, tachypnea, apnea and hypotonia. It is important to realize that there 
might be no symptoms in presence of biochemical evidence of hypoglycemia 
(Asymptomatic hypoglycemia)(Volpe, 2008). Neonates with ‘symptomatic hypoglycemia’ 
can be classified into four categories according to the clinical setting of hypoglycemia, time 
of presentation, and severity of presentation (Volpe, 2008): 
7.1 Early transitional adaptive hypoglycemia 
It occurs in first 6-12 hours of life, after sudden withdrawl of maternal nutrient supply due to 
cord clamping. This manifests in neonates, who fail to mount adequate metabolic adaptive 
response in the face of falling blood glucose levels, in immediate postnatal life. If the mother 
receives excess glucose in intravenous fluids during intrapartum period, the glycolytic and 
gluconeogenic responses of the neonate are blunted and insulin secretion increases in 
immediate postnatal period. Large for gestational age infants born to diabetic (IDM) or non-
diabetic mothers, neonates who experience hypothermia or asphyxia are at risk for very early 
hypoglycemia. This type of hypoglycemia lasts for brief duration, is mild in severity and 
responds rapidly to treatment. The prognosis depends largely on the underlying cause. 
7.2 Secondary associated hypoglycemia 
This can occur as an associated finding with a variety of illnesses. It is often  seen in 
appropriate for gestational age (AGA) term and preterm neonates, and is associated with 
illnesses particularly involving central nervous system e.g. birth asphyxia, intracranial 
hemorrhage, congenital anomalies and systemic disorders. The association with brain 
disorders is of particular interest as these may have adverse impact on regulation of hepatic 
glucose production. This variety of hypoglycemia is also characterized by short duration, 
mild severity and rapid response to treatment (Volpe, 2008). 
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7.3 Classic transient neonatal hypoglycemia 
This group encompasses predominantly small for gestation (SGA) term infants, who may 
also have polycythemia concomitantly. The onset of hypoglycemia is in later part of first 
day. Hypoglycemia is usually moderate to severe, duration can be prolonged and often high 
glucose infusion rates are required to maintain euglycemia.  
7.4 Severe recurrent hypoglycemia 
Recurrent and persistent hypoglycemia is the hallmark of this variety. This type occurs in 
term AGA neonates who have either hyperinsulinism or endocrinopathies or hereditary 
metabolic defects. The hypoglycemia is variable in onset according to the underlying cause, 
usually severe, difficult to treat, prolonged and invariably symptomatic. The prognosis 
depends on the timely detection of the disorder, institution of specific therapy, and the 
ability to maintain normal blood glucose levels.  
8. Monitoring of blood glucose 
8.1 Who should be monitored? 
All preterm and SGA neonates merit blood glucose screening as they have decreased body 
stores of glycogen and they often harbor co-morbidities putting them at risk for hypoglycemia. 
The large for gestation age infants and IDM neonates usually have excess insulin secretion in 
the immediate neonatal period putting them at risk of hypoglycemia. All ‘unwell’ neonates 
should also be routinely monitored for hypoglycemia. (Deshpande & Ward Platt 2005). The 
indications of monitoring blood glucose in neonatal age group are shown in Figure 2. 
 
Due to maternal indications 
 Maternal drug ingestion eg β- 
blockers, oral hypoglycemics, β-
sympathomimetics 
 Insulin dependent diabetic mothers 
 Gestational diabetic mothers 
 Massively obese mothers 
 Mothers given large amounts of 
parenteral glucose during labor and 
delivery 
 Mothers given parenteral glucose 
too rapidly prior to delivery 
 Neonatal indications 
 Prematurity 
 Small or large for gestational age 
 Hypothermia 
 ‘Sick looking’ or ‘unwell’ neonate 
 Sepsis 
 Hypoxia ischemia 
 Polycythemia 
 Congenital heart diseases 
 Total parenteral nutrition 
 Blood  exchange transfusion 
 Suspected inborn errors of metabolism 
Fig. 2. Indications of monitoring blood glucose 
8.2 What should be the monitoring schedule? 
The neonates in whom there is increased consumption of glucose because of increased 
insulin levels become symptomatic very early in postnatal life. It is also evident that the 
levels of alternative ‘brain fuels’ would also be less due to presence of anabolic hormone 
insulin. Hence IDM and severely intrauterine growth retarded neonates can become 
symptomatic very early in life and merit screening right from cord blood. Some severely 
IUGR infants may develop hypoglycemia in-utero (Soothill et al., 1987; Economides & 
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Common clinical signs include jitteriness, irritability, varying degree of altered 
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might be no symptoms in presence of biochemical evidence of hypoglycemia 
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can be classified into four categories according to the clinical setting of hypoglycemia, time 
of presentation, and severity of presentation (Volpe, 2008): 
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It occurs in first 6-12 hours of life, after sudden withdrawl of maternal nutrient supply due to 
cord clamping. This manifests in neonates, who fail to mount adequate metabolic adaptive 
response in the face of falling blood glucose levels, in immediate postnatal life. If the mother 
receives excess glucose in intravenous fluids during intrapartum period, the glycolytic and 
gluconeogenic responses of the neonate are blunted and insulin secretion increases in 
immediate postnatal period. Large for gestational age infants born to diabetic (IDM) or non-
diabetic mothers, neonates who experience hypothermia or asphyxia are at risk for very early 
hypoglycemia. This type of hypoglycemia lasts for brief duration, is mild in severity and 
responds rapidly to treatment. The prognosis depends largely on the underlying cause. 
7.2 Secondary associated hypoglycemia 
This can occur as an associated finding with a variety of illnesses. It is often  seen in 
appropriate for gestational age (AGA) term and preterm neonates, and is associated with 
illnesses particularly involving central nervous system e.g. birth asphyxia, intracranial 
hemorrhage, congenital anomalies and systemic disorders. The association with brain 
disorders is of particular interest as these may have adverse impact on regulation of hepatic 
glucose production. This variety of hypoglycemia is also characterized by short duration, 
mild severity and rapid response to treatment (Volpe, 2008). 
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7.3 Classic transient neonatal hypoglycemia 
This group encompasses predominantly small for gestation (SGA) term infants, who may 
also have polycythemia concomitantly. The onset of hypoglycemia is in later part of first 
day. Hypoglycemia is usually moderate to severe, duration can be prolonged and often high 
glucose infusion rates are required to maintain euglycemia.  
7.4 Severe recurrent hypoglycemia 
Recurrent and persistent hypoglycemia is the hallmark of this variety. This type occurs in 
term AGA neonates who have either hyperinsulinism or endocrinopathies or hereditary 
metabolic defects. The hypoglycemia is variable in onset according to the underlying cause, 
usually severe, difficult to treat, prolonged and invariably symptomatic. The prognosis 
depends on the timely detection of the disorder, institution of specific therapy, and the 
ability to maintain normal blood glucose levels.  
8. Monitoring of blood glucose 
8.1 Who should be monitored? 
All preterm and SGA neonates merit blood glucose screening as they have decreased body 
stores of glycogen and they often harbor co-morbidities putting them at risk for hypoglycemia. 
The large for gestation age infants and IDM neonates usually have excess insulin secretion in 
the immediate neonatal period putting them at risk of hypoglycemia. All ‘unwell’ neonates 
should also be routinely monitored for hypoglycemia. (Deshpande & Ward Platt 2005). The 
indications of monitoring blood glucose in neonatal age group are shown in Figure 2. 
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8.2 What should be the monitoring schedule? 
The neonates in whom there is increased consumption of glucose because of increased 
insulin levels become symptomatic very early in postnatal life. It is also evident that the 
levels of alternative ‘brain fuels’ would also be less due to presence of anabolic hormone 
insulin. Hence IDM and severely intrauterine growth retarded neonates can become 
symptomatic very early in life and merit screening right from cord blood. Some severely 
IUGR infants may develop hypoglycemia in-utero (Soothill et al., 1987; Economides & 
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Nicolaides, 1989) and would not be expected to achieve normal metabolic adaptation soon 
after birth. These neonates merit cord blood glucose estimation and routine screening in the 
postnatal life at least for initial 48 hours. The neonates with low body glycogen stores like 
preterm and IUGR neonates should get first screening within 1 hour of life. All neonates 
who are symptomatic should get blood glucose levels checked immediately. Many 
textbooks and guidelines recommend blood glucose monitoring at pre-fixed time periods 
after birth, such as at 1 h, 2 h, 3h,6h and then 6 hourly till 48-72 hours by when feeding is 
likely to be established. Blood glucose estimation should be done immediately before a feed, 
as the purpose of screening is to identify the minimum blood glucose level (Lucas et al., 
1981).  
8.3 How should blood glucose be measured? 
An ideal diagnostic method should be precise, rapid, inexpensive, available at bedside, and 
should require small blood volume. At beside, the blood glucose measurements are done by 
point of care glucose meters. They measure blood glucose within few seconds and require 
small sample volumes (as small as 0.3 μL). For treatment decisions, the clinical practices are 
dependent on point of care measurements rather than laboratory estimations. The small 
volume of blood required by such approach has been shown to reduce the need for blood 
transfusions (Madan et al., 2005). Apart from the devices used, the estimation of blood 
glucose levels can also be affected by the properties of sample used for analysis.  
8.3.1 Devices for screening of blood glucose 
Since the introduction of reagent strip blood glucose tests in the 1970s for blood glucose 
screening in newborn infants, the world has witnessed dramatic developments in point of 
care devices for blood glucose measurements. Dextrostix was the first dry reagent, which 
was interpreted with change in color and hence was dependent on subjective interpretation. 
Then came the era of photometric devices (reflectance meters). In this method, the blood 
was required to be placed on the strips for specific time periods, wiped and then inserted 
into a meter . Sources of error in glucose estimation while using these methods are possible 
contamination by alcohol skin-cleansers, not covering the whole surface of the test-pad with 
blood, and failure to time the reaction accurately before wiping the strip. The paper-strip 
methods tend to underestimate the neonatal blood glucose values even when these 
precautions are adopted. The common glucose strips  used in neonatal practice were 
Dextrostix (Ames Co., Slough, England) (Chantler et al., 1967; Wilkins & Kalra 1982; 
Williams, 1997), BM-test-Glycemie (Boehringer Mannheim, Mannheim, Germany) (Wilkins 
& Kalra, 1982; Reynolds & Davies, 1993), and Chemstrip bG (Boehringer Mannheim, 
Mannheim, Germany) (Kaplan et al., 1989; Holtrop et al., 1990). Recently, point of care 
testing is being done by glucose meters, which utilize enzyme reactions (glucose oxidase or 
glucose dehydrogenase) to generate electric signals, which are measured by a meter. The 
size of the current is proportional to the amount of glucose in the blood sample leading to 
increased accuracy (Beardsall, 2010).  
However it is important to know that these methods were primarily designed for diabetic 
patients and not for the glucose screening of newborns. The sensitivity of these methods is 
likely to be highest at  blood glucose levels in diabetic range and may drop at extreme 
values. In intensive care units, a number of potential inaccuracies may arise because of 
presence of metabolic acidosis (Tang et al., 2000), hypoxia (Tang et al., 2001), hypoperfusion 
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(Atkin et al., 1991) or edema (Critchell et al., 2007). If the devise uses glucose oxidase 
method, it may give abnormally low glucose values at high blood oxygen levels (Tang et al., 
2001). High hematocrit levels in preterm and IUGR neonates might display falsely low 
glucose levels with these methods and this effect is most marked at low blood glucose levels 
(Kaplan et al., 1989; Tang et al., 2000). High bilirubin levels can also interfere with some 
analyzers (Jain et al., 1996). The data of their use in neonatal age group is limited. In a study 
comparing five glucometers namely Reflolux S (Boehringer), Advantage and Glucotrend 
(Roche); Elite XL (Bayer) and Precision (Abbott) with plasma glucose measured in the 
laboratory (Aeroset; Abbott); none of the five glucometers was satisfactory as the sole 
measuring device. For detection of glucose concentrations <2.6 mmol/L, the Precision 
glucometer had the highest sensitivity (96.4%) and negative predictive value (90%). For 
lower glucose concentrations (<2.0 mmol/L), the Glucotrend glucometer performed even 
better (sensitivity 92.3%, negative predictive value 96.3%) (Ho et al., 2004). A recent 
retrospective study compared three meters (Elite™ XL, Ascensia™ Contour™ and ABL 735) 
with laboratory hexokinase reference method. All three POCT systems tended to 
overestimate glucose values. The Elite XL appeared to be more appropriate than Contour to 
detect hypoglycemia, however with a low specificity. Contour additionally showed an 
important inaccuracy with increasing hematocrit. The sensitivity to detect hypoglycemia 
with a cutoff value <2.5 mmol/L was 86% and 43% for Elite XL and Contour respectively 
(Beardsall, 2010).  
With modern blood gas and electrolyte analyzers, it is possible to directly measure blood 
glucose levels by electrochemical biosensors. The comparative data for glucose biosensor 
technology versus traditional methods of blood glucose estimation in the neonatal age 
group is sparse. In a recent study, an amperometric electrode with glucose oxidase 
membrane incorporated in a multi-analyte analyzer was compared with 
hexokinase/glucose-6-phosphate dehydrogenase method. It showed a sensitivity and 
specificity of 55% and 100% respectively below a cutoff of <2.5mmol/L and 89% and 95% 
respectively below a cutoff of <3.0mmol/L of laboratory reference value (Beardsall 2010). 
Another study compared blood glucose measurements obtained by point-of-care testing 
using an AVL Omni 9 blood gas analyzer with those obtained in the central laboratory using 
a DADE Dimension RXL analyzer. There was a good correlation (r = 0.92) between the two 
for glucose values <3 mmol/L. The limits of agreement for the AVL Omni 9 when compared 
with the DADE Dimension RXL analyser were -0.1 +/- 0.5 mmol/L. (Newman et al., 2002). 
Laboratory analyses are done by a number of different enzymes which measure glucose e.g. 
glucose oxidase, hexokinase or glucose dehydrogenase. Glucose measured by these methods 
is the most practical method for measurement of glucose levels. The plasma glucose levels 
measured by these enzymes are less affected by interference by metabolites and are not 
affected by hematocrit (Beardsall, 2010).  
8.3.2 Continuous glucose monitoring 
Continuous glucose monitoring is possible by placement of subcutaneous glucose 
monitoring sensors. This glucose oxidase based platinum sensor catalyzes interstitial 
glucose and an electrical current is produced every 10 seconds. This current is recorded by a 
monitor and displayed as real time trend. The glucose value is averaged for past 5 min and 
thus profile of glucose trend is generated. This displays trend of tissue glucose levels over 
time, like continuous saturation monitors. The glucose levels in newborns can fluctuate 
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(Atkin et al., 1991) or edema (Critchell et al., 2007). If the devise uses glucose oxidase 
method, it may give abnormally low glucose values at high blood oxygen levels (Tang et al., 
2001). High hematocrit levels in preterm and IUGR neonates might display falsely low 
glucose levels with these methods and this effect is most marked at low blood glucose levels 
(Kaplan et al., 1989; Tang et al., 2000). High bilirubin levels can also interfere with some 
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comparing five glucometers namely Reflolux S (Boehringer), Advantage and Glucotrend 
(Roche); Elite XL (Bayer) and Precision (Abbott) with plasma glucose measured in the 
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measuring device. For detection of glucose concentrations <2.6 mmol/L, the Precision 
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lower glucose concentrations (<2.0 mmol/L), the Glucotrend glucometer performed even 
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widely especially those requiring intensive care. This means that by periodic spot 
monitoring we may miss undetected periods of hypoglycemia as well as hyperglycemia 
(Beardsall et al., 2005). Their use in management of adults and children with diabetes has 
led to stringent control over blood glucose levels, with reduction in episodes of 
hyperglycemia and hypoglycemia. Commercial devices are available such as CGMS Gold or 
Guardian (Medtronic Watford UK) or Free Style Navigator (Abbott Maidenhead, Berks, 
UK). The initial devices could not display real time trends limiting their clinical potential. 
However it is possible with more recent models, which have been successfully used to 
monitor post-cardiac surgery pediatric patients. During the management of infants with 
neonatal diabetes, these can be linked to subcutaneous insulin pumps (Corstjens et al., 2006). 
Their clinical application can be extended to the management of preterm and sick neonates 
who are at risk of hypoglycemia and hyperglycemia. However the benefits and risks need to 
be fully evaluated before their introduction into clinical care. Microdialysis is another 
method of continuous glucose monitoring. A semi-permeable dialysis fiber or double lumen 
catheter with micro-holes is placed in subcutaneous tissue. Isotonic glucose free fluid passes 
through the device collecting dialysate of interstitial fluid. Thus the dialysate contains 
glucose equal in concentration to that of interstitial fluid. Commercial devices are available 
such as the CMA Microdialyses catheter (Solna Sweden), which can be used in neonates. 
However these devices are expensive, invasive, need calibration, and there is a significant 
lag time in collection and measurement. Although they have been used as research tool, 
their routine clinical use is limited (Baumeister et al., 2001). In a recent study comparing 
Continuous Glucose Monitor Sensor (CGMS system gold, Medtronic, MiniMed, Northridge, 
California) with glucose oxidase method in blood gas analyzer (Radiometer, ABL800Flex, 
Copenhagen, Denmark), 81% of total 265 episodes of low interstitial glucose concentrations 
were not detected with blood glucose measurement (Harris et al., 2010). The non-invasive 
devices utilizing optical sensors (spectrophotometry) or transdermal devices using reverse 
iontophoresis are being evaluated for possible clinical utilization. They are in early  phase of 
development and their clinical potential is yet to be evaluated in neonates (Beardsall, 2010). 
Thus, at present, there is no reliable and accurate point-of-care method for blood glucose 
estimation in the low ranges of blood glucose encountered in newborn infants. Laboratory 
systems that provide timely results may be the preferred option; these facilities require 
certification by the institutional clinical pathology services and other accrediting agencies, as 
well as initial and ongoing assessment and maintenance of instrument function, technical 
training of the users, and data quality monitoring. Thus far, there are no satisfactory 
methods for noninvasive monitoring of glucose or alternate substrates. Such monitoring 
devices, however, would have a major impact on clinical decision making. Continuous 
glucose monitoring with subcutaneous perfusion devices has been used to a limited extent. 
8.3.3 Properties of the sample and sources of error 
Arterial blood has a slightly higher glucose concentration than venous, while the capillary 
blood has intermediate values. This difference is usually not clinically significant. The 
difference of blood glucose levels between arterial and venous blood depends upon tissue 
glucose demands and is greatest in anaerobic conditions. In presence of peripheral 
circulatory failure, capillary sampling is unreliable as the blood flow is reduced. The blood 
sample must be a free-flowing sample and squeezing the tissues to get blood causes 
hemolysis. The glucose estimations performed with ‘squeezed’ sample are not true values 
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and deproteinization is required to get true values. Contamination by the alcohol antiseptic 
solutions during skin preparations might give erroneously high values (Grazaitis & Sexson 
1980; Togari et al., 1987). The sample should be analyzed immediately or it should be 
deproteinized (e.g. using perchloric acid) and chilled to avoid glycolysis. Sodium fluoride 
added to blood inhibits glycolysis and gives freedom to process sample after some time. But 
the fluoride is not able to completely prevent glycolysis, thus getting falsely low blood 
glucose values in samples sent to a distant laboratory (Elimam et al., 1997). Commercially 
available sodium-fluoride coated tubes do not always ensure a fluoride concentration 
sufficient to inhibit glycolysis (Joosten et al., 1991). Chan et al. observed that glucose levels 
in blood fall about 0.3–0.34 mmol/L over the first hour, in samples collected into either 
heparin or sodium fluoride containing tubes (Chan et al., 1989). High hematocrit values may 
be associated with falsely low blood glucose estimation. Red blood corpuscles contain less 
proportion of water than an equivalent volume of plasma. Thus in equal volume of blood 
and plasma, the glucose concentration is expected to be higher in plasma, on average by 
about 18% (Aynsley-Green, 1991). Furthermore, the diffusion of plasma into the testpad of 
the strip is impeded due to higher sample viscosity. This problem can be tackled by 
estimating plasma glucose after getting plasma from a heparinized microhaematocrit tube 
(Kaplan, Blondheim et al. 1989). Presence of hemolysis also gives falsely low values. The 
presence of hemoglobin or release of reduced glutathione competes with the chromogen for 
hydrogen peroxide released in the assay. Deproteinization of the sample reduces the 
interference with blood glucose estimations by hemolysates, uric acid, and bilirubin 
(Williams, 1997). 
9. Prevention 
The earliest and common cause of low blood glucose levels is delay in the normal metabolic 
adaptation after birth. Hence oral feeds within half hour of life should be promoted in 
healthy appropriately grown term infants. In preterm infants of <32 weeks gestation or 
those with asphyxia or respiratory distress or any illness interfering with enteral nutrition, 
intravenous dextrose infusions should be started. Glucose delivery through intravenous 
infusions should match the amount of glucose production by endogenous hepatic output. 
For most well-grown preterm infants, it is approximately 6 mg /kg/ min (around 90 mL 
10% dextrose/kg per day (Sunehag et al., 1993). The occurrence of hypoglycemia should be  
unusual with such fluid regimens, in these preterm infants, (Hawdon et al., 1992) and 
enteral feeds can be gradually increased along with. Near-term infants of 33-36 weeks 
gestational age require careful nursing as they may not be able to establish good feeding due 
to physiological handicaps and increased demands. Supplementary feeds may be required if 
breastfeeding is not fully established. If possible first option should be expressed breast 
milk, and formula milk can be used if breast milk is unavailable or inadequate. In neonates 
who remain hypoglycemic despite an adequate enteral intake, or for those unable to tolerate 
milk, an intravenous dextrose infusion is necessary. Some IUGR infants require glucose 
intake in excess of 10 mg/kg/min. Hyperinsulinism may be the likely mechanism of such 
high glucose requirements (Collins et al., 1990) and these babies may have insulin values 
above those seen in healthy term babies (Hawdon et al., 1993a, 1993b). They may be 
described as ‘functionally’ hyperinsulinemic as they also demonstrate increased insulin 
sensitivity (Bazaes et al., 2003). 
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10. Treatment of neonatal hypoglycemia 
A ‘symptomatic’ neonate should be treated with intravenous dextrose and this should be 
instituted as early as possible if the blood glucose concentrations are below 45-50 mg/dL 
(Volpe, 2008). Glucose ‘minibolus’ (200 mg glucose/kg, 2 mL/kg of 10% dextrose) is 
effective in rapidly correcting neonatal hypoglycemia. A minibolus should be given when 
blood glucose concentration needs to be raised quickly, such as in a symptomatic neonate 
with neurological signs in association with a low blood glucose concentration. A minibolus 
should always be followed by intravenous glucose infusion. The glucose infusion should be 
started at an infusion rate of 6-8 mg/kg per min (Lilien et al., 1980). The glucose infusion 
rate (GIR) should then be titrated with repeated blood glucose estimations. Blood glucose 
should be frequently monitored until it stabilizes. After commencing intravenous infusion, 
blood glucose should be repeated with in half an hour. The glucose infusion rate should be 
hiked by 2 mg/kg per min if the repeat screen is also in ‘hypoglycemic’ range. Once blood 
glucose levels are stabilized, preprandial blood glucose may be monitored at 4 to 8 hour 
intervals (Cornblath & Ichord, 2000). Boluses of hypertonic glucose solution should be 
avoided as they can precipitate rebound hypoglycemia. Baby should be offered enteral feeds 
if clinically there is no contraindication. Amino-acids like alanine promote gluconeogenesis 
and help to maintain blood glucose levels. Breast milk in particular promotes ketogenesis 
(de Rooy & Hawdon, 2002). After 12-24 hours of intravenous glucose infusion, addition of 
sodium 1 to 2 mEq/kg/day is indicated to prevent iatrogenic hyponatremia. After 24-48 
hours, 1 to 2 mEq/kg/day of potassium should be added to the parenteral fluids (Cornblath 
& Ichord, 2000). If baby remains symptomatic or if plasma glucose concentrations cannot be 
maintained over 45 mg/dL (2.6 mmol/L), even at glucose infusion rate of 12 mg/kg/min, 
hydrocortisone (5 mg/kg intravenously every 12 hours) should be added to the regimen 
(Volpe, 2008). If the concentration of glucose infusion exceeds 12.5% to 15% through 
peripheral vein, a PICC (peripherally inserted central catheter) line should be placed, as 
concentrated solutions can cause injury to peripheral veins. If the rate of glucose infusion 
exceeds 10-12 mg/kg/min or the hypoglycemia is present after 5 to 7 days, the infant may 
have refractory or persistent hypoglycemia (Cornblath & Ichord, 2000).  
Once the blood glucose levels are maintained in euglycemic range of 70-100mg/dL, the 
glucose infusion should be tapered by 2mg/kg/min every 6 to 12 hourly. The gradual 
reductions in the rate of intravenous glucose infusion should be attempted as they avoid 
wide swings in blood glucose concentrations. The glucose infusion rate should be reduced 
while increasing oral intake (Williams, 1997) and glucose levels should be closely monitored 
to keep them >50mg/dL (Volpe, 2008). Intramuscular glucagon (see below) may act as a 
temporary measure to raise blood glucose, if there is difficulty in placing intravenous line 
quickly. Glucagon promotes early neonatal glycogenolysis from liver and also stimulates 
gluconeogenesis and ketogenesis (Milner & Wright, 1967). An intramuscular bolus dose of 
200 μg/kg increases the blood glucose level (Hawdon et al., 1993c). It has been used 
successfully to treat hypoglycemia in infants of diabetic mothers (Wu et al., 1975) and 
growth-restricted infants (Carter et al., 1988). Side-effects of glucagon include vomiting, 
diarrhea, and hypokalemia; at high doses it may stimulate insulin release. Controlled 
studies of the relative efficacy of glucagon and the more conventional alternative of glucose 
infusion at concentrations >6mg/kg per min are needed (Williams, 1997). An algorithm for 
the management of a neonate with hypoglycemia is presented in Figure 3 (Narayan & 
Wazir, et al. 2010). 
 




GIR: Glucose Infusion Rate   BS:Blood Sugar(Glucose) 
Fig. 3. Management algorithm for neonatal hypoglycemia  
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11. Refractory or persistent neonatal hypoglycemia 
Refractory or persistent hypoglycemia can be defined as the persistent requirement of a 
glucose infusion rate more than 12 mg/kg/min to maintain normoglycemia or persisting or 
hypoglycemia beyond first 5 to 7 days of life. The causes of refractory or persistent 







Anterior pituitary "aplasia" 




Isolated growth hormone deficiency 
Adrenogenital syndrome 
Adrenal hemorrhage 
Hormone Excess with Hyperinsulinism Beckwith-Wiedemann syndrome 
Hereditary defects of pancreatic islet cells 
Hereditary Defects in Carbohydrate 
Metabolism 
Glycogen storage disease 
Fructose intolerance 
Galactosemia 
Glycogen synthase deficiency 
Fructose, 1-6 diphosphatase deficiency 
Ketogenetic and ketolytic defects 
Hereditary Defects in Amino Acid 
Metabolism 




Hereditary Defects in Fatty Acid 
Metabolism 
3-OH-3-methyl glutaryl CoA lyase 
deficiency 
Acyl CoA dehydrogenase--medium, long 
chain deficiency 
Mitochondrial/3-oxidation & degradation 
defects 
Table 1. Causes of Refractory or Persistent Hypoglycemia 
The most common cause of persistent or refractory hypoglycemia is congenital 
hyperinsulinism, also called as persistent hyperinsulinemic hypoglycemia of infancy (PHHI). 
Although a glucose infusion rate exceeding 12 mg/kg per min suggests hyperinsulinism, the 
diagnosis is confirmed by the presence of- 
1. Hyperinsulinemia (plasma insulin >2 μU/mL, depending on sensitivity of insulin 
assay), in presence of documented laboratory hypoglycemia (<50 mg/dL)  
2. and/or evidence of excessive insulin effect 
a. Increased glucose consumption rate (>8 mg/kg/min) 
b. Hypofattyacidemia (plasma free fatty acids <1.5 mmol/L)  
c. Hypoketonemia (plasma β-hydroxybutyrate <2.0 mmol/L)  
d. Glycemic response to 1 mg IV glucagon 50 µg/kg (max 1mg)  (increase in  glucose 
>30 mg/dL)  
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Insulin level should be obtained only during presence of hypoglycemia. Simultaneous 
measurement of blood glucose level may be done to find out the insulin-glucose ratio. 
Elevated insulin-glucose ratios are found in hyperinsulinemic states (normal - up to 0.2; 
elevated - >0.4). A ‘normal’ level of insulin is abnormal if it occurs in the face of 
hypoglycemia, especially in the context of high glucose requirement to maintain 
normoglycemia. 
PHHI results from an inappropriate insulin secretion by the β-cells of pancreatic islets of 
Langerhans (Arnoux et al., 2010). Insulin decreases plasma glucose concentration by 
inhibiting glucose release from the liver (by glycogenolysis and gluconeogenesis), and by 
increasing glucose uptake in muscle and adipose tissues. It also inhibits lipolysis and hence 
production of fatty acids and ketone bodies is markedly reduced. Hence, the brain is unable 
to get alternative fuels in presence of hypoglycemia and thus is particularly vulnerable to 
hypoglycemic injury.  
PHHI presents as severe hypoketotic hypoglycemia. There is a risk of neonatal seizures and 
brain damage if it is left untreated. Hypoglycemia occurs early within 72 h after birth and 
half of the patients become symptomatic in the form of seizures. Majority of neonates are 
macrosomic. The affected neonates may present with abnormal movements as 
tremulousness, hypotonia, cyanosis, hypothermia or a life-threatening event. On external 
examination, they may have mild hepatomegaly. Sometimes typical facial features in form 
of high forehead, large and bulbous nose with short columella, smooth philtrum and thin 
upper lip can be appreciated. However, hyperinsulinism can be associated with syndromes 
such as Beckwith–Wiedemann syndrome (BWS), Perlman syndrome, Kabuki syndrome, 
Sotos syndrome, congenital disorders of glycosylation type Ia or Ib (CDG) (de Lonlay et al., 
1999), or Usher syndrome type Ic. Hypoglycemia may be detected in such neonates by 
routine measurement of blood glucose. The hypoglycemia is severe and rates of intravenous 
glucose administration to maintain euglycemia are usually in excess of 12 mg/kg per min. 
Subcutaneous or intramuscular administration of glucagon can be used to raise blood 
glucose concentrations transiently.  
Hyperinsulinemia in the neonatal age group may also be seen for transient periods in 
conditions like acute fetal distress, small weight for gestational age and gestational diabetes. 
The severity is usually mild in such cases. These neonates respond to diazoxide, and 
hyperinsulinemia resolves spontaneously within several days or weeks. All neonates with 
hyperinsulinemia should be screened for hyperammonemia to diagnose hyperinsulinemia 
hyperammonia (HI/HA) syndrome (GLUD1 gene), urine organic acids to diagnose short 
chain hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency (HADH gene) and plasma 
acylcarnitines chromatographies, for CDG syndromes, as these 3 diseases may present in the 
neonatal period as apparently isolated hyperinsulinism (Arnoux et al., 2010). Other genes 
which can be suspected are SLC16A1 gene (Otonkoski et al., 2003) and HNF4A gene when 
the newborn is macrosomic with a family history of  maturity onset diabetes of young 
(Pearson et al., 2007). Finally, familial forms or consanguinity and syndromic forms have to 
be checked as these are associated with  diffuse HI (Arnoux et al., 2010). 
The treatment of such a condition should be aggressive as the glucose levels are very low 
and there is deficiency of alternative brain fuels in hyperinsulinemic neonates. Majority of 
these neonates are already on intravenous glucose administration when the diagnosis of 
hyperinsulinemia is established. Medical management consists of drugs such as Diazoxide, 
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Hyperinsulinemia in the neonatal age group may also be seen for transient periods in 
conditions like acute fetal distress, small weight for gestational age and gestational diabetes. 
The severity is usually mild in such cases. These neonates respond to diazoxide, and 
hyperinsulinemia resolves spontaneously within several days or weeks. All neonates with 
hyperinsulinemia should be screened for hyperammonemia to diagnose hyperinsulinemia 
hyperammonia (HI/HA) syndrome (GLUD1 gene), urine organic acids to diagnose short 
chain hydroxyacyl-CoA dehydrogenase (SCHAD) deficiency (HADH gene) and plasma 
acylcarnitines chromatographies, for CDG syndromes, as these 3 diseases may present in the 
neonatal period as apparently isolated hyperinsulinism (Arnoux et al., 2010). Other genes 
which can be suspected are SLC16A1 gene (Otonkoski et al., 2003) and HNF4A gene when 
the newborn is macrosomic with a family history of  maturity onset diabetes of young 
(Pearson et al., 2007). Finally, familial forms or consanguinity and syndromic forms have to 
be checked as these are associated with  diffuse HI (Arnoux et al., 2010). 
The treatment of such a condition should be aggressive as the glucose levels are very low 
and there is deficiency of alternative brain fuels in hyperinsulinemic neonates. Majority of 
these neonates are already on intravenous glucose administration when the diagnosis of 
hyperinsulinemia is established. Medical management consists of drugs such as Diazoxide, 
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Nifedipine and Octreotide. Diazoxide blocks insulin secretion by activating (opening) the 
SUR1 receptors. Transient and persistent hyperinsulinemia (involving genes other than 
those encoding SUR1 and Kir6.2) respond to diazoxide. However, most of neonatal and 
isolated persistent HI is resistant to diazoxide. Diazoxide is tolerated well by neonates 
except in premature neonates because of sodium and fluid retention, which may lead to 
edema, pulmonary hypertension or heart failure. The most frequent adverse effect of 
prolonged use is hypertrichosis. Hematological side effects are very rare in routine doses. 
Diazoxide unresponsiveness is defined by the occurrence of 2 episodes of hypoglycemia 
[<54 mg/dL (<3 mmol/L)] in 24-hour period. In such cases, Octreotide must be tried before 
considering surgery (Thornton et al., 1993). Doses vary from 10 to 50 μg/kg/day 
intravenously, administered continuously or subcutaneously every 6 or 8 h. Higher doses 
may worsen hypoglycemia by suppressing both glucagon and growth hormone. Some 
patients may have vomiting and/or diarrhea and abdominal distension after starting 
therapy, which spontaneously resolves within 7–10 days. Gallbladder sludge or stones may 
appear during therapy. The dose of octreotide should be progressively increased according 
to the weight gain of the baby, to prevent recurrence of hypoglycemia. Other drugs such as 
calcium channels blockers (nifedipine, 0.5– 2 mg/kg/day in 2 oral doses) can be tried. 
Surgery is the other treatment option  if  medical management fails. Patients requiring 
surgical treatment must be assessed for histological form of HI (Shilyansky et al., 1997; 
Rahier et al., 1998). HI has two histological forms (focal form and diffuse form) and the 
choice of surgery is different for each form. The focal form is defined by focal adenomatous 
hyperplasia of islets β-cells within the pancreatic tissue and it requires partial and selective 
pancreatectomy (Goossens et al., 1989; Arnoux et al., 2010). However all the β-cells of the 
pancreas are abnormal in diffuse form, so that a subtotal pancreatectomy may improve the 
patient’s condition. Positron emission tomography (PET) utilizing 18F-fluoro-L-DOPA 
isotope localizes the focal lesion (Ribeiro et al., 2007; Barthlen et al., 2008) and differentiates 
between the two histological forms. Pancreatic catheterization with pancreatic venous 
sampling was previously used to distinguish the two forms but now it has been replaced by 
PET scan (Arnoux et al., 2010). 
12. Summary  
Neonatal hypoglycemia is a common metabolic disorder and the operational threshold 
values of blood glucose <40 mg/dL (plasma glucose< 45 mg/dL) should be used to guide 
management. All “at risk” neonates and sick infants should be monitored for blood glucose 
levels. Term healthy AGA infants without any risk factors need not be monitored routinely. 
Screening for hypoglycemia can be done by point of care devices but confirmation requires 
laboratory estimation of blood glucose levels. Treatment however should not be delayed 
while awaiting laboratory confirmation. Asymptomatic hypoglycemia can be managed with 
a trial of measured oral feed if blood glucose is >25 mg/dL and there is no contraindication 
to feeding. Symptomatic hypoglycemia should be treated with a mini-bolus of 2 ml/kg  10% 
dextrose followed by continuous infusion of 6-8 mg/kg/min of 10%dextrose. Refractory or 
persistent  hypoglycemia should be suspected and investigated if the glucose infusion 
requirement is consistently more than 12 mg/kg/min or the hypoglycemia persists more 
than 5-7 days. Babies with hypoglycemia should be followed up for neurodevelopmental 
sequelae. 
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1. Introduction 
Hypoglycaemia is a common problem in the neonatal period, and it frequently reflects 
difficulties in adapting to extra uterine life. Strategies to facilitate this physiological 
adaptation should be enhanced. (Sem fetal neo del 2005) 
Incidence is variable depending on the definition criteria used in different studies, but 
according to Cornblath (Cornblath et al 1993, 2000 as cited by Fernández Loranzo et al 2011) 
it varies from 5-7% in term newborns and from 3.2 to 14.7% in preterm infants. Respective to 
weight, it occurs in 8% of Large for Gestational Age (LGA) and up to 15% of Small for 
Gestational Age (SGA) infants.  
There is still no universal consensus on how to define hypoglycaemia. Establishing a 
universal cut-off glucose value is difficult and considerations must be made regarding the 
measuring device used, type of sample (blood, serum or plasma), moment of measurement 
after birth, duration and degree of hypoglycaemia and characteristics of the newborn. Based 
on the World Health Organization (WHO) recommendations (WHO 1997 as cited by 
Fernández Lorenzo et al 2011) thresholds would be:  
Sick newborn, (signs of illness):  <2.5mmol/L or 45 mg/dL 
Healthy term / preterm (feeding well):  < 1.1 mmol/L or < 19.8 mg/dL 
Most expert authors support the cut-off value of 36mg/dL for asymptomatic healthy 
newborns, rather than the WHO suggested threshold, and some authors even suggest that 
values down to 1.7mmol/L should be accepted in an otherwise healthy term infant  
(Fugelseth 2001). In a recent review on neonatal hypoglycaemia, operational thresholds of 
less than 40mg/dL (2.2mmol/L) during the first 24 hours and less than 50mg/dL 
(2.8mmol/L) thereafter are suggested (Chan 2011). Other definitions have been suggested 
such as using an epidemiological concept: considering hypoglycaemia when glucose levels 
are 2 standard deviations below the mean value for infants of the same age (which would be 
around 20-30mg/dL). However, this value does not seem like the optimal threshold, so this 
definition is rarely used in clinical practice or for study purposes.  
Experts agree that the neurological disabilities associated to neonatal hypoglycaemia 
depend on gestational and chronological age and associated risk factors such as Hypoxic-
Ischemic Encephalopathy (HIE) and that they frequently result after situations of persistent 
and severe hypoglycaemia (Fernández Lorenzo et al 2011). What is more, the vast majority 
of healthy term newborns with isolated glucose levels under the target of 45 mg/dL will 
have a normal neurological prognosis. (Hay et al 2009)  
Recent consensus workshop (Straussman & Levitsky 2010) results reveal that there has been 
little progress in establishing a clear numerical definition for hypoglycaemia, but 
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understanding of underlying pathogenic mechanisms (specially in persistent 
hypoglycaemias), new information in genetic causes and promising information based on 
neuroimaging to define neurological outcomes, help define new strategies in preventing and 
treating hypoglycaemia in newborns (Chan, 2011).  
2. Glucose metabolism physiology in the term and preterm newborn 
Glucose is the most important foetal energy substrate (mainly for brain metabolism). Foetal 
glucose needs are met thanks to the continuous transplacental glucose transfer, and 
although the necessary enzyme systems needed for gluconeogenesis develop early during 
pregnancy, the foetus only produces its own glucose in extreme conditions such as maternal 
starvation. (Gustaffson 2009). The foetal glucose level is 60-80% of that of the mother’s.  
In order to provide the foetus with glucose, the mother undergoes different metabolic 
changes throughout gestation, such as increase in hepatic glucose production. Also, during 
the first trimester, the mother has a higher sensitivity to insulin that leads to fat depot 
formation. Later on, on the third trimester, when the baby has its own fat depots, the mother 
metabolizes these depots via lypolisis for her own needs under the influence of specific 
hormone changes therefore saving glucose for foetal use only.  
The foetus is exposed to high insulin concentrations, as it has a very important anabolic 
action. During the third trimester, insulin stimulates fat deposition and increases energetic 
stores in the form of glycogen.  
At birth, the constant placental supply is interrupted. Healthy term infants are prepared to 
adapt to this new situation thanks to a series of metabolic and hormonal changes that will 
ensure that the newborn’s glucose demands (Central Nervous System (CNS) in particular) 
will de adequately met in the first 48 hours, while sufficient enteral feeding is being 
established. It has been demonstrated that early, frequent, breastfeeding together with skin 
to skin contact, promote adequate transition and meet the needs of healthy full-term infants. 
(Wight, 2006; Achoki et al, 2010).  
First, an increase in glucagon and catecholamine levels and a decrease in insulin levels occur. 
This induces hepatic glucose production, (which in a healthy full term baby is 4-
6micrgo/kg/min, three times that of an adult). This rate of hepatic glucose production is 
proportional to the baby’s estimated brain weight. During the first 10 hours of life, it occurs by 
glycogenolisis. After, it takes places via gluconeogenesis (production of glucose “de novo” 
from alanine, pyruvate, lactate and glycerol). To further help in neoglucogenesis, lypolisis is 
stimulated (to levels comparable to an adult fasting), due to an increase in TSH levels after 
birth, which generates glycerol and free fatty acids. These free fatty acids play an important 
role as they promote further neoglucogenesis, and together with ketone bodies and lactate, are 
used as an alternative energy substrate for the brain. (Gustaffson, 2009; Mitanchez, 2007)) 
After birth, an adequate balance between tissue consumption of glucose, hepatic glucose 
production and exogenous glucose supply is necessary to establish glucose homeostasis. 
Glucose levels in the newborn decrease in the first two hours, but steadily rise afterwards 
and thereafter remain constant. Hypoglycaemia occurs when this equilibrium fails, and is 
usually transient.  
In the presence of persistent hypoglycaemia, three main possible scenarios must be 
considered: depletion of energetic storage (prematurity and intra-uterine growth 
restriction), increase tissue energetic consumption and foetal hyperinsulinism. (Mitanchez, 
2008; Wight, 2006; Ward Platt & Desphande 2005).  
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Preterm and intrauterine growth restricted (IUGR) newborns have different patterns of 
adaptation to that of a full-term neonate: they both have limited energy depots, and they have 
a higher risk of impaired compensatory ketogenesis. (Ward Platt & Desphande 2005). These 
babies are capable of neoglucogenesis and lypolisis, with some differences and restrictions.  
Preterm infants have limited energy stores plus immature metabolic pathways to ensure an 
adequate glucose production, that lead to a larger fall in blood glucose in the first hours after 
birth. Because they have limited glycogen liver storage depots (since this takes place mainly 
during the third trimester), glycogenolisis is limited, therefore neoglucogenesis (from glycerol, 
alanine and lactate) is the main pathway for glucose production. Because neoglucogenesis 
requires some time to begin, in the absence of adequate glycogenolisis, hypoglycaemia in these 
“babies is hard to” avoid if exogenous glucose is not administered (Mitanchez, 2007), although 
some authors suggest that though neoglucogenesis occurs at slower rates in these infants than 
in term newborns, it may be just sufficient to prevent hypoglycaemia in the first hours of life 
(Gustafsson, 2009). Lypolisis occurs. However,  the depot fat in an infant born after at 28 weeks 
is only 2% of total body weight (7 times less than in term infants) therefore the degree of 
lypolisis is decreased (Gustafsson, 2009; Diderholm , 2009).  
Preterm  infants  are  therefore at higher risk for hypoglycaemia  because of their limitations 
for adequate glucose metabolism, but also because other clinical conditions which are 
associated with hypoglycaemia are common in this population, such as perinatal asphyxia, 
hypoxia, sepsis, and hypothermia. Preterm infants are less capable of compensating  these 
glucose alterations than term infants are, being the final goal to ensure sufficient energy 
substrate for the brain to use, and even moderate hypoglycaemia can lead to an adverse 
neurodevelopmental outcome. Enteral feeding is a stimulus for postnatal metabolic 
adaptation. Thus, early milk feeding should be encouraged as soon as possible when 
tolerated, even at a minimal level (Mitanchez, 2007).  
On the other hand, preterm infants (particularly those less than 30 weeks of gestational age 
(GA)) frequently have impaired insulin – glucose balance, leading to hyperglycaemia during 
the first weeks of life. This occurs because processing of pro-insulin in the pancreatic beta-
cells is deficient, therefore preterm infants are partially resistant to insulin. Exogenous 
insulin infusion is efficient and may be used with caution. (Mitanchez, 2008). These patterns 
of metabolic adaptation are further influenced by feeding practices. (Ward Platt & 
Desphande, 2005) 
As mentioned before, compared to adequate for gestational age (AGA), infants with IUGR 
have smaller energy depots. Gluconeogenesis has been shown to occur effectively from 
glycerol in these infants (50% of glycerol is converted to glucose and this rate increases in 
babies who do not receive extra parenteral glucose infusion) and from pyruvate. Ketogenesis 
is severely limited in preterm infants. Lypolisis also occurs but is limited because it correlates 
with birth weight (that is: the rate of lypolisis depends on the amount of stored fat), and it is 
therefore reduced in IUGR babies (Gustafsson, 2009, Mitanchez, 2007). 
Infants born to diabetic mothers are at risk for hypoglycaemia, due to increased levels of 
insulin in the baby. This increase occurs due to increased maternal glucose levels 
throughout the pregnancy. Despite insulin normally reducing lypolisis, this does not 
happen in these babies, probably as a compensation for the lower level of glucose 
production seen in these newborns (Gustafson, 2009).  
There is limited information on metabolism in newborn LGA infants. These babies tend to 
have increased lypolisis rates (partly due to higher body and brain weight) and variable 
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degrees of insulin resistance (as happens with obese children in later periods of life) 
(Gustafsson, 2009).  
3. Defining aetiology and risk factors  
When considering aetiology and risk factors in hypoglycaemia, the differentiating marker is 
whether it is transient (< 3-5 days) or persistent (> 5-7 days). (Fernández Lorenzo et al,  2011; 
Cloherty & Stark, 2009;  Polin & Yoder 2007; Chan 2011).  
3.1 Transient hypoglycaemia 
Low endogenous glucose production or low glycogen deposits.  
This occurs in situations where glucose metabolic pathways are impaired or immature such 
as in preterm infants, intrauterine growth retardation (IUGR) and small for gestational age 
(SGA) newborns and in situations of insufficient calorie intake (feeding difficulties, 
problems with breastfeeding or intolerance of enteral feedings etc…).  
Increase in glucose use or diminished exogenous administration.  
Exposure to situations with high energy consumption rates such as perinatal stress (asphyxia, 
sepsis, respiratory distress, hypothermia, congenital cardiopathy…). In these situations, 
anaerobic glycolisis occurs due to decreased tissue perfusion and low oxygen blood content. 
When polycythemia occurs, the higher number of red blood cells consume glucose at higher 
rates than normal, as would happen during and after an exanguinotransfussion procedure. An 
abrupt cease in intravenous glucose administration may induce transient hypoglycaemia that 
is normally reverted reinitiating the glucose infusion. 
 
RISK FACTOR MECHANISM 
Preterm and Intrauterine Growth 
Restriction 
Low glycogen deposits 
Restriction in fluids / energy 






Pancreatic islets dysregulation Syndrome
Pancreatic islets adenoma Persistent hyperinsulinism 
Perinatal stress; asphyxia, sepsis 
Polycythemia, hypothermia 
Low glycogen deposits 
Hyperinsulinism 
Feeding difficulties 
Fluid / energy restrictions 
Maternal drugs: propanolol, oral 
antidiabetic preparations Altered cathecolamin response 
Adrenal insufficiency
Hypothalamic / Hypopituitaric deficiency Counter-regulatory hormone deficiency 
Inborn errors in metabolism Enzyme defects, altered glucogenolisis, neoglucogenesis or fatty acid oxidation. 
Table 1. Risk factors and physiopathological mechanisms that cause hypoglycaemia 
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Transient hyperinsulinemic hypoglycaemia 
There are many situations where the newborn is exposed to intra-uterine hyperinsulinism, 
rendering the infant prone to hypoglycaemia after birth, when that hyperinsulinism persists 
until pancreatic beta cells commence to work and regulate insulin secretion, but the constant 
transplacental glucose supply has been terminated.  
Diabetic mothers (specially those needing insulin during gestation, which implies worse 
glucose regulation), big for gestational age neonates, erytroblastosis, misplaced umbilical 
arterial line (near the pancreas) or if the mother receives intrapartum Pre-par* or other beta-
sympaticomimetics that interrupt glycogenolisis, tiazides, clorpropamide, anti-
hyperglycaemic agents or glucose infusion rates of more that 10g/h before birth, may 
develop transient hyperinsulinemic hypoglycaemia. In the Beckwith-Wiedemann Syndrome 
(LGA newborn, macroglosia, onphalocele and visceromegaly), hypoglycaemia occurs 
secondary to transient hyperinsulinism due to pancreatic beta cells hypertrophy.  
3.2 Persistent hypoglycaemia 
When persistent hypoglycaemia occurs (that is, need for glucose infusion for more than 5-7 
days, in particular when high rates are required) other clinical scenarios must be ruled out 
and specific diagnostic procedures must be started.  
Prolonged neonatal hyperinsulinemic hypoglycaemia may occur as a result of 
nesidioblastosis, pancreatic adenoma or beta cell hyperplasia, that is, clinical situations that 
increase insulin production at the pancreatic beta cell. However, up to 30-40% of persistent 
hyperinsulinism cases are congenital or genetic, with increasing knowledge of genetic 
mutations in specific calcium channels that control insulin secretion. This will be further 
explained.  
Other causes of persistent hypoglycaemia are syndrome such as Usher Syndrome (hearing 
loss and retinitis pigmentosa), endocrine disorders (pituitary hormone deficiencies or 
primary adrenocortical insufficiency) and inborn errors of carbohydrate metabolism 
(glucogenosis, hereditary fructose intolerance and galactosemia) or amino-acid metabolism 
(methylmalonic and glutaric acidemias, leucinosis (MUSD), carnitine deficiency and 
others…) and defects in fatty acid beta-oxidation.    
4. Clinical manifestations of hypoglycaemia in the neonatal period 
These are unspecific and may resolve within minutes-hours after normoglycaemia is 
restored, unless cerebral damage has occurred. 
Neurological symptoms such as irritability, tremor, jitteriness, hypotonia, exaggerated Moro 
reflex, and weak cry may appear gradually and progress towards seizures, acute 
encephalopathy, lethargy and coma. Altered state of consciousness is a common finding, 
with alternate jitteriness and stupor (Chan, 2011).  
Jitteriness is not very specific of hypoglycaemia though a frequent form of presentation, as it 
may be present in up to 44% of healthy term infants (Alkalay et al, 2005). In some cases, it 
may be pathological, resembling a brainstem release reflex (impaired function of superior 
cortical inhibitory structures that normally control the brainstem). As for tremor, it is also 
frequent in healthy term newborns, and only normally correlates to hypoglycaemia or 
hypocalcaemia when it persists despite suckling stimulation, rather than stopping as it does 
in healthy babies. As for seizures, these may present very early after hypoglycaemia 
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degrees of insulin resistance (as happens with obese children in later periods of life) 
(Gustafsson, 2009).  
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RISK FACTOR MECHANISM 
Preterm and Intrauterine Growth 
Restriction 
Low glycogen deposits 
Restriction in fluids / energy 






Pancreatic islets dysregulation Syndrome
Pancreatic islets adenoma Persistent hyperinsulinism 
Perinatal stress; asphyxia, sepsis 
Polycythemia, hypothermia 
Low glycogen deposits 
Hyperinsulinism 
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Table 1. Risk factors and physiopathological mechanisms that cause hypoglycaemia 
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Transient hyperinsulinemic hypoglycaemia 
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appears, but normally occur after persistently or recurrently low glucose values over at least 
12 hours.  
Other clinical manifestations include tachypnea, cyanosis (due to apnea, autonomic 
response or decreased pulmonary flow) or apnea spells. Difficulty to suck and feeding 
problems may also occur. Autonomic alterations are frequent, such as hypothermia or 
unstable temperature, pallor, profuse sweating or bradycardia (Alkalay et al, 2005). 
5. Monitoring glucose levels and how to do so?  
In the presence of asymptomatic newborns with any of the known risk factors (preterm, 
IUGR, SGA and LGA infants; newborns with diabetic mothers; perinatal stress situations; 
maternal drugs before or during labour, infants requiring intensive care, those with 
polycythemia and syndromes such as Beckwith-Wiedemann) glucose must be closely 
monitored. Blood glucose should also be monitored in infants receiving long duration 
parenteral nutrition, even when stable. Healthy asymptomatic newborns without risk 
factors do not need routine evaluation.  Chan 2011 
Glucose determination must be done at the first hour of life, and afterwards, depending on 
different guidelines (Fernández Lorenzo et al, 2011) every 2-4 hours for the first 8 hours of 
life, and every 6-8 hours for the following 24 hours of life. The main point however, is to 
carefully assess glucose metabolism during the more vulnerable stages of transition. 
Normally, if glucose levels are maintained in the first hours of life (when hypoglycaemia is 
most likely), they rarely fall afterwards. Nevertheless, periodic measurements (more or less 
frequently depending on glucose values and associated risk factors) must be performed 
during at least the first critical 24 hours.  
Specifically, suggested controls in newborns of diabetic mothers would imply: glucose 
testing in the first hour of life, and afterwards, every 6-12 hours, since hypoglycaemia is 
most probable around the first six hours of life. These controls may be suspended after 12 
hours of normal glucose values.  
In preterm and SGA infants however, controls should be more frequent, every 2-4 hours 
depending on glucose values: are they normal, just on the limit or actually low? Do they 
require clinical management that must be monitored? 
On the other hand, whenever a newborn presents with clinical symptoms that could be due 
to hypoglycaemia, particularly if the newborn has risk factors for hypoglycaemia, rapid 
glucose determination is imperative, as early treatment is essential to prevent brain damage. 
This implies having a wide scope of suspicion in any situation, as symptomatic 
hypoglycaemia con vary from very unspecific clinical symptoms such as discrete irritability 
to more alarming and obvious presentations such as seizures, and recognition is 
determinant.  
6. Diagnosis  
In order to diagnose hypoglycaemia, a cut-off value has to be established. There is still no 
evidence of what that numerical value is, and it probably differs amongst different babies 
(term, preterm, IUGR, asphyxiated, septic… ) as tolerance thresholds of glucose values are 
probably different in each of these scenarios (sick babies are probably more susceptible to 
hypoglycaemia than healthy term newborns, specially if hypoglycaemia persists or is 
severe). Therefore, in order to diagnose hypoglycaemia, operational guidelines exist, and 
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diagnosis is normally made in the presence of blood glucose concentration <45mg/dL 
(<2.5mmol/L) in the first hours – days of life. (Fugelseth, 2001). Later on, a certain degree of 
glucose control is expected and hypoglycaemia is diagnosed with glucose levels < 50-55 
mg/dL. (Chan , 2011).  
Accurate measurement of blood glucose levels in the newborn is important in order to 
prevent and treat hypoglycaemia effectively, therefore reducing the risk of adverse 
neurological outcomes. Commonly used Point of care (POC) glucose testing provides 
immediate results with small sample volumes. This enables treatment, when necessary, to 
start fast and permits the necessary modifications according to the infants´ clinical situation. 
These devices are perfected constantly, and yet, they still lose accuracy at the limits of both 
low and high glucose values (hypoglycaemia with blood glucose <2.0 mmol/l or <2.6 
mmol/l and hyperglycaemia with blood glucose >10 mmol/l). Knowing these limitations is 
important and so strictly speaking, these devices cannot be completely relied on for an 
accurate diagnosis. However, as a screening tool, they are essential, and when accuracy is 
doubtful, laboratory confirmation is necessary. This will require intermittent blood samples 
and results are somewhat delayed. Less invasive and continuous methods of glucose 
monitoring are under development. These devices provide constant information and  being 
increasingly used for control and care of patients with diabetes mellitus, but they are not 
currently in use in neonates (Beardsall, 2010).  Continuous interstitial glucose monitoring 
has been tested on newborns thought to be at risk for hypoglycaemia, and though 
apparently reliable, it is still not known how to best interpret the results, and therefore more 
studies are needed before implementation of this technique. (Harris et al, 2010; Hay et al , 
2010 as cited in Chan, 2011).  
When using laboratory measurement of glucose, it is important to know what sample is 
used. Glucose concentration in whole blood is up to 15% lower than that in plasma and may 
be even lower in the presence of a high hematocrit. Once the sample has been taken, 
analysis should be performed rapidly, as glucose values in blood can decrease by 15 to 20 
mg/dL per hour in blood samples at room temperature. (Chan, 2011).  
Diagnosis of hypoglycaemia begins with determining low glucose levels in the presence or 
not of clinical symptoms. It should be emphasized that surveillance and intervention 
thresholds are not the same: when treating hypoglycaemia, the desired range for 
normoglycaemia should be  72-90 mg/dL (4-5 mmol/L), as opposed to the diagnostic 
suggested thresholds of <46mg/dL (<2.6mmol/L) (Kalhan &  Peter-Wohl, 2000).  
This is normally a transient problem in adaptation in a newborn with frequently 
recognisable risk factors or other treatable underlying causes such as sepsis, insufficient 
exogenous glucose administration or errors in administration. However, when 
hypoglycaemia is persistent (at least more than 72 hours, and specifically more than the first 
week of life), and high rates of iv glucose (some times up to 12 mg/kg/min) are required to 
maintain normal glucose levels, specific laboratory test must be begun to rule out causes of 
persistent hypoglycaemia in order of frequency (Chan, 2011): prolonged neonatal 
hyperinsulinemic hypoglycaemia,  congenital hyperinsulinemic hypoglycaemia, endocrine 
disorders and inborn errors of metabolism. 
The diagnostic algorithm requires defining ketone body production, and plasma levels of 
both free fatty acids and of lactic acid. With these three parameters, we can establish which 
diagnosis is most probable:  
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both free fatty acids and of lactic acid. With these three parameters, we can establish which 
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Fig. 1. Algorithm for hypoglycaemia diagnosis 
Ketone body production is the normal alternative pathway to obtain energy in the absence 
of sufficient glucose supply. Free fatty acids are oxidized to obtain ketone bodies, which are 
an important  energy substrate for the heart, muscle and brain. In this scenario, high levels 
of lactic acid suggest a defect in neoglucogenesis, whereas low lactic levels suggest glycogen 
storage disease or hypopituitarism.  
On the other hand, in the absence of ketone body production and with low free fatty acid 
levels, hyperinsulinism must be suspected, as insulin inhibits glycogenolisis (turning 
glycogen stores into glucose), neoglucogenesis (de novo glucose production from non-
carbohydrate sources such as lipids and proteins) lipolysis and therefore ketogenesis. No 
ketosis with high levels of free fatty acids in the setting of hypoglycaemia suggests fatty acid 
oxidation defects, because free fatty acids cannot be used to produce ketone bodies as an 
alternative energy substrate in the presence of hypoglycaemia.  
First level laboratory tests:  
Glycaemia / Insulinemia  ratio  
Ketone bodies in urine (3 beta hidroxybutiric acid) 
Lactate / Piruvate ratio 
Plasmatic insulin higher than 13mU/ml when plasmatic glucose is lower than 40mg/dL 
(that is, a glucose/insulin rate < 3:1) without ketosis and low free fatty acids is 
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patognomonic of hyperinsulinism: excessive insulin levels despite having low glucose levels 
without the normal alternative energy ketone body production. 
Second level laboratory tests:  
Ketone bodies and organic acids in blood  
Organic acids in urine 
This is a first step towards diagnosing possible inborn errors in metabolism, specially 
specific enzyme defects found in organic acidemias.  
Third level laboratory tests:  
Thyroid hormones (T4, TSH) 
Glucagon 
Cortisol / ACTH (poner nombre entero) / Growth Hormone (GH) 
Amino-acids in blood and in urine 
Growth hormone and Cortisol are counter-regulatory hormones that normally rise with 
hypoglycaemia. If there are low levels of GH (< 7-10 ng/mL) or of cortisol (<20 microg/dL) 
this suggests an isolated hormone deficiency or hypopituitarism.  
Glucagon basal levels are suggestive, but specifically, an increase in plasma glucose of more 
than 30 mg/dl after glucagon administration suggests that the hepatic glycogen stores are 
not depleted, which is also characteristic of hyperinsulinism.  
Diagnostic criteria to define hyperinsulinism are: 
Glucose < 40mg/dL   
Insuline > 13 microU/mL 
Glucose/insuline ratio < 3:1 
Glucose intravenous needs > 6-8 mg/kg/min 
Negative ketone bodies in plasma and urine (3-beta-hidroxi-butiric acid < 1mmol/L) 
Low free fatty acids (< 1 mmol/L) 
Cortisol > 20 microg/dL 
GH > 7-10 ng/mL 
Glucemic reaction to glucagon administration > 30 mg/dL (ie: positive response) 
7. Persistent hypoglycaemic hyperinsulinism 
When hypoglycaemia persists for more than 5 days, initial laboratory tests must commence 
to rule out other possible causes of persistent hypoglycaemia. In this scenario, persistent 
hypoglycaemic hyperinsulinism is a frequent entity and deserves a mention of its own, as it 
is a major cause of hypoglycaemic brain injury and mental retardation. (Kapoor et al, 2009a; 
2009b). 
In normal conditions, the pancreatic islet beta cells produce insulin that is secreted outside 
the cell via an ATP sensitive potassium channel (ATP-K). Genetic mutations that produce 
altered proteins that form part of different sub units of this channel explain the 
dysregulation of insulin secretion (that is: excess secretion even in the presence of low 
plasma glucose levels).  
It has two main characteristics: high glucose needs to maintain normoglycaemia and 
responsiveness to exogenous glucagon. Hypoglycaemia occurs due to a dysregulated insulin 
secretion with defects in the normal counter-regulatory hormones (cortisol or GH). It is 
possible that there may be an increased insulin sensitivity in these patients, although this has 
not been proven. The excess insulin secretion leads glucose into the insulin sensitive tissues 
(mainly skeletal muscle, adipose tissue and liver) so hypoglycaemia occurs. On the other hand, 
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patognomonic of hyperinsulinism: excessive insulin levels despite having low glucose levels 
without the normal alternative energy ketone body production. 
Second level laboratory tests:  
Ketone bodies and organic acids in blood  
Organic acids in urine 
This is a first step towards diagnosing possible inborn errors in metabolism, specially 
specific enzyme defects found in organic acidemias.  
Third level laboratory tests:  
Thyroid hormones (T4, TSH) 
Glucagon 
Cortisol / ACTH (poner nombre entero) / Growth Hormone (GH) 
Amino-acids in blood and in urine 
Growth hormone and Cortisol are counter-regulatory hormones that normally rise with 
hypoglycaemia. If there are low levels of GH (< 7-10 ng/mL) or of cortisol (<20 microg/dL) 
this suggests an isolated hormone deficiency or hypopituitarism.  
Glucagon basal levels are suggestive, but specifically, an increase in plasma glucose of more 
than 30 mg/dl after glucagon administration suggests that the hepatic glycogen stores are 
not depleted, which is also characteristic of hyperinsulinism.  
Diagnostic criteria to define hyperinsulinism are: 
Glucose < 40mg/dL   
Insuline > 13 microU/mL 
Glucose/insuline ratio < 3:1 
Glucose intravenous needs > 6-8 mg/kg/min 
Negative ketone bodies in plasma and urine (3-beta-hidroxi-butiric acid < 1mmol/L) 
Low free fatty acids (< 1 mmol/L) 
Cortisol > 20 microg/dL 
GH > 7-10 ng/mL 
Glucemic reaction to glucagon administration > 30 mg/dL (ie: positive response) 
7. Persistent hypoglycaemic hyperinsulinism 
When hypoglycaemia persists for more than 5 days, initial laboratory tests must commence 
to rule out other possible causes of persistent hypoglycaemia. In this scenario, persistent 
hypoglycaemic hyperinsulinism is a frequent entity and deserves a mention of its own, as it 
is a major cause of hypoglycaemic brain injury and mental retardation. (Kapoor et al, 2009a; 
2009b). 
In normal conditions, the pancreatic islet beta cells produce insulin that is secreted outside 
the cell via an ATP sensitive potassium channel (ATP-K). Genetic mutations that produce 
altered proteins that form part of different sub units of this channel explain the 
dysregulation of insulin secretion (that is: excess secretion even in the presence of low 
plasma glucose levels).  
It has two main characteristics: high glucose needs to maintain normoglycaemia and 
responsiveness to exogenous glucagon. Hypoglycaemia occurs due to a dysregulated insulin 
secretion with defects in the normal counter-regulatory hormones (cortisol or GH). It is 
possible that there may be an increased insulin sensitivity in these patients, although this has 
not been proven. The excess insulin secretion leads glucose into the insulin sensitive tissues 
(mainly skeletal muscle, adipose tissue and liver) so hypoglycaemia occurs. On the other hand, 
 
Hypoglycemia – Causes and Occurrences 
 
94
insulin inhibits glycogenolisis (turning glycogen stores into glucose), neoglucogenesis (de 
novo glucose production from non-carbohydrate sources such as lipids and proteins) lipolysis 
and therefore ketogenesis (oxidation of fatty acids to produce alternative energy substrate 
ketone bodies). As was mentioned before, the normal counter-regulatory cortisol and glucagon 
responses are blunted, so hypoglycaemia persists. In this scenario, the brain is being deprived 
of any form of energy substrate, as glucose (its main energy source) is depleted in plasma, but 
also, alternative energy sources (ketone bodies and lactate) are characteristically low in these 
cases, so the risk for brain damage is increased greatly.  
Understanding this is crucial, as management to prevent brain damage will differ from 
other underlying processes. Initially, 2.6 mmol/l was suggested as definition for 
hypoglycaemia based on the neurophysiological changes associated to hypoglycaemia, but 
these were established under conditions of non-hyperinsulinism, that is, the brain does have 
alternative energy fuel. Later, “operational thresholds” were suggested for different groups 
of neonates (Cornblath, 2000), since there is still uncertainty as to what levels of 
hypoglycaemia and for what duration, promote brain injury. And though many centres 
have accepted 2.6mmol/L as the operational threshold for hyperinsulinism, based on the 
complete absence of alternative energy sources for the brain in a crucial moment (intense 
development in the neonate and during infancy), a higher threshold of at least 3.5-6 mmol/L 
is necessary in order to prevent cerebral glycopenia, as the brain will be completely 
dependant on glucose plasma levels for an adequate glucose intake (Hussain et al, 2007). 
There is great variability in terms of clinical presentation, histology, genetics and treatment 
response and hyperinsulinism can be classified according to three main characteristics: 
(Giurgea et al, 2005) 
Onset of hypoglycaemia: neonatal period or later during infancy 
Histological lesion: focal or diffuse 
Genetic transmission: sporadic recessive or less frequently, dominant 
Hyperinsulinism may be isolated or may be part of a more complex syndrome. The former 
tends to present early in the neonatal period and is frequently severe as compared to 
syndromic hyperinsulinism  which commonly has later onset during infancy, with a milder 
presentation. Severity is evaluated considering the exogenous glucose administration rate 
required for normoglycaemia and the response to medical treatment which may be highly 
variable amongst individuals. (Cloherty & Stark, 2009; Chan, 2011; Arnoux et al, 2010). 
Over the past decades, there is increasing information on the genetic aspects of 
hyperinsulinism. Congenital hyperinsulinism is caused by mutations in genes involved in 
regulation of insulin secretion. To date, seven genes involved have been identified (ABCC8, 
KCNJ11, GLUD1, CGK, HADH, SLC16A1 and HNF4A). These genes encode glucokinase, 
glutamate dehydrogenase, the mitochondrial enzyme short-chain 3-hydroxyacyl-CoA 
dehydrogenase plus the proteins that form the subunits of the ATP-K channel (which are the 
most common underlying mechanisms). Severe forms of congenital hyperinsulinism, that is, 
those with early neonatal presentation, are caused by mutations in these ATP-K channel 
subunits:  ABCC8 or sulfonylurea receptor gene (SUR1) and KCNJ11 or inward-rectifying 
potassium channel gene (KIR6.2), both located in the 11p15.1 region. Mutations in HNF4A, 
GLUD1, CGK, and HADH lead to transient or persistent hyperinsulinism, whereas 
mutations in SLC16A1 cause exercise-induced hyperinsulinism.  
In focal pancreatic islet-cells hyperplasia,  mutations of the ABCC8 or the KCNJ11 genes are 
inherited from the father, with a loss of the maternal allele specifically in the hyperplasic 
islet cells. In diffuse isolated hyperinsulinism, genetic inheritance is heterogeneous and may 
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be recessive (ABCC8 and KCNJ11) or dominant (ABCC8, KCNJ11, GCK, GLUD1, SLC16A1, 
HNF4A and HADH). Syndromic hyperinsulinism is always diffuse and genetic inheritance 
depends on the specific syndrome. (Arnoux et al, 2010 ; Giurgea, 2005 ; Kapoor et al, 2009a) 
Despite the increasing amount of genetic information already available, there are still up to 
50% of the cases where no known genetic alteration can be identified.  
Therefore, defining the histological forms of hyperinsulinism is particularly important as 
they involve different genetic mutations and inheritance but most importantly, because they 
have different treatment options. Focal hyperplasia consists of a focal adenomatoid 
hyperplasia of islet cells, while diffuse forms involve all the pancreatic beta cells of the 
whole pancreas. Infants suffering from ATP-K hyperinsulinism present shortly after birth 
with severe and persistent hypoglycaemia, and the majority do not respond to medical 
treatment. Up to 40-60% of the children with ATP-K hyperinsulinism have focal lesions in 
the pancreas and are candidates for local resection which is effective while avoiding the 
long-term complications of near-total pancreatectomy such as diabetes-mellitus. Diffuse 
hyperinsulinism however, when resistant to medical treatment (octreotide, diazoxide, 
calcium antagonists and continuous feeding) may require subtotal pancreatectomy.  
To distinguish between focal and diffuse forms, trans-hepatic catheterisation with 
pancreatic venous sampling has been used, but is being replaced by [(18)F] Fluoro-L-Dopa 
PET scan, which is easier to perform, and is not only a diagnostic tool, but may also be used 
to guide laparoscopic surgery. Therefore, rapid genetic analysis combined with an 
understanding of these histological features (focal or diffuse disease) and the introduction of 
(18)F Fluoro-L-Dopa PET scan, have totally transformed the clinical approach to this 
complex metabolic alteration (Arnoux et al, 2010; Kapoor et al 2009).     
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Before considering possible surgical treatments (once the diagnosis of hyperinsulinism has 
been made), medical treatment must be started, with the goal of maintaining glucose values 
within a normal target range. Initially exogenous glucose administration will be required and 
glucagon infusion may be useful in certain emergency situations. In terms of specific medical 
treatment, oral diazoxide is the first line option. If the infant does not respond, somatostatin 
analogues and calcium antagonists may be considered. Except for ATP-K channel defects 
hyperinsulinism (ABCC8 and KCNJ11), most forms are sensitive to diazoxide.  
In conclusion, there are two main points that sum up the management of hyperinsulinism 
cases: prevention of brain damage by normalizing glycaemia and screening for focal forms 
as they may be definitively cured after a limited pancreatectomy. (Arnoux et al, 2010).      
8. Treatment for hypoglycaemia  
When treating hypoglycaemia, there are two mains aspects that must be considered and that 
will define a different approach: first, whether the neonate is symptomatic or not and 
secondly, the initial glucose values. (Fernández Lorenzo et al, 2011; Chan, 2011). 
8.1 Asymptomatic hypoglycaemia  
When glucose levels are under 46mg/dl (2.6mmol/L) but higher than 30mg/dL, and the 
baby has no feeding intolerance or difficulty, breastfeeding is the first option, together with 
supplementation either with extracted mothers´ milk or adapted infant formula if necessary.  
This provides a higher glucose intake than offering plain 5% glucose solution orally. 
Capillary glycaemia controls are needed every 20-30 minutes after intake. If 
normoglycaemia has been achieved, normal feedings can be established (preferably 
breastfeeding ad libitum, that is, as often as the baby needs, but at least every two-three 
hours), and considering adding supplements of the mothers´ extracted breast milk or 
adapted formula if necessary).  
If there are feeding difficulties or intolerance, or if glucose levels are below 30mg/dL, 
intravenous exogenous glucose administration must be considered. 10% glucose infusion at 
a rate of 5-8 mg/kg/min will be required as a starting point. As feeding tolerance 
recuperates, oral feedings must begin, promoting the physiological fractioned enteral 
feeding pattern that will better regulate insulin secretion. As glucose levels are maintained, 
parenteral glucose administration must be tapered until complete and exclusive fractioned 
enteral nutrition has been established.  
In some cases, if an intravenous line is difficult to obtain, or if a baby is persistently 
hypoglycaemic but asymptomatic despite fractioned enteral feedings, continuous enteral 
feeding may be considered, which provides a continuous glucose intake, but requires 
adequate gastrointestinal tolerance.  
8.2 Symptomatic hypoglycaemia  
When hypoglycaemia persists (less than 46 mg/dL or 2.6mmmol/L) and symptoms are 
present, rapid glucose correction is warranted. An intravenous bolus of 10% glucose must 
be administered at a dose of 2ml/kg/dose (200mg/kg/dose). Higher glucose concentrations 
should not be used, in order to avoid the possible insulin peak secretion that may occur in 
response to the bolus. In the presence of seizures, higher doses of 4ml/kg/dose 
(400mg/kg/dose) must be considered. In any case, after bolus administration, a continuous 
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glucose perfusion must be started to prevent rebound hypoglycaemia due to peak insulin 
secretion; again, around 5-8 mg/kg/min to begin with.  
 
 
Fig. 2. Treatment algorithm for neonatal hypoglycaemia 
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Depending on glycaemia control afterwards, the exogenous glucose intake may be increased 
further either initially increasing perfusion rate (up to a maximum volume intake the baby 
will tolerate according to gestational age, weight and clinical status) or, more frequently, 
increasing the glucose concentration using 12% or 15% glucose solutions. This implies a 
central line must be placed, as with increasing concentration, osmolarity increases and 
peripheral lines risk extravasation. In this case, it is preferable not to use umbilical lines, 
specifically to avoid using the umbilical artery, as malposition of this artery line may cause 
hyperinsulinism due to direct pancreatic stimulus, and further hypoglycaemia.  
When glucose needs exceed 12mg/kg/min, glucocorticoid therapy is an option,, due to 
stimulation of neoglucogenesis and reduction in peripheral glucose utilization. 
Hydrocortisone (5mg/kg/day divided in two doses orally or intravenously) or prednisone 
(2mg/kg/day orally or intravenously) are used over several days until glycaemia recovers 
and doses can be gradually decreased. In this scenario (persistently high needs of exogenous 
glucose administration, despite glucocorticoid treatment) or in emergency situations where 
glucose bolus alone is not effective or cannot be administered rapidly enough, glucagon is 
an alternatively, though infrequently used. A wide rang of initial bolus doses have been 
reported, but in a recent review, the suggested  initial dose is 0.2-0.3 mg/kg (either 
intramuscular administration or as a slow intravenous push over one minute) with a 
maximum doses of 1mg. Blood glucose should rise in the next 20-30 minutes. If not, another 
does can be administered, and if there is still no response, glycogen store disorders must be 
ruled out. This is only a temporary option, while interventions are planned to provide 
sufficient glucose and to start diagnosis of hyperinsulinism which may prompt use of 
diazoxide or somatostatin as mentioned earlier (Chan, 2011).  
9. Neurological outcome  
There is increasing concern about neurodevelopment after  hypoglycaemia and many 
studies have tried to establish a correlation between hypoglycaemia and brain damage, 
dating since the 1960´s. But, to date there is still not sufficient adequate information to define 
a precise cut-off glucose value, below which irreversible brain damage occurs, at a specific 
moment or for a defined period of time, in a given infant or in a subset of specific infants. 
There seems to be consensus that it is after recurrent, protracted, severely low glucose 
concentrations (less than 18-20mg/dL (< 1mmol/L) for more that 1-2 hours) specially when 
accompanied by severe neurological symptoms such as seizures or coma, that adverse 
neurological outcome is to be expected (Rozance & Hay,2006; Cornblath, 2000; Alkalay,  
2005; Vannuci, 2001). There is also consensus that in order to define CNS injury as a 
consequence of hypoglycaemia, other obvious CNS lesions must be absent (such as hypoxia-
ischemia, intracranial haemorrhage, infection, etc.). Other conditions such as confirmed or 
suspected hyperinsulinemic hypoglycaemia in the presence of seizures, for example, 
contribute to the diagnosis of hypoglycaemic injury (Rozance & Hay, 2006).  
Because we do not know what the absolute threshold value is, operational thresholds have 
been suggested, where clinical guidance is compulsory, so an infant with neurological 
symptoms will need more urgent evaluation than an asymptomatic newborn, regardless of 
the glucose value (Williams, 2005).  
In the preterm population, there are no conclusive studies regarding neurological outcome 
in case of hypoglycaemia, but they suggest that even mild but repeated hypoglycaemia 
could be detrimental on brain development. Retrospective data from a multicenter trial of 
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nutrition in premature infants found lower Bayley mental and psychomotor scores at 18 
months in infants with at least five confirmed hypoglycaemia events, with a higher rate of 
developmental delay and cerebral palsy, but however failed to confirm these findings at 7.5 
and 8 years of age (Lucas et al, 1988; Cornblath, 1999 as cited in Chan, 2011).  
Considering the innate risk for adverse neurodevelopment in the preterm infant, emphasis 
must be put on monitoring glucose levels in these infants to avoid further possible CNS 
injury (Wayenberg & Pardou, 2008). 
It is worth pointing out that the physiopathological mechanisms that promote injury in 
hypoglycaemia vary from injury mechanisms in HIE, with some areas being more sensitive 
to deprivation of glucose and others to deprivation of oxygen and a greater tendency 
towards selective neuronal necrosis in hypoglycaemic babies. Also, concurrent 
hypoglycaemia and HIE have worst prognosis than either condition  individually, therefore 
extreme caution must be taken to maintain normoglycaemia in an HIE setting (Vannuci,  
2001; Garg & Devaskar, 2006).   
Neonatal hypoglycaemia can lead to reduced head circumference at follow-up, lower 
psychomotor scores, motor deficit and mental retardation. Specifically neonates with 
recurrent episodes had lower psychomotor scores than those with a single episode. (Lucas, 
1988; Nunes, 2000; Greery, 1966 as cited in Alkalay 2005).  
Hypoglycaemia episodes with seizures have worse outcomes than hypoglycaemia episodes 
alone. At follow-up, many of those that had hypoglycaemia and seizures develop epilepsy 
of different types such as infantile spasms and partial seizures. Electroencephalographic  
recordings do not show specific patognomonic features that may result diagnostic (Alkalay, 
2005). 
Parieto-occipital diffusion restriction seen on MRI scans have been reported associated with 
neonatal hypoglycaemia and can result in long-term disability, epilepsy, and visual 
impairment (Finlan et al, 2006; Tam et al, 2008).  The aetiology of this pattern of injury is 
unclear; however, transient hyperinsulinism may be an independent risk factor. Magnetic 
resonance brain imaging can help define the extent of brain injury and guide follow-up. In a 23 
case follow-up, with severely low and persistent or recurrent glucose values, abnormal brain 
imaging findings were associated with profound hypoglycaemia and involved occipital lobes 
in 82% the cases. Half of these infants had visual impairment (Alkalay et al, 2005b).   
In relation to this, a cohort of 45 neonates with  diffusion-weighted  MRI studies after 
hypoglycaemia was studied retrospectively to  determine  whether  hypoglycaemic  injury,  
as  indicated  by  diffusion restriction in the occipital lobes, correlated with visual evoked 
potentials and long-term cortical visual dysfunction. They saw that diffusion-weighted 
imaging studies performed within 6 days after initial hypoglycaemia were sensitive in term 
(50% had restricted diffusion in occipital lobes) but not in preterm neonates (none had this 
alteration), as opposed to those performed after, and were associated with abnormal visual 
evoked potentials detected within 1 week after birth. Cortical visual impairment happened 
in a signicant proportion of patients with recurrent hypoglycaemia and correlated 
significantly with low mesial occipital apparent diffusion coefcient values. They concluded 
that diffusion restriction, with low apparent diffusion coefcient values, in the mesial 
occipital poles, may indicate poor visual outcomes in acute settings after neonatal 
hypoglycaemia  (Tam et al, 2008).  
While occipital lobe injury patterns have been widely described, other brain injury patterns 
have also been identified when studying MRI scans performed on term neonates with 
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symptomatic hypoglycaemia and compared to neurologically normal infants. White matter 
abnormalities occurred in 94% of the infants (43% of theses were severe lesions), with 
predominant posterior lobe alterations in 29% of the cases. Cortical abnormalities were 
identified in 51% of infants; 30% had white matter haemorrhage, 40% basal ganglia and or 
thalamic lesions, and 11% had an abnormal posterior limb of the internal capsule. Three 
infants had middle cerebral artery territory infarctions. It was noted that early MRI ndings 
predicted neurodevelopmental outcomes better than the severity or duration of 
hypoglycaemia: 65% of these infants had impaired neurologic development at 18 months, 
which were related to the severity of white matter injury and involvement of the posterior 
limb of the internal capsule (Burns et al, 2008).  
10. Prevention 
Despite controversy and gaps in knowledge as to what level of hypoglycaemia and for how 
long, brain injury occurs, it is clear that hypoglycaemia can and must be prevented. In the 
majority of healthy newborn infants, if hypoglycaemia occurs, it is merely a transient 
adaptation process. However, although the majority of term newborns without risk factors 
will adapt correctly, there is up to 10% of these infants that will have significant 
hypoglycaemia in the first 3-4 hours of life, and will probably be asymptomatic. Helping 
these infants adapt is best achieved when promoting early skin to skin contact as soon as the 
baby is born (this promotes mother-child bonding, more effective breast feeding and better 
temperature control) and early and frequent breast feeding. On the other hand, infants with 
risk for hypoglycaemia are more vulnerable and may not adapt as easily as a healthy 
newborn, despite applying these strategies. Preventing significant hypoglycaemia in this 
subset population implies controlling these infants at risk in the first hours of life and 
thereafter periodically depending on the infants’ clinical status and glucose levels, and 
adapting treatment options to the babies’ situation.  
11. Conclusions 
Hypoglycaemia in the neonatal period is a frequent problem. In the majority of cases, in 
healthy term newborns, it is merely a transient adaptation process from intra-uterine life to 
extra-uterine conditions. However, there are infants who for different reasons are at risk of 
more significant and persistent hypoglycaemia, that will have less capacity to adapt to extra-
uterine life and that will require frequent monitoring and treatment when necessary.  
The goal is to maintain normoglycaemia in order to assure an adequate energy substrate for 
all organs but most importantly for the brain in order to prevent brain injury. To achieve 
this, many cut-off values have been proposed, and perhaps the most accepted concept is that 
of defining specific “operational thresholds” for different groups of infants at risk, that is, 
the glucose value for a given infant where treatment is required, the point where we must 
intervene. There is consensus in the need of preventing hypoglycaemia, which means 
looking out for it in infants at risk, and promptly treating it if present (from more frequent 
feeding to parenteral glucose infusion to glucagon if necessary).  
Hypoglycaemic induced brain damage occurs when hypoglycaemia is severely low in a 
persistent or recurrent manner, and is more likely when acute neurological symptoms such 
as seizures are present. Occipital lobe affectation has been widely described, but recent 
research opens the scope of brain injury to white matter and to vascular lesions as well.  
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In the setting of persistent hypoglycaemia, persistent hyperinsulinemic hypoglycaemia, 
inborn errors of metabolism and endocrine disorders must be ruled out. Specifically, when 
considering persistent hyperinsulinemic hypoglycaemia, innovations in diagnosis at a 
molecular and radiological level have been particularly important in terms of differentiating 
focal from diffuse forms, which, if unresponsive to medical treatment may be candidates for 
curative partial pancreatectomy.  
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1. Introduction 
Intravenous glucose infusions into peripheral veins are often needed, in addition to oral 
feedings, to elevate blood glucose levels in the management of neonatal hypoglycemia. 
Central venous catheters are rarely inserted, when the duration of such treatment is less 
than a few days. More than half of peripheral venous cannulations extravasate by 36 h, or 
even faster, if medication is administered concomitantly (Möller et al., 1996, Hecker et al., 
1991). Complications, including local swelling and in the worst cases damage to tissue may 
occur.  Intravenous solutions containing 10 or 15 percent glucose are most commonly used 
in hypoglycemic infants. A glucose concentration of 15% has generally been regarded as the 
highest acceptable for use in solutions infused into peripheral veins in neonates. (Kien, 
1993). However, 10% and even 15% glucose infusions increase fluid load especially in 
patients, who need high glucose intakes to reach sufficient energy intake or to maintain 
normal plasma glucose levels. Although large fluid volumes of short duration are well 
tolerated in neonates (Leake, et al, 1976), the effect of continuous rapid infusions on the fluid 
clearance have not been determined.  First voiding might be delayed due to elevated 
Arginine vasopressin levels in newborn infants delivered vaginally after a prolonged and 
stressful labor (Vuohelainen T et al., 2007 and 2008).  A poor fluid tolerance during the first 
days of life can be anticipated and cautious fluid administration might be indicated 
especially in such infants. 
Earlier studies suggest that the development of phlebitis does not depend so much on the 
osmolarity of the solution as other factors causing phlebitis, for example material of the 
catheter (Madan et al., 1992). Factors affecting the development of infusion phlebitis include 
vein characteristics, size and material of the catheter, duration of infusion and the 
osmolarity and pH of the infusion solution. Experimental infusions of 10% glucose with 
electrolytes (pH 4.93, osmolarity 727 mOsm/kg) into rabbit ear veins cause phlebitis by 
reason of its acidity and an infusion of amino acids (pH 6.29, osmolarity 929 mOsm/kg) by 
reason of its high osmolarity. On the other hand, admixture of these solutions causes only 
minor phlebitic changes and the fluid components eliminate each others’ damaging effects on 
the tissue (Kuwahara et al., 1998a). In the same animal model, the tolerance of peripheral 
venous endothelial cells was for 8 h in 820 mOsm/kg, 12 h in 690 mOsm/kg and 24 h in 550 
mOsm/kg solutions, respectively, suggesting that a planned volume of solutions with high 
osmolarity should be infused rapidly rather than slowly to avoid the development of phlebitis 
(Kuwahara et al. 1998b). In the management of hypoglycemia, however, only continuous 
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reason of its acidity and an infusion of amino acids (pH 6.29, osmolarity 929 mOsm/kg) by 
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minor phlebitic changes and the fluid components eliminate each others’ damaging effects on 
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infusions can be used. In such occasions the effect of the infusion rate on the risk of phlebitis 
seems not have been established. Earlier surveys suggest that high infusion flow rates might 
even markedly increase the risk of infusion failure (Hecker 1989, Hecker, et al 1991). 
The occurrence of phlebitis has been evaluated in adults in a comparison of peripheral 
infusions of nutrient solutions with and without 20% fat emulsion (Daly et al., 1985). 
Adding fat to the fluids did not protect the veins from the development of phlebitis. 
Infiltration was more dependent on the catheters than on the osmolarity of solutions. In 
keeping with this, peripheral intravenous nutrition caused phlebitis in all patients using 
Teflon cannulas, but in only 7% using silicone catheters. The risk of phlebitis was very low 
even when nutrition solutions of an osmolarity of 1250 mOsm/kg were administered via the 
latter catheters (Madan et al., 1992).   
Glucose solutions are acid and hyperosmolar, the 15% solution pH ranging between 3.5–5.5 
and osmolarity 832.5 mOsm/kg and the 20% solution 4.0 and 1110 mOsm/kg.  In spite of 
this, the latter solution might be a better choice in the management of hypoglycemia, 
because the fluid administration rate of the 20% solution to reach the same glucose intake is 
25% lower compared to 15% glucose solution. Thus, risk of excessive fluid load can be 
decreased by using 20% glucose instead of 15% glucose infusion.  As far as we know no 
earlier studies comparing the infusions of 15 % and 20% glucose into peripheral veins of 
newborn infants have been done. 
The purpose of our study was to evaluate, whether peripheral intravenous 20% glucose 
solutions are as well tolerated as  15% glucose solutions in the management of neonatal 
hypoglycemia.  
2. Patients and methods 
The study was undertaken in the neonatal unit of Tampere University Hospital (Vanhatalo 
and Tammela, 2010). Newborn infants with hypoglycemia for which initiation of 
intravenous glucose infusion was prescribed at the discretion of the attending physician, 
were included in the study if they fulfilled the following criteria: (1) birth weight of 2000 g 
or more, (2) no significant malformations diagnosed, (3) intensive care not needed, (4) 
written informed consent obtained from the parents. Infants in intensive care were excluded 
in order to minimize confounding factors, including need of vasoactive infusions and/or 
multiple intravenous medications. 
Hypoglycemia was defined as a plasma glucose level below 2.6 mmol/L and hyperglycemia 
as above 7.7 mmol/L. All infants received either their own mother's or banked pooled breast 
milk. On-demand breast and/or bottle feeding was preferred. Breast-fed infants were 
weighed before and after feedings, in order to measure the ingested milk volume. The 
minimum cumulative amount of breast milk was 80 mL, divided by 8-10 feedings, in the 
first day of life. The cumulative milk volume was daily increased by 80 mL, up to 170 
mL/kg/day. Increasing the daily number of oral feedings was the first treatment for 
hypoglycemia. Gavage feeding was used in babies, who were sucking poorly. Intravenous 
glucose infusion was started at the discretion of the attending physician in cases with 
symptomatic hypoglycemia, recurrent blood glucose levels below 2.6 mmol/L, in spite of 
increased oral or tube feedings, and in hypoglycemic infants, who tolerated poorly enteral 
feedings. The infants were randomized to receive either 20% (group 20%, 60 infants) or 15% 
(group 15%, 61 infants) peripheral intravenous glucose infusions at an initiation glucose intake 
rate of 8 mg/kg/min, i.e. 2.4 mL/kg/h in the group 20% and 3.2 mL/kg/h in the 15% group. 
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The group allocation of each patient was written in a sealed envelope, which was opened after 
the written consent was received from the parents. Because infusion rates were dependent on 
the glucose concentration the group allocation was not possible to be blinded.  
The infants’ plasma glucose levels were measured every 4 h and the infusion rate reduced 
after each measurement by 0.5 mL/kg/h at blood glucose levels between 3.5–4 mmol/L and 
by 1 mL/kg/h at blood glucose levels above 4 mmol/L. The infusion was stopped when the 
plasma glucose level was 3.5 mmol/L or higher at an infusion rate of 2 mL/h. Plasma glucose 
surveillance was continued, until levels had remained normal (more than 2.9 mmoL/L) for 24 
h after discontinuation of the glucose infusion. When the cannulation site had to be changed, 
local signs of phlebitis at the previous site were scored from 0 to 3 using a modified Maddox 
scale (Maddox and Rush, 1977), by the attending physician. Cumulative severity, i.e. the sum 
of scores for phlebitis, was calculated during the infusion period. Number of cannulation site 
changes, duration of intravenous infusions and daily weights of the infants were recorded. 
Weight changes were calculated as percentages of birth weight. Preterm infants were born at 
less than 37 weeks' gestational ages. Infants with birth weight less than 2 SD from the mean for 
gestational age were defined as small for gestational age (SGA). 
 
0 No pain around the tip of the catheter, no color, no redness, no hardening,  
vein not hard when palpated. 
1+ Pain around the tip of the catheter and redness 
2+ Pain around the tip of the catheter, redness and swelling 
3+ Pain around the tip of the catheter, redness, swelling and hardening 
Table 1. Modified Maddox score scale (Maddox and Rush, 1977): observation criteria for 
phlebitis. 
2.1 Statistical analysis 
Irritation in the site of infusion, number of cannula site changes and weight gain were 
chosen as primary end points. The sample size was calculated on the assumption that either 
glucose solution might reduce the mean number of cannula site changes from 1.5 to 1.0. 
With 80% power and statistical significance level below 0.05 the sample size would be 57 in 
each group. The dropout rate was estimated to be about 5%, and thus the goal was to recruit 
60 infants for both groups. 
t-test, Mann–Whitney U-test and analysis of variance for repeated measures were used in 
the statistical analysis, as appropriate. P-value less than 0.05 was regarded as statistically 
significant.  
The ethical committee of the hospital had approved the study.  
3. Results 
During the study period, hypoglycemia was diagnosed in 465 neonates. Of these, 108 did 
not fulfill the inclusion criteria; 357 were eligible. The parents refused consent in 12 of these 
cases and in 224 cases the attending physician had no possibility to request consent because 
of lack of time, or lack of possibility to contact the mother. Sixty infants were allocated to the 
group 20% and 61 to the group 15%. (Figure 1) 
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Fig. 1. Allocation of the study groups  
The infants in the 20% and 15% groups were born at similar (mean (SD)) weeks' gestation 
(group 20% 39 (1.5) weeks vs. group 15% 39 (1.3) weeks) and birth weights (3605 (593) g vs. 
3486 (626) g, respectively). Female/male ratios did not differ (23/38 vs. 24/36). 
Similar percentages of infants in both groups had been delivered via caesarean section, were 
SGA or had birth weights >4500 g (Table 2). Few cases in either group were born from twin 
pregnancies and asphyxia was rare. Prematurity, need for phototherapy and antibiotic 
 
 20% Glucose group 15% Glucose group 
 N (%) N (%) 
Cesarean section  7 (12) 6 (11) 
Small for gestational age (SGA) 0 (0) 2 (5) 
Birth weight > 4500 g 2 (3) 3 (5) 
Female/male 24/36 23/38 
Twins 3 (5) 2 (3) 
Premature 8 (13) 4 (7) 
Five minute Apgar score < 7 2 (3) 4 (7) 
Phototherapy 20 (33) 14 (23) 
Intravenous antibiotics 12 (20) 6 (11) 
The differences between the groups were not statistically significant 
Table 2. Clinical characteristics of the infants in the study groups 
465 hypoglycemic 
neonates  
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treatment due to suspected or confirmed infection was more common in the group 20%, but 
the differences did not reach statistical significance. About half of the cases in both groups 
were infants of diabetic mothers (mean 30 (SD 49) % vs. 30 (SD 50) %). In the group 20%, 25 
mothers and in the group 15%, 21 mothers had gestational diabetes, five versus nine 
mothers had type 1diabetes and seven versus 12 mothers were on insulin medication in the 
20 and 15% groups, respectively, NS. Three mothers had pre-eclampsia in the group 20% 
and five in the group 15%. Ten mothers had hypertension in the group 20% and six in the 
group 15%. Ten mothers had signs of chorioamnionitis at delivery in the group 20% and six 
in the group 15%, respectively. 
The concentrations of electrolytes in the glucose solutions, adjusted according to the plasma 
sodium and potassium levels, were similar in the two groups: the mean (SD) sodium 
concentrations being 38 (15) mmol/L versus 39 (12) mmol/L  and potassium concentrations 
12 mmol/L  versus 13 mmol/L, respectively. Seven (12%) infants in the group 20% and 11 
(18%) in the group 15% also received antibiotic treatment, the mean durations of antibiotic 
treatment being 6.0 (0.6) versus 5.2 (1.3) days, NS.  
The mean (SD) duration of cannulation was in the group 20% 4.2 (1.4) days and in the group 
15% 3.9 (1.3) days, NS. The number of cannulation site changes were median 1 (range 0–5) in 
the group 20% and 1 (range 0–6) in the group 15%, respectively, NS. In the 20% group 35 
infants (59%) and in the 15% group 36 (60%) had some signs of phlebitis, NS. The 
cumulative severity score for phlebitis was low in both groups, in the 20% glucose group a 
median of 1 (range 0–7) and in the 15% group 1 (range 0–8), NS. 
When the infants, who received antibiotics, were omitted, in infants receiving only 
intravenous glucose infusions, the mean (SD) duration of cannulation was in the group 20% 
4.0 (1.3) days and in the group 15% 4.0 (1.3) days, NS. The number of cannulation site 
changes were median 1 (range 0–6), and 1 (range 0–5), respectively, NS. In the 20% group 31 
(63%) and in the 15% group 33 infants (61%) had some signs of phlebitis, NS. The 
cumulative severity score for phlebitis was in the 20% group median 1 (range 0–8) and in the 
15% glucose group 1.5 (range 0–8), NS. 
Average plasma glucose levels were similar in both groups in the 20% group 4.6 (0.41) and 
in the 15% group 4.5 (0.37) mmol/L. High plasma glucose levels occurred in nine cases in 
the 20% glucose group and in 11 in the 15% group, and low levels in 37 versus 43 infants in 
the 20% and 15% groups, respectively, NS. 
Weight as a function of infusion time and relative weight changes in the two groups were 
similar  (Figure 2), NS. 
4. Discussion 
A recruitment bias is possible in this cohort in that the attending physician was not able to 
contact some mothers to obtain informed consent. A significant number of eligible infants 
were thus left out. This circumstance can be explained by the fact that a substantial 
proportion of hypoglycemia cases are admitted outside office hours, during which time the 
paediatricians on call are often too busy, and during the night reluctant to disturb the 
parents’ sleep in order to recruit their baby for the study. It is also not possible to postpone 
the start of intravenous glucose infusion for long in hypoglycemic patients. 
Maternal diabetes mellitus is one of the most important risk factors for neonatal 
hypoglycemia, and its severity might affect the need and duration of intravenous glucose 
infusion of the infants. Both small and large birth weight for gestational age might also be 
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Fig. 2. Relative change in weight (% from birth weight) during intravenous glucose infusion. 
Circles indicate the 15% glucose and squares the 20% glucose group. X axis: weight changes. 
Y axis: time (days). 
associated with a prolonged need of intravenous glucose infusion. The groups were, 
however, quite well matched for the percentages of mothers having gestational diabetes, 
type 1diabetes, for receiving insulin medication, and percentages of either SGA or LGA 
infants. Breast milk feeding is a cornerstone in the prevention and management of neonatal 
hypoglycemia, and weaning from intravenous glucose infusion is not possible without a 
successful feeding. The same feeding protocol was used in both groups.  
Concomitant use of intravenous antibiotics during intravenous glucose infusion increases 
obviously the risk of phlebitis, and is therefore a confounding factor in the comparison 
between 15% and 20% glucose groups. The percentage of infants receiving antibiotics was 
somewhat, although not significantly higher in the 20% group. The higher osmolarity of the 
20% glucose solution was, however, not associated with an increased rate or severity of 
phlebitis in our infants. In addition, omitting the antibiotic-treated cases did not change the 
result. The electrolyte concentrations in the 15 % and 20 % glucose infusion fluids were 
similar. As intravenous glucose was administered at the same rate (mg/kg/min) in both 
study groups, the 15% glucose group received fluids at a 33% higher rate than the 20% 
glucose group. The differences in fluid infusion rates might even have balanced the local 
effect of different glucose concentrations on the vessel wall at the infusion site. 
The clinical classification of phlebitis also involves risk of bias, as observation and 
classification is subjective. The observers rating the severity of the phlebitis were not aware 
of the glucose concentration used in each case. Accidental detachment of intravenous lines 
occurs only rarely and the most common reason for a cannulation site change is local 
irritation and swelling at the infusion site. The number of cannulation site changes would 
thus seem to be a fairly objective measure of extravasation of fluids. According to earlier 
work, extravasation of peripheral fluid infusions occurs by 36 h in more than half of the 
patients (Möller, et al., 1996, Hecker et al.,1991). In our patients the mean duration of 
cannulation was about four days in both groups, suggesting that the median number of 
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cannulation changes in the cases on both groups is in accordance with the previous data. 
Thus, the duration of cannulation, number of cannulation changes and phlebitis severity 
scores were similar in both groups. One can assume, that the safety of peripheral 20 or 15% 
glucose intravenous infusions is similar also in neonates, who need intravenous glucose 
infusions for other reasons than hypoglycemia, including short-term parenteral nutrition.  
The occurrence of phlebitis has been evaluated in adults in a comparison of peripheral 
infusions of nutrient solutions with and without 20% fat emulsion (Daly JM et al., 1985). 
Adding fat to the fluids did not protect the veins from the development of phlebitis. 
Infiltration was more dependent on the catheters than on the osmolarity of solutions. In 
keeping with this, peripheral intravenous nutrition caused phlebitis in all patients using 
Teflon cannulas, but in only 7% using silicone catheters. The risk of phlebitis was very low 
even when nutrition solutions of an osmolarity of 1250 mOsm/kg were administered via the 
latter catheters (Madan M et al., 1992). In our study, the same peripheral catheters were used 
in both groups and therefore the role of catheter type in the development of phlebitis cannot 
be established here. 
Although infants in the 20% glucose group received 33% less fluids than those in the 15% 
group, no differences in weight changes were seen. Our infants were all quite healthy, 
having no or mild neonatal problems in addition to hypoglycemia and would thus seem to 
tolerate excess amounts of fluids well. Our study was not powered to establish, whether less 
fluid intake would be beneficial by decreasing risk of respiratory problems and need of 
oxygen supplementation in the 20% glucose group compared to the 15% glucose group. In 
patients who do not tolerate fluids normally, as in cases of birth asphyxia, renal failure, 
bronchopulmonary dysplasia or inappropriate antidiuretic hormone excretion, reduction of 
fluid intake by using 20% instead of 15% glucose might have beneficial effect on the 
outcome of the patient. 
5. Conclusion 
Intravenous 20% glucose solutions can be infused into peripheral veins as safely as 15% 
glucose solutions. The risks of excess fluid intake, in addition to oral feeding, need to be 
established in further studies in infants with neonatal hypoglycemia. 
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1. Introduction  
Although it is noted throughout the literature that adverse effects occur, one review of 
safety reporting determined clinical trials only report adverse effects between 29% 
(laboratory adverse effects) and 39% (clinical adverse effects) (Ioannidis, et al, 2001). It is 
important to keep these numbers in mind when looking at the number of drug-induced 
hypoglycemia cases. Seltzer’s review of the literature from 1940 to 1989 reveals 1418 
documented cases of drug-induced hypoglycemia. Based on estimates of the lack of adverse 
effect reporting, it is unlikely that these cases were the only incidents of drug-induced 
hypoglycemia that occurred during this time (Seltzer, 1989).  
It is also reasonable to look at estimates of adverse drug effects (ADEs) in hospitalized 
patients. Such estimates indicate ADEs may account for between 3 and 5% of all hospital 
admissions (Pandit et al, 1993). In a 2006 study it was determined approximately 22% of 
admissions attributed to ADEs were due to hypoglycemia at a university hospital versus 23% 
at a community hospital (Kilbridge et al, 2006). These admissions were related to an overall 
admission rate attributed to ADEs of 4.4% at the university hospital and 6.2% at a community 
hospital (Kilbridge et al, 2006). In addition there are estimates that as many as 30% of 
hospitalized patients experience an ADE while in the hospital (Pandit et al, 1993). Estimates of 
3 – 4.5 billion dollars, which is now outdated, just begin to attribute a cost to treating ADEs. 
However, the cost is probably grossly underestimated since the actual number of ADEs 
reported is underestimated (Pandit et al, 1993). Not only is the cost of managing an ADEs a 
significant issue but the risk of mortality must be considered as well. Mortality has been 
estimated to occur in as many as 140,000 patients each year (Pandit et al, 1993). One study 
looking at death due to drug-induced hypoglycemia determined a 1.3% mortality rate 
(Juurlink et al, 2003).  
The incidence and impact of drug-induced hypoglycemia should be contrasted with the 
incidence and impact of hypoglycemia in patients with diabetes mellitus (DM) – type 1 or 
type 2. For patients with type 1 DM, it is estimated that hypoglycemia, by the numbers 
(blood glucose less than 50 – 60 mg/dL), occurs 1 in 10 times when patients check their 
blood glucose (Cryer et al, 2003). While the number of asymptomatic hypoglycemia 
episodes is undocumented, it is estimated that patients with type 1 DM experience “an 
average of 2 symptomatic hypoglycemic episodes per week.and an episode of severe, at 
least temporarily disabling hypoglycaemia once a year” (Cryer et al, 2003). The incidence of 
hypoglycemia in patients with type 2 DM is more challenging. When comparing the 
incidence of severe hypoglycemia in patients with type 1 DM versus patients with type 2 
DM being treated with insulin, estimates are anywhere from 10% to equal incidence of 
hypoglycemia (Cryer et al, 2003). Other studies that have tried to quantify the incidence of 
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hypoglycemia in type 2 patients have varied from an overall incidence of 20% in patients 
taking oral agents to 0.5% episodes of severe hypoglycemia in patients using insulin 
(Jennings AM et al, 1989 & Miller CD et al, 2001).  Unfortunately, as with drug-induced 
hypoglycemia, hypoglycemia may result in death. One estimate of the rate of death from 
hypoglycemia is 2 to 4% of patients with type 1 DM, but, as with the incidence of 
hypoglycemia, there is not a reliable estimate of death attributed to hypoglycemia in 
patients with type 2 DM (Cryer et al, 2003). However, a 1999 review of cases of 
hypoglycemic coma provides some perspective on potential morbidity and mortality. In this 
study, out of 102 reported cases, 5 patients died. (Ben-Ami et al, 1999).  
These statistics emphasize the importance of recognizing and treating hypoglycemia as well 
as ADEs when they occur. The numbers also serve as a reminder to all healthcare providers 
of their responsibility in the prevention of ADEs, especially drug-induced ADEs. However, 
in order to prevent ADEs, one must know what patients are at risk for development of an 
ADE. The risk for drug-induced hypoglycemia, the mechanism of potentially causative 
agents as well as management and prevention are discussed below in effort to make 
healthcare providers aware of this potential ADE and how to avoid it. 
2. Definition of hypoglycemia 
Before determining if a patient is experiencing drug-induced hypoglycemia, the definition of 
hypoglycemia should be established. Since all patients respond to blood glucose 
concentrations differently, it is challenging to establish a blood glucose at which every patient 
will experience symptoms. However, it is widely accepted that most patients will begin to 
experience symptoms when their blood glucose level is less than 3.3 mmol/l (60 mg/dL). The 
symptoms patients commonly experience are listed in Table 1 below and can be manifestations 
of the response by the autonomic nervous system as well as the brain’s response to being 
deprived of glucose (Cryer et al, 2003, White, 2007). Physiologic responses with escalating 
hypoglycemia are shown in Table 2. Severe episodes of hypoglycemia may be characterized by 
loss of consciousness and/or seizures and, in instances of sustained hypoglycemia, may result 
in brain damage or death (Cryer et al, 2003). The blood glucose level at which a patient 
experiences symptoms of hypoglycemia can be influenced by other factors such as: the 
frequency of hypoglycemic episodes, which may result in hypoglycemic unawareness; 
frequent hyperglycemia episodes, and increased caffeine intake (Cryer et al, 1999).  
 
Neurogenic Symptoms of 
Hypoglycemia 
Neuroglycopenic Symptoms of  
Hypoglycemia 
Physical Signs of 
Hypoglycemia 
Anxiety/arousal Blurry vision Increased systolic 
blood pressure 





Sweating  Emotional lability
Fatigue 





Adapted from Cryer et al, 2003 and White, 2007  





Blood glucose level Classification Physiologic response 
70 mg/dl (3.9 mmol/l) Hypoglycemia  Glucagon release 
 Epinephrine release 
 Growth hormone release 
 Cortisol release 
54 mg/dl (3 mmol/l) Symptomatic hypoglycemia  Autonomic symptoms 
36 mg/dl (2 mmol/l) Hypoglycemia affecting 
brain function 
(neuroglucopenia) 
 Cognitive decline 
18 mg/dl (1 mmol/l) Severe neuroglucopenia  Coma 
 Seizures 
Adapted from White, 2007  
Table 2. Physiologic response based on blood glucose level 
It is important to note that monitoring blood glucose levels is the best way to monitor 
hypoglycemia since hemoglobin A1C (A1C) does not adequately depict hypoglycemia given 
that A1C provides a measure of average control of blood glucose over the past 2 to 3 months 
(American Diabetes Association, 2011).  
In one technical review of hypoglycemia in patients with diabetes, it was noted that 
hypoglycemia resulted in “physical morbidity” as evidenced in the physical symptoms and 
even neurologic impairment patients may experience as well as “psychological morbidity” 
which were differences in moods and outlook as a result of experiencing hypoglycemia 
(Cryer PE et al, 2003). Specific manifestations of physical and psychological morbidity are 
detailed in Table 3. When thinking of these symptoms of hypoglycemia, it should be 
recognized that they can make patients feel uncomfortable physically as well as socially 
since experiencing these symptoms may result in patients receiving unwanted attention. It is 
important to consider that hypoglycemia affects patients both physically, psychologically, 
and can have a significant impact on a patient’s overall sense of well-being. Although the 
same evidence does not exist for patients that experience drug-induced hypoglycemia, it 
could be argued that the toll is equally as hard on these individuals and therefore, 
emphasizes the importance of avoiding drug-induced hypoglycemia.   
   
Examples of Physical Morbidity 
Associated with Hypoglycemia 
Examples of Psychological Morbidity 
Associated with Hypoglycemia 
Physical symptoms – anxiety, hunger, 
palpitations, sweating, hunger 
Fear of experiencing hypoglycemia 
Neurologic impairment – changes in 
behavior, decline in cognitive function, 
seizures, coma  
Guilt related to being fearful of 
experiencing hypoglycaemia 
Anxiet 
overall happiness  
Adapted from Cryer PE et al, 2003 
Table 3. Physical and psychological morbidity associated with hypoglycemia. 
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3. Risk factors 
Table 4 lists patient characteristics that may increase the risk of drug-induced hypoglycemia. 
Specific pharmacokinetic and pharmacodynamic drug parameters may affect the level of 
risk associated with the described patient characteristics.   
 
Risk Factors Mechanism 
Advancing age 
Decreased symptoms/decreased awareness, 
decreased counterregulatory response to low 
blood glucose 
Renal insufficiency Decreased insulin clearance 
Hepatic insufficiency Decreased gluconeogenesis 
Decreased food intake (skipping meals) Insufficient glucose intake 
Excessive alcohol intake Decreased gluconeogenesis 
Polypharmacy Increased risk of drug interactions resulting in hypoglycemia 
Table 4. Risk factors for drug-induced hypoglycemia 
It should be noted that the risk factors associated with drug-induced hypoglycemia are similar 
to the risk factors associated with the development of hypoglycemia in patients with DM. In 
particular it is known that advanced age, alcohol intake, and polypharmacy are all risk factors 
for hypoglycemia in patients with type 1 diabetes (Zammitt et al, 2005). As noted above, these 
are risk factors that may also place patients at risk for drug-induced hypoglycemia. In addition 
to the risk factors discussed above, risk factors that place patients with type 1 diabetes at risk 
for hypoglycemia are:  caffeine intake; variations in sleep; and physical activity, in particular 
exercise, in relation to meals and medications (Zammitt et al, 2005). However, it is unknown 
how these factors affect the risk of hypoglycemia in patients with type 2 diabetes (Zammitt et 
al, 2005). It is known that patients with type 2 diabetes who have been taking in insulin for 
more than 10 years are increased risk for experiencing hypoglycemia (Zammitt et al, 2005). 
Obviously, the greatest concern for the development of drug-induced hypoglycemia becomes 
when patients have pre-exsiting diabetes and then are placed on a medication that has the 
potential to cause hypoglycemia.  
4. Glucose regulation 
Changes in serum glucose levels are a result of the following process:  glucose absorption from 
the gastroinstestinal tract, release of stored glucose through hepatic glycogenolysis, and 
creation of glucose from non-glucose sources through hepatic gluconeogenesis. 
Glycogenolysis releases glucose through breakdown of glycogen, the stored form of glucose, 
and glycogenolysis creates glucose from amino acid and lactate. All three processes affect 
glucose levels based on proximity to meals. The rate of rise of serum glucose during and after 
meals is predominantly a result of the rate of gastric emptying. Rate of gastric emptying 
determines amount of glucose absorbed in gastrointestinal tract. During periods of fasting, 
glucose levels are regulated by glycogenolysis and gluconeogenesis. Glycogenolysis impacts 
serum glucose levels in the first 8 to 12 hours of fasting, while gluconeogenesis contributes 





The processes above are all regulated by glucoregulatory hormones. The hormones, their 
site of origin, and specific gluco-regulatory actions are listed in table 5. In addition to those 
listed, blood glucose levels are affected by epinephrine, cortisol, and growth hormones 
(Aronoff et al, 2004).  
 
Hormone Site of origin/production Action 
Insulin Beta (β)-cells of the pancreas Induces uptake of glucose by cells 
Inhibits glucagon secretion post-
prandially 
Enhances protein and fat synthesis 
Stimulates glycogenesis in the liver 
Glucagon Alpha (α)-cells of the 
pancreas 
Stimulates hepatic glycogenolysis, 
hepatic gluconeogenesis, and 
hepatic ketogenesis 
Amylin Β-cells of the pancreas Slows gastric emptying 
Inhibits glucagon secretion post-
prandially 
Decreases food intake  
Glucagon-like 
peptide 1 (GLP-1) 
L-cells of the intestine Slows gastric emptying 
Stimulates glucose-dependent 
(prandial) insulin secretion 
Inhibits glucagon secretion post-
prandially 





L-cells of the intestine Stimulates glucose-dependent 
(prandial) insulin secretion 
Inhibits glucagon secretion post-
prandially 
Table 5. Gluco-regulatory hormones 
Insulin and glucagon play large roles in the overall regulation of blood glucose (Figure 1). 
Increases in serum blood glucose stimulate insulin release from the pancreas. The amount of 
insulin released is dependent on the level of blood glucose. Insulin is not released until 
blood glucose levels reach 3.3 mmol/l (59.4 mg/dl). Insulin acts to both decrease existing 
glucose in the blood and to decrease production of further glucose. Insulin binds to 
receptors on fat, muscle, and liver cells to stimulate glucose uptake. Additional serum 
glucose is converted to glycogen, the storage form of glucose, through hepatic glycogenesis. 
Insulin decreases production of glucose from gluconeogenesis and glycogenolysis by 
inhibiting glucagon release from the pancreas. The combination of these actions results in a 
decrease in serum blood glucose. Glucagon serves as the hormone that balances the glucose 
lowering effects of insulin. Glucagon controls fasting levels by stimulating gluconeogenesis 
and glycogenolysis in the liver. Stimulation of these mechanisms results in release of 
glucose, increasing serum blood glucose levels. Release of glucagon from the pancreas 
occurs when serum glucose levels fall below approximately 5 mmol/l (90 mg/dl) (Aronoff 
et al, 2004).   
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5. Causative agents  
5.1 There are a number of agents implicated in causing hypoglycemia; however, the level of 
evidence available varies significantly amongst agents. The most highly documented drug-
induced hypoglycemia occurs with medications used to treat hyperglycemia. The specific 












Table 6. Anti-diabetic agents with greatest evidence of causing hypoglycaemia  
Of potentially greater concern are the agents which are used for indications other than 
hyperglycemia because the hypoglycemic episodes are often less predictable and/or 
unexpected. These agents often have very little or no quality evidence to document the 
frequency and severity of their hypoglycemic effects. This is illustrated in the systematic 
review of literature through 2007 conducted by The Hypoglycemia Task Force of The 
Endocrine Society which identified hypoglycemia associated with 164 different medications 
(Murad et al, 2009). This study found that no individual or class of drugs has high quality 
evidence supporting its impact on glucose levels, though drugs used to treat hyperglycemia 
were not included. Table 7 provides a list of the most commonly cited agents in the 
literature and their level of evidence. Level of evidence was defined by use of the GRADE 
approach to literature evaluation. Available evidence was evaluated for quality of study 
design, strength of association of the medication to the reported adverse effects, and 
quantity of evidence available (Murad et al, 2009). 
 
Moderate Quality Evidence
Agent/Class Mechanism of hypoglycemia
Fluoroquinolones (gatifloxacin) Unclear
May increase insulin secretion from pancreas 
Indomethacin Increase insulin secretion from pancreas, decrease in 
insulin clearance, decrease in gluconeogenesis, and 
increase in glucose uptake in periphery
Pentamadine Increased insulin secretion from pancreas through cell 
damage
Quinine Increased insulin secretion from pancreas
Poor Quality Evidence




Beta blockers Mask signs/symptoms of hypoglycemia, increase in 
glucose uptake in the periphery
Ethanol Decrease in gluconeogenesis in the liver
Lithium Unclear
Propoxyphene Unclear
Sulfamethoxazole Increase insulin secretion from pancreas
Table 7. Strength of evidence of drug-induced hypoglycemia and proposed mechanisms 
(Murad, et al, 2009). 
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Drug-induced hypoglycemia may be a result of direct changes to glucose homeostasis or 
indirect effects on a patient’s ability to recognize onset of hypoglycemia. Changes that affect 
glucose homeostasis include direct increase in insulin secretion from the pancreas, indirect 
increase in insulin secretion through decreased degradation of incretin hormones (GLP-1 
and GIP), cytotoxic effects on pancreatic cells leading to increase insulin release, decrease in 
gluconeogenesis, increase in glucose utilization and storage, decrease in glucagon release 
from the pancreatic α cells, and decreased gastric emptying (Pandit et al, 1993). Many agents 
affect glucose homeostasis through a combination of these mechanisms. Location of 
mechanism is exhibited in table 8. 
 


























 Indomethacin  Pramlintide 
Table 8. Location of action of agents implicated in drug-induced hypoglycemia 
5.2 Specific agents 
Specific agents, including risk factors and frequency of hypoglycemic events, are discussed 
below. 
5.2.1 Fluoroquinolones 
Fluoroquinolones are antibiotics which exhibit their antimicrobial activity through 
inhibition of DNA gyrase and topoisomerase IV, enzymes involved in bacterial cell division 
(Product Information: Tequin, 2006). The class includes the following agents:  ciprofloxacin, 
gatifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and rofloxacin. Though there 
are reports of hypoglycemia with most agents in this class, a majority of the evidence with 
fluoroquinolone-induced hypoglycemia is with gatifloxacin (Murad et al, 2009). The exact 
mechanism of this hypoglycemic effect is not clear; however, it is proposed that 
fluoroquinolones increase insulin secretion from the pancreas and may have a 
pharmacokinetic or pharmacodynamic interaction with various antidiabetic agents, 
including sulfonylureas. The adverse effect does not appear dose-related and presents 
typically within the first three days of therapy for less severe hypoglycemia (Frothingham, 
2005; Gajjar, et al, 2000; Park-Wyllie et al, 2006; Product Information: Tequin, 2006). More 
severe episodes, specifically those requiring hospitalization or prolonged hospitalization, 
are more common after three days of therapy. Hypoglycemia has been reported with 
intravenous and oral therapies in both outpatient and inpatient settings, and 
discontinuation of the medication is often required to resolve the glucose abnormalities 
(Murad et al, 2009). Though new onset diabetes has been reported, risk factors for patients 





concomitant use of hypoglycemic medications, advanced age, and decreased renal function 
(Frothingham, 2005; Product Information: Tequin, 2006; Yip & Lee, 2006). 
5.2.2 Indomethacin 
Indomethacin belongs to the class of agents called non-steroidal anti-inflammatory drugs 
(NSAIDs). Anti-inflammatory agents, including salicylates, are all thought to increase risk of 
hypoglycemia, with indomethacin having the greatest evidence, likely due to the population 
being treated. Though often used for osteoarthritis and other inflammatory conditions, 
indomethacin may also be used to close a patent ductus arteriosis in neonates, often  in 
those born prematurely. Increases in pancreatic insulin secretion, decreases in insulin 
clearance, increases in glucose utilization in the periphery, and decreases in gluconeogenesis 
all appear to contribute to the hypoglycemic effects of these drugs. Less than three per cent 
of neonates exposed to therapeutic levels of intravenous indomethacin for patent ductus 
arteriosis experience hypoglycemia (Product Information: Indocin, 2010). Whether this effect 
is dose-related is unclear; however, the risk may be significantly decreased by use of a 
concomitant infusion of intravenous glucose (Hosono, 1999). 
5.2.3 Pentamidine 
Pentamidine is an anti-fungal agent which exhibits its effects through inhibition of microbial 
nuclear metabolism. Direct cytotoxic effects on beta cells of the pancreas results in increased 
secretion of insulin. This early release of insulin is due to the lytic effects on the cell which 
result in cell death. This can ultimately result in insulin-dependent diabetes as a result of 
this cell loss (Pandit et al, 1993). Pentamidine is associated with a 6-40% risk of 
hypoglycemia in patients receiving intravenous or intramuscular administration. 
Hypoglycemia is most commonly seen in patients with acquired immune deficiency 
syndrome (AIDS) treated for Pneumocystis carinii (Murad et al, 2009 & Product Information: 
Pentin, 2008) (Product Information: Pentam, 2008 & Product Information: Nebupent, 2008). 
The risk of hypoglycemia and resultant pancreatic damage associated with pentamidine is 
greater with higher doses, higher cumulative doses, and prolonged use (Pandit et al, 1993). 
There also appears to be increased risk with use of pentamidine mesylate compared to 
pentamidine isothionate (Waskin, 1996). 
5.2.4 Quinine 
Quinine is an anti-malarial agent used acutely for systemic and cerebral disease. More 
than 300 cases of hypoglycemia have been reported with quinine therapy and 30 clinical 
studies have demonstrated similar findings (Murad et al, 2009). The crux of the 
hypoglycemic effects of quinine appear to be the result of increased insulin secretion from 
beta cells. Though this is most common in patients infected with malaria, there are reports 
of quinine-induced hypoglycemia in patients without malaria. Patients with malaria often 
exhibit more severe or sustained hypoglycemia since the organism responsible for 
malaria, Plasmodium falciparum, independently lowers glucose levels. There is also an 
increased risk of hypoglycemia with higher doses of quinine and with infusion times of 
intravenous doses of less than one hour. Manufacturers recommend intravenous infusions 
occur over four hours to minimize risk of hypoglycemia (Product Information: Qualaquin, 
2010). Quinine-induced hypoglycemia can be resistant to traditional therapy with glucose 
and glucagon; however, treatment with octreotide has been shown to be beneficial (Pandit 
et al, 1993). 
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5.2.5 Beta blockers 
Non-selective beta-adrenergic antagonists, also known as beta blockers, are vasodilators 
which are often used to treat hypertension and cardiac disease. A list of non-selective beta 
blockers is provided in table 9 below. These agents have been linked with hypoglycemic 
effects in patients with and without diabetes (Murad et al, 2009). Oral formulations are most 
commonly the culprit; however, hypoglycemia associated with topical formulations is 
documented (Pandit et al, 1993). Though there are numerous reports of hypoglycemia 
associated with beta blockers , the quality of the data is limited. Murad, et al, theorizes that 
the high numbers of reports are a representation of the frequency of use of these agents 
more than the frequency of the actual hypoglycemic events (Murad et al, 2009).  
There are two proposed mechanisms for this hypoglycemic effect in beta blockers. First, 
there is a blunting of the signs and symptoms of hypoglycemia (White, 2007). The exception 
to this blunting effect is sweating, an important educational point for all patients (Product 
Information:  Innopran XL, 2010). The second mechanism is a direct potentiation of the 
effects of insulin. This heightened insulin effect increases glucose utilization in the periphery 
and inhibits lipolysis. Further, there is a diminished physiologic response to hypoglycemia 
in patient receiving beta blockers, specifically a decrease in glycogenolysis and 
gluconeogenesis (Pandit et al, 1993 & White, 2007). Patients at greatest risk for 
hypoglycemia with beta blockers include patients with hepatic disease, patients on 
hemodialysis, neonates, and patients with type 1 diabetes (Product Information:  Innopran 
XL, 2010). Use of selective beta blockers, such as atenolol, metoprolol, and bisoprolol are 
thought to have a decreased risk of hypoglycaemia and may be a reasonable alternative to 
patients unable to tolerate non-selective agents (Pandit et al, 1993). 
  














Table 9. Non-selective beta-adrenergic antagonists (beta blockers) 
5.2.6 ACE inhibitors 
Angiotensin converting enzyme (ACE) inhibitors are a class of drugs that are typically used 
for hypertension and cardiovascular disease. Eleven studies document the potential for 





captopril (Murad et al, 2009; Herings et al, 1995). All members of this class are listed in table 
10 below. Though the mechanism for this drug-induced hypoglycaemia is not well defined, 
it is proposed that the increase in bradykinins associated with ACE inhibitor use may cause 
an increase in insulin sensitivity (Pandit et al, 1993; Vuorinen-Markkola & Yki-Jarvinen, 
1995). One study by Pollare, et al, suggests that captopril increases glucose utilization in the 
periphery compared to use of hydrochlorothiazide (Pollare et al, 1989); however, Wiggam, 
et al, demonstrates in one study that ACE inhibitors have no impact on hepatic or peripheral 
insulin sensitivity (Wiggam et al, 1998). Because of the contradicting information available, 
the actual impact of ACE inhibitors on blood glucose is not clear. ACE inhibitor therapy is a 
mainstay of hypertension, diabetes, and cardiovascular disease management. To date, there 
is insufficient evidence available to warrant discontinuation of this therapy in patients at 
risk for hypoglycemia with these disease states; however, in patients with suspected 














Table 10. Angiotensin Converting Enzyme (ACE) Inhibitors 
5.2.7 Ethanol 
Despite the poor level of evidence, ethanol has been touted as one of the most common 
causes of drug-induced hypoglycaemia in the United States (Pandit et al, 1993). The 
proposed mechanism is a direct suppression of gluconeogenesis in the liver, a process that 
typically occurs in more long-standing fasting states. Some studies suggest that this 
hypoglycemic potential is present in both occasional and chronic alcohol consumers and is 
more common with use of non-carbohydrate laden drinks (Pandit et al, 1993). Because of 
this, patients at greater risk for hypoglycemia should avoid consuming alcohol. 
6. Prevention  
One easy way to prevent drug-induced hypoglycemia is to avoid the medication that poses the 
potential for drug-induced hypoglycemia in patients that are at high risk for drug-induced 
hypoglycemia. Unfortunately, it may not be practical to avoid certain medications that may 
cause drug-induced hypoglycemia. As when deciding to use any medication, weigh the 
benefit of using the medication versus risk, in this case drug-induced hypoglycemia.  
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If avoiding the agent is not possible, attempt to minimize the risk of hypoglycemia by 
keeping in mind the following restrictions. Use extended-release/sustained-released 
products if that is an option for the medication needed (Pandit et al, 1993). Reinforce with 
patients the need to avoid alcohol intake (Pandit et al, 1993). Minimizing the lenth of time 
and dose of an offending agent may also be beneficial. Since hypoglycemia awareness is 
largely reliant on patient perception of the signs and symptoms of hypoglycemia, education 
is key (Cryer et al, 2003). Therefore, it is important to review the signs and symptoms of 
hypoglycemia with patients and caregivers. One way to monitor patients for evidence of 
hypoglycemia is to monitor their blood glucose concentrations, which is especially in 
important in patients with pre-existing diabetes. Blood glucose should be carefully 
monitored with initiation, dose changes, or discontinuation of any medication in patients 
with diabetes. It is usually recommended for patients to regularly check their fasting blood 
glucose readings during the initiation of a medication that can cause drug-induced 
hypoglycemia. The healthcare provider can make patient specific recommendations on how 
often to monitor blood glucose based on the patient’s underlying risk for hypoglycemia (e.g. 
patients already taking 1 or more agents that can cause drug-induced hypoglycemia or those 
patients with a diagnosis of diabetes) as well as any manufacturer recommendations. In 
addition to instructing the patient to monitor and record their blood glucose levels at home, 
it is helpful for a healthcare provider to review the history of the patient’s blood glucose 
levels at every visit and ask about signs and symptoms of hypoglycemia. Tracking the 
patient’s weight and reviewing the trend over the time the patient is taking a potentially 
offending agent may also provide insight into whether the patient is experiencing 
asymptomatic hypoglycemia, especially when reviewed with the patient’s fasting blood 
glucose levels. When at all possible, patients should not be taking multiple agents that may 
cause drug-induced hypoglycemia. Healthcare providers should also be diligent to review a 
patient’s medication profile for drug interactions, pharmacokinetics and pharmacodynamic, 
with potentially offending hypoglycemic agents. Tables 11 and 12 provide a summary of 




Use extended or sustained release products when possible 
Avoid alcohol intake 
Minimize the length of time on an offending agent 
Utilize the lowest effective dose of the offending agent 
Avoid having multiple medications in the patient’s profile that can cause hypoglycemia 
Screen the patient,s medication profile for drug interactions – pharmacokinetic and 
pharmacodynamic 
 
Table 11. Specific Prescribing Considerations When Prescribing Medications with a Potential 





Prescriber Considerations Patient Education Points 
Monitor blood glucose levels at clinic visits Demonstration of self-monitoring of 
blood glucose 
Discussion of timing of blood glucose 
monitoring and target levels 
Inquire about experiences with hypoglycemia, 
including specific signs/symptoms 
Monitor for signs/symptoms of 
hypoglycemia 
Review appropriate treatment of 
hypoglycemia 
Weigh the patient at clinic visits and review the 
trend 
 
Table 12. Monitoring Points When Patients Are Taking Medications with a Potential to 
Cause Drug-Induced Hypoglycemia 
7. Management 
When measures to prevent drug-induced hypoglycemia do not work or when appropriate 
prevention measures were not able to be undertaken, hypoglycemia, especially symptomatic 
hypoglycemia, must be treated. Specific, evidence-based recommendations for management 
of drug-induced hypoglycemia are not readily available. In the absence of guidelines for 
drug-induced hypoglycemia, patients who experience this should be treated according to 
readily accepted guidelines for managing hypoglycemia in patients with diabetes (Cryer et 
al, 2009, American Diabetes Association, 2011). 
7.1 Signs and symptoms of hypoglycemia 
As described in the section “Defining Hypoglycemia,” patients may experience a variety of 
nonspecific symptoms (neurogenic symptoms and neuroglycopenic symptoms) as well as 
physical signs than can be attributed to hypoglycemia. Since there are not clear distinctions 
in hypoglycemic symptoms that occur regardless of the source of the symptom – drug-
induced, diabetes mellitus, or  another disease state, it is important that patients and 
caregivers be knowledgeable of the signs and symptoms of hypoglycemia. Sometimes 
friends and family members are the ones that recognize the patient is experiencing 
symptoms that can be attributed to hypoglycemia (Cryer et al, 2003). In particular they may 
notice changes in the patient’s behavior, mood, speech, or train of thought as the patient is 
trying to communicate with them.       
7.2 Differential diagnosis 
When hypoglycemia is suspected it is important to recognize that the signs and symptoms a 
patient may complain of or present with are nonspecific and often other causes of the signs 
and symptoms must be ruled out. In 2009 the Endocrine Society released a clinical practice 
guideline specifying a workup strategy for patients who experience hypoglycemia in the 
absence of DM (Cryer, et al, 2009). The guidelines instruct the healthcare provider to review 
the patient’s past medical history, physical exam, review of systems, laboratory data, and 
medications – current and past. These guidelines detail additional workup to undertake if 
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Avoid having multiple medications in the patient’s profile that can cause hypoglycemia 
Screen the patient,s medication profile for drug interactions – pharmacokinetic and 
pharmacodynamic 
 
Table 11. Specific Prescribing Considerations When Prescribing Medications with a Potential 





Prescriber Considerations Patient Education Points 
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monitoring and target levels 
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including specific signs/symptoms 
Monitor for signs/symptoms of 
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Review appropriate treatment of 
hypoglycemia 
Weigh the patient at clinic visits and review the 
trend 
 
Table 12. Monitoring Points When Patients Are Taking Medications with a Potential to 
Cause Drug-Induced Hypoglycemia 
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friends and family members are the ones that recognize the patient is experiencing 
symptoms that can be attributed to hypoglycemia (Cryer et al, 2003). In particular they may 
notice changes in the patient’s behavior, mood, speech, or train of thought as the patient is 
trying to communicate with them.       
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patient may complain of or present with are nonspecific and often other causes of the signs 
and symptoms must be ruled out. In 2009 the Endocrine Society released a clinical practice 
guideline specifying a workup strategy for patients who experience hypoglycemia in the 
absence of DM (Cryer, et al, 2009). The guidelines instruct the healthcare provider to review 
the patient’s past medical history, physical exam, review of systems, laboratory data, and 
medications – current and past. These guidelines detail additional workup to undertake if 
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the cause of hypoglycemia is not apparent (Cryer, et al, 2009). However, the guidelines are 
very specific in stating that patients should be confirmed to have Whipple’s triad- 
documented by signs and/or symptoms of hypoglycemia along with a low blood glucose 
concentration and recovery of the patient/resolution of the hypoglycemic signs/symptoms 
when the patient’s blood glucose is raised – before the additional workup is pursued (Cryer, 
et al, 2009).        
7.3 Treatment of hypoglycemia 
While it is important to determine the cause of a patient’s hypoglycemia, once signs and 
symptoms of hypoglycemia are recognized it is imperative to quickly treat the patient’s 
hypoglycemia. Since there are no guidelines that are specific to managing drug-induced 
hypoglycemia, the current recommendations for managing hypoglycemia in patients with 
DM should be followed. Regardless of the cause of hypoglycemia, patients that are 
conscious should be given 15 – 20 g of glucose or any carbohydrate that contains glucose 
(American Diabetes Association, 2011). See Table 13 for specific examples of 15 – 20 g 
carbohydrate sources (National Diabetes Information Clearinghouse, 2008). The patient’s 
blood glucose should be monitored in 15 minutes and they should continue to receive 15 – 
20 g of glucose until their blood glucose level is greater than 70 mg/dl (3.9 mmol/l). Once 
the patient’s blood glucose is above 70 mg/dl (3.9 mmol/l), the patient should eat 
something more substantial (a meal or snack) to maintain their blood glucose in a normal 
range, usually 70 -130 mg/dl (3.9 – 7.2 mmol/l) (American Diabetes Association, 2011).  
 
Product 1 serving = 15 g carbohydrates 
Glucose Products 3 – 4 tablets 
1 serving of glucose gel 
Beverages 4 oz. = ½ cup of fruit juice 
4 oz = ½ cup of non-diet soft drink 
8 oz = 1 cup of milk 
Hard Candy 5 – 6 pieces 
Sugar or honey 1 tablespoon 
Adapted from National Diabetes Information Clearinghouse, 2008. 
Table 13. Quick Sources of Glucose  
Hypoglycemia is defined as severe when a patient cannot treat their hypoglycemia on their 
own due to loss of consciousness. In cases of severe hypoglycemia, caregivers should 
administer glucagon (American Diabetes Association, 2011). It should be noted that 
glucagon is a prescription medication, available as a glucagon kit, whereas the glucose 
products routinely used for mild to moderate hypoglycemia are available without a 
prescription. Caregivers should be trained on glucagon administration since it requires 
preparation of the dose and intramuscular administration (Lilly, 2005). It is also important 
for patient and caregivers to routinely check the expiration date on the glucagon kit to 
ensure it is still in date (American Diabetes Association, 2011). Although there are numbers 
indicating the occurrence of hypoglycemia, it is unclear how often drug-induced 





patient’s risk for severe hypoglycemia. If a patient is taking multiple agents that can alter 
their blood glucose or if they have multiple risk factors for hypoglycemia then it would be 
reasonable for the patient to be provided with a prescription for a glucagon kit and for their 
caregiver(s) to receive appropriate training. If the patient’s hypoglycemia is severe enough 
to warrant attention of emergency personnel, then additional measures to raise their blood 
glucose may include the administration of intravenous dextrose sources.           
In addition to quickly trying to reverse the patient’s hypoglycemia once it has occurred, a 
plan should be developed to prevent future episodes of hypoglycemia. As discussed in the 
“Prevention” section in Table 12, prescribing of the medication suspected to be causing 
hypoglycemia should be continued under close supervision. Providers should recognize 
that if offending drugs must be continued that there may need to be decreases in the dose, 
duration, or timing of administration.   Once an episode of hypoglycemia has occurred, 
afterwards is an appropriate time to re-visit how the situation was managed and to make 
sure there is an action plan for any future episodes. A summary of general principles of the 
management of drug-induced hypoglycemic episodes are found below in Table 14.  
 
Initial Treatment of Hypoglycemia 
Recognition of signs and symptoms of hypoglycemia – differentiation between mild – 
moderate versus severe 
Appropriate treatment of hypoglycemia – patient-treated with a quick acting glucose 
source versus caregiver assisted with glucagon or healthcare provider treatment with 
dextrose 
Plan for Prevention of Future Episodes of Hypoglycemia 
Evaluation of offending medication for adjustment in dosage and length of therapy 
Consider of timing of administration of medication with meals  
Consistent intake of meals/snacks 
Institute blood glucose monitoring 
Table 14. General Management of Drug-Induced Hypoglycemia 
7.4 Resolution of hypoglycemia 
Once a patient has experienced a hypoglycemic episode, the patient and healthcare 
providers will be anxious for it be resolved. Since the mechanism by which each offending 
medication causes hypoglycemia is different, the time to resolution of hypoglycaemia will 
vary accounting for both pharmacokinetic and pharmacodynamic properties of the 
offending medication as well as any other interfering medications. The mechanism by which 
hypoglycemia occurs will also determine whether the effects are reversible. In the case of 
pentamidine, the beta cell loss that may occur is not reversible (Pandit et al, 1993).   
8. Discussion 
When evaluating drug-induced hypoglycemia in comparison to what is reported in the 
literature, it is important to remember that the cases reported in the literature could be a 
result of publication bias. Many of the cases denoted patients with hospitalization and 
morbidity indicating patients were experiencing severe hypoglycemia (Murad et al, 2009). 
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8. Discussion 
When evaluating drug-induced hypoglycemia in comparison to what is reported in the 
literature, it is important to remember that the cases reported in the literature could be a 
result of publication bias. Many of the cases denoted patients with hospitalization and 
morbidity indicating patients were experiencing severe hypoglycemia (Murad et al, 2009). 
 
Hypoglycemia – Causes and Occurrences 
 
128 
Mild cases of hypoglycemia, even potentially asymptomatic cases, have not necessarily been 
documented in the literature, reinforcing the under-reporting of drug-induced 
hypoglycemia (Murad et al, 2009). In the most recent systematic review conducted, the 
reviewers noted that cases in the literature were patients who were taking medications at 
their recommended doses; however, the patients still experienced severe, symptomatic 
hypoglycemic episodes (Murad et al, 2009). This systematic review did reinforce the risk 
factors for drug-induced hypoglycemia that had been reported in earlier literature. Cases 
identified for the review were often patients of advanced age and who were experiencing 
renal and/or hepatic insufficiency. However, one additional patient risk factor that was 
identified was severe systemic disease (Murad et al, 2009). The drugs most often implicated 
in the reported cases were anti-diabetic agents, specifically insulin and sulfonylureas, as 
denoted in Table 6 (Murad et al, 2009). 
9. Conclusion 
Hypoglycemia is a potentially common and underreported complication of medication use 
which can result in significant morbidity and mortality. Patients must be educated on 
common signs and symptoms of hypoglycemia, especially when specific symptoms may be 
masked by medications. Specific characteristics, including renal insufficiency, hepatic 
insufficiency, and advancing age, may predispose patients to development of drug-induced 
hypoglycemia. Patient evaluation may help the clinician identify patients at greatest risk 
and avoid complications associated with the more commonly associated drugs. Preventative 
strategies include drug avoidance, minimizing time or dose of offending agents, using 
controlled-release formulations where available, limiting use of the medication or multiple 
medications which may cause hypoglycemia, and frequent, proactive blood glucose 
monitoring. Though these strategies may not prevent all occurrences, they may limit the 
number or severity of those that do happen. In the case of a hypoglyemic episode, 
management strategies should include those used in managing hypoglycemia of non-drug-
induced origin.  
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failure, renal failure, hormonal deficiencies, alcohol abuse and reactive hypoglycemia. The 
medication history is an integral part in the evaluation of a patient with hypoglycemia. A 
variety of medications have been associated with hypoglycemia, and the list of these 
medications is expanding (Comi, 1993). The common causes of acute hypoglycemia are 
related to therapy for diabetes mellitus – insulin and its analogues or oral antidiabetic drugs 
(OAD). Determining the aetiology of hypoglycemia poses little difficulty in patients known 
to be taking parenteral or oral hypoglycaemic agents. Severe hypoglycemia, associated with 
coma or requiring assistance of another person for reversal occurs at least once a year in 10% 
of patients treated with insulin, with a mortality of 2-4%. There is difficulty assessing the 
absolute rates but the frequency of iatrogenic hypoglycemia is substantially lower in type 2 
than in type 1 diabetes. Thus, the rates of severe hypoglycemia in type 2 diabetes are 
approximately 10% of those in type 1 diabetes even during aggressive insulin therapy 
(Marks, 1981). 
Episodes of hypoglycemia may occur also in patients without diabetes mellitus, insulin or 
OAD therapy. In these patients, hypoglycemia absents often among diagnostic concerns 
what might worsen subsequently their prognosis. It is necessary to consider the possibility 
of drug induced hypoglycemia after excluding its organic aetiology (endocrinopathies, 
malnutrition, cancer etc.).  There are various groups of drugs with provable hypoglycemic 
effects that may potentiate diabetes mellitus treatment or lead to hypoglycemia in 
nondiabetic patients as well (Table 1). Some prospective studies carried out in last decade 
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find that hypoglycemia is present in 12% patients with beta-blocker poisoning and in 30.9% 
patients with salicylate poisoning. Among drug-induced hypoglycemias in non-diabetic 
subjects, alcohol represents the most frequent cause, followed by beta-blockers, and 
salicylates  (Guettier & Gorden, 2006).  
2. Most common drugs leading to hypoglycemia 
2.1 Insulin and its analogues 
Insulin is a hormone central to regulating carbohydrate and fat metabolism in the body. 
Insulin causes cells in the liver, muscle, and fat tissue to take up glucose from the blood, 
storing it as glycogen in the liver and muscle. cells. Insulin also influences other body 
functions, such as vascular compliance and cognition. Once insulin enters the human brain, it 
enhances learning and memory and benefits verbal memory in particular. Enhancing brain 
insulin signalling by means of intranasal insulin administration also enhances the acute 
thermoregulatory and glucoregulatory response to food intake, suggesting central nervous 
insulin contributes to the control of whole-body energy homeostasis in humans. Insulin is a 
peptide hormone composed of 51 amino acids and has a molecular weight of 5808 Da (Fig. 1). 
It is produced in the islets of Langerhans in the pancreas (Chang et al., 1997).  
 
 
Fig. 1. Pro-insuline with C-peptide. 
Insulin replacement therapy has witnessed several major developments since its inception in 
the early 20th century, allowing for treatment approaches that seek to mimic normal insulin 
physiology and achieve tight glycemic control. Hypoglycemia can hinder these efforts as the 
glycemic control trials in both type 1 and type 2 diabetes have shown (UK Hypoglycaemia 
Study Group, 2007).  
The data on the frequency of hypoglycemia in diabetic subjects is uncertain. Depending on 
the severity of the hypoglycemic event, hypoglycemia is defined as asymptomatic, mild or 
severe. While there is much more information on the frequency of severe hypoglycemia, 
little is known on the real frequency of asymptomatic and mild hypoglycemia. (MacLeod et 
al., 1993) 
Insulin resistance with hyperinsulinemia is a prominent feature in the early stages of the 
disease. Thus, type 2 diabetics benefit from measures to improve insulin sensitivity, such as 
caloric restriction, exercise and weight management, early in their disease. With progression 
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of type 2 diabetes, there is ultimately a progressive loss of pancreatic b-cell function and 
endogenous insulin secretion. At this stage, most patients require exogenous insulin therapy 
to achieve optimal glucose control (Abraira et al, 1995). 
A relative or absolute excess in insulin mainly occurs in excessive dose of insulin or when an 
incorrect dose is given at the wrong time. Hypoglycemia also occurs during prolonged 
fasting, after exercise, in renal or liver failure. The risk of severe hypoglycemia in insulin-
requiring patients with type 2 diabetes has consistently been reported to be significantly 
reduced compared with the risk in type 1 diabetic patients undergoing intensive insulin 
therapy. The lower incidence of  severe hypoglycemia in type 2 diabetes may result from 
insulin resistance.  In the randomized Diabetes Control and Complications Trial (DCCT), 
hypoglycemia occurred approximately once per week in the standard insulin treatment 
group (under 3 doses of insulin daily) and approximately twice per week in the intensive 
treatment group (3 and more doses of insulin daily).  Most patients with type 1 diabetes lose 
their ability to secrete glucagon in response to hypoglycemia shortly after developing 
diabetes, and thus the incremental secretion of epinephrine assumes a primary role in the 
hormonal response to hypoglycemia in this disease (DCCT Research Group, 1993). 
Basdevant et al. reported that during a one-year period of observation, 17% of patients with 
type 1 diabetes mellitus on the intensive insulin treatment had a severe hypoglycemic 
reaction. Because the ability to secrete epinephrine is also impaired in approximately 25% of 
patients with longstanding type 1 diabetes mellitus, such patients may  manifest the 
syndrome of “hypoglycemic unawareness”, resulting in a tendency to develop frequent, 
severe and  prolonged hypoglycemia (Basdevant et al, 1982).  
In the DCCT study 9.8% of subjects in the standard treatment diabetic group had severe 
hypoglycemia during the 12 months of study. In the same study, subjects the intensive 
treatment group had a threefold increase in the incidence of serious hypoglycemia 
compared with those in the standard treatment group. Other authors have also noted an 
increased risk of hypoglycemia in patients with diabetes  controlled very  rigidly (DCCT 
Research Group, 1993).   
On the other side, tight glycemic control has been shown to reduce mortality in surgical 
intensive care patients and in long-term medical intensive care patients. But, the high 
incidence of hypoglycemia may override the potential beneficial effects of intensive insulin 
therapy. In the studies by van den Berghe et al., the proportion of patients experiencing 
severe hypoglycemia in the intensive treatment group was 5.1% in surgical and 18.7% in 
medical patients, whereas in the conventionally treated group the incidences were 0.8% and 
3.1%, respectively (Van den Berghe et al., 2001).  
2.2 Sulfonylurea derivates 
Sulfonylureas were introduced into medical practice in 1955 for the treatment of diabetes 
and other conditions, and have been used by both diabetic and nondiabetic subjects.  
Sulfonylureas bind to an ATP-dependent K+ (K+ATP) channel on the cell membrane of 
pancreatic beta cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing 
the electric potential over the membrane to become more positive. This depolarization opens 
voltage-gated Ca2+ channels. The rise in intracellular Ca2+ leads to increased fusion of 
insulin granulae with the cell membrane, and therefore increased secretion of pro-insulin. 
The structure of sulfonlyureas is on the fig. 2.  
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Fig. 2. Structure of the sulfonylureas 
Sulfonylureas also sensitize β-cells to glucose, and hey limit glucose production in the liver,, 
they decrease lipolysis,, and decrease clearance of insulin by the liver. Sulfonylureas 
produce hypoglycemia by releasing preformed insulin from b-cells by a direct action, and 
possiblyby sensitizing them to the action of certain endogenous insulinotrophs such as 
leucine (Kunte H et al, 2007).   
The sulfonylureas resemble one another more than they differ, and the greatest differences 
are found in their blood glucose-lowering potencies and in the way in which they are 
eliminated from the body .  The hypoglycemic potency of an individual agent is a function 
of  the biological half-life of the drug itself and its active metabolites. 
Sulfonylureas, as opposed to metformin, the thiazolidinediones, exenatide, symlin and other 
newer treatment agents may induce hypoglycemia as a result of excesses in insulin 
production and release. This typically occurs if the dose is too high, and the patient is 
fasting. Some people attempt to change eating habits to prevent this, however it can be 
counter productive. Like insulin, sulfonylureas can induce weight gain, mainly as a result of 
their effect to increase insulin levels.  
Sulfonylureas are potentially teratogenic and cannot be used in pregnancy or in woman 
who may become pregnant. Impairment of liver or kidney function increases the risk of 
hypoglycemia, and are contraindications for the use of sulfonylureas (Campbell, 1985).  
Second-generation sulfonylureas have increased potency by weight, compared to first-
generation sulfonylureas. All sulfonylureas carry an FDA-required warning about increased 
risk of cardiovascular death. The ADVANCE trial (Action in Diabetes and Vascular 
Disease), found no benefit from tight control with gliclazide for the outcomes of heart attack 
(myocardial infarction), cardiovascular death, or all-cause death (Patel et al, 2005). 
Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) and the VADT 
(Veterans Affairs Diabetes Trial)  studies showed no reduction in heart attack or death in 
patients assigned to tight glucose control with various drugs (Gerstein et al., 2007; Reaven et 
al., 2004). 
Various sulfonylureas have different pharmacokinetics. The choice depends on the 
propensity of the patient to develop hypoglycemia. Long-acting sulfonylureas with active 
metabolites can induce prolonged hypoglycemia. The shorter-acting agents may not control 
blood sugar levels adequately, but the hypoglycemia does not last so long.  
Due to varying half-life, some drugs have to be taken twice or three times a day rather than 
once. The short-acting agents may have to be taken about 30 minutes before the meal, to 
ascertain maximum efficacy when the food leads to increased blood glucose levels. 
Some sulfonylureas are metabolised by liver metabolic enzymes and inducers of this 
enzyme system (e.g rifampicin) can therefore increase the clearance of sulfonylureas. In 
addition, because some sulfonylureas are bound to plasma proteins, use of drugs that also 
 
Drugs and Hypoglycemia 
 
135 
bind to plasma proteins can release the sulfonylureas from their binding places, leading to 
increased clearance. 
Mild sulfonylurea-induced hypoglycemia produces only few symptoms and mostly they are 
of a subacute neuroglycopenic variety. Although mild hypoglycemia causes unpleasant 
symptoms and disrupts  patients daily activities, severe hypoglycemia can result  in coma, 
seizures and death  (Herbel & Boyle, 2000) 
Hypoglycemia due to ingestion of sulfonylures has been documented as a accidental 
ingestion and also when ingested in a suicide attempt leading to death. Sulfonylurea 
compounds have also been reported to cause severe hypoglycemia when prescribed 
simultaneously with either a second blood glucose-lowering agent or a nonhypoglycemic 
drug that prolongs the activity of the sulfonylurea. The different drugs which were involved 
include phenformin or buformin, salicylate, alcohol,  phenylbutazone,  sulfadimidine or 
sulfamethoxazole for urinary tract infection (Bandyopadhyay, 2004). 
2.3 β-blockers 
Beta blockers block the action of endogenous catecholamines (adrenaline and noradrenaline) 
on β-adrenergic receptors. There are three known types of beta receptor, designated β1, β2 
and β3 receptors. β1-adrenergic receptors are located mainly in the heart and in the kidneys. 
β2-adrenergic receptors are located mainly in the lungs, gastrointestinal tract, liver, uterus, 
vascular smooth muscle, and skeletal muscle. β3-adrenergic receptors are located in fat cells. 
Stimulation of β2 receptors induces smooth muscle relaxation induces tremor in skeletal 
muscle, and increases glycogenolysis in the liver and skeletal muscle. Stimulation of β3 
receptors induces lipolysis. 
Spontaneous hypoglycemia may occur in diabetic and nondiabetic patients receiving β-
adrenoceptor antagonists. This complication of treatment with β-blockers was first 
described by Kotler et al. in 1966. Mechanism of β-blocker-induced hypoglycemia includes 
inhibition of hepatic gluconeogenesis, which is normally potentiated by the sympathetic 
nervous system. Reduction of lipolysis with decreased plasma concentrations of 
nonesterified fatty acid increase β-blockers the glucose uptake of skeletal muscles. Non-
selective β-blockers, which are currently used only in a limited way, may intensify 
hypoglycemia-induced hypoglycemic therapy or delay and suppress clinical manifestations 
of hypoglycemia (tachycardia, tremor) (Abramson et al, 1965). Sweating as a symptom of 
hypoglycemia remains preserved even when taking β-blockers, therefore, attention or this 
symtome should be given in the absence of other symptoms of hypoglycemia and 
neuroglycopenia. In addition, β-adrenergic antagonists block the effect of adrenaline as a 
counter-regulatory mechanism, resulting in a reduction in glycogenolysis. However, cases 
of severe hypoglycemia were also described with the use of therapeutic doses of 
cardioselective beta-blockers (Miller et al., 2001). 
At risk of hypoglycemia are particularly insulin-dependent diabetics, but severe 
hypoglycemia while taking β-blockers have been described as well in non-diabetic 
hemodialysated patients during dialysis (Murata et al., 1981). The literature has described 
the emergence of severe hypoglycemia in the treatment of glaucoma with eye drops 
containing timolol in patients with diabetes mellitus type 1 (Angelo-Nielsen, 1980).  
2.4 ACE inhibitors 
Angiotensin converting enzyme inhibitors (ACEI) are potent antihypertensive agents with 
multiple pleiotropic effects, which are used for the treatment of hypertension, heart failure 
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or in patients after myocardial infarction. ACE inhibitors block the conversion of 
angiotensin I to angiotensin II. Under normal conditions, angiotensin II will have the 
following effects: 
 vasoconstriction, which lead hypertension  
 constriction of the efferent arterioles of the kidney, leading to increased perfusion 
pressure in the glomeruli  
 contribute to ventricular remodeling and ventricular hypertrophy of the heart  
 stimulation of the adrenal cortex to release aldosterone, with sodium retention.  
 stimulation of the posterior pituitary to release vasopressin (anti-diuretic hormone - 
ADH), which acts on the kidneys to increase water retention.  
 decrease renal protein kinase C (Acharya et al, 2003) 
With ACE inhibitor use, the effects of angiotensin II are prevented.  
Unlike other groups of drugs they have a relatively low incidence of adverse effects. 
Hypertension, chronic heart failure and coronary heart disease in diabetics are very frequent 
co morbidities and ACEI are due they indifferent effect on the metabolism of glucose and 
lipids and proven renoprotective effect in these patients the drugs of first choice. The 
association between use of ACE inhibitors and episodes of hypoglycemia in patients with 
diabetes mellitus is controversial. Were the cases illustrated the need to reduce doses of 
insulin or oral hypoglycemic agents failure after initiation of ACEI therapy and few cases of 
ACEI-associated hypoglycemia, although it has been reported particularly in patients with 
the presence of severe co-morbidities - heart failure, chronic kidney disease and the like 
(Herings et al., 1995) 
Possible mechanism of the hypoglycemic effect of ACEI is not yet well understood, may 
involve increased insulin sensitivity of peripheral tissues, blocking of angiotensiogen II as 
one of the counter-regulatory hormones with similar effects as adrenaline, speeding up 
absorption of subcutaneous insulin etc. (Buchanan et al., 1993). 
Nevertheless, it appears that some episodes of hypoglycemia associated with ACEI use were 
the result of potentiation of hypoglycemic effects of other drugs and ACE inhibitors remain 
a safe choice for treatment of patients with diabetes mellitus (Seghieri et al., 1992). 
2.5 Salicylates 
Salicylic acid is a monohydroxybenzoic acid, a type of phenolic acid and a beta hydroxy 
acid. It is derived from the metabolism of salicin. This colorless crystalline organic acid is 
widely used in organic synthesis and functions as a plant hormone. The salts and esters of 
salicylic acid are known as salicylates. 
Salicylates in the past short period of use as hypoglycemic drugs, but to achieve the 
hypoglycemic effect, administration of high doses was necessary, which had many adverse 
effects (Baron, 1982). Since diabetics are at increased incidence of coronary heart disease, 
myocardial infarction or cerebrovascular diseases, today we meet with frequent use of 
antiplatelet drugs in this population, especially acetylsalicylic acid, which is used in the 
primary and secondary prevention of cardiovascular events. Symptomatic hypoglycemia 
was described in many cases of the use of salicylates, especially in young children. 
Salicylates in therapeutic doses have the hypoglycemic potential similar to some 
sulphonylurea agent or metformin (Micossi et al, 1978). On the other hand, lotions 
containing salicylates are used to treat certain skin disorders, and the drug can be absorbed 
through the skin and has been associated with life-threatening complications. A case of 
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severe refractory hypoglycemia in a man with terminal kidney disease using a salicylate 
lotion for treatment of psoriasis has been described in the literature (Raschke et al, 1991). 
Intentional salicylate overdose usually occurs predominantly in adolescents and young 
adults. Overdoses in children are usually accidental and in the elderly they occur as 
therapeutic misadventures. Elderly patients with chronic salicylate overdose tend to present 
with nonspecific findings such as deterioration of cognition, or self care, pulmonary edema 
or failure to thrive. Important clinical clues may be tachypnea, hyperpnea and an 
unexplained positive ion gap metabolic acidosis (Marks & Teale , 1999) 
The mechanism of the hypoglycemic effect of salicylates is not precisely known, yet. 
Possible mechanisms include a reduction of hepatic gluconeogenesis and increase of insulin 
secretion, increases glucose utilization in peripheral tissues due to disconnection of 
oxidative phosphorylation or reduction of the concentration of circulating nonesterified 
fatty acid by suppression of lipolysis. Meanwhile organic acids (pyruvate and lactate) 
accumulate in the periphery because ATP is no longer being generated through the Krebs 
cycle, as several of the Krebs cycle enzymes are blocked by excess salicylate. The body 
becomes increasingly dependent on the less efficient anaerobic energy pathways by way of 
which more energy is dissipated as heat. This produces fever and increased utilization of 
glucose. This inhibition of glucose oxidative metabolism is particularly hazardous to the 
brain because of the inability of neuronal tissue to employ fatty acids. The resulting lipolysis 
increases production of ketones and organic acids culminating in metabolic acidosis when 
the body’s buffering capacity becomes sufficiently depleted. These metabolic changes 
eventually lead to renal depletion of fluid and electrolytes, hypoglycemia, hypokalemia and 
a mixed picture of respiratory and metabolic alkalosis coupled with metabolic acidosis 
(Rumore & Kim, 2010).  
2.6 Paracetamol 
Paracetamol (acetaminophen - fig.3) intoxication, most frequently in suicidal intent, may 
lead to liver necrosis with severe hypoglycemia. Paracetamol toxicity is one of the most 
common causes of poisoning worldwide. In the United States and the United Kingdom it is 
the most common cause of acute liver failure (Khashab et al, 2007).  
 
 
Fig. 3. Structure of the paracetamol (acetaminophen) 
Hypoglycemia while taking paracetamol in the usual therapeutic doses has been described 
in a child, but also had documented hypoglycemia after salicylates. Two case reports of 
patients with anion gap metabolic lactic acidosis and hypoglycemia were presented in 
literature. Both patients subsequently died of acute liver failure secondary to paracetamol  
hepatotoxicity. The development of lactic acidosis with hypoglycemia might have been 
caused by a deficit in gluconeogenesis secondary to severe hepatic failure and/or a toxic 
metabolite of paracetamol (Bandyopadhyay, 2004). 
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2.7 Antibiotics and chemotherapeutics 
2.7.1 Trimethoprim-sulfamethoxazole  
Trimethoprim-sulfamethoxazole or Co-trimoxazole is a sulfonamide antibiotic combination 
of trimethoprim and sulfamethoxazole, in the ratio of 1 to 5, used in the treatment of a 
variety of bacterial infections. The synergy between trimethoprim and sulfamethoxazole 
was first described in a series of in vitro and in vivo experiments published in the late 
1960´s. Trimethoprim and sulfamethoxazole have a greater effect when given together than 
when given separately, because they inhibit successive steps in the folate synthesis pathway. 
Sulfamethoxazole acts as a false-substrate inhibitor of dihydropteroate synthetase. 
Sulfonamides such as sulfamethoxazole are analogues of para-aminobenzoic acid (PABA) 
and are competitive inhibitors of the dihydropteroate-synthetase, and, thus, inhibiting the 
production of dihydropteroic acid. Trimethoprim acts by interfering with the action of 
bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid. Folic acid is an 
essential precursor in the de novo synthesis of the DNA nucleosides (fig. 4) (Brumfitt & 
Hamilton-Miller, 1993).  
 
 
Fig. 4. Mechanism of co-trimoxazole effects 
Bacteria are unable to take up folic acid from the infection host and, thus, are dependent on 
their own synthesis.  Inhibition of the enzyme starves the bacteria of two bases (thymidine 
and uridine) which are necessary for DNA replication and transcription. 
Sulfonamide antibiotics may potentiate the hypoglycaemic effect of sulphonylureas, but can 
also cause hypoglycemia in patients not taking this type of OAD. Several cases of severe and 
fatal hypoglycemia especially in combination of sulfamethoxazole with older types of 
sulphonylureas have been described (Hekimsoy et al., 1997). For structural similarity of 
sulfamethoxazole and sulphonylureas it is assumed to have the similar mechanism of action 
on pancreatic cell, namely that in the perceptive group of patients there is an increased 
release of insulin due to the modification of K+ channel of the β-cells (Mihic et al., 1975). 
Hyperinsulinemic hypoglycemia associated with trimethoprim-sulfamethoxazole has 
generally been reported in adults who had renal impairment or in patients with AIDS using 
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high dose of trimethoprim-sulfamethoxazole. High insulin and C-peptide levels were 
documented at the time of hypoglycemia (Rosinini et al. 2008). 
2.7.2 Ciprofloxacin and other fluoroquinolons 
Ciprofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class.  
It is a second-generation fluoroquinolone antibacterial. It functions by inhibiting DNA 
gyrase, a type II topoisomerase, and topoisomerase IV, enzymes necessary to separate 
bacterial DNA, thereby inhibiting cell division. Thus, it kills bacteria by interfering with the 
enzymes that cause DNA to rewind after being copied, which stops synthesis of DNA and 
of proteins (Kawahara, 1998). 
Ciprofloxacin is one of the most commonly used fluoroquinolones in clinical practice. 
Hypoglycemia after its administration has been described only in isolated cases so far, 
especially in patients concomitantly receiving older types of sulphonylureas. Fluoroquinolones 
are widely associated with dysglycemias, particularly in diabetic patients receiving 
hypoglycemic agents. Renal insufficiency has been also implicated to precipitate 
hypoglycemia after fluoroquinolones combinated with sulfonylureas. The cellular mechanisms 
by which sulfonylureas and ciprofloxacin interact to produce hypoglycemia are poorly 
described but likely to be complex and multifactorial. Mechanisms might include interactions 
at one or more of the P450 isoenzymes or ciprofloxacin-related blockage of ATP-potassium 
channels that are responsible for insulin control (Roberge et al., 2000). Since the bounding of 
the ciprofloxacin to plasma proteins is relatively weak, probably it does not interact with OAD 
at that level. Sulfonylurea-induced hypoglycemia after using of ciprofloxacin can be serious 
and refractory to traditional therapy. In the report by Roberge et al, the patient developed 
hypoglycemia after treatment with ciprofloxacin for one week (Roberge et al., 2000). On the 
other hand, in the case report of Lin et al,, a 68-year-old man with a history of coronary artery 
disease, atrial fibrillation, and type 2 diabetes on OAD therapy (glyburide) developed 
significant hypoglycemia after one dose of ciprofloxacin (Lin et al., 2004).  
Other fluoroquinolones can also induce severe hypoglycemia, especially in the combination 
with sulfonylurea derivates. Sporadic published case reports have linked administration of 
fluoroquinolone antibiotics, in particular gatifloxacin, with early-onset hypoglycemia in 
patients with diabetes. Most reported patients were aged over 65 years and were 
concomitantly receiving the sulfonyureas. fluoroquinolones have been demonstrated to 
augment insulin release in a dose-dependent manner from isolated pancreatic islet cells and 
to increase insulin levels in patients with type 2 diabetes mellitus. Gatifloxacin therapy is 
associated with a higher incidence of hypoglycemia than therapy with non-
fluoroquinolones in the group of older patients (LeBlanc et al 2004; Baker & Hangii , 2002). 
2.7.3 Tetracyclines  
Tetracyclines are broad-spectrum polyketide antibiotics. Tetracyclin alone is produced by 
the Streptomyces genus of Actinobacteria. They are protein synthesis inhibitors. 
Tetracyclines bind to the 30S subunit of microbial ribosomes. They inhibit protein synthesis 
by blocking the attachment of charged aminoacyl-tRNA. Thus, they prevent introduction of 
new amino acids to the nascent peptide chain. The action is usually inhibitory and reversible 
after withdrawal of the drug (Olson et al., 2006). 
The mechanism of tetracyclins-induced hypoglycemia is still not clear. Increased sensitivity 
to insulin and decreased clearance if insulin were implicated. Miller reported ocytetracyclin-
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induced hypoglycemia in a patient with diabetes with initially uncontrolled glycemia 
because of glandular fever (Miller, 1966). In the case report of Basaria et al., severe 
hypoglycemia occurred in young non-diabetic man with Marphan´s syndrome with 
doxycyklin therapy due to acne (Basaria et  al, 2002). Moreover, severe hypoglycemia 
occurred in non-diabetic patient after intrapleural administration of tetracycline, for the 
purpose of pleurodesis.  
2.7.4 Pentamidine 
Pentamidine is a biguanide, which was originally used in the treatment of trypanosomiasis. 
However, in recent decades, it is also often used to treat pneumocystis pneumonia (PCP) 
caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii), predominantly 
in patients with HIV infection. Pentamidine is also used as a prophylactic against PCP in 
patients receiving chemotherapy, as they also have a depressed immune system as a direct 
side-effect of the drugs used. Additionally, pentamidine has good clinical activity in treating 
leishmaniasis, and yeast infections caused by Candida albicans (Nguewa et al.). 
Hypoglycemia occurs in about 10-40% of patients treated with pentamidine at higher doses 
and is considered the most common metabolic abnormality associated with this treatment 
(Waskin et al., 1988). The prevalence of hypoglycemia is more common in patients with 
AIDS infection than in other patients treated with pentamidine. Hypoglycemic reaction is 
usually seen after several days from the start of the treatment. However, several cases of 
hypoglycemia were described after several hours of pentamidine treatment. Episodes of 
hypoglycemia can be frequent, severe and can lead to irreversible damage of central nervous 
system (Satler & Waskin, 1987). The mechanism of hypoglycemia includes mainly cytolytic 
response of pancreatic cells with subsequent release of insulin. Prolonged treatment with 
pentamidine may lead to destruction of pancreatic cells and the onset of insulin-dependent 
diabetes mellitus. Hypoglycemia have also been reported after pentamidine aerosol therapy 
(Hauser et al., 1991).  
2.7.5 Quinine and quinidine 
Quinine (fig. 5) is a natural white crystalline alkaloid having antipyretic, antimalarial, 
analgesic and anti-inflammatory properties. Though it has been synthesized in the 
laboratory, the bark of the cinchona tree is the only known natural source of quinine. 
Quinine was the first effective treatment for malaria caused by Plasmodium falciparum, 
appearing in therapeutics in the 17th century. It remained the antimalarial drug of choice 
until the 1940s, when other drugs replaced it. Since then, many effective antimalarials have 
been introduced, although quinine is still used to treat the disease in certain critical 
situations. As of 2006, quinine is no longer recommended by the WHO as first line treatment 
for malaria and should be used only when artemisinins are not available. It is sometimes 
also used in the treatment of lupus erythematodes and rheumatoid arthritis (Kaufman & 
Rúveda, 2005). 
Quinine-induced hypoglycemia is dose-dependent and, several fatal cases of hypoglycemia 
by the treatment of tropical malaria were reported. Quinine sulfate causes hypoglycemia 
also in nondiabetic patients, particular by increasing insulin release. Quinine is excreted by 
the kidneys, so the presence of chronic kidney disease increases the risk of quinine-induced 
hypoglycemia (Harats et al, 1984). 
 




Fig. 5. Structure of quinine 
Quinidine is a stereoisomer of quinine, and it acts as a class I antiarrhythmic agent in the 
heart. Quinidine primarily works by blocking the fast inward sodium influx (INa). 
Quinidine's effect on INa is known as a use dependent block – at higher heart rates, the block 
increases, while at lower heart rates the block decreases. The effect of blocking the fast 
inward sodium influx causes decrease of the cardiac action potential in the phase 0 of the 
heart depolarization (Jones et al., 1986). 
2.8 Disopyramide 
Disopyramide, group I antiarrhythmic drug, is mainly used for the treatment of ventricular 
and supraventricular rhythm disturbances. Commonest side effects result from 
disopyramide's anticholinergic activity.  It is also used in ventricular arrhythmia and 
supraventricular arrhythmia that might follow myocardial infarctions. It has no effect on alpha 
or beta adrenergic receptors. Disopyramide is an analogue of quinidine and hence has similar 
effects, that means, it stimulates insulin secretion and may lead to hyperinsulinemic 
hypoglycemia. It is excreted by the kidneys, therefore older patients and patients with chronic 
kidney disease using this drug are at risk of hypoglycemic episodes (Cacoub et al., 1989).  
2.9 Sertraline 
Unlike other groups of antidepressants from the selective serotonin reuptake inhibitors 
(SSRI) group, sertraline has linear pharmacokinetics, so an increase in dose leads to a 
proportional increase in its plasma concentrations. Sertraline is primarily used to treat major 
depression in adult outpatients as well as obsessive–compulsive, panic, and social anxiety 
disorders in both adults and children. In 2007, it was the most prescribed antidepressant on 
the U.S. retail market. Hypoglycemia has been described in several cases, mostly in diabetic 
patients stabilized on long-term treatment of OAD, in which treatment with sertraline was 
added. The most likely mechanism of potentiating effect of antidiabetic agents is inhibition 
of cytochrome P-450. Although the mechanism of action of SSRIs is usually thought to 
involve an increase of the synaptic concentration of serotonin secondary to blockade of its 
reuptake by nerve terminals, it is also possible that nonneuronal mechanisms contribute. 
Sertraline treatment may have potentiated hypoglycemia-induced epinephrine secretion by 
a direct action in the adrenal medulla (Pollak et al., 2001). 
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Vacor is a rodenticide containing N-3-pyridylmethylurea (PNU), which is chemically related 
to alloxan and streptozotocin. Vacor is a potent b-cell toxin that initially produces severe 
hypoglycemia by washing out stored insulin, followed by complete destruction of b-cells 
and fatal diabetes. Accidental ingestion of Vacor has resulted in severe hypoglycemia. It is 
suggested that the mechanism of Vacor toxicity involves niacinamide antagonism (Johnson 
et al, 1980) 
2.11 Ethanol 
Substance use disorders are a major public health problem facing many countries. The most 
common substance of abuse/dependence in patients presenting for treatment is alcohol. The 
World Health Organization (WHO) estimates that there are about 2 milliards people 
worldwide who consume alcoholic beverages, about 140 million people throughout the 
world suffer from alcohol dependence, and 76.3 million patients with diagnosable alcohol 
use disorders. Alcohol causes 1.8 million deaths (3.2% of total) and a loss of 58.3 million (4% 
of total) of Disability-Adjusted Life Years (DALY). Unintentional injuries alone account for 
about one third of deaths, while neuropsychiatric conditions account for approximately 40% 
of the 58.3 million DALYs. Alcohol consumption is the leading risk factor for disease burden 
in low mortality developing countries and the third largest risk factor in developed 
countries (White et al., 1993). Generally, the WHO European Region has the highest 
proportion in the world of total ill health and premature death due to alcohol. At a societal 
level, the European Union is the heaviest-drinking region in the world, with over one fifth of 
the European population aged 15 years and above reporting heavy episodic drinking (five 
or more drinks on an occasion, or 50g alcohol) at least once a week (Fig 6).  
 
 
Fig. 6. Alcohol consumption in the world (litres per capita) 
Heavy episodic drinking is widespread across all ages and all of Europe, and not only among 
young people or those from northern Europe. Alcohol consumption has health and social 
consequences via intoxication (drunkenness), alcohol dependence, and other biochemical 
effects of alcohol. Overall there is a causal relationship between alcohol consumption and more 
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than 60 types of disease and injury. Alcohol is estimated to cause about 20–30% of oesophageal 
cancer, liver cancer, cirrhosis of the liver, homicide, epileptic seizures, and motor vehicle 
accidents worldwide. The risk of death from a chronic alcohol-related condition is found to 
increase linearly from zero consumption in a dose–response manner with the volume of 
alcohol consumed (WHO Global Status Report on Alcohol, 2004).  
Although alcoholism is a very common condition, alcohol related hypoglycemia is a relative 
rare complication of alcohol abuse. In one older clinical study authors proved that alcohol 
associated hypoglycemia at an emergency department constituted only 0.9% of ethanol 
detectable cases over 3-month period. On the other hand, only a few hypoglycemic clinical 
features are exhibited other like coma, and many symptoms and signs of hypoglycemia are 
identical to those of alcohol intake. Thus, hypoglycemia in these patients could be 
unrecognised even by first aid or emergency physician. Assessment of plasma glucose is 
cheap, quick and reproducible and prolongated hypoglycemia may lead to irreversible brain 
damage or death. Alcohol related hypoglycemia often develops slowly and probably 
accounts for some deaths of chronic alcohol abusers and drunks who are confined in police 
cells to sober up overnight. That’s why the assessment of plasma glucose level is necessary 
in chronic abusers admitted to emergencies (Fishbain & Rotundo).  
In healthy individuals 2-3 days of fasting are necessary for depletion of hepatic glycogen 
reserve. Alcohol-related fasting hypoglycemia results from depletion of glycogen storage by 
starvation, and impairment of gluconeogenesis in liver cells. Thus, in chronically 
malnutricient patient it could develop within 6-36 hours after ingestion of a moderate to 
high dose of alcohol. In addition, suppression of counter-regulatory mechanisms (e.g. 
glucagon, growth hormone or epinephrine secretion) is also contributing to development of 
hypoglycemia (Chen & Ng, 2003). 
Alcohol-related reactive hypoglycemia often occurs after drinking alcohol with some 
calories rich beverages (gin-tonic, rum-cola). This combination can lead to profound 
hypoglycemia 3-4 hours afterward, probably due to attenuation of counter-regulatory 
mechanism. Acute and sustained alcohol use can suppress growth hormone release in 
response to insulin-induced hypoglycemia. At night, acute and chronic alcohol 
administration is associated with a 75% reduction in the usual night time sleep-related 
release of growth hormone (Flanagan et al, 1998).  
Many drugs interact with alcohol resulting in undesirable outcomes. There are two types of 
alcohol-drug interactions: pharmacokinetic and pharmacodynamic. Acute alcohol use 
increases the risk of severe hypoglycemia in patients with 2. type diabetes mellitus treated 
with derivates of sulfonylurea. Alcohol may prolong glipizide’s effect on blood glucose by 
delaying glipizide absorption and elimination.  In addition, alcohol enhanced glucose-
lowering action of insulin Weathermon & Crabb , 1999). 
3. Conclusion 
The most common cause of medication-induced hypoglycemia is improper management of 
diabetes. Missing meals, overexertion, and intentional or unintentional overdose of 
medications used to treat the condition can all cause blood glucose levels to drop. 
Cases of hypoglycemia were also described for other pharmaceuticals, but rather of sporadic 
outbreaks which do not meet very often in clinical practice. It should be noted that any 
quantitative disturbance of consciousness or sudden change in behavior in patients with 
diabetes mellitus with far offset the amount of glucose patterns, or an elderly patient with 
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polypolymorbid possibly with chronic kidney disease may be caused by the effect of 
hypoglycemic drugs. In the clinical practice, it is necessary to think about this eventuality and 
carry out blood glucose testing for each suspected hypoglycemia. Acute treatment of dru-
induced hypoglycemia is different from the treatment of hypoglycemia from other causes. 
When relapse hypoglycemia after discontinuation of the suspect drug it is  necessary to revise 
the diagnosis and rule out organic causes of hypoglycemia (endocrinopathy, malignancy, 
insulinoma, etc.). Table 2 summarised the most common drugs with hypoglycemic effects.  
 
Drug  Mechanism of Action Clinical Significance 
Alcohol (ethanol) Impairs gluconeogenesis and 
increases insulin secretion. 
+++
Pentamidine  Cytolytic response in pancreas 
accompanied by insulin release. 
+++
Triazole antifungals Enhance the effect of sulfonylureas. +++
Case Series  
β-Adrenergic antagonists Inhibit glycogenolysis; attenuate 
signs and symptoms of 
hypoglycemia. 
++
Chloramphenicol May inhibit metabolism of 
sulfonylureas. 
++
Chloroquine  Unknown (hypoglycemia leading to 
death has been reported in overdose). 
++
Disopyramide  Unknown; appears to result from 
endogenous insulin secretion. 
++
Phenylbutazone Reduces clearance of sulfonylureas. ++
Salicylates  Increase insulin secretion and 
sensitivity; may alter 
pharmacokinetic disposition of 
sulfonylureas. 
++
Case reports  
Anabolic steroids Decrease glucose tolerance. +
Angiotensin-converting 
enzyme inhibitors 
May improve insulin sensitivity, 
particularly in skeletal muscle. 
+
Clofibrate  Unknown. +
Gatifloxacin  Unknown. +
Monoamine  
oxidase inhibitors  
May increase insulin release and 
decrease sympathetic response to 
hypoglycemia. 
+
Saquinavir  Unknown. +
Sulfonamides  Alter clearance of sulfonylureas. +
Table 2. Most common hypoglycemic pharmaceuticals and their clinical significance.   
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1. Introduction 
1.1 Epidemiology and basic characteristics 
Endogenous hyperinsulinism is characterized by repeated hypoglycemic episodes caused 
by autonomous hypersecretion of insulin produced by adenoma or multiple 
microadenomatosis originating in the beta-cells of the pancreas. The process is either 
localized into one or less frequently few solid tumors or is more diffuse within the islets of 
Langerhans. Endogenous hyperinsulinism is not regulated by plasma glucose and therefore 
clinical signs of hypoglycemia manifest whenever during the day. The term „organic 
hyperinsulinism“ is sometimes used showing that real endocrine pancreatic disease may be 
present in comparison with „functional hyperinsulinism“ characterized by reactive changes 
in a consequence of eating habits. 
Insulinoma (ICD-08151/1, ICD-08151/3) together with gastrinoma, VIPoma, 
somatostatinoma, glucagonoma and PPoma are members of  nesidioma family which are 
recognized as neuroendocrine tumors of the pancreas. Some of them produce one hormone 
only and may therefore cause typical clinical symptoms. However, combined production of 
hormones may be also found and clinical diagnosis could be difficult when different 
symptoms would be combined. Positive but weak staining for gastrin or other hormones 
besides insulin may be sometimes present without any symptoms. On the other hand, 
neuroendocrine tumor in the pancreas can be described by histological examination in 
patients without typical clinical symptoms and malignant tumors are then confirmed. 
Insulinoma has incidence of 0.05-0.1 cases per 100 000 inhabitants in the Czech Republic 
(Škrha, 2001) but slightly more (0.4 per 100 000) has been described at the Mayo clinic 
register (Service et al., 1991). Data may depend on the database availability in different 
countries. It is predominantly present in women as compared to men. The proportion of 
insulinoma was around 60 % in women at Mayo clinic whereas our register involves 75 % of 
women (Service et al., 1991, Škrha et al., 2009). Insulin-producing tumors occur in more than 
50 % of neuroendocrine tumors of the pancreas followed by gastrinomas in 30 %, VIPomas 
in 10-15 % and by others in less than 10 % (Perry & Vinik, 1995). 
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Solitary adenoma usually occurs in more than 80 % of patients but few adenomas may be 
sometimes found in different size and stage of development and thus they have not been 
removed during the first operation (Service et al., 1991). Repeated surgical treatment is then 
necessary. Multiple adenoma is more frequently present in patients with multiple endocrine 
neoplasia (MEN I) (Demeure et al., 1991, Fabbri et al., 2010). However, in only few percents 
of adults the hypoglycemic syndrome has been associated with hyperplasia of the beta-cells 
(Harrison et al., 1984, Service et al., 1999, Stefanini et al., 1974). It may be caused by 
neodifferentiation of islet cells from ductal epithelium in the exocrine pancreas. Previously, 
nesidioblastosis was described in histological finding, more frequently found in newborns 
or children than in adults (Stefanini et al., 1974). It was suggested to use the term  
„hyperplasia of islet cells“ instead of nesidioblastosis because heterogenous descriptions 
exist (Weinstock et al., 1986). It is supposed that insulinoma and diffuse hyperplasia are two 
edge variants of hyperfunctional syndrome and some forms exist in between. The genetic 
background contributing to different histological findings has not been elucidated yet. The 
above heterogeneity confirms that histological finding need not always correspond with 
hormonal activity and clinical symptoms. In addition, beta cell hyperplasia contributes to 
persistent hyperinsulinemic hypoglycemia of infancy, caused by mutations in the islet ATP-
sensitive potassium channel, and to non-insulinoma pancreatogenous hypoglycemia in 
adults (Ouyang et al., 2011). 
Insulinoma is usually localized within the pancreas, extrapancreatic tumors (e.g. in 
duodenum or small intestine) are extremly rare (Service et al., 1991, Škrha, 2001). One case 
report describes the insulin producing carcinoid of ovary (Morgello et al., 1988). The most of 
insulinoma cases are benign whereas malignant forms have been described in 5 to 10 % of 
patients (Perry & Vinik, 1995, Service et al. 1991). However, various forms have been found 
by histological examination when different stages of angioinvasion were combined with the 
presence or absence of micrometastases in lymphnodes. It may strongly influence further 
decision on chemotherapy and follow-up treatment. 
2. Diagnosis of insulinoma 
The patients with unregulated insulin overproduction develop clinical symptoms associated 
with hypoglycemia. Two main tasks may be arised to establish proper diagnosis of 
insulinoma. Firstly, to evaluate correctly clinical picture suspicious from hypoglycemia and, 
secondly, to prove the association of typical symptoms with low blood glucose 
concentration. The diagnosis is therefore based on clinical and biochemical finding still 
before imaging of the process. 
2.1 Clinical symptoms 
Hypoglycemia may be associated with either neurogenic (adrenergic) or neuroglycopenic 
symptoms (Dizon et al., 1999) (Table 1). Symptoms are dependent on depth and duration of 
hypoglycemia. Slightly decreased plasma glucose to 3.0-3.6 mmol/l stimulates 
catecholamine secretion explaining neurogenic symptoms. They are rare in patients with 
insulinoma although they may be solely present in up to 10-15 % of patients (Fajans & Vinik, 
1989). On contrary, neuroglycopenic symptoms develop when glucose supply to central 
nervous system is significantly reduced. Manifested symptoms may frequently induce a 
suspicion of neurologic or psychiatric disorders and the patient admitted to the appropriate 
department may be treated not seldom like primary neurological or psychiatric disease. 
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Unsuccessful treatment with psychiatric or neurologic drugs with persisting symptoms 
needs to be reevaluated and when fasting hypoglycemia is confirmed a suspicion on 




sweatting, tremor, palpitation, tachycardia, anxiety 
 
Neuroglycopenic 
confusion, dizziness, weakness, unconsciousness, blurred vision, amnesia, dysartria, 
somnolence, cramps, headache, diplopy, parestesia, coma
Table 1. Hypoglycemic symptoms 
Hypoglycemic symptoms develop in the fasting state, several hours after the last meal. This 
is typically in the morning after the overnight fast when neuroglycopenic symptoms may be 
present. Their manifestation with proven hypoglycemia and improvement after a sweet 
meal, formerly described as Whipple trias, are great support for clinical diagnosis of 
autonomous (endogenous) insulin oversecretion. It does not exclude symptoms developing 
just after the meal ingestion when overstimulation of insulin secretion especially by sugars 
exists (Del Sindaco et al., 1997, Service et al., 1999). In such cases functional hyperinsulinism 
may be falsely diagnosed and proper differentiation between functional and endogenous 
hyperinsulinism needs to be decided (see 3. Differential diagnosis). 
Certain neuroglycopenic symptoms are repeated by the single patient during hypoglycemic 
episodes although they offer very different picture. It has not been explained yet why the 
same symptoms are always present in the same patient. They may differentiate one patient 
from the other. On the other hand, the patient can describe if the frequency of episodes 
would be increased or if their expression would be strenghten. Such information may help 
to clinician in decision of further examination and treatment. The severity of symptoms 
correspond to sensitivity of the central nervous system to hypoglycemia but not exactly to 
hyperinsulinemia which was significantly different in the patients. 
Neuroglycopenic symptoms are the crucial point in diagnosis of insulinoma and their 
careful analysis is considered as the basis for following steps. Their evaluation cannot be 
substituted by other examination including imagining of the pancreas.  
2.2 Laboratory examinations 
The estimation of biochemical variables involving plasma glucose and insulin 
concentrations during development of clinical symptoms may support not only diagnosis, 
but it may further characterize the severity of the process and therefore the importance of 
surgical treatment. Severe hypoglycemia and high serum insulin levels should indicate 
operation without any delay because profound hypoglycemia is dangerous to the patient. In 
addition, randomly confirmed hypoglycemia during development of clinical symptoms in 
patient examined by neurologist or psychiatrist may be the only one impuls to send the 
patient to endocrinologist. When blood glucose is not determined, the patient can be treated 
on epilepsy or psychiatric disorders several months or even years without significant 
success and the proper diagnosis of insulinoma is delayed.  
Blood glucose concentration associated with neuroglycopenic symptoms can be often found 
below 2.5 mmol/l in insulinoma patients whereas neurogenic symptoms associated with 
blood glucose around 3.5 mmol/l frequently exist by functional (reactive) hyperinsulinemia. 
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However, hypoglycemia was rarely reported without any clinical symptoms when 
insulinoma was later confirmed (Service, 1995). 
Suspicion on insulinoma suggested from clinical symptoms of neuroglycopenia and 
hypoglycemia needs to be further confirmed. This first step in diagnosis of endogenous 
hyperinsulinism may be done by GPs as well as by specialists in neurology, psychiatry, 
internal medicine or endocrinology/diabetology. Diagnostic process is then simplified if the 
patient would be sent immediately to appropriate center specialised in endocrine disorders. 
2.2.1 Fasting test 
Patient with a suspicion on insulinoma is admitted to hospital to confirm the autonomous 
hypersecretion of insulin as a typical feature of insulinoma. The best option for this purpose 
is to use the test inhibiting insulin secretion because the absence of insulin inhibition 
confirmes dysregulation of the hormone secretion by autonomous process. This may be 
proved by prolonged fasting when the patient drinks only water and blood samples for 
glucose, insulin and C-peptide determinations are drawn in regular interval (every 4-6 
hours). Plasma glucose drops down during the test and when clinical symptoms develop, 
the last blood sample is drawn and the fasting is stopped.  Some delay of clinical symptoms 
following the lowest plasma glucose concentration may be sometimes present. It is 
elucidated by later decline of intracellular glucose in the brain in comparison with the 
changes in plasma glucose concentration. Due to activated contrainsulary hormones by 
hypoglycemia blood glucose concentration goes already up when symptoms develop in a 
consequence of the lowest intracellular glucose concentration.  
The fasting test may be performed up to 72 hours but in the most of patients it is stopped 
within 24 hours. At our department we could stop the test within 24 hrs in more than 80 % of 
patients with insulinoma (Škrha et al., 2009). In some very rare insulinoma cases no 
neuroglycopenic symptoms have been observed still after 72 hrs (Jordan & Kammel, 1976). The 
patients with insulinoma are adapted on low glucose concentration and symptoms are 
therefore weak. Typical picture of hypoglycemia unawereness develops (Mitrakou et al., 1993). 
Plasma glucose and insulin concentrations are always used in clinical practice in diagnosis 
of insulinoma but sometimes the ratio of serum insulin/glucose concentration may further 
support diagnosis of endogenous hyperinsulinism. The results may be more expressive 
when the patient would add the physical training during the fasting. In subjects with 
insulinoma plasma glucose concentration drops whereas in those with functional 
hypoglycemia the glucose concentration may arise (Fajans & Vinik, 1989). Our results 
obtained in 114 patients with endogenous hyperinsulinism are shown in Table 2. 
 
Laboratory variableratory Before fastingBefore 
fastin 
End of fastingEnd 
of 
Duration of fasting (h) - 18 (2-60) 
Plasma glucose (mmol/l) 3.4±1.4 1.7±0.4 




C-peptide (nmol/l) 1.13±0.61 1.16±0.73 
Table 2. Biochemical variables in insulinoma patients before and at the end of fasting test. 
The results are expressed as the means ± SD. 
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Glucose and insulin in the fasting test 
The patients with endogenous hyperinsulinism have plasma glucose concentration at the 
end of the fasting test below 2.5 mmol/l but in some cases slightly higher levels may be 
seen, especially when the lowest level was reached still before developed neuroglycopenic 
symptoms. In about 7 % of normal population plasma glucose concentration after 72 hrs of 
fasting may be below 2.7 mmol/l (Service et al., 1999). Evaluation of both glucose 
concentration and clinical symptoms is therefore recommended. 
Majority of patients with insulinoma has increased serum insulin concentration when 
fasting is stopped. However, in some patients the insulin concentration remains within the 
normal limits and it brings difficulties to confirm diagnosis of hyperinsulinism (Škrha et al., 
2009). Evaluation of all insulin concentrations and their oscillations during the fasting is 
necessary. In our group of insulinoma patients the insulin concentration below 20 mU/l 
were found in 12 of 114 patients (10 %) at the end of the test. 
The insulin/glucose ratio is also sensitive parameter although it reflects the fluctuations of 
both biochemical variables. Their dynamic changes causing stepwise increase of this ratio 
during the fasting test differ from obese patients with hyperinsulinemia who have the ratio 
increased at the beginning but its decreasing value may be found during the test. Numerical 
value of the ratio has to be compared with clinical finding during the test. The normal values 
in our population when glucose is expressed in mmol/l and insulin in mU/l are below 6,0 
mU/mmol. We found borderline values of this ratio in 5 of 114 patients with insulinoma. 
According to our experience, the most important for the diagnosis of insulinoma is time 
development of plasma glucose concentrations associated with neuroglycopenic symptoms 
manifesting during the fasting test.  
C-peptide and proinsulin 
Serum C-peptide concentration is increased in insulinoma but the basal values cannot be 
distinguished from those found in obese persons. Its concentration decreases with fasting in 
healthy persons but it remains high in patient with insulinoma. C-peptide values may provide 
better information at the end of fasting than at basal state. In addition, C-peptide has to be 
used when suspicion on hypoglycemia factitia has been arised (see 3. Differential diagnosis).  
Higher plasma proinsulin concentration depending on the greater proinsulin release from 
the beta cells is sometimes determined in insulinoma patients.  It may be usefull especially 
in cases with normal insulin concentration. Proinsulin is not routinelly used for diagnosis of 
insulinoma and it cannot distinguish benign and malign forms of insulinoma (Fajans  
Vinik, 1989).  
2.2.2 Suppressive and stimulating tests 
Different tests either suppressing insulin secretion or stimulating insulin release and 
consequently changing plasma glucose concentrations have been used (C-peptide 
suppressive test, tolbutamide test, calcium test etc.) previously mainly for the research 
purposes (Fajans  Vinik, 1989, Service et al., 1992). However, they do not significantly 
improve the diagnosis in routine clinical practice.  
In conclusion, diagnosis of endogenous (autonomous) hyperinsulinism has to be done from 
clinical symptoms and biochemical results. If any doubts would exist, repeated fasting test 
may bring better data for proper diagnosis than the other tests. The evaluation should also 
respond key question concerning the treatment. Insulinoma should be treated by surgical 
removal of the tumor and this procedure needs to localise the tumor before the surgery. 
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2.2.3 Insulin sensitivity 
Repeated attempts have been made to elucidate the estimation of insulin sensitivity in 
diagnosis of insulinoma (Gin et al., 1987, Nauck et al., 1990, Škrha et al., 1996). 
Hyperinsulinemic clamp technique enabled to study insulin action both in the hormonal 
hyperactivity and following the removal of the tumor (Škrha et al., 1993). The amount of 
glucose infused during the clamp and maintaining the plasma glucose at constant level by 
exogenous insulin infusion was found increased in insulinoma patients as compared to 
healthy persons (Gin et al., 1998). The amount of glucose infused dropped down after 
removal of the tumor. Constant infusion of insulin during the clamp resembles C-peptide 
suppressive test causing a decrease of endogenous insulin and C-peptide secretion. 
Impaired suppressibility of C-peptide was found in insulinoma patients compared to 
healthy controls (Yki-Järvinen et al., 1984).   
However, similar non-suppressibility of C-peptide was found in obese Type 2 diabetic 
patients (Škrha et al., 1996). Insulin resistance was found in insulinoma patients by clamp 
technique (Del Prato et al., 1993, Nankervis et al., 1985, Škrha et al., 1989, de Kreutzenberg et 
al., 1995). Decreased insulin clearance and decreased glucose production in the liver 
contributing to fasting hypoglycemia were observed in insulinoma patients (Škrha et al., 
1989, Del Prato et al., 1993). However, we found in some of insulinoma patients nearly 
normal insulin action and we concluded that this parameter depends on concomitant 
obesity which may strongly impair the insulin sensitivity (Škrha et al., 1996). Decreased 
insulin sensitivity cannot be used as reliable sign of insulinoma. Hyperinsulinemic clamp 
technique can differentiate between patients responding and non-responding to diazoxide 
treatment (Škrha et al. 1989). 
2.3 Localization techniques  
Several techniques involving non-invasive and invasive tests may be used to localize the 
insulinoma with different sensitivity and specificity. They have both advantages and 
disadvantages. Significant development of imaging technique during the past twenty years 
has contributed to better localization of insulinoma and thus to preoperative decisions.  
Simple transabdominal ultrasonography does not bring useful information because of the 
great number of negative data. Although it is noninvasive and simply performing its low 
sensitivity, mainly due to minimal discrimination of the small size tumor tissue from the 
surrounding tissue, it cannot be used for localization of the tumor. Only up to one third of 
the tumors may be found by this imaging (Bottger et al., 1990). 
Computer tomography is very popular but large differences exist between the centers 
(Pasieka et al., 1992, Vinik et al., 1991). Positive results may be obtained in 25-60 % 
depending on the experience of radiologists.  Similar may be true for nuclear magnetic 
resonance when insulinomas were proved in low or high percentage of the patients (Liessi 
et al., 1992). In a recent study the sensitivity of preoperative CT and nuclear magnetic 
resonance was 62 and 82 %, respectively (Varma et al., 2011). Octreoscan based on the 
binding of isotope-labelled somatostatin with its receptors placed on the cell membrane of 
neuroendocrine tumor was repeatedly used to visualize the localization of insulinoma. 
However, differences were found between the cells possessing somatostatin receptors. 
About 50 % or less cases of insulinoma  can be proved by octreoscan whereas more than 70 
% positive cases with gastrinoma have been found (Krenning et al., 1994, Proye et al., 1998, 
Zimmer et al., 1996) by using this technique. Octreoscan does not seem to be reliable method 
detecting localization of insulinoma. 
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Better results have been obtained with endoscopic ultrasonography, sensitivity of which 
was described in 77 till 94% (Glover et al., 1992, Roesch et al., 1992, Varma et al., 2011). 
Insulinoma localized in the head and body of the pancreas can be preferably proved by this 
technique whereas tumors of the tail remain often not discovered. More invasive 
examination is arteriography visualizing vasculature of the pancreas. Finding of pathologic 
imaging during parenchymal phase may support diagnosis of insulinoma (Fig.1). Positive 
results have been found in 40 to 60 % in different centres (Pasieka et al., 1992, Vinik et al., 
1991). Combining arteriography and CT is superior to single arteriography or CT (Li et al., 
2010). In case of successful fine needle aspiration the tumor can be verified with 





Fig. 1. Digital subtraction angiography of splenic artery with insulinoma localized in the tail 
of pancreas (arrow) 
Some centres use transhepatic cathetrisation of the portal system when blood samples 
drawn by catheter from different parts of portal vein are tested for insulin concentration 
(Vinik et al., 1991). The main goal of this examination is to differentiate between head, body 
and tail of the pancreas as a source of measured insulin gradient. The results may be 
strenghten when calcium is selectively infused into different arteries (superior mesenteric 
artery, splenic artery or gastroduodenal artery) and blood is taken from the portal system 
(Doppman et al., 1995). Few centres received very positive results (Vinik et al., 1991). 
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Fig. 2. Histological picture of insulinoma. Immunohistochemical examination found strong 
positivity of insulin  and weak positivity of gastrin. 
Our own results of localization of insulinoma are shown in Table 3. In 72 of 103 operated 
patients (70 %) the topographical localization of the tumor was only done before surgical 
treatment by combining different techniques when evaluating patients from the whole 
period of three decades. 
 
Method Imagine techniques 
(before surgery) 
Surgical finding 
in preoperatively detected insulinoma 
 Detected Undetected Agreement Other placement Undiscovered 
US 4 (8 %) 47 (92 %) 2 - 2 
EU 40 (83%) 8 (17%) 33 5 2 
CT 20 (24%) 65 (76%) 15 5 - 
AG 39 (43%) 52 (57%) 25 8 6 
Table 3. Preoperative localization of insulinoma and surgical finding by preoperatively 
localized tumors 
The transabdominal ultrasonography was tested at our department between 1980-1995 but 
positive results were extremely rare. This method is not more used in diagnostic algorithm. 
The quality of CT has been significantly improved during the past twenty years and present 
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results are  better then three decades ago (nearly 50 % positive cases in the last decade). 
However, when evaluating all patients together, positive results are low (see  Table 3). 
Localization of insulinoma was confirmed in only 75 % of patients with positive CT scan. 
Angiography brought positive results in more than 40 % but the agreement with localization 
of the tumor during operation was done in only 64 % of positive findings. Method of choice 
seems to be endoscopic ultrasonography which detected more than 83 % of tumors and their 
localization was confirmed in the same proportion (82,5 %).  
The results of imaging techniques depend on both size and properties of the insulinoma 
related to surrounding tissue as well as on the experience of examining staff. Best results 
have been observed by combining CT with endoscopic ultrasonography. In 2001-2010 we 
examined 51 patients with insulinoma and positive results of imaging techniques were 
obtained in  38 of them (75 %).  
3. Differential diagnosis 
Diagnosis of insulinoma has to be evaluated in consideration of all causes associated with 
hypoglycemia. Several classifications of hypoglycemic states exist but for clinical purposes 
combination of two of them is reliable. Firstly, association with ingestion of the meals can 
differentiate two main groups: a) hypoglycemia developing in the fasting state, typically 
after an overnight fast, and, b) postprandial hypoglycemia. Secondly, hypoglycemia can be 
classified according to pathogenesis when balance between glucose influx into blood stream 
and its removal would be impaired.  Both classifications can be combined and diagnosis in 
the respective patient may be based on detailed analysis of history and symptoms (Table 4). 
Evaluation of history of hypoglycemic episodes can disclose when symptoms have 
developed. It is the basis of clinical classification if hypoglycemia could be found either by 
healthy person or by ill patient already treated for some disease (Service, 1995). Specific case 
may be arised when first hypoglycemia episode develops during the stay at hospital. 
3.1 Hypoglycemia manifesting predominantly in the fasting state 
Hypoglycemia manifesting after an overnight fast needs carefull analysis because it 
demonstrates that the patient cannot maintain spontaneously plasma glucose concentration 
within the normal ranges. This condition is frequently caused by certain disease which 
needs to be elucidated or confirmed. Some clinical diagnoses may be a signal of serious 
prognosis and their knowledge and intensive treatment is therefore necessary. Both 
impaired glucose production and accelerated glucose utilization may participate on 
development of mild or severe hypoglycemic episodes (Table 4). 
 
i. Fasting hypoglycemia 
           States with diminished glucose production 
- lack of contrainsular hormones 
- enzyme defects 
- liver disease 
- renal failure 
- impaired nutrition 
- alcohol consumption 
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ii. Fasting and postprandial hypoglycemia 
            States with accelerated glucose utilization 
                      Exogenously caused hyperinsulinism  
- diabetes treated with insulin  
- diabetes treated with oral agents 
- hypoglycemia factitia 
                      Endogenous hyperinsulinism 
- insulinoma 
- hyperinsulinemic hypoglycemia in infants 
- autoimmune syndromes causing hypoglycemia 
- extrapancreatic tumors 
- defects in oxidation of free fatty acids 
- drugs other then primary oral hypoglycemic agents 
- other conditions 
iii. Reactive (postprandial) hypoglycemia 
- alimentary, postoperative 
- functional 
- prediabetes 
- inborn errors of metabolism (enzyme defects) 
- newborn of diabetic mother 
Table 4. Classification of hypoglycemic states according to the relationship with fasting and 
with underproduction or overutilization of glucose 
Hypoglycemia due to diminished glucose production 
Plasma glucose concentration depends on permanent glucose supply into the blood stream 
and removal by the cells using glucose as a simple source of energy. Glucose can be relased 
from glycogen or it is produced by gluconeogenesis. The glycogen stores cover the needs for 
few hours only whereas gluconeogenesis provided mainly by the liver and kidney depends 
both on substrate delivery and on metabolic pathways. Each failure may contribute to 
impaired glucose metabolism and consequently to lower plasma glucose concentration. 
Defects in glucose production may be caused either by some chronic diseases (chronic liver 
and kidney diseases etc.) or by exogenous factors like alcohol or drugs. 
Lack of contraregulatory hormones like glucagon, catecholamines, growth hormone and 
cortisol manifesting by development of insufficiency in the respective organ is associated 
with mild hypoglycemia in the fasting state. Inborn hypopituitarism is characterized by 
fasting hypoglycemia, low plasma insulin levels, increased insulin sensitivity in the 
peripheral tissues, diminished responsiveness on hypoglycemia and lowered mobilization 
of free fatty acids. Similar features have been found in aquired hypopituitarism as well 
(Samaan, 1989). Adrenal insufficiency is associated with impaired mineral metabolism, low 
blood pressure, weakness and mild hypoglycemia. Untreated hypothyroidism develops 
impaired gluconeogenesis when mild hypoglycemia develops.   
Inborn errors of metabolism characterized by enzyme defects are associated with fasting 
hypoglycemia. This group contains glycogen storing disease, galactosemia and hereditary 
fructose intolerance (Talente et al., 1994, Tsalikian & Haymond, 1983).   
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Severe acute hepatitis needs intensive treatment with glucose whereas chronic liver disease 
frequently develops mild hypoglycemia. Multiple metastases may be associated with low 
plasma glucose because both diminished glucose production and accelerated glucose 
consumption by the tumor may contribute to impaired glucose balance (Eastman et al., 
1992). Renal failure is associated with mild hypoglycemia and diminished gluconeogenesis 
in the kidneys was proved (Garber et al., 1974). Severe hypoglycemia may be developed in 
malnutrition by kwashiorkor or anorexia nervosa and hypoglycemic coma may cause death 
in advanced cases (Ratcliffe & Bevan, 1982).  
Special care in differential diagnosis of insulinoma needs to be done to alcohol induced 
hypoglycemic episodes. Alcohol consumption in the evening without substantial meals 
may be followed by unconsciousness in the morning. Profound hypoglycemia below 2.0 
mmol/l may be found in a consequence of diminished glucose production in the liver when 
glycogen stores were exhausted. Ethanol is oxidized to acetaldehyde which blocks 
gluconeogenesis.  Severe hypoglycemia is then falsely recognized like insulinoma. However, 
taken history may simply disclose the right cause of this hypoglycemic state. We evaluated 
several cases of alcohol induced hypoglycemia which was previously diagnosed as 
suspicion on insulinoma. 
Diagnosis of certain disease associated with fasting hypoglycemia needs to be always 
confirmed because it is of great importance for proper treatment. 
3.2 Hypoglycemia manifesting in fasting and postprandial state  
The most of hypoglycemic episodes comes both in the fasting and postprandial conditions, 
typically in diabetic patients. They are caused by overutilization of glucose in the target 
tissues by increased insulin action.  
Hypoglycemia due to accelerated glucose utilization  
The most frequent hypoglycemic states are caused by hypoglycemic drugs in diabetic 
patients. Insulin, sulphonylurea or different combinations of antidiabetic drugs may 
contribute to hypoglycemia, especially when the patient is intensivelly treated to target 
values of diabetes control. This issue is specific chapter in diabetes books and it is not 
analyzed here. Confirmation of drug treatment in diabetic patients may exclude the majority 
of cases from consideration on insulinoma. However, newly developed repeated 
hypoglycemic episodes in Type 2 diabetic patient without any evidence on drug 
involvement have been described and insulinoma was later confirmed (Škrha et al., 1990).  
Special attention needs to be done to hypoglycemia in infancy when different types of 
„persistent hyperinsulinemic hypoglycemia in infancy“ (PHHI) have been described 
(Stanley, 1997). Congenital hyperinsulinism is a life threatening state in a newborn and 
sometimes only pancreatectomy may resolve this serious condition (De Lonley-Debeney et 
al., 1999). In other cases hypoglycemia develops later and more frequently it may be 
induced by fasting or it occurs between breast feeding (Thornton et al., 1998). Such latent 
hypoglycemia may be dangerous for development of the central nervous system 
manifesting by mental retardation. The early diagnosis and effective treatment are therefore 
absolutely necessary. Diagnosis is supported by hyperinsulinemia and increased plasma C-
peptide concentration in hypoglycemic state together with low free fatty acids and beta-
hydroxybutyrate (Cresto et al., 1998). In some children hyperammonemia was proven 
(Kitaura et al., 1999, Stanley et al., 1998). Persistent hyperinsulinemic hypoglycemia in 
infancy was subdivided into three types (Stanley, 1997). 
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Rapid development of severe hypoglycemia in a newborn just after delivery is typical by 
autosomal recessive form of congenital hyperinsulinism which is caused by gene mutation 
for sulphonylurea receptor (SUR1) associated with potassium channel in the beta-cells 
(Thomas, et al., 1995, Nestorowicz et al., 1996). Persistent insulin hypersecretion is due to 
closed KATP- channel and opened calcium channel. Histological picture disclosed two forms 
– diffuse and focal. Diffuse form called nesidioblastosis has all islets hyperactive whereas 
the other one is caused by focal hyperplastic adenomatosis (Sempoux et al., 1998). Partial 
pancreatectomy is sufficient for treatment of focal form but diffuse nesidioblastosis needs to 
be treated by total pancreatectomy. 
Autosomal dominant form is usually manifested later following months or even years and 
clinical symptoms may be induced by fasting (Thornton et al., 1998). Drug treatment with 
diazoxide is often effective. Glucokinase gene mutation was found in this form (Glaser et al., 
1998) and it is evident that recessive and dominant forms are totally different not only by 
gene determination but by treatment as well. 
Hyperinsulinemic hypoglycemia with hyperammonaemia is the third form characterized 
by gene mutation of mitochondrial glutamate dehydrogenase. Increased alpha-ketoglutarate 
production stimulate insulin secretion whereas ammonium detoxification by lowered 
glutamate supply into liver causes hyperammonaemia (Zammarchi et al., 1996, Stanley et 
al., 1998, Kitaura et al., 1999).  
Modern polypills treatment contributes to drug interactions. It may be therefore important 
to summarize which drugs accelerate the hypoglycemic effects of sulphonylurea drugs in 
Type 2 diabetes (Table 5). 
 
a. Sulphonylurea release from the binding with albumin 
- salicylic acid, acetylsalicylic acid 
- nonsteroid antiflogistics 
- sulphonylamides 
- trimetoprim 
- fibrates  
b. Competitive inhibitors of sulphonylurea metabolism 
- alcohol 
- H2 – blockers 
- sulphonylamides 
- anticoagulant drugs 
- pyrazolon derivatives 
- allopurinol 
- inhibitors of monoaminooxidase  
c. Inhibitors of sulphonylurea excretion 
- probenecide 
- acetylsalicylic acid 
- nonsteroid antiflogistics 
- allopurinol 
- sulphonylamides 
Table 5. Drugs accelerating the effects of sulphonylurea derivatives with possible 
hypoglycemia development 
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Arteficially induced hypoglycemia by using hypoglycemic agents, especially insulin or 
sulphonylurea derivatives, are clasified as hypoglycemia factitia. Severe hypoglycemia with 
neuroglycopenic symptoms may develop and clinical picture is fully comparable with 
insulinoma, mainly when hypoglycemia would be detected in fasting state. Clinical symptoms 
associated with profound hypoglycemia and hyperinsulinemia may be summarized as 
insulinoma and because no tumor localization is done, an exploratory laparotomy is indicated.  
The cause of hypoglycemic drug administration in non-diabetic subjects may be undiscovered 
but sometimes mental or psychiatric problems are present. Health care personel (nurses, 
physicians etc.) between this drug abuse has been repeatedly found.   
Insulin administration may decrease endogenous secretion of both insulin and C-peptide. 
Finding of increased serum insulin concentration together with decreased C-peptide levels 
may support suspicion on hypoglycemia factitia. More difficulties bring sulphonylurea 
derivatives because no suppresion of C-peptide is present and low drug plasma or urine 
concentration is often missed. In such cases, proinsulin may be used to exclude diagnosis of 
hypoglycemia factitia because its plasma concentration in this case is within the normal 
limits whereas it is increased in insulinoma patients (Table 6). 
We examined five patients with hypoglycemia factitia sent to our department as a suspition 
on insulinoma. One of them was nine times admitted to the hospital and twice indicated for 
exploratory laparotomy before the Münchhausen syndrome was confirmed. 
 
Laboratory variable Insulinoma Hypoglycemia factitia caused by insulin 
Hypoglycemia factitia  
caused by sulphonylurea 
Plasma glucose ↓↓↓ ↓↓↓ ↓↓↓ 
Plasma insulin ↑ - ↑↑↑ ↑↑↑ ↑↑↑ 
Serum C-peptide ↑ - ↑↑ ↓ - ↓↓ ↑ - ↑↑ 
Plasma proinsulin ↑ - ↑↑ ↔  ↔ 
Sulphonylurea 
(urine) negative Negative positive 
Table 6. Laboratory variables compared in insulinoma patients with hypoglycemia factitia 
subjects 
Other conditions may contribute to increased glucose removal from the blood stream but 
they are rare and single patients have been reported like case reports. Insulin antibodies or 
insulin receptor antibodies were rarely associated with hypoglycemia (Redmon et al., 1992, 
Service 1995, Walters et al., 1987). Extrapancreatic (non-islet cells) tumors like 
leiomyosarcoma, fibrosarcoma, mezotelioma, hepatoma and different cancers may be 
associated with hypoglycemia but with normal or low insulin concentration. In some of 
them increased plasma concentration of IGF-2 or „big-IGF-2“ has been observed. High 
insulin levels were found in fibrosarcoma, bronchial carcinoid, neurofibrosarcoma and small 
cell cervical carcinoma. In such cases insulinoma is considered until ectopic insulin 
production would be confirmed. Different clinical picture and progression of malignant 
disease may differentiate these patients from those with insulinoma. 
Rare carnitine deficiency is associated with impaired beta-oxidation of fatty acids. In such 
situation the organism cannot yield energy from fatty acids and alternative substrate like 
glucose is then utilized. Substrate deficit caused by blocked beta-oxidation creates 
consuption of glucose with severe hypoglycemia (McGarry & Foster, 1980). 
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Hypoglycemia may be caused by other drugs which stimulate insulin secretion (chinin) or 
decrease glucose production (beta-blockers, salicylates) or induce complex of not fully 
discovered mechanisms (haloperidol, disopyramide, pentamidine). Glucose consumption by 
Plasmodium falciparum was observed in malaria. 
3.3 Reactive hypoglycemia 
Reactive or postprandial hypoglycemia is a common diagnosis associated with weakness and 
other neurogenic (adrenergic) symptoms. The patient thinks on a serious disease and asks for 
help. Correct diagnosis and simple recommendation of reliable regimen including dietary 
councelling may totally remove the symptoms. In patients after gastric surgery when the 
meals containing saccharides quickly stimulate insulin secretion, glycemia drops down in 30 to 
60 min. Sweating, tachycardia a weakness develop and only omitting of sweets may 
significantly improve the patient´s clinical state. Similar symptoms caused by sweets ingested 
in the morning develop mainly in some young women who do not eat typical breakfast. No 
previous operation on gut has been done by them before. They frequently do not take 
breakfast but after coming to their office they eat sweets like chocolate with coffee or tea. 
Chocolate without substantial meal induces insulin hypersecretion with  small decrease of 
plasma glucose. Similar pattern may be obtained during oral glucose tolerance test (oGTT) 
with decreased plasma glucose to 2.9-3.3 mmol/l in 120 or 180 min (Brun et al., 1995). Such 
condition improves only after dietary recommendation when sweets are omitted. Analysis of 
symptoms can usually confirm this diagnosis. 
Reactive hypoglycemia is frequently considered as insulinoma. In majority of patients  
neuroglycopenic symptoms are lacking. Hypoglycemia is not confirmed in some patients 
and the term „pseudohypoglycemia“ is then used. If changes in dietary regimen would not 
be successful, fasting test is recommended to exclude uncertain cause of the weakness and 
other adrenergic symptoms. The patient with reactive hypoglycemia has normal glycemia 
without any significant decrease during the test.  
4. Treatment 
Recurrent profound hypoglycemia due to insulinoma or autonomous hyperplasia of the 
beta cells is dangerous to the patients because it may cause acute accidents like stroke or 
arrythmias, and consequently sudden death, especially with increasing age. They may also 
initiate chronic deterioration of intelectual function when they are present for a long time. 
The proper treatment strategy is therefore necessary and individual assessment of the risk 
has to be evaluated. The causal treatment involves surgical removal of the insulinoma or 
diffuse hyperplastic beta cell tissue (in case of „microadenomatosis“). When surgery is 
unsuccessful or the risk of operation is too high in old and polymorbid patient then dietary 
regimen and drug treatment have to be used (Škrha et al., 2009). 
4.1 Surgical treatment 
Selective removal of the tumor in case of solitary insulinoma is a method of choice. 
Enucleation of insulinoma maximally preserving the surrounding pancreatic tissue is now 
prefered against blind resection (Škrha, 2001) . It needs to have accurate localization of the 
tumor which enables to decide if laparoscopic technique or classical laparotomy may be 
introduced. The latter is started by gentle manual palpation of the pancreas, confirming the 
place with tumor and compares this finding with the results of preoperative imaging. 
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Perioperative ultrasound may sometimes help in confirming the tumor (Norton et al., 1988). 
If localization of the tumor would not make possible  enucleation due to close proximity of 
the vessels, resection is decided. Blind resection is no more recommended although in 
patients with serious hypoglycemias and high hormonal activity it has to be suggested 
when no localization of the tumor has been done both before or during the operation. Small 
tumor with diameter below 5 mm may be overlooked and when neither serious symptoms 
nor high hormonal activity are present it can be better to operate for the second time than to 
make blind resection. Both types of operations may be subsequently associated with 
complications. Following resection, subfrenic inflammation causing localized abscess, sepsis 
or fistulae may be developed (Geoghegan et al., 1994). Fistulae develop sometimes after 
enucleation as well (Pasieka et al., 1992). 
Insulinoma may be localized within the whole pancreatic tissue. However, results from 
different centres bring various finding (Rothmund et al., 1990). It may be partly influenced by 
the  number of evaluated patients. Some authors describe the predominance of insulinoma 
within the head of pancreas, the others found regular distribution between all three parts of 
pancreas. In our group of 103 operated patients we found 93 solitary insulinoma distributed in 
30 % in the head, 28 % in the body and 42 % in the tail (Fig. 3). Other two patients had diffuse 
microadenomatosis, two patients with not proven insulinoma during the first operation were 
successfully reoperated. Removal of insulinoma is followed by hyperglycemia developing in a 
consequence of suppressed beta-cell function by insulinoma. Its manifestation in the next day 
after the operation usually confirms surgical success. In case that hypoglycemia persists 
postoperatively in spite of removed insulinoma, multiple tumor may be present. In patients 
with diffuse hyperplasia the total pancreatectomy may sometimes be necessary with 
subsequent substitution of both exocrine and endocrine functions. 
 
 
Fig. 3. Insulinoma localized in cut head of the pancreas. 
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4.2 Conservative treatment 
Insulinoma can be operated in every age and therefore high age is not a contraindication. In 
case of advanced ischemic heart disease with chronic heart failure or clustering with other 
risks the operation cannot be recommended and the patients are treated conservatively. 
Diabetic diet excluding free sugars which may induce hypoglycemic attacks is recommended 
because it does not stimulate insulin secretion like free diet containing sugars. Several doses of 
meals mainly in the night are sometimes necessary when severe hyperinsulinism has been 
developed. Free sugars are used during hypoglycemic attack but not in its prevention. Dietary 
regimen is often combined with the insulin secretion blocking agent (Fajans & Vinik, 1989). 
Diazoxide, a thiazide derivative, or somatostatin analogues decrease insulin levels and then 
hypoglycemic attacks develop less frequently or they are much less severe. Diazoxide acts as 
potassium channel opener and thus calcium channel is subsequently closed. This blockade 
of calcium movement in the beta cell lowers insulin secretion. Doses of 3 to 8 mg/kg daily 
are recommended but in some cases only 100 mg is sufficient to relief the clinical symptoms. 
Somatostatin treatment uses the presence of its receptors on beta cells which are less 
frequent than in other neuroendocrine tumors. Such therapy is therefore not so successful as 
in patients with gastrinoma. Not all patients respond on both drug therapy and then dietary 
regimen remains as the only one option.  
From our group of 113 patients with organic hyperinsulinism total of 103 were operated and 
remaining 10 were primarily treated conservatively during 10-22 years. Additional 8 
patients without removal of insulinoma during the operation have been treated 
conservatively as well. Interesting information was done when preoperative localization 
was compared with the finding in surgery. Operation could confirm localization in 80 %  (54 
of 68) of preoperatively found insulinoma when CT scan, angiography and endoscopic 
ultrasonography could be combined to visualize the tumors. When analyzing the results of 
localization of the tumors with surgical finding in 103 operated patients, localization was 
done in 68 (66 %)  preoperatively, in 27 (26 %) cases the tumor was found and removed 
during the operation and in 8 (8 %) patients no insulinoma was found during the operation. 
Operation was successful in 92 % of our patients with organic hyperinsulinism. 
Malignant insulinoma and its treatment 
Malignant insulinoma (ICD-08151/3) occurs in 5-10 % of all insulinoma cases. It grows very 
slowly and develops typical neuroglycopenic symptoms. When diagnosed and confirmed 
organic hyperinsulinism it may be found by CT scans like solitary tumor in the pancreas but 
not seldom with already developed metastases in the lymph nodes or in the liver. 
Chemotherapy involves combination of streptozotocin with 5-fluorouracil or other cytostatic 
drugs. It is recommended to combine chemotherapy with surgical treatment with the 
removal of primary tumor or metastases in the liver. In one of our patient (56 yrs old 
woman) total pancreatectomy was combined with transplantation of the liver after the liver 
removal because multiple large metastases have been present. Consequently isolated islets 
of Langerhans were injected into the portal system using transhepatic cathetrization. One 
year later the patient does not suffer from any problems. Malignant insulinoma although 
successfully removed may develop late metastases which are no more hormonaly active. 
5. Prognosis 
Benign insulinoma are cured by surgical removal and its recurrency is extremely rare. 
Multiple adenoma in different stage of development may cause repeated hypoglycemia 
when only one tumor was removed. Conservative treatment with diazoxide may be 
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successful many years, e.g. in patient with microadenomatosis. The patients after total 
pancreatectomy have sometimes problems with diabetes and sufficient enzyme substitution 
has to be added as well. Malignant insulinoma has poor prognosis because of high mortality 
and the patients die after several years with dissemination of the process. 
6. Algorithm of diagnosis and treatment 
Our own experience is the background to suggest algorithm of diagnosis and treatment in 
patients with endogenous hyperinsulinemia (Fig. 4). Analysis of clinical symptoms and 
biochemical finding of hypoglycemia in the fasting state in patients without any serious 
disease may serve as the basis for diagnosis of insulinoma. When the diagnosis is confirmed 
by fasting test the localization of the tumor has to be done. Surgical treatment is a method of 
choice whereas conservative treatment is followed after unsuccessful operation or in severly 
polymorbid patients when operation brings high risk. 
 
 
Fig. 4. Algorithm of diagnosis and treatment in patients with suspicion on insulinoma. 
The dotted line expresses the level where diagnosis of endogenous hyperinsulinism need to 
be established and where the operation has to be decided 
7. Conclusions 
Insulinoma is a rare endocrine disease. Its diagnosis may be sometimes overlooked because 
clinical symptoms of hypoglycemia may resemble different disease. Better knowledge of 
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neuroglycopenic symptoms may strongly improve diagnostic process and initiate further 
examinations. When any doubts on clinical picture exist, detailed differential diagnosis 
should be performed. Localization of the tumor is recommended just after confirmation that 
endogenous hyperinsulinism is a source of fasting hypoglycemia. Although the imaging 
techniques have significantly improved localization of the tumors in the past decade, some 
tumors have not been localized and exploration by laparotomy has to be done. Primary 
surgical treatment is a method of choice whereas conservative treatment may be suggested 
when operation was failed or poor clinical state could bring difficulties to surgical 
treatment. Follow-up of insulinoma patients is recommended but recurrent tumors are very 
rare. It may be important especially in cases with signs of perineural invasion or 
angioinvasion when cytostatic drugs should be decided. Close collaboration with 
oncological department is then necessary.  
8. Acknowledgment 
The authors are indebted to Marcela Jarolímková for technical assistance.  This chapter was 
supported by the research project of Ministry of Education and Sports, Nr. MSM0021620807. 
9. References 
Bottger, T.C., Weber, W., Beyer, J.  (1990). Value of tumor localization in patients with 
insulinoma. World Journal of Surgery, Vol. 14, Nr. 1 (January-February 1990), pp. 
107-112, ISSN 0364-2313  
Brun, J.F., Fédou, C., Bouix, O., Raynaud, E., Orsetti, A. (1995). Evaluation of a standardized 
hyperglucidic breakfast test in postprandial reactive hypoglycemia. Diabetologia, 
Vol. 38, Nr.4 (April 1995), pp. 494-501, ISSN 0012-186X 
Cresto, J.C., Abdenur, J.P., Bergada, I.  Martino, R. (1998). Long term follow up of 
persistent hyperinsulinemic hypoglycemia of infancy. Archives of Disease in 
Childhood, Vol. 79, Nr. 5 (November 1998) , pp. 440-444, ISSN 0003-9888 
Del Prato, S., Vigili de Kreutzenberg, S., Dorella, M., Avogaro, A., Marescotti, M.C.  
Tiengo, A.  (1993). Mechanisms of fasting hypoglycemia and concomitant insulin 
resistance in insulinoma patients. Metabolism-Clinical and Experimental, Vol. 42, Nr. 1 
(January 1993), pp. 24-29, ISSN 0026-0495 
Del Sindaco, P., Casucci, G., Pampanelli, S, Polonsky, K., Fanelli, C., Torlone, E., 
Santeusiano, F., Brunetti, P.  Bolli, G.B. (1997). Late post-prandial hypoglycemia 
as the sole presenting feature of secreting pancreatic beta-cell adenoma in a 
subtotally gastrectomised patient. European Journal of Endocrinology, Vol. 136, Nr. 1 
(January 1997), pp. 96-99, ISSN 0804-4643 
De Kreutzenberg, S.V., Riccio, A., Dorella, M., Avogaro, A., Marescotti, M.C., Tiengo, A.  
Del Prato, S.   (1995). Surgical removal of insulinoma restores glucose recovery 
from hypoglycemia but does not normalize insulin action. European Journal of 
Clinical Investigation, Vol. 25, Nr. 5 (May 1995), pp. 360-367, ISSN 0014-2972 
De Lonley-Debeney, P., Travert, F.P., Fournet, J.C., Sempoux, C., Vici, C.D., Brunelle,F., 
Touati, G., Rahier, J., Junien C., Nihoul-Fekete, C., Robert, J.J., Saudubray, J.M. 
(1999). Clinical features of 52 neonates with hyperinsulinism. New England Journal of 
Medicine, Vol. 340, Nr. 15 (April 1999) , pp. 1169-1175, ISSN 0028-4793  
Demeure, M.J., Klonnoff, D.C., Karam, J.H., Duh., O. & Clark, O.H. (1991). Insulinomas 
associated with multiple endocrine neoplasia type I: the neded for a different surgical 
approach. Surgery, Vol. 110, Nr. 6 (December 1991), pp. 998-1005, ISSN 0039-6060 
 
Insulinoma – Diagnosis and Treatment 
 
169 
Dizon, A.M., Kowalyk, S., Hoogwerf, B.J. (1999). Neuroglycopenic and other symptoms in 
patients with insulinoma. American Journal of Medicine, Vol. 106, Nr. 3 (March 1999), 
pp.307-310, ISSN 0002-9343 
Doppman, J.L., Chang, R., Fraker, D.L., Norton, J.A., Alexander, H.R., Miller, D.L., Collier, 
E., Skarulis, M.C.  Gorden, P.    (1995). Localization of insulinomas to regions of 
the pancreas by intra-arterial stimulation with calcium. Annals of Internal Medicine, 
Vol. 123, Nr. 4, pp. 269-273, ISSN 0003-4819 
Eastman, R.C., Carson, R.E., Orloff, D.G., Cochran, C.S., Perdue,J.F., Rechler, M.M., Lanau, 
F., Roberts, C.T., Shapiro, J., Roth, J.  Leroith, D. (1992). Glucose utilization in a 
patient with hepatoma and hypoglycemia. Assessment by a positron emission 
tomography. Journal of Clinical Investigation, Vol. 89, Nr. 6 (June 1992), pp. 1958-
1963, ISSN 0021-9738 
Fabbri, H.C., de Mello, M.P., Soardi, F.C., et al. (2010). Long-term follow-up of an 8-year-old 
boy with insulinoma as the first manifestation of a familial form of multiple 
endocrine neoplasia type 1. Arquivos Brasileiros de Endocrinologia e Metabologia, Vol. 
54, Nr. 8 (November 2010), pp. 754-760, ISSN 0004-2730 
Fajans, S.S. & Vinik, A.I. (1989). Insulin-producing islet cell tumors. Endocrinology and Metabolism 
Clinics of North America, Vol. 18, Nr. 1 (March 1989), pp. 45-74, ISSN 0889-8529 
Garber, A.J., Bier, D.M., Cryer, P.E., Pagliara, A.S. (1974). Hypoglycemia in compensated 
chronic renal insufficiency. Diabetes, Vol. 23, Nr. 12, pp. 982-986, ISSN 0012-1797 
Geoghegan, J.G., Jackson, J.E., Lewis, M.P.N. Owen, E.R.T.C., Bloom, S.R., Lynn, J.A.  
Williamson,R.C.N. (1994). Localization and surgical management of insulinoma. 
British Journal of Surgery, Vol. 81, Nr. 7 (July 1994), pp. 1025-1028, ISSN 0007-1323 
Gin, H., Brottie, E., Dupuy, B., Guillaume, D., Ponzo, J.  Aubertin, J. (1987). Use of the 
glucose clamp technique for confirmation of insulinoma autonomous 
hyperinsulinism. Archives of Internal Medicine, Vol. 147, Nr. 5 (May 1987), pp. 985-
987, ISSN 0003-9926  
Gin, H., Catargi, B., Rigalleau, V., Rullier, E., Roger, P. & Tabarin, A. (1998). Experience with 
the Biostator for diagnosis and assisted surgery of 21 insulinomas. European Journal 
of Endocrinology, Vol. 139, Nr. 4 (October 1998), pp. 371-377, ISSN 0804-4643 
Glaser, B., Kesavan, P., Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, C.A., 
Thornton, P.S., Permutt, M.A., Matchinsky, F.M.  Herold, K.C. (1998). Familial 
hyperinsulinism caused by an activating glucokinase mutation. New England 
Journal of Medicine, Vol. 338, Nr. 4 (January 1998), pp. 226-230, ISSN 0028-4793 
Glover, J.R., Shorvon, P.J., Lees, W.R. (1992). Endoscopic ultrasound for localization of islet 
cell tumors. Gut, Vol. 33, Nr. 1 (January 1992), pp. 108-110, ISSN 0017-5749 
Harrison, T.S., Fajans, S.S., Floyd, J.C., Thompson, N.W., Rasbach, D.A., Santen, R.J.  
Cohen, C. (1984). Prevalence of diffuse pancreatic beta islet cell disease with 
hyperinsulinism: problems in recognition and management. World Journal of 
Surgery, Vol. 8, Nr. 4 , pp. 583-589, ISSN 0364-2313 
Jordan, R.M.  Kammer, H. (1976). An insulinoma without fasting hypoglycemia. American 
Journal of Medical Sciences, Vol. 272, Nr.  2, pp. 205-209, ISSN 0002-9629 
Kitaura, J., Miki, Y., Kato, H., Sakakihara, Y.  Yanagisawa, M. (1999). Hyperinsulinemic 
hypoglycemia associated with persistent hyperammonaemia. European Journal of 
Pediatrics,Vol. 158, Nr. 5 (May 1999), pp. 410-413, ISSN 0340-6199  
Krenning, E.P., Kwekkeboom, D.J., Oei, H.Y., Dejong, R.J.B., Dop, F.J., Reubi, J.C.  
Lamberts, S.W.J. (1994). Somatostatin receptor scintigraphy in 
gastroenteropancreatic tumors: an overview of European results. Annals of the New 
York Academy of Sciences, Vol. 733,  pp. 416-424, ISSN 0077-8923 
 
Hypoglycemia – Causes and Occurrences 
 
168 
neuroglycopenic symptoms may strongly improve diagnostic process and initiate further 
examinations. When any doubts on clinical picture exist, detailed differential diagnosis 
should be performed. Localization of the tumor is recommended just after confirmation that 
endogenous hyperinsulinism is a source of fasting hypoglycemia. Although the imaging 
techniques have significantly improved localization of the tumors in the past decade, some 
tumors have not been localized and exploration by laparotomy has to be done. Primary 
surgical treatment is a method of choice whereas conservative treatment may be suggested 
when operation was failed or poor clinical state could bring difficulties to surgical 
treatment. Follow-up of insulinoma patients is recommended but recurrent tumors are very 
rare. It may be important especially in cases with signs of perineural invasion or 
angioinvasion when cytostatic drugs should be decided. Close collaboration with 
oncological department is then necessary.  
8. Acknowledgment 
The authors are indebted to Marcela Jarolímková for technical assistance.  This chapter was 
supported by the research project of Ministry of Education and Sports, Nr. MSM0021620807. 
9. References 
Bottger, T.C., Weber, W., Beyer, J.  (1990). Value of tumor localization in patients with 
insulinoma. World Journal of Surgery, Vol. 14, Nr. 1 (January-February 1990), pp. 
107-112, ISSN 0364-2313  
Brun, J.F., Fédou, C., Bouix, O., Raynaud, E., Orsetti, A. (1995). Evaluation of a standardized 
hyperglucidic breakfast test in postprandial reactive hypoglycemia. Diabetologia, 
Vol. 38, Nr.4 (April 1995), pp. 494-501, ISSN 0012-186X 
Cresto, J.C., Abdenur, J.P., Bergada, I.  Martino, R. (1998). Long term follow up of 
persistent hyperinsulinemic hypoglycemia of infancy. Archives of Disease in 
Childhood, Vol. 79, Nr. 5 (November 1998) , pp. 440-444, ISSN 0003-9888 
Del Prato, S., Vigili de Kreutzenberg, S., Dorella, M., Avogaro, A., Marescotti, M.C.  
Tiengo, A.  (1993). Mechanisms of fasting hypoglycemia and concomitant insulin 
resistance in insulinoma patients. Metabolism-Clinical and Experimental, Vol. 42, Nr. 1 
(January 1993), pp. 24-29, ISSN 0026-0495 
Del Sindaco, P., Casucci, G., Pampanelli, S, Polonsky, K., Fanelli, C., Torlone, E., 
Santeusiano, F., Brunetti, P.  Bolli, G.B. (1997). Late post-prandial hypoglycemia 
as the sole presenting feature of secreting pancreatic beta-cell adenoma in a 
subtotally gastrectomised patient. European Journal of Endocrinology, Vol. 136, Nr. 1 
(January 1997), pp. 96-99, ISSN 0804-4643 
De Kreutzenberg, S.V., Riccio, A., Dorella, M., Avogaro, A., Marescotti, M.C., Tiengo, A.  
Del Prato, S.   (1995). Surgical removal of insulinoma restores glucose recovery 
from hypoglycemia but does not normalize insulin action. European Journal of 
Clinical Investigation, Vol. 25, Nr. 5 (May 1995), pp. 360-367, ISSN 0014-2972 
De Lonley-Debeney, P., Travert, F.P., Fournet, J.C., Sempoux, C., Vici, C.D., Brunelle,F., 
Touati, G., Rahier, J., Junien C., Nihoul-Fekete, C., Robert, J.J., Saudubray, J.M. 
(1999). Clinical features of 52 neonates with hyperinsulinism. New England Journal of 
Medicine, Vol. 340, Nr. 15 (April 1999) , pp. 1169-1175, ISSN 0028-4793  
Demeure, M.J., Klonnoff, D.C., Karam, J.H., Duh., O. & Clark, O.H. (1991). Insulinomas 
associated with multiple endocrine neoplasia type I: the neded for a different surgical 
approach. Surgery, Vol. 110, Nr. 6 (December 1991), pp. 998-1005, ISSN 0039-6060 
 
Insulinoma – Diagnosis and Treatment 
 
169 
Dizon, A.M., Kowalyk, S., Hoogwerf, B.J. (1999). Neuroglycopenic and other symptoms in 
patients with insulinoma. American Journal of Medicine, Vol. 106, Nr. 3 (March 1999), 
pp.307-310, ISSN 0002-9343 
Doppman, J.L., Chang, R., Fraker, D.L., Norton, J.A., Alexander, H.R., Miller, D.L., Collier, 
E., Skarulis, M.C.  Gorden, P.    (1995). Localization of insulinomas to regions of 
the pancreas by intra-arterial stimulation with calcium. Annals of Internal Medicine, 
Vol. 123, Nr. 4, pp. 269-273, ISSN 0003-4819 
Eastman, R.C., Carson, R.E., Orloff, D.G., Cochran, C.S., Perdue,J.F., Rechler, M.M., Lanau, 
F., Roberts, C.T., Shapiro, J., Roth, J.  Leroith, D. (1992). Glucose utilization in a 
patient with hepatoma and hypoglycemia. Assessment by a positron emission 
tomography. Journal of Clinical Investigation, Vol. 89, Nr. 6 (June 1992), pp. 1958-
1963, ISSN 0021-9738 
Fabbri, H.C., de Mello, M.P., Soardi, F.C., et al. (2010). Long-term follow-up of an 8-year-old 
boy with insulinoma as the first manifestation of a familial form of multiple 
endocrine neoplasia type 1. Arquivos Brasileiros de Endocrinologia e Metabologia, Vol. 
54, Nr. 8 (November 2010), pp. 754-760, ISSN 0004-2730 
Fajans, S.S. & Vinik, A.I. (1989). Insulin-producing islet cell tumors. Endocrinology and Metabolism 
Clinics of North America, Vol. 18, Nr. 1 (March 1989), pp. 45-74, ISSN 0889-8529 
Garber, A.J., Bier, D.M., Cryer, P.E., Pagliara, A.S. (1974). Hypoglycemia in compensated 
chronic renal insufficiency. Diabetes, Vol. 23, Nr. 12, pp. 982-986, ISSN 0012-1797 
Geoghegan, J.G., Jackson, J.E., Lewis, M.P.N. Owen, E.R.T.C., Bloom, S.R., Lynn, J.A.  
Williamson,R.C.N. (1994). Localization and surgical management of insulinoma. 
British Journal of Surgery, Vol. 81, Nr. 7 (July 1994), pp. 1025-1028, ISSN 0007-1323 
Gin, H., Brottie, E., Dupuy, B., Guillaume, D., Ponzo, J.  Aubertin, J. (1987). Use of the 
glucose clamp technique for confirmation of insulinoma autonomous 
hyperinsulinism. Archives of Internal Medicine, Vol. 147, Nr. 5 (May 1987), pp. 985-
987, ISSN 0003-9926  
Gin, H., Catargi, B., Rigalleau, V., Rullier, E., Roger, P. & Tabarin, A. (1998). Experience with 
the Biostator for diagnosis and assisted surgery of 21 insulinomas. European Journal 
of Endocrinology, Vol. 139, Nr. 4 (October 1998), pp. 371-377, ISSN 0804-4643 
Glaser, B., Kesavan, P., Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, C.A., 
Thornton, P.S., Permutt, M.A., Matchinsky, F.M.  Herold, K.C. (1998). Familial 
hyperinsulinism caused by an activating glucokinase mutation. New England 
Journal of Medicine, Vol. 338, Nr. 4 (January 1998), pp. 226-230, ISSN 0028-4793 
Glover, J.R., Shorvon, P.J., Lees, W.R. (1992). Endoscopic ultrasound for localization of islet 
cell tumors. Gut, Vol. 33, Nr. 1 (January 1992), pp. 108-110, ISSN 0017-5749 
Harrison, T.S., Fajans, S.S., Floyd, J.C., Thompson, N.W., Rasbach, D.A., Santen, R.J.  
Cohen, C. (1984). Prevalence of diffuse pancreatic beta islet cell disease with 
hyperinsulinism: problems in recognition and management. World Journal of 
Surgery, Vol. 8, Nr. 4 , pp. 583-589, ISSN 0364-2313 
Jordan, R.M.  Kammer, H. (1976). An insulinoma without fasting hypoglycemia. American 
Journal of Medical Sciences, Vol. 272, Nr.  2, pp. 205-209, ISSN 0002-9629 
Kitaura, J., Miki, Y., Kato, H., Sakakihara, Y.  Yanagisawa, M. (1999). Hyperinsulinemic 
hypoglycemia associated with persistent hyperammonaemia. European Journal of 
Pediatrics,Vol. 158, Nr. 5 (May 1999), pp. 410-413, ISSN 0340-6199  
Krenning, E.P., Kwekkeboom, D.J., Oei, H.Y., Dejong, R.J.B., Dop, F.J., Reubi, J.C.  
Lamberts, S.W.J. (1994). Somatostatin receptor scintigraphy in 
gastroenteropancreatic tumors: an overview of European results. Annals of the New 
York Academy of Sciences, Vol. 733,  pp. 416-424, ISSN 0077-8923 
 
Hypoglycemia – Causes and Occurrences 
 
170 
Li, X.H., Zhang, J.L. & Liu, Y.F. (2010). Localization of small sized insulinoma by mean of 
combining arteriography with CT: a case report and review of the literature. 
Hepatogastroenterology, Vol. 58,  Nr. 104  (November 2010), pp. 1579-1583, ISSN 0172-
6390 
Liessi, G., Pasquali, C., D´Andrea A.A., Scandellari, C.  Pedrazzoli, S. (1992). MRI in 
insulinomas: preliminary findings. European Journal of Radiology, Vol. 14, Nr. 1 
(January-February 1992) , pp. 46-51, ISSN 0720-048X 
McGarry, J.D. & Foster, D.W. (1980). Systemic carnitine deficiency. New England Journal of 
Medicine, Vol. 303, Nr. 24, pp. 1413-1415, ISSN 0028-4793  
Mitrakou, A., Fanelli, C., Veneman, T., Perriello, G., Calderone, S., Platanisiotis, D., Rambotts, 
A., Raptis, S., Brunetti, P., Cryer, P., Gerich, J.  Bolli, G. (1993), Reversibility of 
unawareness of hypoglycemia in patients with insulinoma. New England Journal of 
Medicine,Vol. 329, Nr. 12 (September 1993), pp. 834-839, ISSN 0028-4793 
Morgello,  S., Schwartz, E., Horwith, M., King, M.E., Gorden, P.  Alonso, D.R. (1988). 
Ectopic insulin production by a primary ovarian carcinoid. Cancer, Vol. 61, Nr.4 
(February 1988) , pp. 800-805, ISSN 0008-543X 
Nankervis, A., Proietto, J., Aitken, P. & Alford, F. (1985). Hyperinsulinemia and insulin 
insensitivity: studies in subjects with insulinoma. Diabetologia, Vol. 28, Nr. 7 (July 
1985), pp. 427-431, ISSN 0012-186X  
Nauck, M., Stöckman, F. & Creutzfeld, W. (1990). Evaluation of a euglycemic clamp 
procedure as a diagnostic test in insulinoma patients. European Journal of Clinical 
Investigation, Vol. 20, Nr. 1 (February 1990), pp. 15-28, ISSN 0014-2972 
Nestorowicz, A., Wilson, B.A., Schoor, K.P., Inoue, H., Glaser, B., Landau, H., Stanley, C,.A., 
Thornton, P.S., Clement, J.P., Bryan, J., Aguilarbryan, L.  Permutt, M.A. (1996).  
Mutations in the sulfonylurea receptor gene are associated with familial 
hyperinsulinism in Ashkenazi Jews. Human Molecular Genetics, Vol. 5, Nr. 11 
(November 1996), pp. 1813-1822, ISSN 0964-6906 
Norton, J.A., Cromack, D.T., Shawker, T.H., Doppman, J.L., Comi, R., Gorden, P., Maton, 
P.N., Gardner, J.D.  Jensen, R.T. (1988). Intraoperative ultrasonographic 
localization of islet cell tumors. A prospective comparison to palpation. Annals of 
Surgery, Vol. 207, Nr. 2 (February 1988), pp. 160-168, ISSN 0003-4932 
Ouyang, D., Dhall, D., Yu, R. (2011). Pathologic pancreatic endocrine cell hyperplasia. World 
Journal of Gastroenterology, Vol. 17, Nr.2 , pp. 137-143, ISSN 1007-9327  
Pasieka, J.L., McLeod, M.K., Thompson, N.W.  Burney, R.E. (1992). Surgical approach to 
insulinomas. Archives of Surgery, Vol. 127, Nr. 4 (April 1992) , pp. 442-447, ISSN 
0004-0010 
Perry, R.R. & Vinik, A.I. (1995). Diagnosis and management of functioning islet cell tumors. 
Journal of Clinical Endocrinology and Metabolism, Vol. 80, Nr. 8 (August 1995), 
pp.2273-2278, ISSN 0021-972X 
Proye, Ch., Malvaux, P., Carnaille, B., Pattou, F., Godchaux, J.M., Mannoury, V., Filoche, B., 
Pans, J.C., Huglo, D.  Lefbvre, J. (1998). Noninvasice imaging of insulinomas and 
gastrinomas with endoscopic and somatostatin receptor scintigraphy. British Journal 
of Surgery, Vol. 85, Nr. 9 (September 1998) , pp. 1304-1304, ISSN 0007-1323 
Ratcliffe, P.J. & Bevan, (1985). Severe hypoglycemia and sudden death in anorexia nervosa. 
Psychological Medicine, Vol. 15, Nr. 3, pp. 679-681, ISSN 0033-2917 
Redmon, B., Pyzdrowski, K.L., Elson, M.K., Kay, N.E., Dalmasso, A.P.  Nuttall, F.Q.  
(1992). Hypoglycemia due to a monoclonal insulin-binding antibody in multiple 
myeloma. New England Journal of Medicine, Vol. 326, Nr. 15 (April 1992), pp. 994-998, 
ISSN 0028-4793 
 
Insulinoma – Diagnosis and Treatment 
 
171 
Rosch, T., Lightdale, C.J., Botet, J.F., Boyce, G.A., Sivak, M.V., Yasuda, K., Heyder, N., 
Palazzo, L., Dancygier, H., Schusdziarra, V.  Classen, M. (1992). Localization of 
pancreatic endorcine tumors by endoscopic ultrasonography. New England Journal 
of Medicine, Vol. 326, Nr. 26 (June 1992), pp. 1721-1726, ISSN 0028-4793 
Rothmund, M., Angelini, L., Brunt, M., et al. (1990). Surgery for benign insulinoma: an 
international review. World Journal of Surgery, Vol. 14, Nr. 3 (May-June 1990), pp. 
393-399, ISSN 0364-2313 
Samaan, N.A. (1989). Hypoglycemia secondary to endocrine deficiencies. Endocrinology and 
Metabolism Clinics of North America, Vol. 18, Nr. 1 (March 1989), pp. 145-154, ISSN 
0889-8529 
Sempoux, C., Guiot, Y., Lefevre, A., Nihoul-Fekete, C., Jaubert, F., Saudubray, J.M.  Rahier, 
J. (1998). Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome 
and keys for differential diagnosis.  Journal of Clinical Endocrinology and Metabolism, 
Vol. 83, Nr. 5 (May 1998) , pp. 1455-1461, ISSN 0021-972X 
Service, F.J., McMahon, M.M., O´Brien, P. & Ballard, D.J. (1991). Functioning insulinoma – 
incidence, reccurence, and long-term survival of patients: a 60-year study. Mayo 
Clinics Proceedings, Vol. 66,  Nr. 7 (July 1991), pp. 711-719, ISSN 0025-6196 
Service , F.J., O´Brien, P.CV., Kao, P.C.,  Young, W.F. (1992). C-peptide suppression test: 
effects of gender, age, and body mass index: implications for the diagnosis of 
insulinoma. Journal of Clinical Endocrinology and Metabolism, Vol. 74, Nr. 1 (January 
1992), pp. 204-210, ISSN 0021-972X   
Service, F.J. (1995). Hypoglycemic disorders. New England Journal of Medicine, Vol. 332, Nr. 
17 (April 1995), pp. 1144-1152, ISSN 0028-4793 
Service, F.J., Natt, N., Thompson, G.B., Grant, C.S., van Heerden, J.A., Andrews, J.C., 
Lorenz, E., Terzic, A.  Lloyd,R,V. (1999). Noninsulinoma pacreatogenous 
hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults 
independent of mutations in Kir6.2 and SUR1 genes. Journal of Clinical Endocrinology 
and Metabolism, Vol. 84, Nr. 5 (May 1999), pp. 1582-1589, ISSN 0021-972X 
Stanley, C.A. (1997). Hyperinsulinism in infants and children. Pediatric Clinics of North 
America, Vol. 44, Nr. 2 (April 1997), pp. 363-374, ISSN 0031-3955 
Stanley, C.A., Lieu, Y.K., Hsu, B.Y.L., Burlina, A.B., Greenberg, C.R., Hopwood, N.J., 
Perlman, K., Rich, B.H., Zammarchi, E  Ponz, M. (1998). Hyperinsulinismus and 
hyperammonaemia in infants with regulatory mutations of the glutamate 
dehydrogenase gene. New England Journal of Medicine, Vol. 338, Nr. 19 (May 1998) , 
pp. 1352-1357, ISSN 0028-4793 
Stefanini, P., Carboni, M., Patrassi, N.  Basoli, A. (1974). Hypoglycemia and insular hyperplasia: 
review of 148 cases. Annals of Surgery, Vol. 180, Nr. 1, pp. 130-135, ISSN 0003-4932 
Stefanini, P., Carboni, M., Patrassi, N.  Basoli, A. (1974). Beta islet cell tumors of the pancreas: 
results of a study on 1067 cases. Surgery, Vol. 75, Nr. 4, pp. 597-609, ISSN 0039-6060 
Škrha, J., Svačina, Š., Šrámková, J. & Páv, J. (1989). Use of euglycemic clamping in evaluation 
of diazoxide treatment of insulinoma. European Journal of Clinical Pharmacology, Vol. 
36, Nr. 2, pp. 199-201, ISSN 0031-6970 
Škrha, J., Páv, J., Svačina, Š., Šrámková, J.  Hilgertová, J. (1990). Glucose metabolism in a 
patient with insulinoma complicated by hyperosmolar non-ketotic state. Diabetic 
Medicine, Vol. 7, Nr. 4 (May 1992), pp. 361-363, ISSN 0742-3071 
Škrha, J., Hilgertová, J. & Justová, V. (1993). Insulin action in patients with insulinoma 
influenced by pharmacological and surgical therapy. Experimental and Clinical 
Endocrinology, Vol. 101, Nr. 6, pp. 360-364, ISSN 0232-7384 
 
Hypoglycemia – Causes and Occurrences 
 
170 
Li, X.H., Zhang, J.L. & Liu, Y.F. (2010). Localization of small sized insulinoma by mean of 
combining arteriography with CT: a case report and review of the literature. 
Hepatogastroenterology, Vol. 58,  Nr. 104  (November 2010), pp. 1579-1583, ISSN 0172-
6390 
Liessi, G., Pasquali, C., D´Andrea A.A., Scandellari, C.  Pedrazzoli, S. (1992). MRI in 
insulinomas: preliminary findings. European Journal of Radiology, Vol. 14, Nr. 1 
(January-February 1992) , pp. 46-51, ISSN 0720-048X 
McGarry, J.D. & Foster, D.W. (1980). Systemic carnitine deficiency. New England Journal of 
Medicine, Vol. 303, Nr. 24, pp. 1413-1415, ISSN 0028-4793  
Mitrakou, A., Fanelli, C., Veneman, T., Perriello, G., Calderone, S., Platanisiotis, D., Rambotts, 
A., Raptis, S., Brunetti, P., Cryer, P., Gerich, J.  Bolli, G. (1993), Reversibility of 
unawareness of hypoglycemia in patients with insulinoma. New England Journal of 
Medicine,Vol. 329, Nr. 12 (September 1993), pp. 834-839, ISSN 0028-4793 
Morgello,  S., Schwartz, E., Horwith, M., King, M.E., Gorden, P.  Alonso, D.R. (1988). 
Ectopic insulin production by a primary ovarian carcinoid. Cancer, Vol. 61, Nr.4 
(February 1988) , pp. 800-805, ISSN 0008-543X 
Nankervis, A., Proietto, J., Aitken, P. & Alford, F. (1985). Hyperinsulinemia and insulin 
insensitivity: studies in subjects with insulinoma. Diabetologia, Vol. 28, Nr. 7 (July 
1985), pp. 427-431, ISSN 0012-186X  
Nauck, M., Stöckman, F. & Creutzfeld, W. (1990). Evaluation of a euglycemic clamp 
procedure as a diagnostic test in insulinoma patients. European Journal of Clinical 
Investigation, Vol. 20, Nr. 1 (February 1990), pp. 15-28, ISSN 0014-2972 
Nestorowicz, A., Wilson, B.A., Schoor, K.P., Inoue, H., Glaser, B., Landau, H., Stanley, C,.A., 
Thornton, P.S., Clement, J.P., Bryan, J., Aguilarbryan, L.  Permutt, M.A. (1996).  
Mutations in the sulfonylurea receptor gene are associated with familial 
hyperinsulinism in Ashkenazi Jews. Human Molecular Genetics, Vol. 5, Nr. 11 
(November 1996), pp. 1813-1822, ISSN 0964-6906 
Norton, J.A., Cromack, D.T., Shawker, T.H., Doppman, J.L., Comi, R., Gorden, P., Maton, 
P.N., Gardner, J.D.  Jensen, R.T. (1988). Intraoperative ultrasonographic 
localization of islet cell tumors. A prospective comparison to palpation. Annals of 
Surgery, Vol. 207, Nr. 2 (February 1988), pp. 160-168, ISSN 0003-4932 
Ouyang, D., Dhall, D., Yu, R. (2011). Pathologic pancreatic endocrine cell hyperplasia. World 
Journal of Gastroenterology, Vol. 17, Nr.2 , pp. 137-143, ISSN 1007-9327  
Pasieka, J.L., McLeod, M.K., Thompson, N.W.  Burney, R.E. (1992). Surgical approach to 
insulinomas. Archives of Surgery, Vol. 127, Nr. 4 (April 1992) , pp. 442-447, ISSN 
0004-0010 
Perry, R.R. & Vinik, A.I. (1995). Diagnosis and management of functioning islet cell tumors. 
Journal of Clinical Endocrinology and Metabolism, Vol. 80, Nr. 8 (August 1995), 
pp.2273-2278, ISSN 0021-972X 
Proye, Ch., Malvaux, P., Carnaille, B., Pattou, F., Godchaux, J.M., Mannoury, V., Filoche, B., 
Pans, J.C., Huglo, D.  Lefbvre, J. (1998). Noninvasice imaging of insulinomas and 
gastrinomas with endoscopic and somatostatin receptor scintigraphy. British Journal 
of Surgery, Vol. 85, Nr. 9 (September 1998) , pp. 1304-1304, ISSN 0007-1323 
Ratcliffe, P.J. & Bevan, (1985). Severe hypoglycemia and sudden death in anorexia nervosa. 
Psychological Medicine, Vol. 15, Nr. 3, pp. 679-681, ISSN 0033-2917 
Redmon, B., Pyzdrowski, K.L., Elson, M.K., Kay, N.E., Dalmasso, A.P.  Nuttall, F.Q.  
(1992). Hypoglycemia due to a monoclonal insulin-binding antibody in multiple 
myeloma. New England Journal of Medicine, Vol. 326, Nr. 15 (April 1992), pp. 994-998, 
ISSN 0028-4793 
 
Insulinoma – Diagnosis and Treatment 
 
171 
Rosch, T., Lightdale, C.J., Botet, J.F., Boyce, G.A., Sivak, M.V., Yasuda, K., Heyder, N., 
Palazzo, L., Dancygier, H., Schusdziarra, V.  Classen, M. (1992). Localization of 
pancreatic endorcine tumors by endoscopic ultrasonography. New England Journal 
of Medicine, Vol. 326, Nr. 26 (June 1992), pp. 1721-1726, ISSN 0028-4793 
Rothmund, M., Angelini, L., Brunt, M., et al. (1990). Surgery for benign insulinoma: an 
international review. World Journal of Surgery, Vol. 14, Nr. 3 (May-June 1990), pp. 
393-399, ISSN 0364-2313 
Samaan, N.A. (1989). Hypoglycemia secondary to endocrine deficiencies. Endocrinology and 
Metabolism Clinics of North America, Vol. 18, Nr. 1 (March 1989), pp. 145-154, ISSN 
0889-8529 
Sempoux, C., Guiot, Y., Lefevre, A., Nihoul-Fekete, C., Jaubert, F., Saudubray, J.M.  Rahier, 
J. (1998). Neonatal hyperinsulinemic hypoglycemia: heterogeneity of the syndrome 
and keys for differential diagnosis.  Journal of Clinical Endocrinology and Metabolism, 
Vol. 83, Nr. 5 (May 1998) , pp. 1455-1461, ISSN 0021-972X 
Service, F.J., McMahon, M.M., O´Brien, P. & Ballard, D.J. (1991). Functioning insulinoma – 
incidence, reccurence, and long-term survival of patients: a 60-year study. Mayo 
Clinics Proceedings, Vol. 66,  Nr. 7 (July 1991), pp. 711-719, ISSN 0025-6196 
Service , F.J., O´Brien, P.CV., Kao, P.C.,  Young, W.F. (1992). C-peptide suppression test: 
effects of gender, age, and body mass index: implications for the diagnosis of 
insulinoma. Journal of Clinical Endocrinology and Metabolism, Vol. 74, Nr. 1 (January 
1992), pp. 204-210, ISSN 0021-972X   
Service, F.J. (1995). Hypoglycemic disorders. New England Journal of Medicine, Vol. 332, Nr. 
17 (April 1995), pp. 1144-1152, ISSN 0028-4793 
Service, F.J., Natt, N., Thompson, G.B., Grant, C.S., van Heerden, J.A., Andrews, J.C., 
Lorenz, E., Terzic, A.  Lloyd,R,V. (1999). Noninsulinoma pacreatogenous 
hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults 
independent of mutations in Kir6.2 and SUR1 genes. Journal of Clinical Endocrinology 
and Metabolism, Vol. 84, Nr. 5 (May 1999), pp. 1582-1589, ISSN 0021-972X 
Stanley, C.A. (1997). Hyperinsulinism in infants and children. Pediatric Clinics of North 
America, Vol. 44, Nr. 2 (April 1997), pp. 363-374, ISSN 0031-3955 
Stanley, C.A., Lieu, Y.K., Hsu, B.Y.L., Burlina, A.B., Greenberg, C.R., Hopwood, N.J., 
Perlman, K., Rich, B.H., Zammarchi, E  Ponz, M. (1998). Hyperinsulinismus and 
hyperammonaemia in infants with regulatory mutations of the glutamate 
dehydrogenase gene. New England Journal of Medicine, Vol. 338, Nr. 19 (May 1998) , 
pp. 1352-1357, ISSN 0028-4793 
Stefanini, P., Carboni, M., Patrassi, N.  Basoli, A. (1974). Hypoglycemia and insular hyperplasia: 
review of 148 cases. Annals of Surgery, Vol. 180, Nr. 1, pp. 130-135, ISSN 0003-4932 
Stefanini, P., Carboni, M., Patrassi, N.  Basoli, A. (1974). Beta islet cell tumors of the pancreas: 
results of a study on 1067 cases. Surgery, Vol. 75, Nr. 4, pp. 597-609, ISSN 0039-6060 
Škrha, J., Svačina, Š., Šrámková, J. & Páv, J. (1989). Use of euglycemic clamping in evaluation 
of diazoxide treatment of insulinoma. European Journal of Clinical Pharmacology, Vol. 
36, Nr. 2, pp. 199-201, ISSN 0031-6970 
Škrha, J., Páv, J., Svačina, Š., Šrámková, J.  Hilgertová, J. (1990). Glucose metabolism in a 
patient with insulinoma complicated by hyperosmolar non-ketotic state. Diabetic 
Medicine, Vol. 7, Nr. 4 (May 1992), pp. 361-363, ISSN 0742-3071 
Škrha, J., Hilgertová, J. & Justová, V. (1993). Insulin action in patients with insulinoma 
influenced by pharmacological and surgical therapy. Experimental and Clinical 
Endocrinology, Vol. 101, Nr. 6, pp. 360-364, ISSN 0232-7384 
 
Hypoglycemia – Causes and Occurrences 
 
172 
Škrha, J., Šindelka, G., Haas, T., Hilgertová, J. & Justová, V. (1996). Comparison of insulin 
sensitivity in patients with insulinoma and obese Type 2 diabetes mellitus. Hormone 
and Metabolic Research, Vol. 28, Nr. 11 (November 1996) , pp. 582-585, ISSN 0018-5043 
Škrha, J. (2001). Hypoglycemic syndrome, Grada Publishing, ISBN 80-7169-992-6, Prague, 
Czech Republic (in Czech) 
Škrha, J.,  Šváb, J., Krušina, L., Dušková, J., Hilgertová, J. & Keil, R. (2009). Diagnostics and 
treatment of organic hyperinsulinism – experience in 105 cases. Časopis Lékařů 
Českých, Vol. 148, Nr. 8 , pp. 389-394, ISSN 0008-7335 
Talente, G.M., Coleman, R.A., Alter, C., et al.  (1994). Glycogen storage disease in adults. Annals of 
Internal Medicine, Vol. 120, Nr. 3 (February 1994), pp. 218-226, ISSN 0003-4819 
Thomas, P.M., Cote, G.J., Wohllk, N., Haddad, B., Mathew, P.M., Rabl, W., Aguilarbryan, L., 
Gagel, R.F.  Bryan, J.  , (1995). Mutations in the sulphonylurea receptor gene in 
familial persistent hyperinsulinemic hypoglycemia in infancy. Science, Vol. 268, Nr 
5209 (April 1995), pp. 426-429, ISSN 0036-8075 
Thornton, P.S., Satin-Smith, M.S., Herold, K., Glaser, B., Chiu, K.C., Nestorowicz, A., 
Permutt, M.A., Baker, L.  Stanley, C.A. (1998). Familial hyperinsulinism with 
apparent autosomal dominant inheritance: clinical and genetic differences from the 
autosomal recessive variant. Journal of Pediatrics, Vol. 132, Nr. 1 (January 1998) , pp. 
9-14, ISSN 0022-3476 
Tsalikian, E. & Haymond. M.W. (1983). Hypoglycemia in infants and children. In: Service, F.J. 
(Ed.), 35-71, Hypoglycemic disorders: pathogenesis, diagnosis, and treatment. G.K.Hall, 
Boston, USA 
Varma, V., Tariciotti, L., Coldham, C., Taniere, P., Buckels, J.A. & Bramhall, S.R. (2011). 
Preoperative localization and surgical management of insulinoma: single centre 
experience. Digestive Surgery, Vol. 28, Nr. 1, pp. 63-73, ISSN 0253-4886 
Vinik, A.I., Delbridge, L., Moattari, R., Cho, K.  Thompson, N. (1991). Transhepatic portal 
vein cathetrization for localization of insulinomas. Surgery, Vol.109, Nr. 1 (January 
1991), pp. 1-11, ISSN 00349-6060 
Walters, E.G., Tavare, J.M., Denton R.M. & Walters, G. (1987). Hypoglycemia due to an 
insulin-receptor antibody in Hodgkin´s disease. Lancet, Vol. 1, Nr. 8534 (March 
1987), pp. 241-243, ISSN 0140-6736  
Weinstock, G., Margulies, P., Kahn, E., Susin, M.  Abrams, G. (1986). Islet cell hyperplasia: 
an unusual cause of hypoglycemia in an adult. Metabolism-Clinical and Experimental, 
Vol. 35, Nr. 2 (February 1986), pp. 110-117, ISSN 0026-0495 
Yki-Järvinen, H., Pelkonen, R.  Koivisto, V.A. (1985). Failure to suppress C-peptide 
secretion by euglycemic hyperinsulinemia: a new diagnostic test for insulinoma? 
Clinical Endocrinology, Vol. 23, Nr. 4, pp. 461-466, ISSN 0300-0664 
Zammarchi, E., Filippi, L., Novembre, E.  Donati, M.A. (1996). Biochemical evaluation of a 
patient with a familial form of leucine-sensitive hypoglycemia and concomitant 
hyperammonaemia. Metabolism-Clinical and Experimental, Vol. 45, Nr. 8 (August 
1996) , pp. 957-960, ISSN 0026-0495 
Zimmer, T., Stolzel, U., Baeder, M., Koppenhagen, K., Hamm, B., Buhr, H., Riecken E.O.  
Wiedenmann, B. (1996). Endoscopic ultrasonography and somatostatin receptor 
scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut, 
Vol. 39, Nr. 4 (October 1996), pp. 562-568, ISSN 0017-5749 
11 
Pancreatogenous Hypoglycemic  
Syndrome - Insulinoma or  
Non-Insulinoma Origin (NIPHS) 
Chen-Hsen Lee, Justin Ging-Shing Won and Hsiao-Shan Tseng 
Departments of Surgery, Internal Medicine and Radiology 
 National Yang-Ming University and Taipei  
Veterans General Hospital, Taipei, 
Taiwan  
1. Introduction 
Pancreatogenous hypoglycemic syndrome (PHS) is a heterogeneous disorder that occurs as 
a consequence of inappropriate and unregulated secretion of insulin by pancreatic β-cell 
tumors (insulinomas) or by nesidiodysplastic β-cells presenting as non-insulinoma 
pancreatogenous hypoglycemic syndrome (NIPHS).  NIPHS, formerly termed adult 
nesidioblastosis, is characterized by postprandial hypoglycemia and negative prolonged 
fasts, and yields negative perioperative localization studies for insulinoma but positive 
intra-arterial calcium stimulation (IACS) tests as well as nesidioblastosis in the gradient-
guided resected pancreas (Service et al., 1999a; Won et al., 2006). NIPHS is an increasingly 
recognized entity and appears to develop much more frequently in patients who have 
undergone either a Billroth II operation for peptic ulcer diseases or a Roux-en-Y gastric 
bypass procedure for medically complicated obesity (Service et al., 2005; Patti et al., 2005).  
Even though the histology of the resected pancreatic tissues from those patients resemble 
some of the histologic features observed in patients of congenital hyperinsulinism (CHI), in 
which genetic mutations in the 2 subunits (Kir6.2 and SUR 1) of the pancreatic β-cell ATP-
sensitive potassium channel (KATP) are observed (Kapoor et al., 2006), screening for similar 
mutations in those patients has proven unsuccessful (Service et al., 1999; Patti et al., 2005).  
Although the existence of post-gastric bypass NIPHS as a discrete entity has been strongly 
questioned (Meier et al., 2006), several lines of evidence—the neuroglycopenic nature of 
spells, the usual unresponsiveness to dietary modification, and the very high recurrence rate 
(up to 87%) after gradient-guided pancreatectomy (Vanderveen et al., 2010)—suggest 
functional as well as structural abnormalities of the disorder. 
Traditionally, PHS in adults is most commonly caused by circumscribed solitary or multiple 
insulinomas, while in 0.5-5% of patients, localized or diffuse proliferation of islet cells 
budding from pancreatic ducts (nesidioblastosis) has been defined (Fajans & Vinik 1989).  
With increasing utilization of IACS test, however, evidence shows that NIPHS has been 
found to account for 40-50% of all the patients with PHS (Starke et al., 2006; Thompson 
2007).  In our hospital, we routinely performed IACS tests for patients with documented 
hyperinsulinemic hypoglycemia, and during the past 15 years we found roughly an equal 
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1. Introduction 
Pancreatogenous hypoglycemic syndrome (PHS) is a heterogeneous disorder that occurs as 
a consequence of inappropriate and unregulated secretion of insulin by pancreatic β-cell 
tumors (insulinomas) or by nesidiodysplastic β-cells presenting as non-insulinoma 
pancreatogenous hypoglycemic syndrome (NIPHS).  NIPHS, formerly termed adult 
nesidioblastosis, is characterized by postprandial hypoglycemia and negative prolonged 
fasts, and yields negative perioperative localization studies for insulinoma but positive 
intra-arterial calcium stimulation (IACS) tests as well as nesidioblastosis in the gradient-
guided resected pancreas (Service et al., 1999a; Won et al., 2006). NIPHS is an increasingly 
recognized entity and appears to develop much more frequently in patients who have 
undergone either a Billroth II operation for peptic ulcer diseases or a Roux-en-Y gastric 
bypass procedure for medically complicated obesity (Service et al., 2005; Patti et al., 2005).  
Even though the histology of the resected pancreatic tissues from those patients resemble 
some of the histologic features observed in patients of congenital hyperinsulinism (CHI), in 
which genetic mutations in the 2 subunits (Kir6.2 and SUR 1) of the pancreatic β-cell ATP-
sensitive potassium channel (KATP) are observed (Kapoor et al., 2006), screening for similar 
mutations in those patients has proven unsuccessful (Service et al., 1999; Patti et al., 2005).  
Although the existence of post-gastric bypass NIPHS as a discrete entity has been strongly 
questioned (Meier et al., 2006), several lines of evidence—the neuroglycopenic nature of 
spells, the usual unresponsiveness to dietary modification, and the very high recurrence rate 
(up to 87%) after gradient-guided pancreatectomy (Vanderveen et al., 2010)—suggest 
functional as well as structural abnormalities of the disorder. 
Traditionally, PHS in adults is most commonly caused by circumscribed solitary or multiple 
insulinomas, while in 0.5-5% of patients, localized or diffuse proliferation of islet cells 
budding from pancreatic ducts (nesidioblastosis) has been defined (Fajans & Vinik 1989).  
With increasing utilization of IACS test, however, evidence shows that NIPHS has been 
found to account for 40-50% of all the patients with PHS (Starke et al., 2006; Thompson 
2007).  In our hospital, we routinely performed IACS tests for patients with documented 
hyperinsulinemic hypoglycemia, and during the past 15 years we found roughly an equal 
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incidence of insulinoma and NIPHS (Won et al., 2006), among the latter one-third had had 
gastric bypass surgery that was not bariatric-related.  
2. Clinical presentations 
The hypoglycemic symptoms are usually divided into adrenergic and neuroglycopenic 
symptoms.  The sympathetic adrenergic symptoms include tachycardia, palpitations, 
sweating, tremor, and anxiety.  The glucose deprivation of central nervous system (CNS) 
results in neuroglycopenic symptoms including behavioral changes, confusion, weakness, 
fatigue, loss of consciousness, amnesia, dizziness, blurry vision, diplopia, paresthesia, 
seizures, and coma (Fajans & Vinik 1989).  These symptoms can occur during fasting, after 
exercise, or postprandially (3-5 hours after meal).  Although the adrenergic symptoms are 
not unique to hypoglycemia, the possibility of neuroglycopenia should always be suspected 
in patients whose adrenergic symptoms are followed by spells of disturbed CNS functions, 
patients whose symptoms occur in the setting of a documented absolute hypoglycemia 
(plasma glucose ≤ 45 mg/dl; 2.8 mmol/l), and patients whose symptoms are relieved by 
glucose administration.  A detailed history to ascertain the type of symptoms, the frequency 
of spells and its relationship to meals, and history of gastric bypass surgery should be 
obtained.  Furthermore, clinical evidence of neuroglycopenia should be highly suggestive of 
organic hyperinsulinism, such as PHS, and warrants meticulous attentiveness and further 
testing until proven otherwise (Dizon et al., 1999).  Approximately one-fourth of patients 
with insulinoma develop only neuroglycopenic symptoms (Fajans & Vinik 1989; Dizon et 
al., 1999).   
Insulinoma is typically associated with fasting hypoglycemia, but may occur during both 
fasting and in postprandial states or even exclusively postprandially (Placzkowski et al., 
2009).  In contrast, NIPHS is often manifested as postprandial hypoglycemia, although 
fasting hypoglycemia can also occur.  In a few of our NIPHS patients, persistent 
hypoglycemia during both fasting and postprandial periods requiring continuous infusion 
of dextrose to prevent neuroglycopenia was observed.   
3. Diagnosis 
The diagnosis of PHS requires biochemical confirmation of inappropriately elevated plasma 
insulin concentrations in the settings of absolute hypoglycemia, which may occur 
spontaneously or can be provoked (Service 1999). The diagnostic criteria for 
hyperinsulinemia consist of a plasma insulin level ≥ 6 µU/ml (36 pmol/l), a plasma C-
peptide ≥ 0.6 ng/ml (200 pmol/l), or a plasma proinsulin ≥ 5 pmol/l, and a plasma β-
hydroxybutyrate ≤ 2.7 mmol/l at the time of hypoglycemia (plasma glucose ≤ 45 mg/dl or 
less) (Service 1999b).  Nevertheless, with the development of the more sensitive and highly 
specific assay for insulin, the immunochemiluminometric assay (ICMA), an insulin level of ≥ 
3 µU/ml (18 pmol/l) has been suggested as the criterion for hyperinsulinemia (Service 
1999b).  It is therefore crucial to measure, in addition to insulin, the concentrations of plasma 
C-peptide (a marker of endogenous insulin production), proinsulin, and ketone body (an 
indicator of insulin action) concurrently during a symptomatic hypoglycemia, as occasional 
insulinoma cases have reported persistent low serum insulin levels as determined by ICMA, 
despite the elevated C-peptide and/or proinsulin concentrations (Chia & Saudek 2003; 
Coelho et al., 2009).  Also, it is prudent to measure the level of insulin secretagogues (i.e., 
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sulfonylureas and glinides), if available, to differentiate the factitious hypoglycemia;and 
insulin autoantibody to identify and exclude the insulin autoimmune syndrome, a rare 
disorder reported to occur primarily among persons of Japanese ancestry (Comi 1993) .  Our 
experience shows that, during hypoglycemic spells, the insulin levels tend to be higher in 
patients with insulinoma than in patients with NIPHS, in whom the detected insulin 
concentration may be a little higher than the aforementioned diagnostic criteria. 
4. Laboratory tests  
4.1 72 h fast  
The 72 h supervised fast remains the gold standard for the diagnosis of insulinoma as the 
test enables the clinical demonstration of Whipple’s triad: symptoms and signs consistent 
with hypoglycemia, a concomitant plasma glucose level of 45 mg/dl or less, and 
reversibility of symptoms with administration of glucose (Service & Natt 2000).  In addition, 
the test provides biochemical confirmation of unsuppressed insulin secretion in the settings 
of hypoglycemia by measuring plasma insulin, C-peptide, proinsulin, and β-
hydroxybutyrate concentrations simultaneously, as aforementioned.  In most reports, one-
third of patients with insulinoma develop symptoms within 12 hours, two-thirds within 24 
hours, 95% in 48 hours, and 99% in 72 hours (Service & Natt 2000).  A recent study suggests 
that a 48-h fast may be an alternative, with a sensitivity rate of 95% (Hirshberg et al., 2000).  
In our hospital, we routinely perform the 48-h prolonged fast.  As expected, most patients 
with NIPHS, by definition, do not develop hypoglycemia during a 72 h prolonged fast.  
4.2 The 5-hour oral glucose tolerance test (OGTT) 
In contrast to the 72 h fast testing, the OGTT test may offer biochemical evidence of 
postprandial hypoglycemia associated with clinical symptoms and signs of 
neuroglycopenia, which may be missed in the supervised 72 h fast, though an abnormal 
OGTT is not helpful in the diagnosis or differential diagnosis of organic hyperinsulinism 
(Service 1999a).  Interestingly, very few cases of insulinoma show signs of glucose-induced 
hypoglycemia alone (Wiesli et al., 2002; Kar et al., 2006).   
4.3 Insulin/glucose (I/G) ratio or amended I/G ratio 
These measurements are no longer applied to the diagnosis of organic hyperinsulinism as 
currently most insulin assays have been replaced by the more specific ICMA technique 
worldwide. 
5. Image studies 
Because of the small size (90% tumors usually less than 2 cm in size), potential multiplicity, 
and possible throughout the whole pancreas, preoperative localization of tumors is very 
important and essential in determining prognosis and appropriate surgical intervention. 
There are a variety of preoperative imaging modalities for the detection of insulinomas. 
However, no single one imaging examination could localize tumors in all patients. Most 
experienced endocrine surgeons obtain one or more localization tests before treatment is 
performed. In choosing the localization technique, specific tumor characteristics need to be 
considered. 
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patients with insulinoma than in patients with NIPHS, in whom the detected insulin 
concentration may be a little higher than the aforementioned diagnostic criteria. 
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4.1 72 h fast  
The 72 h supervised fast remains the gold standard for the diagnosis of insulinoma as the 
test enables the clinical demonstration of Whipple’s triad: symptoms and signs consistent 
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reversibility of symptoms with administration of glucose (Service & Natt 2000).  In addition, 
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In contrast to the 72 h fast testing, the OGTT test may offer biochemical evidence of 
postprandial hypoglycemia associated with clinical symptoms and signs of 
neuroglycopenia, which may be missed in the supervised 72 h fast, though an abnormal 
OGTT is not helpful in the diagnosis or differential diagnosis of organic hyperinsulinism 
(Service 1999a).  Interestingly, very few cases of insulinoma show signs of glucose-induced 
hypoglycemia alone (Wiesli et al., 2002; Kar et al., 2006).   
4.3 Insulin/glucose (I/G) ratio or amended I/G ratio 
These measurements are no longer applied to the diagnosis of organic hyperinsulinism as 
currently most insulin assays have been replaced by the more specific ICMA technique 
worldwide. 
5. Image studies 
Because of the small size (90% tumors usually less than 2 cm in size), potential multiplicity, 
and possible throughout the whole pancreas, preoperative localization of tumors is very 
important and essential in determining prognosis and appropriate surgical intervention. 
There are a variety of preoperative imaging modalities for the detection of insulinomas. 
However, no single one imaging examination could localize tumors in all patients. Most 
experienced endocrine surgeons obtain one or more localization tests before treatment is 
performed. In choosing the localization technique, specific tumor characteristics need to be 
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a. Most insulinomas are vascular and visualized in arterial phase imaging. 
b. Most tumors are intrapancreatic. 
c. 80 – 90% are solitary and 80% less than 2 cm in diameter. 
d. Distributed equally within the head, body and tail of the pancreas. 
e. Multiple tumors are found in only 8% of patients associated with MEN-1. 
5.1 Preoperative transabdominal ultrasound 
Just like other abdominal diseases, transabdominal ultrasound is the most convenient 
imaging modality to examine the pancreatic insulinomas. It is noninvasive, radiation free, 
and readily available. However, the pancreas is deeply located in the abdomen and most 
patients with insulinoma are obese due to frequent snacking to resolve hypoglycemic 
symptoms. To fully investigate the whole pancreas demands meticulous technique. Besides 
the usual supine position, placing the patient in recumbent or upright oblique position may 
be necessary. Using the fluid-filled stomach or the spleen as acoustic window is also useful 
to examine the body and tail of pancreas (Galiber et al.,1988; Gorman et al., 1986). 
Usually, insulinoma is detected as a solitary, rounded, well-defined, hypoechoic mass with 
smooth outlines (Galiber et al.,1988). Gorman and colleagues reported 10% insulinoma either 
isoechoic or hyperechoic to surrounding parenchyma that may be due to normal pancreatic 
parenchyma.  It is less echogenic in younger patients than in older ones (Gorman et al., 1986). 
The ultrasound is operator dependent; thus, different detection rates were reported. 
Guettier and colleagues reported only a 14% accurate localization rate, a 72% false negative 
and a 14% false positive rates (Guettier et al., 1986). Grant reported their Mayo Clinic 
experience from July 1982 through October 2004 with a 65% sensitivity and a 91% positive 
predictive value (Grant, 2005). Not surprisingly, the bigger the tumor ,the easier it is to be 
detected. Böttger and colleagues reported a sensitivity of 43% for tumors less than 1 cm in 
diameter, 67% for tumors between 1 and 1.5 cm, and 80% for tumors larger than 1.5 cm 
(Böttger et al., 1990). Kuzin and colleagues reported rates of 10%, 21.4% and 53.8% for 
tumors less then 1 cm,1 to 2 cm and larger than 2 cm, respectively (Kuzin et al., 1998). They 
also found tumor location may affect the sensitivity of this test, with a 50% detection rate for 
tumor at pancreatic body, 16.7% for head and 23% for tail (Kuzin et al., 1998). 
5.2 Endoscopic ultrasound (EUS) 
Compared with transabdominal ultrasound, EUS is close to pancreas and can use high-
frequency probe that improves the image resolution and increases the detection rate of 
insulinoma. The appearance of insulinomas in EUS is similar to that in transabdominal 
ultrasound. Most published series reported high sensitivity. Rösch and colleagues described 
a sensitivity of 82% (Rösch et al., 1992). Nikfarjam and colleagues reported 92% (Nikfarjam 
et al., 2008). But Druce and colleagues reported only 65.4% (Druce et al., 2010). This 
discrepancy implies the importance of expertise to carry out the procedure. Tumor location 
is another important factor. To detect an insulinoma in the pancreatic head portion is easier 
than one in the tail. Schumacher et al. had a 83% sensitivity for tumors at the head and 37% 
at the tail (Schumacher et al., 1996). 
5.3 Computed tomography (CT) 
CT is widely used to scan the pancreatic insulinoma. The reported sensitivity rate varied 
with different techniques. The conventional CT scan had low sensitivity with a range of 16 – 
72% (Chatziioannou et al., 2001). There are at least two reasons to account for the low 
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detection rate. First, most insulinomas are small that conventional CT may skip the tumors. 
Second, small insulinomas appear similar density as normal parenchyma in pre-contrast and 
post-contrast delayed scan of conventional CT. With modern multidetector CT with dynamic 
contrast study, the above mentioned problems can be solved. After taking non-contrast study 
with thick slices (5–8 mm), biphasic images are taken after intravenous injection of 120–150 ml 
non-ionic contrast medium at the rate of 3-5 ml/sec with power injector. The arterial phase is 
taken about 30 seconds after injection and venous phase at 70 seconds. Thin slices and 
reformatted images may help to demonstrate smaller lesions (Chung et al., 1997). Nikfarjam 
and colleagues found the sensitivity rate increased from 24% before 1997 to 80% between 1994 
and 2007 (Nikfarjam et al., 2008). Most insulinomas show isodensity nodule in pre-contrast 
scan and high density in the arterial phase images. Atypical CT appearances of insulinomas 
include a high density mass in pre-contrast CT scan, low density mass in post contrast scan, 
cystic or calcified mass (Chatziioannou et al., 2001). 
5.4 Magnetic resonance imaging (MRI) 
Modern MRI provides a high sensitive test in the localization of insulinoma. High field (1.5 
T or 3 T) magnet combined with torso phased-array coil is used. Antiperistaltic agents may 
be used to decrease artifact caused by bowel movement. The protocol includes axial T1 and 
spin echo image with and without fat suppression, and spoiled gradient-echo (GRE) image 
before and after intravenous administration of gadolinium (Thoeni et al., 2000). Insulinomas 
usually show a low signal intensity in T1-weighted image and high in T2-weighted image, 
and marked enhancement after intravenous gadolinium administration. With modern MRI, 
the detection rates of 70% (Nikfarjam et al., 2008), 75% (Druce et al., 2010), and 85% (Thoeni 
et al., 2000) had been reported. The MRI technique is in constant  evolution. Recently, the 
diffusion weighted image technique is applied to examine the abdomen. It may improve the 
detection of pancreatic insulinomas (Lee et al., 2008). 
5.5 Angiography 
Though angiography was considered also sensitive to localize insulinomas, it was rarely 
performed alone today in this hospital, and usually was combined with hepatic venous 
sampling. To perform angiography, a catheter is advanced through femoral artery and 
selected into the arteries that supplying the pancreas, including the celiac, superior 
mesenteric, splenic and gastroduodenal arteries. Modern angiographic suite is 
armamentarium with digital subtraction technique that will improve the sensitivity of this 
test. However, antiperistaltic agents may be necessary to suppress bowel movement which 
causes motion artifact (Jackson, 2005). Besides, different projections are mandatory to avoid 
overlapping with other organ, such as the spleen, that may interfere with the blush of 
insulinoma. Classical angiographic picture of an insulinoma is a well defined blushing 
appearing in early arterial phase and persist to venous phase. But hypovascular insulinomas 
are not uncommon because of their small sizes. Fulton and colleagues reported 9 of 24 
insulinomas were hypovascular (Fulton et al., 1975). The reported detection rate of 
angiography ranged from 35% (Doherty et al., 1991) to 100% (Geoghegan et al., 1994). 
5.6 Percutaneous transhepatic portal venous sampling (PTPVS) 
The concept of PTPVS is that insulinomas secrete insulin which would be drained into 
adjacent venous system. The closer to the insulinoma, the higher the concentration of insulin 
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would be detected. After puncturing the branch of right portal vein, a catheter with side-
hole at tip was advanced into the splenic vein and superior mesenteric vein. Venography 
was taken first as a map. Then, samplings were taken along the splenic, superior and 
inferior mesenteric veins as well as the portal trunk at 1 to 1.5 cm intervals. Pancreatic veins 
were also sampled when possible (Cho et al., 1982). PTPVS was highly accurate and 
considered to be the gold standard for this purpose (Nikfarjam et al., 2008; Vinik et al., 
1991). However, severe complications, which mainly related to catheterizing the portal vein, 
are not infrequent. Miller and colleagues reported a rate of 6% severe complications (Miller 
et al., 1992). For this reason and the development of other less invasive modality, i.e. 
selective intra-arterial calcium stimulation with hepatic venous sampling, PTPVS is rarely 
performed nowadays. 
5.7 Selective intra-arterial calcium stimulation (IACS) with hepatic venous sampling 
In 1987, Imamura and colleagues described a novel method of intra-arterial injection of 
secretin and then sampling blood from hepatic vein to localize gastrinoma in patients with 
Zollinger-Ellisson Syndrome (Imamura et al., 1987). In 1991, Doppman and colleagues 
adopted the concept but using calcium as secretagogue to localize insulinoma in four cases 
(Doppman et al. 1991). To perform IACS, a catheter with side-hole at the tip is threaded 
through femoral vein into right hepatic vein. After selective angiography, 10% calcium 
gluconate diluted with saline to equivalent to 0.0125 mmol/kg (0.025 mEq/kg) is injected as 
quickly as possible but not spilled into adjacent vessles to avoid bias. In obese patients, the 
dose is adjusted to 0.005mmol/kg. Blood samples are obtained from the right hepatic vein 
before and 30, 60, 90, 120, and 180 seconds after injection of calcium. All the arteries 
supplying pancreas should be studied that including superior mesenteric, gastroduodenal, 
and splenic arteries. Sometimes, dorsal pancreatic artery is also studied if it is large enough 
to be catheterized safely. A two-fold or greater increase of insulin above baseline indicates a 
positive result. A positive result in superior mesenteric artery or gastroduodenal artery 
means the lesion at pancreatic head or uncinate process, while in splenic artery means 
pancreatic body or tail. To further differentiate tumor location in body or tail, two sets of 
splenic artery samplings are collected. One is at proximal injection, another is distal to the 
pancreatic magna artery. If both are positive, the lesion is at pancreatic tail. If only proximal 
one is positive, the lesion is at pancreatic body. Besides the above mentioned arteries, proper 
hepatic artery is also studied to search the possibility of liver metastasis. The time between 
two calcium injections should be at least 5 minutes apart to allow the possible stimulated 
elevation of insulin level to return to its baseline (Jackson, 2005). Since its development, 
IACS is considered the most reliable preoperative localization modality for insulinoma. In 
most reported series, successful rates were more than 90% (Jackson, 2005) .Diazoxide that is 
used to treat hyperinsulinemia should be suspended before IACS test as it may affect the 
result of the test (Doppman et al., 1991). 
Besides insulinomas, beta-cell hyperfunction, the so-called nesidioblastosis, is another 
important cause of PHS. Since most nesidioblastosis did not form discrete nodule, the non-
invasive image studies are usually negative (Raffel et al., 2007; Service et al., 1999a; Starke et 
al., 2006). But the IACS test always shows positive result and is an important clue to the 
diagnosis of nesidioblastosis. Meanwhile, if surgical treatment is to be performed, the 
gradient-guided resection according to the results of IACS test is mandatory (Thompson et 
al., 2000; Tseng et al., 2007). 
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5.8 Somatostatin receptor scintigraphy (SRS) 
The somatostatin receptor scintigraphy (OctreoscanTM), which uses Indium-111 
pentetreotide as a traceable somatostatin analog that predominantly binds to receptor 
subtypes, sst2 and sst5 (Bertherat et al., 2003), serves as a functional imaging modality for 
neuroendocrine tumors and some non-neuroendocrine tumors which contain somatostatin 
receptors. 
The diagnostic accuracy of the SRS is affected by the size and presence of different receptor 
subtypes of the tumors. The sensitivity of SRS in detecting insulinoma is reported to be as 
low as 50-60% (Balon et al., 2001; Mirallie et al., 2002), but the positive predictive value is 
high (Proye et al., 1998). 
The SRS serves as a complementary role in the localization of an insulinoma when the 
diagnosis is established but undetectable or equivocal on CT or MRI. 
6. Treatment 
6.1 Medical treatment 
For the insulinoma patients surgery is not amenable or is contraindicated, and for those with 
unresectable disease, medical treatment with diazoxide, a β-cell KATP channel agonist to 
inhibit insulin secretion, can be used with a reported effective rate of 97% (Gill et al., 1997).  
The usual dosage range is 150 to 450 mg daily, given orally twice or thrice a day.  Side 
effects include nausea, hypertrichosis, and sodium retention.  The addition of a 
benzothiadiazine diuretics, such as chlorothiazide, can combat the edema and potentiate the 
hyperglycemic effect of diazoxide (Fajans & Vinik 1989).  Octreotide, a long-acting 
somatostatin analog that acts mainly via the somatostatin receptor subtype 2, is sometimes 
effective (Vezzosi et al., 2005).  
Once the diagnosis of NIPHS in the patient is confirmed by IACS, medical treatment with 
diazoxide should be tried first.  Our limited experience found that almost all the patients, 
with or without a previous gastric bypass surgery, responded satisfactorily, with alleviation 
of neuroglycopenic episodes presumably in those with intact function of β-cell KATP channel, 
which the action of diazoxide requires (Won et al., 2006).  Whether octreotide or the newer 
analog, pasireotide (SOM230), is effective in patients with NIPHS is unclear and requires 
further study. 
6.2 Surgical treatment 
Surgical resection remains the treatment of choice for insulinomas. Usually, the successful 
rate of surgical treatment is over 90% in experienced hands. However, over resection of the 
pancreas may lead to diabetes which causes another problem affecting the patients’ quality 
of life .With the advancement in imaging technology, increase in knowledge as well as 
improvement in surgical technique, blind resection for an unlocalized insulinoma is no more 
acceptable. Various modalities of resection are available for the surgical treatment of 
insulinomas. Enunciation is usually employed for an insulinoma superficially located and 
away from the main pancreatic duct either in the head or body portion of the pancreas. The 
postoperative occurrence rate of pancreatic fistula varied from 18 to 57%. Enucleation of the 
pancreatic tail insulinomas is also feasible in selective conditions such as a pedunculated or 
a small bulging tumor from pancreatic surface; or a clearly visible image of 2 to 3 mm 
distance between the tumor and main pancreatic duct. In the author's opinion, enucleation is 
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would be detected. After puncturing the branch of right portal vein, a catheter with side-
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and splenic arteries. Sometimes, dorsal pancreatic artery is also studied if it is large enough 
to be catheterized safely. A two-fold or greater increase of insulin above baseline indicates a 
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means the lesion at pancreatic head or uncinate process, while in splenic artery means 
pancreatic body or tail. To further differentiate tumor location in body or tail, two sets of 
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hepatic artery is also studied to search the possibility of liver metastasis. The time between 
two calcium injections should be at least 5 minutes apart to allow the possible stimulated 
elevation of insulin level to return to its baseline (Jackson, 2005). Since its development, 
IACS is considered the most reliable preoperative localization modality for insulinoma. In 
most reported series, successful rates were more than 90% (Jackson, 2005) .Diazoxide that is 
used to treat hyperinsulinemia should be suspended before IACS test as it may affect the 
result of the test (Doppman et al., 1991). 
Besides insulinomas, beta-cell hyperfunction, the so-called nesidioblastosis, is another 
important cause of PHS. Since most nesidioblastosis did not form discrete nodule, the non-
invasive image studies are usually negative (Raffel et al., 2007; Service et al., 1999a; Starke et 
al., 2006). But the IACS test always shows positive result and is an important clue to the 
diagnosis of nesidioblastosis. Meanwhile, if surgical treatment is to be performed, the 
gradient-guided resection according to the results of IACS test is mandatory (Thompson et 
al., 2000; Tseng et al., 2007). 
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always first considered and evaluated before a resection of pancreas. If feasible, it causes 
less damage, avoids sacrificing islets in the pancreatic tail and saves time for operation. A 
distal pancreatectomy (40% distal pancreas resection) is done for multiple or big 
insulinomas ; or the tumor is attached to the pancreatic duct. The spleen should be 
preserved as possible; A Whipple’s operation is rarely necessary for pancreatic head 
insulinoma unless it is big, deep or located near the main duct; Subtotal pancreatectomy 
(60~85% distal pancreatctomy) with enucleation of tumors in the head was advised for 
MEN-1 associated insulinomas because of its multiple and diffuse lesions before the IACS 
test was popular (Thompson 1995). Our recent experiences showed that a solitary 
insulinoma disease may exist in MEN-1 patients, and distal pancreatectomy achieved 
euglycemia for more than 10 years. Individualized judgment according to the IACS 
insulin gradients is mandatory to avoid over resections and ensuing sequellae, although in 
the published large series (Tonelli et al., 2005; Bartsch et al., 2005; Norton et al., 2006) most 
patients needed an extended distal pancreatectomy and enucleation of tumors in the 
head.  
With repeated emphasis on the management of hypoglycemia in medical education as well 
as increased alertness of physicians at emergency department, more and more patients had 
diagnosis of spontaneous pancreatogenous hypoglycemia at its early presentation. It is our 
recommendation that image studies are done to localize the lesion instead of screening for 
diagnosis. However, despite the advancement in imaging technology, up to 25% of 
insulinomas remain occult preoperatively (Norton 1989). An occult insulinoma is defined as 
biochemically proven tumor with indeterminate anatomical site before operation. It should 
not prohibite the physicians from referring to surgery because intraoperative 
ultrasonography(IOUS) and palpation (96~100% sensitivity) by experienced surgeon may 
help to find out the tumor. A preoperative IACS test is helpful to indicate the region the 
tumor is located. It is especially useful in re-do operations or in patients with previous 
episodes of pancreatitis. In both situations dense peripancreatic adhesion usually exists and 
causes difficulties in dissection. Following the guidance of IACS test, a limited regional 
exploration may help to save operation time and prevent post-operative pancreatitis due to 
over manipulation (Tseng et al., 2007). 
In case, IOUS and palpation failed to find the lesion, we recommend a regional resection of 
pancreatic tail (40%) or tail and body (80-85%) as suggested by the insulin gradients in the 
splenic artery alone or plus SMA. This is different from a blind resection and is helpful in 
the surgical treatment of adult NIPHS. Our previous report has shown its advantage over a 
subtotal pancreatectomy in terms of post-operative diabetes (Lee et al., 2002). However, 
long-term follow up is needed to observe any recurrence.   
In summary, the goal of surgical treatment for PHS should aim at post-operative euglycemia 
and long term recurrence free. A blind distal pancreatectomy or an improper extensive 
subtotal pancreatectomy should not be performed. The IACS test plus IOUS is a good 
resection guide in the treatment of PHS. Surgical intervention for NIPHS is reserved for 
those refractory to medical treatment. 
7. Conclusion 
Spontaneous pancreatogenous hypoglycemic syndrome is a rare disease. With typical 
clinical presentation and compatible laboratory tests, it is not difficult for early diagnosis. 
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With pre-operative localization and intra-operative palpation as well as the use of 
intraoperative ultrasonography, blind resection of the distal pancreas is no more accepted. 
The cure rate of surgical treatment for insulinomas is usually more than 90%. Medical 
treatment is for those with high operation risk, previous failure of pre-operative and intra-
operative localization or diffuse islet cell hyperplasia as indicated in the selective intra-
arterial calcium stimulation test. 
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1. Introduction 
Hypoglycemia is a common syndrome. The manifestations of hypoglycemia are nonspecific, 
vary among individuals and may change from time to time in the same individual. They are 
also typically episodic. Thus, although the clinical history is of fundamental importance in 
suggesting the possibility of hypoglycemia, the diagnosis cannot be made solely on the basis 
of symptoms and signs.  
The vast majority of instances hypoglycemia is secondary to treatment of diabetes. Only a 
minority of the cases are due to other relatively unfrequent causes. In practice, the most 
common initial questions are whether the patient truly has hypoglycemia, and if it is likely 
to be reactive or whether there are grounds for considering insulinoma or islet hyperplasia.  
The clinical and physiopathological features, diagnosis and treatment of pancreatic beta cell 
tumors will be discussed in the following chapter.  
2. Historical data 
Low blood glucose concentrations were first described in the 19th century as a feature of 
several diseases. The islets of Langerhans were discovered in 1869 and were named after the 
German pathologist Paul Langerhans who discovered regions within the pancreas that 
produced hormones. Nicholls first described in the findings of an autopsy an islet cell tumor 
in 1902. In 1922 Banting and Best discovered insulin; however, it was not until insulin 
became available for the treatment of diabetes mellitus in the early 1920s that clinical events 
similar to those arising from overtreatment with insulin were identified in nondiabetic 
patients. In 1923, Campbell and Fletcher were the first to describe the hypoglycemic 
complex due to an insulin excess in non-diabetic patients. 
The first resection of an insulinoma was performed in 1927, when WJ Mayo removed an 
insulin-secreting tumor from a physician and injected it into rabbits that developed 
subsequently hypoglycemia. In 1938, Whipple reported a triad, considered pathognomonic 
for insulinoma: blood glucose levels less than 50 mg/dL, neurologic symptoms of 
hypoglycemia and immediate alleviation of symptoms after glucose ingestion. In 1954, 
Wermer described a family with a syndrome often associated with pancreatic and  
other neuroendocrine tumors, the multiple endocrine neoplasia type 1 (MEN1). In 1993,  
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Gagner et al. reported the first successful laparoscopic distal pancreatectomy and 
pancreatoduodenectomy. The first successful laparoscopic resection for pancreatic 
insulinoma was made in 1996. 
3. Clinical spectrum of pancreatic beta cell tumors 
Pancreatogenous hypoglycemia is a syndrome characterized by endogenous hyperinsulinemic 
hypoglycemia that comes from a pancreatic beta-cell malfunction. This malfunction can exist 
as a tumoral mass or a hyperplasia. 
Pancreatic beta-cell tumors usually appear as a well-defined mass producing insulin named 
insulinoma. Commonly insulinomas are sporadic although a low percentage of them are 
associated with inherited diseases. Another small percentage are not tumoral, but a 
hyperplasia of beta cells or nesidioblastosis which develop a similar syndrome to 
insulinomas but with different pathological appearance and therapeutic management.  
3.1 Sporadic insulinoma 
Insulinomas are so rare that few institutions have accrued enough experience to provide 
meaningful data regarding epidemiological or demographic characteristics. The estimated 
incidence of insulinomas in the general population is estimated 1-4 per 1,000,000 yearly. 
However, the incidence has been reported higher in autopsy studies (0.8-10%), suggesting 
that these tumors frequently remain undiagnosed. The mean age of patients at presentation 
is between 47-50 years, patients with MEN 1 are usually younger. In most series, females 
show a discrete predominance over men (ratio 1.5-1:1).  
Insulinomas comprise 70% to 80% of all functional neuroendocrine pancreatic tumors. The 
majority are solitary, benign lesions occurring in a sporadic setting; they are also single , 
small and hypervascular, with 90% measuring less than 2 cm and 30% measuring less than 1 
cm in diameter; approximately 10% are multiple.  
Malignant insulinomas represent about 10% of all insulinomas. Contrary to benign ones, 
malignant are more frequent in men. 
Insulinomas have a lower malignancy rate than other islet cell tumors such as gastrinomas 
and glucagonomas. It is very difficult to distinguish between malignant and benign 
insulinomas since endocrine tumors show frequently mild nuclear and structural atypia. 
Moreover, malignant insulinomas are usually diagnosed intrasurgically or by an image 
evidencing liver metastases, regional nodes or local invasion.  
However, malignant insulinomas, which are solitary and have no evidence of metastases, 
usually have a better prognosis. Several studies have been performed to investigate the 
mean survival of a metastatic insulinoma that has been established in 2.6 years since 
diagnosis (1.6-7.5) (Starke et al., 2005). 
3.2 Multiple endocrine neoplasia type 1 
Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of 
the parathyroid glands, pancreatic islet cells and anterior pituitary; hence the mnemonic 
device of the “3 Ps”. However, the clinical spectrum of this disorder has been expanded.  
A consensus statement from an international group of endocrinologists recommends that 
MEN1 is defined as the presence of two of the three main MEN1 tumor types (parathyroid, 
entero-pancreatic endocrine adenomas, and pituitary adenomas). Familial MEN 1 is defined 
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as an index MEN1 case with at least one relative who has one of the three main MEN1 
tumors. (Brandi, ML et al, 2001) 
Effective treatment is usually available for hyperparathyroidism and pituitary disease; the 
malignant potential of pancreatic endocrine tumors is the primary life-threatening 
manifestation of MEN1. Functioning pancreatic islet cell or gastrointestinal endocrine cell 
tumors become clinically apparent in approximately one third of patients with MEN1. The 
most common cause of symptomatic disease is the Zollinger-Ellison (gastrinoma) syndrome 
(ZES), leading to multiple peptic ulcers. Symptomatic insulinomas also occur with moderate 
frequency, while VIPomas and glucagonomas are rare. 
Insulin-producing pancreatic islet cell adenomas in MEN1 represent about 10% of the 
totality of insulinomas. They are often small, may be multiple, and may be associated with 
the simultaneous presence of other islet cell tumors. The diagnosis of insulinoma depends, 
as in nonfamilial causes, upon the documentation of hypoglycemia with characteristic 
symptoms that are rapidly reversed by the administration of glucose, and inappropriately 
high serum insulin concentrations. 
Approximately 4 to 10 percent of patients with insulinoma have MEN1, and in most of them 
the MEN1 is known or suspected. Treatment is complicated in these patients by the possible 
presence of multiple insulinomas, the likelihood that preoperative or intraoperative location 
techniques may miss small tumors and the continuing risk of recurrence of pancreatic 
tumors after surgery. As a result, some experienced surgeons recommend local excision of 
any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy. This 
approach differs from that in patients with sporadic insulinomas, who typically have a 
solitary tumor and in whom the localization and local excision alone are usually successful. 
In a cohort study of therapeutical response, patients who required additional surgical 
treatment because of failed initial surgery or recurrence of insulinoma over the period 1927 
to 1986 had an increased prevalence of MEN 1 with multiple tumors (25 %) and malignant 
insulinomas (13 %).(Service, FJ, et al. 1991) 
The inheritance of classical MEN1 follows an autosomal dominant pattern. Genetic linkage 
analysis implicated a region on the long arm of chromosome 11 (11q13) as the site of “MEN1 
gene” in 1988. In 1997 the candidate gene was found, the MEN 1 gene, whose protein 
product is termed “menin” was mutated in 14 of 15 families with MEN1.  
Much has been learned about the biochemical and cellular functions of menin, but the 
precise way in which these functions relate with the tumorigenesis is still not well 
established. However, it is clear that most of the MEN1 gene mutations found in MEN1 
patients would be expected to inactivate or disrupt menin function. 
3.3 Noninsulinoma pacreatogenous hypoglycemia or nesidioblastosis 
Noninsulinoma pancreatogenous hypoglycemia or nesidioblastosis is a syndrome 
characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an 
insulinoma which accounts for most cases of hyperinsulinemic hypoglycemia. 
Nesidioblastosis is the name given to the presence of islets in intimate association with 
ducts, leading to the formation of so-called ductulo-insular complexes.  
Nesidioblastosis has mainly been described in neonates. Since Harness et al first described 
nesidioblastosis in adults, it has been reported in association with other diseases, such as 
Zollinger-Ellison syndrome, multiple endocrine adenomatosis, β-cell adenomatosis, 
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Lindau’s disease, bariatric surgery, cystic fibrosis, insulinomas, pancreatic transplantation, 
orbital lymphoma with hypopituitarism and adrenal insufficiency, familial adenomatous 
polyposis, hypergastrinemia, and pancreatic polypeptidemia.(Abellán, P., et al. 2008). 
Sporadic hyperinsulinemic hypoglycemia is the main clinical feature of nesidioblastosis and 
the diagnostic proceedings are the same as those of insulinoma. However, therapeutic 
management differs as the extension of the disease in the pancreatic gland may be diffuse. 
4. Pathogenesis 
Insulinomas are the most frequent functioning endocrine pancreatic tumors. The etiology of 
these kinds of tumors is poorly understood until the moment. Some tumors may harbor 
MEN 1 gene mutations, the susceptibility gene of the MEN 1 syndrome, but most cases 
show wild type MEN 1.  While those tumors originated in the exocrine pancreas have been 
attributed to environmental risk factors and certain mutations, in those from the endocrine 
pancreas the evidence is quite limited. 
In order to improve the diagnosis, prognosis and therapy of insulinoma patients, it is 
important to increase our understanding of the molecular processes underlying tumor 
development and progression. During tumorigenesis in general an alteration in the cell 
physiology takes place as a result of an accumulation of genetic alterations which lead to an 
uncontrolled cell growth, tissue invasion and metastatic spread. The knowledge of these 
molecular alterations permits us a focused molecular treatment in these tumors, especially 
in those with a greater malignant potential. 
Therefore, a brief revision of the possible alterations which lead to tumorigenesis in the 
sporadic insulinoma will be discussed. The altered cellular phenotype in these tumors may 
involve different genes and mutations which participate in self-sufficiency growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), 
unlimited replicative potential, sustained angiogenesis and tissue invasion. It is also 
important to consider that the mechanisms involving MEN 1 insulinoma development and 
sporadic insulinoma are not the same (Jonkers, JMH et al. 2007) (figure 1). 
4.1 Menin molecular interactions 
The MEN 1 gene was the first gene described as a candidate gene implicated in 
insulinoma tumorigenesis. Several studies have been performed which suggest a minor 
role for MEN 1 inactivation by mutation in human sporadic insulinomas. Menin, the 610 
aminoacid protein encoded by MEN1 has been found to partner in vitro with a variety of 
proteins that comprise transcription factors, DNA processing factors, DNA repair proteins 
and cytoskeletal proteins. The role of menin inactivation in tumorigenesis, which takes 
place in the MEN type 1, is diverse participating in mechanisms of failure in DNA repair 
(via FANCD2), transcription and proliferation (via p27/p18), switching growth 
suppression to growth proliferation (via JunD), functional stimulation of S-phase kinase 
and essential component for the S-phase entry, transcriptional activation of NFKB which 
inhibits apoptosis and stimulates cell growth or neutralizing cell growth inhibition 
through SMAD3. 
Although this inactivation only occurs rarely in sporadic insulinomas, studies which focus 
on the molecular alterations of menin interacting proteins should be developed.  
 




Fig. 1. Signaling molecules and paths that may be involved in insulinoma tumorigenesis. 
The upper part (shaded in grey) represents those which participate in MEN 1 and the lower 
part (white) those in sporadic insulinoma. Those whose role have been suggested but not 
confirmed are in white, those with a loss of function are in grey and those with a gain are 
shaded. (Adapted from Jonkers, YMH. et al. 2007) 
4.2 Self-sufficiency in growth signals 
Cell cycle deregulation is one of the defining features of cancer. The roles of several proteins 
have been suggested to stimulate cell proliferation in insulinomas. 
Cyclin dependent kinase 4 (CDK4) together with its regulatory subunit cyclin D governs cell 
cycle progression through G1 phase. The deregulation of this complex has been studied in 
islet -cell proliferation. Several studies show that knock-in mice with an homozygous 
CDK4 mutation develop multiple neoplasia, most commonly endocrine tumors, including 
benign insulinomas. However, CDK4 mutations have not been detected in sporadic human 
insulinomas neither a significantly altered expression of CDK4. On the other hand, 
overexpression of cyclin D1 has been observed in benign insulinomas compared to normal 
pancreatic islets, suggesting that this oncogene is involved at least in the tumorigenesis in a 
certain subgroup of these tumors. 
The Akt 1 gene has also been described to induce -cell proliferation via CDK4 by increasing 
cyclin D1 and D2 levels. Transgenic mice which overexpress a constitutively active form of 
Akt 1 in islet beta cells exhibit striking increases in -cell mass, proliferation, cell mass and 
malignant tumor formation. The Akt 1 gene is located on a region which has often found to 
be gained in insulinomas of malignant behavior. One of the growth factors which seems to 
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cyclin D1 and D2 levels. Transgenic mice which overexpress a constitutively active form of 
Akt 1 in islet beta cells exhibit striking increases in -cell mass, proliferation, cell mass and 
malignant tumor formation. The Akt 1 gene is located on a region which has often found to 
be gained in insulinomas of malignant behavior. One of the growth factors which seems to 
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trigger the PI3K/Akt pathway is the insulin-like growth factor receptor. Several components 
of the IGF system show differences in mRNA expression suggesting a prominent role of this 
system in growth promotion. This pathway has been extensively explored and is one of the 
molecular targets being used recently in malignant insulinomas. Everolimus is an orally 
derivative of rapamycin that inhibits Ser/Thyrosine kinase, the PI3k/Akt/mTOR pathway.  
A gene expression profiling study described the GNAS gene (guanine nucleotide binding 
protein alpha subunit) as the most highly expressed gene in insulinomas compared to normal 
pancreatic tissue. It is also well established that activating mutations of the gene encoding 
GNAS can stimulate proliferation of endocrine cells and are involved in the pathogenesis of 
several tumors. The underlying method of this up regulation is still unknown and until now 
no mutations of this gene have been identified in human insulinomas. 
TGF (transforming growth factor has been associated with the development of 
insulinomas. Immunohistochemistry showed its expression already in benign tumors and 
enhanced expression in malignant insulinomas. TGFsecreted by tumor cells can bind to 
the epidermal growth factor receptor (EGFR) leading to an autocrine activation of the Ras 
signaling pathway and putatively to its oncogenic activity. EGFR is located in chromosome 
7p12, gained in 8% of benign versus 89% of malignant insulinomas, thus, speculating an 
involvement in the malignant progression of insulinomas. 
Recent studies have also shown that gain of chromosome 9q is one of the earliest aberrations in 
insulinoma development. FISH analysis showed multiple copies of cAbl gene in these tumors 
including cases with amplification. cAbl tyrosine kinase gene is a proto-oncogene with growth 
promoting activity. Overexpression of cAbl by means of RT-PCR and inmuhistochemistry 
were found suggesting and early role in some subgroups of insulinomas. 
In conclusion, several proteins involved in self-sufficiency cell growth, including cyclin D, 
Akt 1, GNAS, TNF and cAbl have been suggested to stimulate cell proliferation in 
insulinomas, although their individual roles still remain elusive. 
4.3 Insensitivity to anti-growth signals 
Within a normal tissue, multiple antiproliferative signals operate to maintain cellular 
quiescence and tissue homeostasis. Cancer cells must evade these anti-proliferative signals if 
they are to prosper.  
At the molecular level, many antiproliferative routes are controlled by the retinoblastoma 
protein (pRb). In tumors with pRb inactivation as the basis of pathology somatic loss of one 
Rb allele commonly accompanies a point mutation or micro-deletion of the other allele. 
Deletion of Rb gene has so far been detected only in one human insulinoma. However, other 
mechanisms of inactivations of pRb are phosphorylation, but studies done until the moment 
conclude that pRB may not be strictly involved in de initiation of insulinomas. 
CDKN2 locus on chromosome 9p21 harbors tumor suppressor genes which restrain cell 
growth by affecting the function of pRb and p53. Downregulation of expression of 
CDKN2A/p16, CDKN2B/p15 and CDKN2D/p14 have been studied. Absence of expression 
of p15 was detected in 33% of benign insulinomas. On the other hand, a low frequency of 
alterations were detected in p16 but a down-regulation of p16 protein was detected and it is 
likely to be involved in insulinoma tumorigenesis. Two other inhibitors of CDK2, p21 and 
p27 have been studied. P27 was expressed in 88% of insulinomas, including malignant 
tumors but was also expressed in normal pancreatic islet cells. The strong expression of p21 
and p27 may explain the slow growth in a subset of tumors and suggests differences in 
tumorigenesis between MEN1-associated and sporadic insulinomas.  
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The Raf-1 kinase inhibitory peptide (RKIP) binds to Raf-1 and MEK in vivo and in vitro, 
thus interfering with the activation of the ERK signaling pathway, and plays an important 
role in the inhibition and beta-cell proliferation. Expression of RKIP was studied in 
insulinomas showing an absence of expression in comparison with normal islet cells. 
PTEN (phosphatase with tensin homology) is a potent negative regulator of the PI3K/Akt 
signaling pathway. The PTEN gene is located on chromosome 10q23 a region which is often 
lost in malignant insulinomas.  Loss of PTEN has been associated with malignancy of 
insulinomas, as it was not observed in benign insulinomas.  
In conclusion, evading antiproliferative signals, for example through inactivation of pRb, 
p15, p16 and/or PTEN may be important features involved in the development of 
insulinomas. 
4.4 Evading apoptosis 
The ability of tumor cell population to expand is not only determined by the rate of 
proliferation but also by the rate of cell death or apoptosis. Acquired resistance toward 
programmed cell death (apoptosis) is a hallmark of most types of cancer.  
Certain apoptotic factors such as BcI-2 have been studied, and are frequently expressed in 
gastroenteropancreatic neuroendocrine tumors which are usually slow-growing and less 
aggressive tumors, suggesting that in these tumors BcI-2 expression leads to indolent tumor 
growth. Another factor such as c-Myc  has also been demonstrated to induce highly 
malignant beta-cell tumors in mouse models. All this evidence suggests that suppression of 
apoptosis may contribute also to the initiation of these tumors.  
Survivin, a member of another family of apoptosis inhibitors is a protein that can suppress 
apoptosis and regulate cell division.  The gene encoding this protein, BIRC5, is located in 
chromosome 17q25 a region gained in one third of malignant insulinomas versus none of 
the benign insulinomas.  
The P73 gene, encodes a protein with similar function to p53, and might be an interesting 
candidate for insulinoma progression. It is located on chromosome 1p36, a region that is 
deleted in 44% of malignant insulinomas and associated with metastasic disease.  
In conclusion, due to the overall low proliferation rate in insulinomas, it is tempting to 
speculate that evasion of apoptosis is more important in their development instead of 
increased proliferation. 
4.5 Unrestricted replicative potential 
Human cells carry a cell-autonomous program that limits their multiplication. This program 
is independent from of the cell to cell signaling pathways. The progressive erosion of 
telomers during successive cycles of replication eventually causes cells to lose their ability to 
protect the ends of chromosomal DNA, which results letal to them.  
Telomere maintenance is evident in virtually all types of malignant cells. For this purpose 
the malignant cells up-regulate the expression of telomerase enzymatic activity. Also stem 
cells do have a high telomerase activity. Because pancreatic stem cells are suggested as the 
clonal origin of insulinomas, telomerase activity may be expected in these tumors. This fact 
has not been demonstrated in sporadic insulinomas, however, in MEN1-associated 
insulinomas may play an important role. 
On the other hand, telomeric loss has been shown by array to be associated with malignant 
behavior of insulinomas. In insulinomas with uncertain behavior telomeric losses were more 
 
Hypoglycemia – Causes and Occurrences 
 
192 
trigger the PI3K/Akt pathway is the insulin-like growth factor receptor. Several components 
of the IGF system show differences in mRNA expression suggesting a prominent role of this 
system in growth promotion. This pathway has been extensively explored and is one of the 
molecular targets being used recently in malignant insulinomas. Everolimus is an orally 
derivative of rapamycin that inhibits Ser/Thyrosine kinase, the PI3k/Akt/mTOR pathway.  
A gene expression profiling study described the GNAS gene (guanine nucleotide binding 
protein alpha subunit) as the most highly expressed gene in insulinomas compared to normal 
pancreatic tissue. It is also well established that activating mutations of the gene encoding 
GNAS can stimulate proliferation of endocrine cells and are involved in the pathogenesis of 
several tumors. The underlying method of this up regulation is still unknown and until now 
no mutations of this gene have been identified in human insulinomas. 
TGF (transforming growth factor has been associated with the development of 
insulinomas. Immunohistochemistry showed its expression already in benign tumors and 
enhanced expression in malignant insulinomas. TGFsecreted by tumor cells can bind to 
the epidermal growth factor receptor (EGFR) leading to an autocrine activation of the Ras 
signaling pathway and putatively to its oncogenic activity. EGFR is located in chromosome 
7p12, gained in 8% of benign versus 89% of malignant insulinomas, thus, speculating an 
involvement in the malignant progression of insulinomas. 
Recent studies have also shown that gain of chromosome 9q is one of the earliest aberrations in 
insulinoma development. FISH analysis showed multiple copies of cAbl gene in these tumors 
including cases with amplification. cAbl tyrosine kinase gene is a proto-oncogene with growth 
promoting activity. Overexpression of cAbl by means of RT-PCR and inmuhistochemistry 
were found suggesting and early role in some subgroups of insulinomas. 
In conclusion, several proteins involved in self-sufficiency cell growth, including cyclin D, 
Akt 1, GNAS, TNF and cAbl have been suggested to stimulate cell proliferation in 
insulinomas, although their individual roles still remain elusive. 
4.3 Insensitivity to anti-growth signals 
Within a normal tissue, multiple antiproliferative signals operate to maintain cellular 
quiescence and tissue homeostasis. Cancer cells must evade these anti-proliferative signals if 
they are to prosper.  
At the molecular level, many antiproliferative routes are controlled by the retinoblastoma 
protein (pRb). In tumors with pRb inactivation as the basis of pathology somatic loss of one 
Rb allele commonly accompanies a point mutation or micro-deletion of the other allele. 
Deletion of Rb gene has so far been detected only in one human insulinoma. However, other 
mechanisms of inactivations of pRb are phosphorylation, but studies done until the moment 
conclude that pRB may not be strictly involved in de initiation of insulinomas. 
CDKN2 locus on chromosome 9p21 harbors tumor suppressor genes which restrain cell 
growth by affecting the function of pRb and p53. Downregulation of expression of 
CDKN2A/p16, CDKN2B/p15 and CDKN2D/p14 have been studied. Absence of expression 
of p15 was detected in 33% of benign insulinomas. On the other hand, a low frequency of 
alterations were detected in p16 but a down-regulation of p16 protein was detected and it is 
likely to be involved in insulinoma tumorigenesis. Two other inhibitors of CDK2, p21 and 
p27 have been studied. P27 was expressed in 88% of insulinomas, including malignant 
tumors but was also expressed in normal pancreatic islet cells. The strong expression of p21 
and p27 may explain the slow growth in a subset of tumors and suggests differences in 
tumorigenesis between MEN1-associated and sporadic insulinomas.  
 
Pancreatic Beta Cell Tumors 
 
193 
The Raf-1 kinase inhibitory peptide (RKIP) binds to Raf-1 and MEK in vivo and in vitro, 
thus interfering with the activation of the ERK signaling pathway, and plays an important 
role in the inhibition and beta-cell proliferation. Expression of RKIP was studied in 
insulinomas showing an absence of expression in comparison with normal islet cells. 
PTEN (phosphatase with tensin homology) is a potent negative regulator of the PI3K/Akt 
signaling pathway. The PTEN gene is located on chromosome 10q23 a region which is often 
lost in malignant insulinomas.  Loss of PTEN has been associated with malignancy of 
insulinomas, as it was not observed in benign insulinomas.  
In conclusion, evading antiproliferative signals, for example through inactivation of pRb, 
p15, p16 and/or PTEN may be important features involved in the development of 
insulinomas. 
4.4 Evading apoptosis 
The ability of tumor cell population to expand is not only determined by the rate of 
proliferation but also by the rate of cell death or apoptosis. Acquired resistance toward 
programmed cell death (apoptosis) is a hallmark of most types of cancer.  
Certain apoptotic factors such as BcI-2 have been studied, and are frequently expressed in 
gastroenteropancreatic neuroendocrine tumors which are usually slow-growing and less 
aggressive tumors, suggesting that in these tumors BcI-2 expression leads to indolent tumor 
growth. Another factor such as c-Myc  has also been demonstrated to induce highly 
malignant beta-cell tumors in mouse models. All this evidence suggests that suppression of 
apoptosis may contribute also to the initiation of these tumors.  
Survivin, a member of another family of apoptosis inhibitors is a protein that can suppress 
apoptosis and regulate cell division.  The gene encoding this protein, BIRC5, is located in 
chromosome 17q25 a region gained in one third of malignant insulinomas versus none of 
the benign insulinomas.  
The P73 gene, encodes a protein with similar function to p53, and might be an interesting 
candidate for insulinoma progression. It is located on chromosome 1p36, a region that is 
deleted in 44% of malignant insulinomas and associated with metastasic disease.  
In conclusion, due to the overall low proliferation rate in insulinomas, it is tempting to 
speculate that evasion of apoptosis is more important in their development instead of 
increased proliferation. 
4.5 Unrestricted replicative potential 
Human cells carry a cell-autonomous program that limits their multiplication. This program 
is independent from of the cell to cell signaling pathways. The progressive erosion of 
telomers during successive cycles of replication eventually causes cells to lose their ability to 
protect the ends of chromosomal DNA, which results letal to them.  
Telomere maintenance is evident in virtually all types of malignant cells. For this purpose 
the malignant cells up-regulate the expression of telomerase enzymatic activity. Also stem 
cells do have a high telomerase activity. Because pancreatic stem cells are suggested as the 
clonal origin of insulinomas, telomerase activity may be expected in these tumors. This fact 
has not been demonstrated in sporadic insulinomas, however, in MEN1-associated 
insulinomas may play an important role. 
On the other hand, telomeric loss has been shown by array to be associated with malignant 
behavior of insulinomas. In insulinomas with uncertain behavior telomeric losses were more 
 
Hypoglycemia – Causes and Occurrences 
 
194 
frequently observed than chromosomal instability. This suggests that telomeric loss occurs 
prior to and is causative of chromosomal instability during insulinoma tumorigenesis.  
These data indicate that escape from replicative senescence, which is expected to occur as a 
result of telomeric loss, is the basis of tumor progression.  
Therefore telomeric loss and chromosomal instability seem to accumulate during tumor 
progression and it is tempting to speculate that p16 down regulation and telomerase activity 
in addition ensure unrestricted replicative potential. Inactivation of menin may trigger 
activation of telomerase earlier in tumor development (MEN1). 
4.6 Sustained angiogenesis 
Tumorigenesis in general is critically dependent on the development of vascular supply. 
The fact that endocrine tumors are highly vascular in nature renders analysis of 
angiogenesis as a prognostic factor highly pertinent.  However, in contrast to other cancers, 
a high vessel density in endocrine pancreatic tumors was found to correlate with good 
prognosis as well as with hormone production.  
Endocrine pancreatic tumor cells overproduce the angiogenic peptide vascular endothelial 
growth factor (VEGF), which is likely to play an important role in the angiogenic process 
associated with endocrine tumorigenesis but they seem to lose this expression during tumor 
progression.  In conclusion, although activation of angiogenesis is not indicated in tumor 
progression, it will be necessary to study additional angiogenic factors that may substitute 
loss of blood supply in insulinomas. 
4.7 Markers to predict metastasic disease and clinical outcome in insulinomas 
Certain markers such as CK-19 are associated with malignancy. Immunostaining of CK19 
has resulted a reliable indicator of tumor-specific death in insulinomas. Also, chromosomal 
instability indentified by array has been detected as an optimal predictor of metastasic 
disease. Ki-67 ≥ 2% and p53 overexpression were found to be associated with malignancy in 
a few individual insulinoma cases.  
5. Histopathology  
Insulinomas exhibit four main histological patterns including: solid, trabecular, gland-like 
(tubular or acinar) and mixed forms. Larger tumors are encapsulated but the capsule is 
usually incomplete. Smaller tumors and microadenomas are rarely encapsulated. Tumor 
cells frequently exhibit a bland cytology and cells with large pleomorphic nuclei are rare. If 
present, these features are not predictive of malignant behavior. A relatively uncommon, 
but characteristic finding in insulinomas is the deposite of amyloid. Its major component is 
islet amyloid polypeptide or amylin that can be visualized by immunohistochemistry. 
Calcifications and intracytoplasmatic pigment may unfrequently be seen in insulinomas. 
(Figure 2) 
The majority of insulinomas exhibit immunoreactivity for insulin and proinsulin. 
Insulinomas without any positive staining for insulin are also found indicating that the 
produced insulin is not stored inside the cells, but immediately released. In such cases, 
proinsulin staining or insulin messenger RNA in situ hybridization are valuable 
alternatives, but rarely used and more costly. 
The byosinthesis of insulin takes place usually in the endoplasmic reticulum. In normal 
pancreatic beta-cells, proinsulin-insulin conversion occurs in acidic immature secretory 
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granules of the trans-Golgi apparatus. In contrast to beta-cells, the proinsulin-insulin 
conversion in insulinomas occurs already in the Golgi apparatus, but remains incomplete, 
resulting in the formation of secretory granules containing both proinsulin and insulin.. The 
distribution pattern of proinsulin and insulin has been investigated and no correlation was 
found between a particular staining pattern, histological type, multihormonality or the 
degree of malignancy of insulinoma. (De Lellis, et al.2004). 
Approximately 10-15% of insulinomas are classified as malignant on the basis of the 
presence of organ and/or lymph node infiltration or distant metastases. The most common 
sites of metastases for insulinomas are the peripancreatic lymph nodes with occasional 
hepatic metastases.  
According to the WHO criteria histopathologically pancreatic neuroendocrine tumors 
(including insulinomas) should be classified into four groups (Komminoth, P. et al, 2004):  
- Well differentiated endocrine pancreatic tumors in the absence of all adverse criteria 
- Well differentiated endocrine pancreatic tumors of uncertain behavior: tumor diameter 
> 2cm, >2 mitosis/10 high power fields, angioinvasion or a proliferative index Ki-67 > 
2%. 
- Well differentiated endocrine pancreatic carcinomas: gross local invasion or metastases. 
- Poorly differentiated pancreatic endocrine carcinomas: > 10 mitosis/ 10 high power 
field 
Because these criteria are not always reliable, markers have to be detected to predict a 
possible malignant outcome of insulinomas in an earlier stage. 
In the case of nesidioblastosis, the morphological criteria for establishing its diagnosis are 
the presence of differently-sized islets often with somewhat irregular outline, and 
irregularly sized and poorly defined endocrine cell clusters scattered in the acinar 
parenchyma and often intimately connected with small or large ducts (ductulo-insular 
complexes). Another feature is a distinct islet cell hypertrophy with nuclear enlargement, 
often resulting in the presence of giant and bizarre nuclei. Nesidioblastosis is classified into 
focal and diffuse types characterized by different clinical outcomes. Focal nesidioblastosis 
exhibits nodular hyperplasia of islet-like cell clusters, including ductuloinsular complexes 
and hypertrophied insulin cells with giant nuclei. In contrast, diffuse nesidioblastosis 
involves the entire pancreas with irregularly sized islets. (Figure 2) 
 
 
Fig. 2. Histopathological characteristics of insulinoma and nesidioblastosis. A. Insulinoma 
with peripancreatic fat. Haematoxylin and eosin (100x). B. Nesidioblastosis. Cluster of islets 
of varied size and shape in apposition to pancreatic ductules. Haematoxylin and eosin 
(250x). C. Insulin immunostaining showin insulinoma (right) with pancreatic tissue (100 x). 
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6. Clinical features 
Insulinoma patients characteristically present at diagnosis with symptoms of hypoglycemia, 
especially neuroglycopenic symptoms that may or may not be preceded by symptoms due 
to sympathetic overdrive. The leading symptoms establishing the diagnosis of endogenous 
hyperinsulinism are comprised in the Whipple’s triad. The neuroglycopenic symptoms of 
insulinomas include confusion, visual change, and unusual behavior. Neuroglycopenic 
symptoms are the direct result of central nervous system neuronal glucose deprivation. 
Neurogenic symptoms are the result of the perception of physiologic changes caused by the 
autonomic nervous system discharge triggered by hypoglycemia. Sympathoadrenal 
symptoms may include palpitations, diaphoresis and tremulousness. Amnesia for 
hypoglycemia is common in these patients. (Table 1) 
This common clinical manifestation takes place usually in a fasting state. However, 
postprandial hypoglycemia may be a feature or even the sole manifestation of hypoglycemia 
in some patients. In retrospective reviews done to patients with confirmed insulinoma, 21% 
reported fasting and postprandial symptoms and 6% reported only postprandial symptoms 
(Placzkowski, KA, et al. 2009). The hypoglycemia in patients with insulinoma is primarily 
due to reduced hepatic glucose output rather than increased glucose utilization.  
The mean duration of these symptoms before the diagnosis is established is less than 1.5 
years. However, a few patients can be symptomatic for decades and can be misdiagnosed 
with a neurologic or psychiatric disorder. Clinical manifestations of an insulinoma can 
mimick central nervous system disorders, like epilepsy. 
 


















Table 1. Hypoglycemic symptomatology. 
7. Diagnosis 
Neuroendocrine tumors (NETS) are rare, slow growing neoplasms characterized by their 
ability to store and secrete different peptides and neuroamines. Some of these substances 
cause specific clinical syndromes, whereas others may have elevated plasma or urine levels 
that are not associated with specific syndromes or symptom complexes. 
The biochemical markers are those hormones or amines secreted by the neuroendocrine 
cells from which these tumors are derived. In the case of the insulinoma, derived from the 
beta pancreatic cells, the biochemical marker secreted is insulin which leads in excess, to an 
hypoglycemic syndrome.  
The Whipple’s triad is the cornerstone for the suspicion of an insulinoma, although other 
causes must be ruled out. 
 





1. Hypoglycemia symptoms induced by fasting 
 
2. Blood glucose       < 50 mg/dL + symptoms 
                                                   < 40 mg/dL regardless of symptoms 
 
3. Relief of symptoms when glucose is raised to normal 
Fig. 3. Whipple's triad 
Clinical syndrome is therefore the first step that leads to the suspicion of an insulinoma. 
7.1 Laboratory confirmation 
The diagnosis of an insulinoma can be established by determining plasma proinsulin, 
insulin, c-peptide and glucose levels, which are usually performed during a 72-hour fast. It 
is important to realize that insulin levels are increasingly being determined by 
immunochemiluminiscent assays or specific immunoradiometric assays that do not cross-
react with proinsulin and give lower values than that obtained with most insulin 
radioimmunoassay, which can affect the proposed criteria listed in many reviews for 
diagnosis, which were based on radioimmunoassay results. 
There are six main criteria for the diagnosis of insulinoma: documented blood glucose levels 
of 45 mg/dL or less (2.2 mmol/L), concomitant insulin levels of 6 U/mL or greater (≥ 36 
pmol/L; ≥ 3 U/mL), c-peptide levels 200 pmol/L or greater, proinsulin levels 5 pmol/L or 
greater, hydroxybutyrate levels 2.7 mmol/L or less and absence of sulfonylurea 
(metabolites) in the plasma and/or urine. (Table 2) 
 
Biochemical tests Confirmation of insulinoma 
Plasma glucose <45 mg/dL 
Insulin ≥ 3 U/mL 
C-peptide ≥ 200 pmol/L 
Proinsulin ≥ 5 pmol/L 
hydroxybutyrate < 2.7 mmol/L 
Table 2. Main criteria for the diagnosis of insulinoma 
Further controlled testing under supervision includes the 72-hour fast, which is the gold-
standard criterion for establishing the diagnosis of insulinoma. Actually, 98% of the patients 
with insulinoma will develop symptomatic hypoglycemia within 72 hours. When the 
patient develops symptoms and the blood glucose levels are < 40(45) mg/dL or less (<2.2 
mmol/L), blood should also be drawn for c-peptide, proinsulin and insulin, and the fast 
should be stopped. Failure in appropriate insulin suppression in the presence of 
hypoglycemia substantiates an autonomously secreting insulinoma.  
7.1.1 How to perform a fast test 
The 72-h fast test can be initiated at any hour and may be prolonged until 72-hours. It is 
important to date the onset of fast as well as the last ingestion of calories. During the whole 
test, the patient may only be allowed to drink calorie and caffeine free beverages. It is 
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Biochemical tests Confirmation of insulinoma 
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hydroxybutyrate < 2.7 mmol/L 
Table 2. Main criteria for the diagnosis of insulinoma 
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mmol/L), blood should also be drawn for c-peptide, proinsulin and insulin, and the fast 
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7.1.1 How to perform a fast test 
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important to date the onset of fast as well as the last ingestion of calories. During the whole 
test, the patient may only be allowed to drink calorie and caffeine free beverages. It is 
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important to ensure that the patient is active during waking hours and in some cases some 
exercise can be recommended at the end of the fast if it resulted negative.  
In the basal state with the initiation of the fast state a 6mL extraction for glucose, insulin and 
c-peptide will be done. These measurements should be repeated every 12 hours with a 
previous measurement of capillary glucose at 12, 24, 36, 48, 60 and 72 hours and after 
exercise if it takes place. 
The end of the fast will be when the patient presents signs and symptoms of hypoglycemia 
and plasma glucose is <40 mg/dL. In this moment blood glucose will be drawn as well as 
insulin and c-peptide. Hypoglycemia will not be reversed until the central laboratory 
confirms the glucose value or the patient is unconscious and has fits.  The reversal of the 
hypoglycemia will be with the administrations of oral glucose or intravenous if needed 
(dextrose 40% 250mL). 
At the end of the fast, a measurement of glucose, insulin, c-peptide and sulphonylurea 
screen (blood and urine spot), should be done. If the patient presents no symptoms during 
the fast, it can be finished with a 15-30 min exercise (for example brisk walk) around the 
hospital and re-measuring. 
7.1.2 Interpretation of a fast test 
90% of insulinomas will present hypoglycemia before 72 hour fast and insulin will be 
inappropriately high in relation with glucose levels.(Figure 4) 
 
 
Fig. 4. Plasmatic insulin and glucose limits after a fast in normal subjects and patients 
affected of an insulinoma. The black area represents the normal response to hypoglycemia. 
The striped area represents the usual response in patients affected of an insulinoma. 
(Redrawn from Service, FJ. et al, 1999). 
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Rare disorders, in which the biochemical findings simulate those of an insulinoma because 
they are also associated with endogenous hyperinsulinemia include administration of 
exogenous insulin or sulphonylureas and insulin autoimmune hypoglycemia. 
The fast test permits us to differ between insulinoma, exogenous administration of insulin 
and sulphonylureas administration. If this last is suspected, urine and plasma collection of 
sulphonylureas should be performed. (Table 3) 
 



















   
POSITIVE 
Table 3. Differential diagnosis determined by the results of a fast test. 
Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to 
endogenous insulin or to the insulin receptor. Symptoms can occur postprandially, fasting, 
or in both states. In patients with insulin autoantibodies, insulin secreted in response to a 
meal binds to the antibody and then disassociates in an unregulated fashion causing 
hyperinsulinemia and hypoglycemia. In patients with antibodies to the insulin receptor, 
hypoglycemia occurs as a result of antibody activation of the receptor. The presence of 
insulin or insulin receptor antibodies can distinguish insulin autoimmune hypoglycemia 
from insulinoma. The antibodies do not have to be measured during an episode of 
hypoglycemia.  
7.1.3 48 hour versus 72 hour fast 
It has been proposed that the sensitivity of the 48h fasting test is between 94.5 and 95.7% 
and should be enough for the diagnosis of insulinoma instead of the 72-hour fast. In a series 
of 127 patients with insulinoma, the fast was ended due to hypoglycemia in 42.5% in 12 
hours, 66.9% by 24 hours and 94.5% in 48 hours (Hirshberg, et al. 2000). 
7.1.4 Other laboratory tests 
7.1.4.1 Intravenous secretin test for insulinoma 
In patients harboring and insulinoma, insulin production by normal pancreatic beta cells is 
significantly suppressed. Following intravenous injection of secretin (2 units/kg of body 
weight), plasma insulin rises more than 200% in normal individuals, whereas in patients 
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with insulinoma, the secretin stimulation test does not cause a rise in plasma insulin due to 
the unresponsiveness of insulinoma cells to secretin. (Imamura, M., et al. 1990) 
7.1.4.2 C-peptide inhibition test with hog insulin 
After proinsulin cleavage, insulin and c-peptide are secreted. Infusion of hog insulin for 1 
hour leads to the decrease of plasma c-peptide levels in healthy subjects, but no such 
decrease is observed in insulinoma patients. Insulin release from insulinoma cells is not 
inhibited by the administration of exogenous insulin, whereas insulin secretion from normal 
beta-cells is inhibited by the increased plasma insulin. (Service, FJ., et al. 1992) 
7.2 Diagnostic imaging 
The diagnostic suspicion of an insulinoma is based on symptoms, and laboratory techniques 
usually confirm the diagnosis. The treatment, on the other hand, is usually surgery of the 
tumoral mass as complete as possible, including the primary tumor and metastases if present. 
Imaging of the primary tumor location and the extent of the disease is needed for all phases of 
management of pancreatic neuroendocrine tumors. It is needed to determine whether the 
surgical resection for possible cure or possible cytoreductive surgery is needed and whether 
treatment for advanced metastatic disease is appropriate and during follow-up to assess the 
effects of any antitumor treatment as well as the need for deciding whether additional 
treatments are indicated. Imaging plays also a pivotal role in differentiating these tumors from 
adenocarcinomas of the pancreas. As a result, a fundamental part in the process of the 
diagnosis and treatment of an insulinoma will be the localization with imaging techniques. 
Insulinomas are often of a small size and localization may be difficult. A number of different 
imaging modalities have been widely used including conventional imaging studies (CT, 
MRI, ultrasound, angiography), endoscopic ultrasound, functional localization studies 
measuring hormonal gradients, intraoperative methods particularly intraoperative 
ultrasound and recently PET preoperatively. 
7.2.1 Abdominal ultrasound 
Abdominal ultrasound has the advantages of being a non-invasive technique, free of radiation, 
anatomically precise, low-cost and world-wide used. On the other hand, key major drawbacks 
include its dependence on the operator expertise and on the limitations based on the patient’s 
habitus that is usually unfavorable since many insulinoma patients are overweight or obese. 
Regular ultrasound investigation of the pancreas is rarely helpful in the localization of an 
insulinoma. The sensibility reported with this technique to detect insulinoma is low, about 
9%. However, it is done routinely to exclude the presence of liver metastases before surgery. 
Commonly, it is the first imaging technique to detect liver metastases and therefore leading 
to the performance of more precise techniques which detect the malign insulinoma. 
7.2.2 Endoscopic ultrasonography (EUS) of the pancreas 
EUS is a relatively new technique. It is remarkably accurate locating pancreatic 
neuroendocrine tumors, especially those located in the pancreatic tail (Figure 5). EUS 
requires the availability of expensive echoendosonographic and processing equipment. Such 
equipment is found only in large hospitals or endoscopy units. 
Most gastroenterologists now consider EUS to be the most accurate, least expensive 
preoperative method of locating neuroendocrine pancreatic tumors. The technical 
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advantage of EUS imaging over transabdominal ultrasonography is due to the close 
proximity of the transducer to the target. This permits the use of high scanning frequencies, 
which provide much greater spatial resolution. Rosch et al. prospectively compared the 
accuracy of EUS and ultrasonography, computed tomography, and endoscopic retrograde 
cholangiopancreatography in the detection of pancreatic tumors.22 The sensitivity and 
specificity of EUS in localizing pancreatic tumors is 99 and 100%, respectively, compared 
with ultrasonography (67 and 40%, respectively) and computed tomography (77 and 53%, 
respectively) and is equal to endoscopic retrograde cholangiopancreatography (sensitivity of 
90%).  
In a recent multicenter study, EUS was shown to be the most sensitive localization modality in 
accurate detection of pancreatic tumors (sensitivity of 82 versus 27%) and had a specificity of 
95%. EUS accurately defines the size of tumors to within 2 mm of the excised lesion. 
EUS is a valuable method of localizing insulinomas. The technique requires specialized 
endoscopic skill, but it is both safe and effective in experienced hands. EUS should prove to 
be very helpful for localization of insulinomas undetectable by transabdominal 
ultrasonography or computed tomography, but it is not a satisfactory method for evaluating 
the liver in patients suspected to have metastatic disease. (Andersen, A., et al, 2004) 
 
 
Fig. 5. Endoscopic ultrasonography of a bening insulinoma. The arrow points the tumoral 
mass. 
7.2.3 Computed tomography (CT)  
Although in recent years gadolinium-enhanced MR imaging, somatostatin-receptor 
imaging, and endosonography have emerged as potentially competing or complementary 
techniques to CT, dual-phase helical CT, particularly with technical improvements afforded 
by multidetector CT, remains the dominant imaging modality for the diagnosis of all 
pancreatic neoplasms, including islet cell tumors. In expert hands, helical CT can detect 
about two-thirds of the insulinomas.  
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Because of their rich vascular supply, insulinomas classically are hyperattenuating 
compared with the surrounding pancreatic parenchyma on contrast-enhanced CT. 
Capturing the vascular blush is essential for the diagnosis of small tumors, which often do 
not distort the contour of the pancreas. This is particularly true in the investigation of 
functioning insulinomas because these are often small, with 50% measuring less than 1.3 cm. 
The classic and most common enhancement pattern of islet cell tumors is that of a 
hyperattenuating lesion in the arterial and venous phases. Many small lesions enhance more 
prominently and thus are easier to detect in the arterial phase or become inconspicuous in the 
venous phase. In a series of 11 cases of functioning islet cell tumors reported by Van Hoe et al., 
most lesions were hyperattenuating and two were more conspicuous on arterial phase imaging. 
Helical CT is not only useful for the detection of the insulinoma but also in the staging of 
malignant insulinoma on dual-phase CT.  Three-dimensional CT reconstructions exquisitely 
show local extension and encasement of the major peripancreatic arteries and veins for 
surgical planning. The liver and regional lymph nodes are the most common sites for 
metastases. Like the primary tumor, liver metastases are hypervascular. Arterial phase 
images show the number and size of the hepatic lesions better than images acquired in the 
venous phase, particularly for small metastases. Spread to regional lymph nodes also is more 
conspicuous in the arterial phase. 
The reported sensitivity of CT in localizing functioning islet cell tumors varies from 71% to 
82% because small tumors are more frequently missed. Small hyperattenuating islet cell 
tumors located in the pancreatic neck or body can be confused with adjacent vascular 
structures; multiplanar reconstruction is helpful in separating the lesion from surrounding 
vessels, thus improving diagnostic confidence. (Sheth, S., et al, 2002).   
 
 
Fig. 6. CT scan of malignant insulinoma (no contrast). Hypointense solid irregular mass of 2 
x 3 cm in the tail of the pancreatic gland. Hepatomegaly with multiple metastases, solid and 
hypointense, of different sizes, the bigger one of 5.5cm. 
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7.2.4 Magnetic resonance imaging  
Recent reports have suggested an important role for MRI in the
 
detection of pancreatic NET, in 
particular with the use of fast
 
spin echo and fat saturation techniques. MRI has presented 
excellent results, its sensitivity ranges from 85-95% in the detection of insulinomas (including 
those with less than 1.5 cm in diameter) and the determination of the presence of metastases.  
Using conventional sequences, small insulinomas usually have a low signal on T1-weighted 
sequences and a high signal on T2-weighted sequences. Some insulinomas containing 
fibrous tissue may show low signal intensity on both T1 and T2 weighted images.  
An improvement in MRI techniques is the use of diffusion weighted MRI. Fat suppressed
 
T 1 
weighted sequences have been reported to be particularly
 
useful in imaging pancreatic lesions, 
especially islet cell
 
tumours. The normal pancreas is
 
of relatively high signal intensity on fat 
saturated T 1 weighted
 
images. Islet cell tumors are of lower signal intensity than
 
normal 
pancreatic tissue. This increased contrast between tumors
 
and pancreas explains the greater 
detection rate with fat suppressed
 
T 1 weighted images. (Semelka, RC., et al, 2000) 
7.2.5 Angiography and arterial stimulation of the pancreas 
Although most insulinomas are small, they have been successfully detected by computed 
tomography and magnetic resonance imaging recently. However, preoperative localization 
of the insulinomas by arterial stimulation with venous sampling is crucial when they show 
atypical findings on these imaging modalities.  
That is, it is difficult to determine whether the tumor is benign or malignant, whether it is a 
nonfunctioning tumor accompanying an extra or undetectable pancreatic insulinoma, or 
whether it is one of the multiple insulinomas. Morphological imaging modalities do not 
reflect hormonal functions; however, the addition of angiography and arterial stimulation 
helps regionalize a tumor by verifying the hormonal function. This procedure enhances a 
more accurate surgical approach in clinical exploration and can prevent a possible 
resurgery. Thus, for atypical insulinomas, preoperative localization of insulinomas by 
angiography and arterial stimulation may be particularly important. 
Mesenteric angiography is a well established invasive technique in which pancreatic 
endocrine tumors appear as a well circumscribed blush, usually four to eight seconds after 
the contrast injection. The reported sensitivity for the detection of primary tumors ranges 
between 28 and 70 percent. The accuracy for diagnosing hepatic metastases is higher 
(sensitivity 62 to 78 percent). 
Arterial stimulation venous sampling involves selective injections into arteries supplying 
the pancreas of a stimulating secretagogue. Insulin production is measured in the pancreatic 
gland by a catheterization of the main arteries (superior mesenteric artery, gastroduodenal 
artery, hepatic artery and splenic artery). Insulin secretion is stimulated by an injection in 
each of these arteries of calcium (0.025 mEq/kg) diluted in a 5 mL injection. Plasma 
extractions are done at 0, 30, 60, 90 and 120 seconds after the injection. The test is considered 
positive if there is an increase of insulin two-fold greater the basal between 30 and 120 
seconds. This technique permits de location of the tumor in the portion of the pancreas 
which is irrigated by one of these arteries. 
Results with this technique are encouraging. One report evaluated 24 patients with proven 
hyperinsulinemia. Seven of these patients had negative imaging technique and in all of them 
calcium infusion permitted localization of the source of insulin secretion. Although helpful, 
angiography and arterial stimulation is an invasive and costly technique that should be 
reserved for atypical insulinomas or when nesidioblastosis is suspected. 
 
Hypoglycemia – Causes and Occurrences 
 
202 
Because of their rich vascular supply, insulinomas classically are hyperattenuating 
compared with the surrounding pancreatic parenchyma on contrast-enhanced CT. 
Capturing the vascular blush is essential for the diagnosis of small tumors, which often do 
not distort the contour of the pancreas. This is particularly true in the investigation of 
functioning insulinomas because these are often small, with 50% measuring less than 1.3 cm. 
The classic and most common enhancement pattern of islet cell tumors is that of a 
hyperattenuating lesion in the arterial and venous phases. Many small lesions enhance more 
prominently and thus are easier to detect in the arterial phase or become inconspicuous in the 
venous phase. In a series of 11 cases of functioning islet cell tumors reported by Van Hoe et al., 
most lesions were hyperattenuating and two were more conspicuous on arterial phase imaging. 
Helical CT is not only useful for the detection of the insulinoma but also in the staging of 
malignant insulinoma on dual-phase CT.  Three-dimensional CT reconstructions exquisitely 
show local extension and encasement of the major peripancreatic arteries and veins for 
surgical planning. The liver and regional lymph nodes are the most common sites for 
metastases. Like the primary tumor, liver metastases are hypervascular. Arterial phase 
images show the number and size of the hepatic lesions better than images acquired in the 
venous phase, particularly for small metastases. Spread to regional lymph nodes also is more 
conspicuous in the arterial phase. 
The reported sensitivity of CT in localizing functioning islet cell tumors varies from 71% to 
82% because small tumors are more frequently missed. Small hyperattenuating islet cell 
tumors located in the pancreatic neck or body can be confused with adjacent vascular 
structures; multiplanar reconstruction is helpful in separating the lesion from surrounding 
vessels, thus improving diagnostic confidence. (Sheth, S., et al, 2002).   
 
 
Fig. 6. CT scan of malignant insulinoma (no contrast). Hypointense solid irregular mass of 2 
x 3 cm in the tail of the pancreatic gland. Hepatomegaly with multiple metastases, solid and 
hypointense, of different sizes, the bigger one of 5.5cm. 
 
Pancreatic Beta Cell Tumors 
 
203 
7.2.4 Magnetic resonance imaging  
Recent reports have suggested an important role for MRI in the
 
detection of pancreatic NET, in 
particular with the use of fast
 
spin echo and fat saturation techniques. MRI has presented 
excellent results, its sensitivity ranges from 85-95% in the detection of insulinomas (including 
those with less than 1.5 cm in diameter) and the determination of the presence of metastases.  
Using conventional sequences, small insulinomas usually have a low signal on T1-weighted 
sequences and a high signal on T2-weighted sequences. Some insulinomas containing 
fibrous tissue may show low signal intensity on both T1 and T2 weighted images.  
An improvement in MRI techniques is the use of diffusion weighted MRI. Fat suppressed
 
T 1 
weighted sequences have been reported to be particularly
 
useful in imaging pancreatic lesions, 
especially islet cell
 
tumours. The normal pancreas is
 
of relatively high signal intensity on fat 
saturated T 1 weighted
 
images. Islet cell tumors are of lower signal intensity than
 
normal 
pancreatic tissue. This increased contrast between tumors
 
and pancreas explains the greater 
detection rate with fat suppressed
 
T 1 weighted images. (Semelka, RC., et al, 2000) 
7.2.5 Angiography and arterial stimulation of the pancreas 
Although most insulinomas are small, they have been successfully detected by computed 
tomography and magnetic resonance imaging recently. However, preoperative localization 
of the insulinomas by arterial stimulation with venous sampling is crucial when they show 
atypical findings on these imaging modalities.  
That is, it is difficult to determine whether the tumor is benign or malignant, whether it is a 
nonfunctioning tumor accompanying an extra or undetectable pancreatic insulinoma, or 
whether it is one of the multiple insulinomas. Morphological imaging modalities do not 
reflect hormonal functions; however, the addition of angiography and arterial stimulation 
helps regionalize a tumor by verifying the hormonal function. This procedure enhances a 
more accurate surgical approach in clinical exploration and can prevent a possible 
resurgery. Thus, for atypical insulinomas, preoperative localization of insulinomas by 
angiography and arterial stimulation may be particularly important. 
Mesenteric angiography is a well established invasive technique in which pancreatic 
endocrine tumors appear as a well circumscribed blush, usually four to eight seconds after 
the contrast injection. The reported sensitivity for the detection of primary tumors ranges 
between 28 and 70 percent. The accuracy for diagnosing hepatic metastases is higher 
(sensitivity 62 to 78 percent). 
Arterial stimulation venous sampling involves selective injections into arteries supplying 
the pancreas of a stimulating secretagogue. Insulin production is measured in the pancreatic 
gland by a catheterization of the main arteries (superior mesenteric artery, gastroduodenal 
artery, hepatic artery and splenic artery). Insulin secretion is stimulated by an injection in 
each of these arteries of calcium (0.025 mEq/kg) diluted in a 5 mL injection. Plasma 
extractions are done at 0, 30, 60, 90 and 120 seconds after the injection. The test is considered 
positive if there is an increase of insulin two-fold greater the basal between 30 and 120 
seconds. This technique permits de location of the tumor in the portion of the pancreas 
which is irrigated by one of these arteries. 
Results with this technique are encouraging. One report evaluated 24 patients with proven 
hyperinsulinemia. Seven of these patients had negative imaging technique and in all of them 
calcium infusion permitted localization of the source of insulin secretion. Although helpful, 
angiography and arterial stimulation is an invasive and costly technique that should be 
reserved for atypical insulinomas or when nesidioblastosis is suspected. 
 
Hypoglycemia – Causes and Occurrences 
 
204 
7.2.6 Scintigraphy with octeotride  
The absence of somatostatin receptors in half of insulinomas and the lack of spatial 




imaging with Octreoscan has been introduced in an attempt to
 
improve topographic assessment of insulinomas. The results were
 
disappointing, since 
Octreoscan scintigraphy with planar imaging
 
led to detection of only 20–50% of insulinomas  
7.2.7 Positron emission tomography PET 
The results of 18-fluordeoxyglucose (18-FDG) PET imaging for insulinomas are not very 
promising, maybe due to the low proliferative potential of these tumor cells. Positive results 
have been shown using 11 C-5-hydroxi-L-tryptophan, 18-3, 4-Dihydroxy-6-fluoro-DL-
phenylalanine and 67-Ga-DOTA-DPhe 1-Tyr 3-octeotride due to selective uptake in tumor 
tissue compared to surrounding tissue. These techniques produce very good tumor visibility 
and can be used for the examination of both the thorax and abdomen. However, the lack of 
general availability of PET scanning and high cost, limits its use. 
7.2.8 PET/TC 
The 18-fluorine-18-fluoro-2-deoxyglucose Positron Emission Tomography coupled with 
computed tomography is a non invasive exploration. Several studies have shown that PET-
CT has superior efficacy over conventional imaging techniques in distinguishing a benign 
pancreatic tumor from a malignant one. It contributes to the diagnosis of cancer in patients 
with a doubtful mass, much more in case of chronic pancreatitis. 
7.2.9 Intraoperative localization techniques 
Intraoperative ultrasonography allows high resolution examination of the pancreas. When 
combined with palpation of the organ, the sensitivity for tumor detection ranges 83 to 100 
percent. Intraoperative transillumination has equivalent efficacy (sensitivity of 83 percent). 
Neither of these tests should replace preoperative imaging; they are used as adjuncts to 
intraoperative palpation. (Figure 7) 
Diagnostic algorithm for insulinomas 
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8. Staging of insulinoma tumors 
After the performance of imaging techniques, insulinomas which are the most frequent 
neuroendocrine pancreatic tumors, must be classified.  The classification proposed by AJCC 
(American Joint Committee on Cancer) ENETS (European Neuroendocrine Tumor Society) 
for neuroendocrine pancreatic tumors is the following (Table 4): 
 
 
Table 4. Staging of TNEs of the pancreas according to AJCC and ENETs 
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The WHO has an alternative classification and staging for pancreatic neuroendocrine 
tumors, which considers also certain anatomopathological findings. The proliferative rate 
has been repeatedly shown to provide significant prognostic infromation for NETs. The 
proliferatice rate can be assessed as the number of mitosis per unit area of tumor (usually 
expressed as mitosis per 10 high power microscopic fields or 2mm) or as the percentage of 
neoplastic cells immunolabeling for the proliferation marker Ki-67.  The use between mitotic 
count and Ki-67 is controversial. When the amount of tumor tissue is limited, it may not be 
able to perform an accurate mitotic count. In these cases Ki 67 staining provides a more 
accurate assessment of proliferative rate, and it is particularly helpful to separate well-
differentiated tumors from poorly differentiated neuroendocrine carcinomas, which usually 
have dramatically different Ki 67 labelling rates. However, when adequate tissue is present 
to perform an accurate mitotic count, there are no data to demonstrate that the Ki67 labeling 
index adds important information, and in some cases, the two measures of proliferative rate 















1 Benign - Good differentiation - < 2 <2 <2 
1 Undefined - Good differentiation +/- >2 2-5 <2 
2 Malignancy low grade + 
Good 
differentiation + >3 5-15 2-10 
3 Malignancy high grade + 
Poor 
differentiation + whatever >15 >10 
Table 5. WHO staging for pancreatic neuroendocrine tumors 
9. Medical management of insulinoma related to hormone hypersecretion 
Benign insulinomas, as well as malignant, usually produce high concentrations of insulin 
secretion developing the well-known hypoglycemic syndrome. Independently of their 
surgical possibilities, hypoglycemia must be controlled. 
With insulinomas, dietary modification with frequent small feedings may help control 
hypoglycemia. Sometimes endovenous glucose infusion may be needed to maintain 
acceptable glucose levels usually in the preopreatory or when it is a high secreting 
malignant insulinoma. Glucose infusion must be done with care as patients may develop in 
rare cases acidosis secondary to large volumes of glucose infusion (Ramos,A., et al., 2010). 
When diet modification does not control the symptoms, pharmacological treatment must be 
used. There are several pharmacological treatments the most frequently used is diazoxide 
followed by somatostatin analogues. (Hirshberg, B., et al 2005) 
9.1 Diazoxide 
Administration of diazoxide (200-600 mg/day) successfully controls hypoglycemia in 50 to 
60 % of the patients. The most common side effect reported with diazoxide is hirsutism as 
well as nausea at higher dose administration. Also, diazoxide frequently leads to fluid 
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retention requiring diuretics such as triclormetiazide which not only counteracts this side-
effect but has also a hyperglycemic effect. 
Diazoxide enables the control of the hypoglycemia by two mechanisms: it inhibits insulin 
secretion by beta-cell pancreatic cells and it has a peripheral effect stimulating 
glucogenolisis. Treatment with diazoxide has proven to be efficient, including cases with 
nesidioblastosis in which surgery seemed to be a very radical option. In advanced metastatic 
disease in which surgery is not an option, diazoxide has demonstrated in some studies to be 
more effective in the symptomatic control at short-time. 
9.2 Calcium antagonists and others 
Calcium antagonists may also be useful controlling hypoglycemia because they inhibit 
insulin secretion by the blockage of the calcium receptor. There are some works on 
advanced metastatic disease that describe a better symptomatic control with verapamil 
added to the long-acting somatostatin analogues. On the other hand, the data of their use is 
limited, therefore limiting their use to cases with advanced disease in which other 
treatments are uneffective. 
Other options to control hypoglycemia may be beta blockers, that can be useful, although 
they might be used with precaution as they can mask hypoglycemia symptoms. Other 
pharmacological treatments include phenytoin or glucagon. Glucocorticoids increase 
gluconeogenesis and create insulin resistance, so they can also be useful. The recommended 
dose is of 1mg/kg of prednisone. 
9.3 Somatostatin analogues 
Long-acting somatostatin analogues have proved to be a novel and very useful treatment in 
the control of hypoglycemia.  
Lately the presence of somatostatin in pancreas islets and other areas of the digestive tract, 
as well as its inhibitory effect of the secretion of other hormones, such as insulin, its role as 
neurotransmisor or neuromodulator and cytostatic effect have been recognized. 
Somatostatin was therefore considered as a possible treatment for those endocrinological 
syndromes caused by excess hormone production. However, human somatostatin has a 
very short half-life effect, which made the development of what today we know as the long-
acting somatostatin analogues. 
Their main indication is in the preoperatory phase, or in cases of recurrence and malignancy. 
Also, although it is not their main indication, cases of complete resolution in benign 
insulinomas have been reported. These analogues function predominantly over subtype 2 
somatostatin receptor and less over subtype 5, controlling therefore about 50% of the 
hypoglycemic events caused by insulinomas. The somatostatin subtype 5 receptor has been 
involved in insulin secretion and seems to be related with a more aggressive tumoral behavior.  
New somatostatin analogues are being developed with a greater affinity to this and other 
receptors such as BIM23244 and SOM230.An important aspect before starting the treatment of 
an insulinoma with somatostatin analogues is to analyze the possible efficacy by the 
performance of an Octreoscan or by demonstrating an improvement on glucose and insulin 
levels with short-acting somatostatin analogues. This is important because their use in tumors 
which do not  express subtype 2 may worse the hypoglycemia by the inhibition of the 
contrarregulatory response of glucagon and growth hormone without affecting insulin 
secretion. Another possible problem when long-acting somatostatin analogues are used long-
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term, is a desensibilization of the tumor by a decrease in the expression of the 
somatostatinreceptors. Initially this can be overwhelmed by increasing the dose of the 
analogue or decreasing the interval administration, but can cause at the end a therapeutic fail.  
9.4 New agents to control hypoglycemia 
Recent studies in small numbers of patients show that mTOR inhibitors, such as rapamycin 
or everolimus, may control hypoglycemia in patients with metastasic insulinomas.  
Everolimus is an orally derivative of rapamycin that inhibits Ser/Thyrosine kinase mTOR. 
The PI3k/Akt/mTOR pathway has an important role in pancreatic cancer biology. It has 
demonstrated to have an antitumor activity, but its effects on pancreatic beta cells remains 
unclear. Data suggest that functional insulin receptors are present on beta cells and mediate 
insulin stimulated insulin production and release and that mTOR inhibition downstream of 
insulin receptors may decrease insulin production and release. It is also possible that 
everolimus induces insulin resistance peripherically. 
Recent case series have reported malignant insulinomas with severe hypoglycemic 
syndrome who were able to cease, or significantly reduce symptoms after the introduction 
of everolimus.  
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UNCONTROLLED HYPOGLYCEMIA 
 
DRUG CLASS SYMPTOM CONTROL ADVERSE EFFECTS 
Diazoxide Alpha adrenergic agonist 






















Prednisone Glucocorticoids unknown Cushingsyndrome 
Glucagon Glucagon palliation risk of rebound hypoglycemia 
Table 6. Medical Therapy for Uncontrolled hypoglycemia 
10. Surgical treatment of benign insulinoma or primary tumor  
All experts agree that surgical resection of an insulinoma either benign or malignant should 
be considered whenever possible. Local resection or enucleation of the insulinoma is 
generally recommended, and more advanced surgical resections such as Whipple resections 
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are not routinely recommended and should be considered only in carefully selected 
patients. (Figure 7 and 8) 
Generally pancreatic neuroendocrine tumors are surgically approached by a laparotomy to 
allow an extensive exploration of the entire abdomen and search for lymph node metastases. 
Insulinomas in non-MEN 1 with benign characteristics are increasingly being treated with a 
laparoscopic approach; in 85% of patients, there are single tumors, they are invariably 
intrapancreatic, and if they can be localized preoperatively, they can be cured in 70% to 






Fig. 7. Bening insulinoma. .Upper image:. Intraoperatory ultrasonography. .Lower image:. 
Enucleation of the same tumoral mass. 
When clinical examinations including angiography stimulation suggest nesidioblastosis, a 
partial pancreatectomy is usually performed. Even if a frozen biopsy confirms the diagnosis 
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of nesidioblastosis, the extent of pancreatic resection remains questionable. A distal 
pancreatectomy which can control the symptoms of the majority of patients, is well 
tolerated, and does not induce endocrine or exocrine insufficiency. Recovery after a partial 
pancreatectomy can remove enough abnormal proliferative tissue to achieve 
normoglycemia. However, some investigators recommend an initial near-total 
pancreatectomy. Such extensive resections lead to an increased risk of post-surgical diabetes 
and pancreatic insufficiency. It seems that the best recommendation is a 70%-80% 
pancreatectomy, administration of diazoxide when hypoglycemia persists post-operatively, 





















Distal pancreatectomy (spleen 
preserving)  
Fig. 8. Therapeutical algorithm for benign insulinoma or primary located disease 
11. Additional management in advanced insulinomas 
Malignant insulinomas, although unfrequent, may require multiple managements involving 
a mutidisciplinar follow-up. Firstly hypoglycemic syndrome must be adequately controlled. 
Secondly, surgical approach must be used if possible, to control metastasic and primary 
disease. When curative surgery is not possible, usually due to metastasic disease, debulking 
surgery is often a beneficial treatment for local (intestinal obstructions, etc.) and endocrine 
symptoms. On the other hand, when the disease is extended and surgical approach is not 
possible, other therapeutic options can be used depending on the organ affected.(Figure 9 
and 10). 
11.1 Surgical approach of metastasic disease 
Hepatic resection is indicated for the treatment of metastasic liver disease in the absence of 
diffuse bilobar involvement, compromised liver function or extensive extrahepatic 
metastases. 
However, the role of cytoreductive surgery in these cases is controversial. Whereas 
numerous uncontrolled studies provide evidence that surgical resection may improve 
symptom control and perhaps extend survival, neither result is proven at the present. 
Nevertheless, because of the low efficacies of other tumor treatments, most conclude that 
surgical resection should be attempted in any patient with a malignant insulinoma if it is 
thought that at least 90% of the visible tumor could be removed. Unfortunately, surgical 
resection of at least 90% of all visible tumor is possible only in 5% to 15% of patients with 
insulinoma and metastasic disease. 
 






Fig. 9. Metastasic disease of insulinoma.Upper image: single hepatic metastases. Lower 
image: multiple hepatic metastases. 
Transplantation for metastasic disease has been proposed for the occasional, younger 
patient with a metastasic insulinoma that is unresectable and limited to the liver, especially 
if it is symptomatic and cannot be controlled by other available therapies, that liver 
transplantation remains an option that should be considered.  
11.2 Other invasive therapies 
Hepatic artery embolization is recommended as a palliative option in patients with hepatic 
metastases who are not candidates for surgical resection, have an otherwise preserved 
performance status, have disease primarily confined to the liver, and have a patent portal 
vein. The response rates associated with embolizations, as measured either by decrease in 
hormonal secretion or by radiographic regression are generally greater than 50%. Improved 
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techniques have, in recent years, reduced the incidence complications related to 
embolization, making embolization an important and generally safe treatment. A number of 
techniques can be used and include bland embolization, chemoembolization, embolization 
with chemotherapy and embolization using radioisotopes. These techniques should be 
considered especially for a patient with a functional secreting insulinoma in which the 
hormone excess cannot be controlled by other methods. (O’Toole, D., et al 2005) 
Other approaches to the treatment of hepatic metastases in a patient with malignant 
insulinoma include the use of radiofrequency and crioablation, either alone or in conjuction 
with cytoreductive surgery. These approaches can be performed using a percutaneous or 
laparoscopic approach. Although they seem to be less morbid than either hepatic resection 
or hepatic artery embolization, the clinical benefit of these approaches in patients with 
asymptomatic, small volume disease has not been clearly established. Similarly, these 
approaches may not be applicable in patients with large-volume hepatic metastases. 
Ablative techniques should therefore be considered as a treatment option only in carefully 
selected patients. (Steinmuller, T., et al 2008) 
Peptide receptor radionuclide therapy can be an option in those pancreatic tumors which 
have an overexpression of somatostatin receptors. This expression is not frequent within 
insulinomas.  
11.3 Radiotherapy 
Experience with external beam radiotherapy in the management if islet tumor cells is 
limited. Although pancreatic neuroendocrine carcinomas were previously considered to be 
radioresistant, data from published case reports and small case series suggest that 
radiotherapy can produce high rates of symptom palliation and freedom from local 
progression in patients who are not candidates for surgical resection. There are no specifical 
data on the rate of symptom control in patients with symptomatic insulinomas.  
However, radiotherapy with or without biphosphonates has proven to be highly useful in 
patients with painful bony metastases. 
11.4 Traditional chemotherapeutic agents  
A number of chemotherapeutic agents either alone or in combination have been reported to 
have sufficient antitumor activity to be clinically useful. Systemic chemotherapy is 
recommended for patients with unresectable liver or lung metastases. Trials using 
chemotherapeutic drugs including doxorubicin, streptoxocin, 5-FU, temozolamide, and 
dacarbazine have established cytotoxic effects in pancreatic tumors. The combination of 
doxorubicin and streptozocin has a reported 69% objective response rate in the treatment of 
patients with advances islet cell carcinoma. A retrospective review from the MD Anderson 
Center reported an objective response rate of 39% with the combination of 5FU, doxorubicin 
and streptozocin. Fine et al have reported on the synergy between capecitabine and 
temozolamide for the induction of apoptosis in neuroendocrine cell lines. Recently, an oral 
regimen using temozolamide and thalidomide was found to be useful in a number of 
neuroendocrine malignancies. (Kouvaraki, M., et al. 2004) 
11.5 Newer agents 
11.5.1 Biotherapy: Somatostatin analogues and interferon 
Somatostatin analogues have a double purpose in the treatment of insulinomas, firstly they 
can control hypoglycemia and secondly they are used in those patients with advanced 
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disease for their possible effect on tumor growth. The clinical benefit of the direct antineoplasic 
effects of somatostatin analogues either with or without interferon remains uncertain, 
although recent studies suggest they have a cytostatic effect in 40 to 70% of patients and cause 
a tumor reduction of less than 15% with both agents. This tumoristatic effect can be long 
lasting especially in those with low proliferative rate. (Plockinger, U., et al. 2007) 
11.5.2 Anti-angiogenic treatments 
Recent studies using vascular endothelial growth factor (VEGF) pathway inhibitors such as 
bevacizumab have suggested that these agents may have a modest antitumor activity in 
patients with malignant pancreatic tumors. Actually there are several active studies 
combining chemotherapy and bevacizumab in adavanced pancreatic NETs. However the 
recruited patients are small, and for the moment there are no specifical results for malignant 
insulinomas.  
Sunitinib inhibits celular signaling by targeting multiple receptor tyrosine kinases. These 
include all receptors for platelet-derived growth factor (PDGF-Rs) and VEGF receptors, which 
play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous 
inhibition of these targets therefore leads to both reduced tumor vascularization and cancer 
cell death, and ultimately tumor shrinkage. In phase 1 and 2 trials, sunitinib showed antitumor 
activity in patients with pancreatic neuroendocrine tumors. A phase 3 has been recently 
conducted in well-differentiated pancretic neuroendocrine tumors in which the results were 
promising causing a discontinuation of the study. Median progression-free survival was 11.4 
months in the sunitinib group as compared with 5.5 months in the placebo group (hazard ratio 
for progression or death, 0.42; 95% confidence interval [CI], 0.26 to 0.66; P<0.001). There are no  
results for the moment specifical in malignant insulinomas. (Raymond, E., et al 2011) 
11.5.3 Inhibiton of m-TOR 
Everolimus, an inhibitor of mTOR has also being study recently not only from the 
antihipoglycemic but also from the antitumoral point of view. Its efficacy has been studied 
combined with somatostatin analogues in neuroendocrine tumors. Considering 
insulinomas, the mean survival without progression was estimated in 63 weeks. (Yao et al., 
2008). Considering other studies with pancreatic NETs in general, everolimus (at a dose of 
10 mg/day) caused a 65% reduction in the estimated risk of progression (progression-free 
survival of 11 months with everolimus versus 4.6 months with placebo, p< 0.001). 
Confirmatory studies of these promising results are being performed. 
12. Posttreatment surveillance 
After the complete removal of the tumor, a patient with a benign insulinoma is cured, but 
periodic follow-up is necessary in those with metastasic insulinoma or multiple endocrine 
neoplasia type 1 (MEN1). 
12.1 MEN 1 
All patients with MEN 1 syndrome should be followed with every 3-6 months during the 
first year after resection with physical examination, tumoral markers and calcium levels as 
appropriate and with imaging studies such as CT/MRI. The follow-up tests must be 
repeated every 6 months, 1-3 years after surgery and annually thereafter.  
All close family members of patients with MEN 1 should be genetically counseled and 
genetic testing should be considered. 
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techniques have, in recent years, reduced the incidence complications related to 
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12.2 Malignant insulinoma 
There are no evidence-based guidelines for follow-up after resection of a malignant 
insulinoma. Consensus derived guidelines from the National Cancer Network following 
treatment of an islet cell tumor include the following: 
- Three and six months postresection: history and physical examination, tumor markers 
(insulin) and CT/MRI. 
- Long-term: history and physical examination with tumor markers every 6-12 months 
for years 1 to 3. Imaging studies are recommended only if clinically indicated. 
13. Conclusions 
Pancreatic beta cell tumors are a relatively rare cause of hypoglycemia. The suspicion of a 
probable insulinoma by the physician is important as the diagnosis of these tumors may be 
delayed up to 1-2 years and may be confused with other diseases such as neurological or 
psychiatric. 
The diagnostic suspicion of an insulinoma is based on symptoms, and laboratory techniques 
usually confirm the diagnosis. The treatment, on the other hand, is usually surgery of the 
tumoral mass as complete as possible, including the primary tumor and metastases if 
present and possible. Imaging of the primary tumor location and the extent of the disease is 
needed for all phases of management of insulinomas, especially if they are malignant. 
The development of new treatments based upon a better knowledge of the molecular 
pathways involved in tumorigenesis make the therapeutic future of these tumors promising, 
leading to a better prognosis in those with a more aggressive behavior. 
On the other hand, the low incidence of these tumors makes especially important their 
management in specialized centers with experience and modern imaging and diagnostic 
techniques. 
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1. Introduction  
Swine production is continuously improving the quality of its products although of your 
living together with carcass fat content. The strategy of industry is offers natural products as 
special cuts semi prepared food. Others questions are the swine importance for Human 
medicine is related the products that are makes from swine used in Humans. The great 
variety of products originated of swine and used in Human medicine and mainly the use of 
organs as skin, cardiac valves for transplant shall to be interpreted as result of similarly that 
there is between the organisms: human and swine. 
The pancreas swine is an organ that itself get insulin. This hormone is essentials for 
diabetics. It allows the entry of glucose in the cells and also decreases its fee in the blood 
avoiding that way that the glucose levels becomes fatal. 
Other utility of pancreas of swine for Human is in the supply of pancreatic islets for 
implants into diabetic peoples that haven´t. These implants will let the diabetics free of 
injections of insulin for many years. Actually the insulin is also made by genetic engineering 
through bacterial multiplication. 
The pituitary gland of swine is used for get of ACTH. This hormone is used in human 
medicine for treatment of arthritis and inflammatory diseases that causes great suffering for 
many peoples in worldwide. 
The thyroid of swine is used for get medicaments that will be used by peoples that have 
thyroid glands with lower actives.  
The skin of swine may to be used temporally by Human in cases of burn that causes great 
discontinuity of your skin.  
The gut mucosa of swine is used for obtaining of a substance called Heparin. This substance 
has function of blood clotting and is applied in Human medicine in hemorrhagic cases. 
The heart of swine is used for get the cardiac valves that will may be transplanted in adults 
and also into children. The swine used for provide these valves weight of 16 to 25 Kg. 
Theses valves are withdraw of heart and conserved in the chemical preparation and they 
can be preserved for five years. The cardiac valves of Human can be replaced by mechanic 
valves made with artificial materials. The swine valves however have advantage on this 
mechanics on this account are less rejected by organism and have similar structure of valves 
human and also resist more against infections.   
Modified genetically swine can produce Human hemoglobin (blood pigment that takes the 
oxygen for the all the body). In current researchers were injected three embryos of swine 
with copy of two genes responsible for producing of human hemoglobin. The technique 
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made with that 15% of hemoglobin found was of human type. The two hemoglobins may be 
after separate by difference of electric charge. This product can to be stocked by months to 
the contrary of normal blood that itself conserve just for one week.  
By similarity among swine and Human is being possible the realization of all events cited 
above. Also by similarity among both our study will has as focus the monitoring of some 
biochemical parameters into an experimental infection caused by Leptospira interrogans wolffi 
sorovar in eight swine. The biochemical parameters were tracked during 36 days. The main 
parameter analyzed was the glucose fee during all occurrence of septicemia. This chapter 
also will discuss the relation of occurrence of hypoglycemia caused by the septicemia in pigs 
that collaborates with critical condition of animal leading it the die. 
2. Some drawbacks of swine 
The swine when are produced without hygienic conditions can represent a high risk for 
several diseases. The medical science considers that swine can to be host of many parasites and 
potential diseases. The meat of swine may content dangers toxins, vermin and latent diseases. 
Many theses infestations are found also in others animals, but some veterinary said that swine 
are more predisposed that the others animals, on this account are opportunist and highly 
omnivores with extensive feeding and including virtually any type of food comestible.   
The swine meat contains amount of fat similar with others meat as birds and bovine and 
also it is responsible by nourish million of people in worldwide. Other advantage of 
consuming of swine meat is the great amount of protein for that the swine meat has both an 
economic and of public health. It is the meat further consumed in the worldwide allowed 
survival of many peoples. 
However the swine meat also may forward many diseases as Leptospira interrogans wolfii 
sorovar. 
The septicemia is an infection in the bloodstream. It appears when an infection is occurring 
in the people; this may be into the lungs, abdomen, and urinary routes or in the skin. The 
infections may also occur after a surgery in an infected area or in a body part that is 
colonized by many bacteria as for example the gut. 
During the septicemia occurrence are found three distinct processes hence interconnected 
that occurs together as infectious focus hemodynamic changes and inflammatory answers 
local and generalized. The treatment of sick with septicemia is made with antibiotic and 
drugs that interfere in cardiac changes without intervene in inflammatory answers can be 
this reason of right mortality of patients with septic shock. Moreover still not has been 
established contribution of each inflammatory mediator in lethally resultant of septic shock. 
3. Sepsis pathophysiology  
The sepsis is defined as systemic inflammatory answers syndrome caused mainly by 
bacterial infections although also may be caused by fungus helminthes and virus. The 
infections caused by gram negatives bacteria are the further frequent, despite of last decade 
have been an increased of cases of sepsis due gram positive bacteria. The definition of sepsis 
included sepsis and also similar diseases from of causes noninfectious as trauma ischemia, 
burning, pancreatitis and hemorrhage. 
The inflammatory response represents an important component of sepsis because elements 
of the response drive the physiological changes that become manifest as the systemic 
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inflammatory response syndrome. The inflammatory response eliminates the invading 
microorganism without to cause damage to issues, organs or other systems. 
Abnormalities in the coagulation system resulting from systemic diseases which cause local 
disturbances in homeostasis and the thrombotic potential of cancer patients have been 
described since the time of Virchow. 
Virchow´s classic triad consists of changes in coagulability endothelial cell injury and 
abnormal blood flow to vital organs. In septic patients, all three classic changes are present 
and culminate in reduced blood flow to vital organs. 
Septic patients frequently have poor tissue perfusion and addition to inappropriate use of 
oxygen with resulting cytopathic hypoxia. The coagulation abnormalities in septic patients 
are profound and have led to a successful; Food and Drug Administration approved 
therapeutic intervention activated protein C. 
The sepsis occurs when patients present hyperthermia or hypothermia, tachycardia, total 
white cell blood number upper of 12.000/mm3 or below of 4.000/mm3 or with further of 
10% of immature forms. A lesion of sepsis that may arise is due the dysfunction of 
syndrome of multiple organs that affects approximately 30% of patients with sepsis while 
almost all develop dysfunction of an organ. The septic shock is characterized by high 
hemodynamic changes.   
The clinical manifestations of sepsis are fever hypercoagulation and periferic hypotension 
caused by release of inflammatory mediators by immune and endothelial cells. The 
triggering factors cellular activation and of cascade of events of plasma are components of 
cell wall of this organisms lipoteichoic acid and peptidoglycan derivatives of gram positive 
bacterial or the lipopolysaccharide of gram negative bacterial. The lipopolysaccharide (LPS) 
is a molecule composed by hydrophilic polysaccharide chain divided in O antigen and core 
lipid A portion. The lipid A is a conserved region of toxin being responsible by your toxicity. 
The LPS importance in the triggering of sepsis was demonstrated after your administration 
in healthy Humans propagation of hemodynamic changes in patients with sepsis in 
experimental models. 
3.1 Hyperinflammatory response 
The sepsis is directly related with the high production of pro-inflammatory molecules. This 
problem have as result a rather simple when the inflammation is excessive. Usually this occurs 
in three cases. First, in septic patients with increased levels of specific mediators such as tumor 
necrosis factor (TNF) are at increased risk for death. Second, injection of TNF molecules at 
experimental animals results in widespread inflammatory changes. Third, experimental 
animals injected with a lethal doses of endotoxin elevated levels of the same mediators. The 
inhibition of these specific mediators improves survival in endotoxin shock models. 
Whereas under normal conditions the endothelium exhibits antithrombotic properties by 
expressing tissue factor pathway inhibitors thrombomodulin surface releasing tissue factor 
during pathogenesis sepsis.Endothelial cells respond to LPS through toll like receptor 
followed by the release of pro-inflammatory cytokines such as interleukin - 6 (IL-6) and 
monocyte chemoattractant protein-1 and increased expression of adhesion molecules 
including intracellular adhesion molecule and vascular cell adhesion molecule. 
The expression levels of cytokines and cell adhesion molecules are regulated by factor in 
inflammation. 
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4. Experimental models 
4.1 Intravenous administration of live bacteria or bacterial components  
Intravenous administration of LPS (endotoxemia) or of bacterial as E. coli  widely used for 
sepsis study, as for example, the hemodynamic changes and cardiac, decrease of urine 
output, reduction of tissue perfusion, hyporesponsiveness vasoconstrictor agents, 
disseminated coagulation and production of large amount of cytokines in the circulation. 
Moreover is a practice model and reproducible in many species as mouse, rabbit, dogs, 
primate and including Humans. However the incidence of sepsis and septic shock in the 
clinic is due the entry of large amounts of LPS or of bacteria in the circulation same when 
amounts this bacterium is small. This puts in doubt effectiveness of this model. 
4.2 Intraperitoenal administration of live bacteria or microbial components 
This model also is very used for study of sepsis for reproduce of signs observed in diseases 
presented reproducibility as observed in endotoxemia model. Furthermore the administration 
of LPS or bacterial in the peritoneal cavity itself close of sepsis situation observed in the clinic 
because the process itself start from infectious focus or of dissemination of LPS administrated 
in the peritoneal cavity and not in the circulation. Even so, the start of process occurs rapidly 
and not gradually as happens in the majorly of clinic cases.  
4.3 Gut injury model with consecutive release of microbial flora  
The injury model with release microbial flora is the further similar to the sepsis situation in 
Humans, arising of traumas with perforations of gut, colitis or postoperative peritonitis. In 
this model after perforation of intestinal wall occurs the gradual liberation of contents 
causing peritonitis that may to evolve for a sepsis and septic shock. 
Although this model is near the clinical and for that to be model further interesting for a 
study of sepsis the majority of studies in experimental sepsis is based into models where the 
bacterial or the LPS are administrated by IV or IP. The literature data shown that the 
pathogeneses of sepsis caused by LPS or bacterial IV differs those induced by an infectious 
focus as happens into peritonitis. The difference of results these models is due the amount of 
stimulus to the local and also administration form inducing the distinct kinetic of liberation 
of inflammatory mediators. 
The biological activities of endotoxin and exotoxin are due of active of serum systems of 
endothelial cells and also leucocytes. Consequently the this infectious process occurs the 
syntheses or release of endogen mediators as cytokines, radioactive oxygen of nitrogen and 
lipid mediators being the activation of inflammatory cells the predominant factor for the 
development of sepsis. 
The introduction of an object as an intravenous catheter, a urinary catheter or drainage-tube 
also may cause septicemia. The probability of septicemia increases with the time during the 
period that the object remains placed. This situation usually occurs between the people 
drugs dependents. 
4.4 Relationship among hypoglycemia and septicemia  
In septicemia the homeostasis finds itself threatened by invaders microorganisms. The body 
reacts to the challenge establishing a complex response: first prioritizing the supply of 
energy for vital organs, second, stimulating immune system and after stimulating the return 
of homeostasis.  
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When an infection occurs the cells need of glucose to synthesize defense molecules and also 
increases your metabolism in result of all changes physiological and morphological caused 
by the diseases. This result in a hypoglycemia by increase of consume of glucose by tissues. 
In majority of domestic animals during a septicemia occurs a hypoglycemia. This 
hypoglycemia caused by septicemia increases much the severity of diseases and also is the 
great responsible by high mortality in these situations. 
Changes of hepatic gluconeogenesis and a depletion in glycogen content at liver is 
responsible by changes of glucose homeostasis this occurs by metabolic hallmarks in shock 
and sepsis. The shock and sepsis-induced glucose dyshomeostasis is characterized by an 
initial hyperglycemia followed by a progressive hypoglycemia. 
The depletion in hepatic glycogen content following endotoxin administration is associated 
with an increase in glycogen phosphorylase coupled with a decrease in glycogen synthase 
activities. 
The endotoxin-induced changes in glucose metabolism are augmented by the in vivo 
treatment of animals with protein kinase C (PKC) activator, PMA, while they are 
antagonized by PKC inhibitors, H7 and polymyxin B. The PKC plays a pivotal role in the 
pathogenesis of altered hepatic glucose homeostasis in shock and sepsis. Since the available 
information regarding the involvement of PKC in glucoregulatory disturbances in shock 
and sepsis derived mainly from the use of activators or inhibitors of PKC. 
Previous studies demonstrated that cystolic PKC activity was inactivated during late phase of 
sepsis in rat liver. During the sepsis, the CLP-induced septic rat model used exhibited two 
metabolically distinct phases: an initial hyperglycemic and a subsequent hypoglycemic phase.  
The finding some authors showed that cytosolic PKC activity was inactivated during late 
stage of sepsis may have a pathophysiological significance in contributing to the 
development of hypoglycemia during late phase of sepsis. 
The kinetic analysis of the data showed by some authors indicated that the Vmax for PM 
Ca2+ pump was decreased by 42% while the Km value for Ca2+ remained unaffected.  
The similarity in the patterns of change in the kinetics between the PKC-mediated 
phosphorylation of PM Ca2+- ATPase and the sepsis-induced impairment of PM Ca2+ 
transport  strongly suggests that the impairment in Ca2+ transport by rat liver PM during 
late sepsis is a result of inactivation of PKC. Thus, a decrease in cytosolic PKC activity, as 
reported in this study, would impair PM Ca2+  transport, impede Ca2+ efflux, and hence 
elevating intracellular Ca2+ in hepatocytes during late phase of sepsis. 
5. Hypoglycemia  
The hypoglycemia is a disorder where the glucose serum concentration finds itself usually 
low. 
Usually the organism keeps the serum glucose concentration in a range of 70 to 110 
mL/deciliter of blood. In hypoglycemia the glucose concentration remains low. This results 
in a malfunction of brain that is sensitive the low glucose serum concentration because the 
glucose is the main energetic source of brain. It reacts through of nervous system and 
stimulates the adrenal glands to release epinephrine. This hormone stimulates the liver to 
release glucose for adjust the glucose concentration into the blood. When the concentration 
becomes very low the brain function may be damaged. 
The hypoglycemia has several different causes between them the excessive secretion of 
insulin by pancreas an excessive dose of drugs for reduce the glucose serum concentration, 
an abnormality in the pituitary or of adrenal or an alteration of carbohydrate storage or into 
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4. Experimental models 
4.1 Intravenous administration of live bacteria or bacterial components  
Intravenous administration of LPS (endotoxemia) or of bacterial as E. coli  widely used for 
sepsis study, as for example, the hemodynamic changes and cardiac, decrease of urine 
output, reduction of tissue perfusion, hyporesponsiveness vasoconstrictor agents, 
disseminated coagulation and production of large amount of cytokines in the circulation. 
Moreover is a practice model and reproducible in many species as mouse, rabbit, dogs, 
primate and including Humans. However the incidence of sepsis and septic shock in the 
clinic is due the entry of large amounts of LPS or of bacteria in the circulation same when 
amounts this bacterium is small. This puts in doubt effectiveness of this model. 
4.2 Intraperitoenal administration of live bacteria or microbial components 
This model also is very used for study of sepsis for reproduce of signs observed in diseases 
presented reproducibility as observed in endotoxemia model. Furthermore the administration 
of LPS or bacterial in the peritoneal cavity itself close of sepsis situation observed in the clinic 
because the process itself start from infectious focus or of dissemination of LPS administrated 
in the peritoneal cavity and not in the circulation. Even so, the start of process occurs rapidly 
and not gradually as happens in the majorly of clinic cases.  
4.3 Gut injury model with consecutive release of microbial flora  
The injury model with release microbial flora is the further similar to the sepsis situation in 
Humans, arising of traumas with perforations of gut, colitis or postoperative peritonitis. In 
this model after perforation of intestinal wall occurs the gradual liberation of contents 
causing peritonitis that may to evolve for a sepsis and septic shock. 
Although this model is near the clinical and for that to be model further interesting for a 
study of sepsis the majority of studies in experimental sepsis is based into models where the 
bacterial or the LPS are administrated by IV or IP. The literature data shown that the 
pathogeneses of sepsis caused by LPS or bacterial IV differs those induced by an infectious 
focus as happens into peritonitis. The difference of results these models is due the amount of 
stimulus to the local and also administration form inducing the distinct kinetic of liberation 
of inflammatory mediators. 
The biological activities of endotoxin and exotoxin are due of active of serum systems of 
endothelial cells and also leucocytes. Consequently the this infectious process occurs the 
syntheses or release of endogen mediators as cytokines, radioactive oxygen of nitrogen and 
lipid mediators being the activation of inflammatory cells the predominant factor for the 
development of sepsis. 
The introduction of an object as an intravenous catheter, a urinary catheter or drainage-tube 
also may cause septicemia. The probability of septicemia increases with the time during the 
period that the object remains placed. This situation usually occurs between the people 
drugs dependents. 
4.4 Relationship among hypoglycemia and septicemia  
In septicemia the homeostasis finds itself threatened by invaders microorganisms. The body 
reacts to the challenge establishing a complex response: first prioritizing the supply of 
energy for vital organs, second, stimulating immune system and after stimulating the return 
of homeostasis.  
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When an infection occurs the cells need of glucose to synthesize defense molecules and also 
increases your metabolism in result of all changes physiological and morphological caused 
by the diseases. This result in a hypoglycemia by increase of consume of glucose by tissues. 
In majority of domestic animals during a septicemia occurs a hypoglycemia. This 
hypoglycemia caused by septicemia increases much the severity of diseases and also is the 
great responsible by high mortality in these situations. 
Changes of hepatic gluconeogenesis and a depletion in glycogen content at liver is 
responsible by changes of glucose homeostasis this occurs by metabolic hallmarks in shock 
and sepsis. The shock and sepsis-induced glucose dyshomeostasis is characterized by an 
initial hyperglycemia followed by a progressive hypoglycemia. 
The depletion in hepatic glycogen content following endotoxin administration is associated 
with an increase in glycogen phosphorylase coupled with a decrease in glycogen synthase 
activities. 
The endotoxin-induced changes in glucose metabolism are augmented by the in vivo 
treatment of animals with protein kinase C (PKC) activator, PMA, while they are 
antagonized by PKC inhibitors, H7 and polymyxin B. The PKC plays a pivotal role in the 
pathogenesis of altered hepatic glucose homeostasis in shock and sepsis. Since the available 
information regarding the involvement of PKC in glucoregulatory disturbances in shock 
and sepsis derived mainly from the use of activators or inhibitors of PKC. 
Previous studies demonstrated that cystolic PKC activity was inactivated during late phase of 
sepsis in rat liver. During the sepsis, the CLP-induced septic rat model used exhibited two 
metabolically distinct phases: an initial hyperglycemic and a subsequent hypoglycemic phase.  
The finding some authors showed that cytosolic PKC activity was inactivated during late 
stage of sepsis may have a pathophysiological significance in contributing to the 
development of hypoglycemia during late phase of sepsis. 
The kinetic analysis of the data showed by some authors indicated that the Vmax for PM 
Ca2+ pump was decreased by 42% while the Km value for Ca2+ remained unaffected.  
The similarity in the patterns of change in the kinetics between the PKC-mediated 
phosphorylation of PM Ca2+- ATPase and the sepsis-induced impairment of PM Ca2+ 
transport  strongly suggests that the impairment in Ca2+ transport by rat liver PM during 
late sepsis is a result of inactivation of PKC. Thus, a decrease in cytosolic PKC activity, as 
reported in this study, would impair PM Ca2+  transport, impede Ca2+ efflux, and hence 
elevating intracellular Ca2+ in hepatocytes during late phase of sepsis. 
5. Hypoglycemia  
The hypoglycemia is a disorder where the glucose serum concentration finds itself usually 
low. 
Usually the organism keeps the serum glucose concentration in a range of 70 to 110 
mL/deciliter of blood. In hypoglycemia the glucose concentration remains low. This results 
in a malfunction of brain that is sensitive the low glucose serum concentration because the 
glucose is the main energetic source of brain. It reacts through of nervous system and 
stimulates the adrenal glands to release epinephrine. This hormone stimulates the liver to 
release glucose for adjust the glucose concentration into the blood. When the concentration 
becomes very low the brain function may be damaged. 
The hypoglycemia has several different causes between them the excessive secretion of 
insulin by pancreas an excessive dose of drugs for reduce the glucose serum concentration, 
an abnormality in the pituitary or of adrenal or an alteration of carbohydrate storage or into 
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the production of glucose by liver. Generally the hypoglycemia may be classified as related 
with drugs or no related. The majority of hypoglycemia cases related into diabetic people 
are related with drugs.  
The hypoglycemia that is not related with drugs may be subdivided into fasting and reactive. 
In this case a reaction occurs to the carbohydrate ingested. Further frequently the 
hypoglycemia is caused by insulin or others drugs as sulfonylurea that are administered to the 
diabetic peoples for reduce the glucose serum concentration. When the dose is very high for 
the food ingested, the drug may cause an excessive reduction of glucose serum concentration.  
The people with severe diabetics are particularly prone for the severe hypoglycemia. This 
occurs because the pancreatic islet cells not produce normally glucagon and the adrenal not 
produce normally epinephrines that are main mechanisms for combat the low glucose 
serum concentration. Some drugs that are not used for treatment of diabetics especially the 
pentamidine used for treat a type of pneumonic related with the SIDA may cause 
hypoglycemia. 
Sometimes the hypoglycemia is observed into people with psychological disorders by 
administer insulin in themselves or oral hypoglycemic. The people that may present these 
types of behavior are those that have access to the drugs as health professional or diabetic’s 
family. 
The alcohol consumption into people that drink heavily without consuming food by long 
period may cause a severe hypoglycemia by stupor.   
A long fasting only leads a hypoglycemia when the people are carriers of other diseases 
especially pituitary diseases or of adrenal or when this people consumes a large amount of 
alcohol. The neonates that present problems often of hypoglycemia need be investigated as 
to the metabolism functioning of carbohydrates or amino acids mainly when that occurs in 
the diseases absence diagnosed as septicemia and endotoxin. When the neonates present 
hypoglycemia periodically is necessary suspect of glycogen storage diseases when this 
clinical is accompanied of hepatomegaly, acidosis and ketosis 
When the animal present hypoglycemia by result of a hydrolytic complication your 
probability to die increases in up to eight times in septicemia situations. The metabolic 
homeostasis need be maintained in neonates because the hypoglycemia may cause 
neurological damage when it isn´t identified 
The carbohydrates reserves of liver may decrease into very low level that people cannot 
keep a glucose serum concentration appropriate. Some people with liver dysfunction into 
only some hours of fasting may cause hypoglycemia. The infants and children with an 
alteration of either of liver enzymatic systems that metabolize the glucose may present 
hypoglycemia between the meals. Others people that were submitted the certain types of 
gastric surgery present hypoglycemia between the meals, the alimentary hypoglycemia, a 
reactive hypoglycemia type. The hypoglycemia occurs because the glucose is quickly 
absorbed stimulating the excessive insulin production. The high insulin concentration 
causes a rapid drop of glucose serum concentration. Rarely the alimentary hypoglycemia 
occurs in people not submitted for gastric surgery. 
The hypoglycemia may be due a kidney or heart failure, a cancer, malnutrition, pituitary or 
adrenal dysfunction or shock an infection serious. 
6. Hypoglycemia in animals 
Some studies realized in rats in 4 day old monitoring the glucose levels during seizures the 
authors reported that the metabolic cerebral balance during sustained seizures suggests that 
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energy balance may be maintained in hyperglycemic animals and its decline occurs slowly 
in normoglycemia, but this not occurs while the animal have more old. The results suggest 
that the hypoglycemia in old animals can become critical when associated with other types 
or metabolic stress. The differences are reflecting in cerebral energy metabolism. In adult 
animals the ATP keeps whether invariable. This decline is rapid when the animals are 
convulsing and slower when the systemic effects of anoxia and convulsions are prevented 
by paralysis and oxygenation. 
The hypoglycemia is characterized by low levels of blood glucose. Against the 
hypoglycemia in the individual is involved the release of glucagon, norepinephrine, cortisol, 
epinephrine and growth hormone. These elements are related with limit glucose utilization. 
The main stimulus for increase of glucose production is the glucagon and it is also a 
response to insulin induced hypoglycemia in the normal individual. When individual has 
diabetes its cells are more prone to low blood sugar due the abnormalities in the cell 
response in relation to hypoglycemia. Some studies verified using a conscious catheterized 
dog model that the hypoglycemia increased glucagon´s ability overcame the inhibitory 
effect of insulin on hepatic glucose production. 
The glucagon is main defense against a low blood glucose level. The insulin exerts a great 
effect on glucagon´s action. The some studies have showed that the glucagon can have such 
a prominent role in counterregulation. 
7. Leptospirose interrogans wolffi sorovar 
Adolf Weil in 1882 described the diseases that He observed in two situations involved four 
patients in 1870. The clinical signs were similar and much private at patients. The disease 
was characterized by sudden appearance, high fever, splenomegaly and icterus.   
In 1881 in Praga city, Weiss described the disease called “icterus catarrhalis” that probably 
will be the disease of Weil. Globig in 1890 described the “Badeepidemie” the disease that 
showed a great differ when compared to disease of Weil. In 1891, F. Muller described the 
Schlamfieberepidemie in chleisen the disease with symptoms much similar. Rimpau et al., 
described Feldfieber in which was the name that descrived the Leptospirose not icterus. The 
Lepiospirose was recognized with different names including bilious typhus by Weil others 
authors called it of Weil disease, icterus infectious. 
The agent was isolated by first time, in Japan, in 1915 by Inada & Ito. The researchers 
isolated Leptospira of minas workers called Spirochaeta icterohaemorrhagiae. 
In 1915, Uhlenhut & Fromme, showed the existence of etiologic agent, inoculating the army 
blood suspect of have Weil disease in guineas pigs. The animals inoculated died and 
Leptospira were identified microscopically, being called of Spirochaeta icterohaemorrhagiae. 
Miyajima, Ido, Hoki, Ito & Wani (1917) demonstrated that mouses were carriers of 
leptospira showed that 40% them were renal carriers. 
8. General characteristics 
The cells are flexible helical with 0.1 µm of diameter and 6-20µm of length. They are faintly 
stained by aniline days. The cells not cored are visible by contrast microscopy or by 
darkfield microscopy. The helical conformation is to right side (clock spring) existing in one 
or both extreme typical hook. Two perisplasmatic flagella (fibril axial and endoflagelo) 
occurs in each cell where is inserted in each extreme and rarely whether overrides in central 
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the production of glucose by liver. Generally the hypoglycemia may be classified as related 
with drugs or no related. The majority of hypoglycemia cases related into diabetic people 
are related with drugs.  
The hypoglycemia that is not related with drugs may be subdivided into fasting and reactive. 
In this case a reaction occurs to the carbohydrate ingested. Further frequently the 
hypoglycemia is caused by insulin or others drugs as sulfonylurea that are administered to the 
diabetic peoples for reduce the glucose serum concentration. When the dose is very high for 
the food ingested, the drug may cause an excessive reduction of glucose serum concentration.  
The people with severe diabetics are particularly prone for the severe hypoglycemia. This 
occurs because the pancreatic islet cells not produce normally glucagon and the adrenal not 
produce normally epinephrines that are main mechanisms for combat the low glucose 
serum concentration. Some drugs that are not used for treatment of diabetics especially the 
pentamidine used for treat a type of pneumonic related with the SIDA may cause 
hypoglycemia. 
Sometimes the hypoglycemia is observed into people with psychological disorders by 
administer insulin in themselves or oral hypoglycemic. The people that may present these 
types of behavior are those that have access to the drugs as health professional or diabetic’s 
family. 
The alcohol consumption into people that drink heavily without consuming food by long 
period may cause a severe hypoglycemia by stupor.   
A long fasting only leads a hypoglycemia when the people are carriers of other diseases 
especially pituitary diseases or of adrenal or when this people consumes a large amount of 
alcohol. The neonates that present problems often of hypoglycemia need be investigated as 
to the metabolism functioning of carbohydrates or amino acids mainly when that occurs in 
the diseases absence diagnosed as septicemia and endotoxin. When the neonates present 
hypoglycemia periodically is necessary suspect of glycogen storage diseases when this 
clinical is accompanied of hepatomegaly, acidosis and ketosis 
When the animal present hypoglycemia by result of a hydrolytic complication your 
probability to die increases in up to eight times in septicemia situations. The metabolic 
homeostasis need be maintained in neonates because the hypoglycemia may cause 
neurological damage when it isn´t identified 
The carbohydrates reserves of liver may decrease into very low level that people cannot 
keep a glucose serum concentration appropriate. Some people with liver dysfunction into 
only some hours of fasting may cause hypoglycemia. The infants and children with an 
alteration of either of liver enzymatic systems that metabolize the glucose may present 
hypoglycemia between the meals. Others people that were submitted the certain types of 
gastric surgery present hypoglycemia between the meals, the alimentary hypoglycemia, a 
reactive hypoglycemia type. The hypoglycemia occurs because the glucose is quickly 
absorbed stimulating the excessive insulin production. The high insulin concentration 
causes a rapid drop of glucose serum concentration. Rarely the alimentary hypoglycemia 
occurs in people not submitted for gastric surgery. 
The hypoglycemia may be due a kidney or heart failure, a cancer, malnutrition, pituitary or 
adrenal dysfunction or shock an infection serious. 
6. Hypoglycemia in animals 
Some studies realized in rats in 4 day old monitoring the glucose levels during seizures the 
authors reported that the metabolic cerebral balance during sustained seizures suggests that 
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energy balance may be maintained in hyperglycemic animals and its decline occurs slowly 
in normoglycemia, but this not occurs while the animal have more old. The results suggest 
that the hypoglycemia in old animals can become critical when associated with other types 
or metabolic stress. The differences are reflecting in cerebral energy metabolism. In adult 
animals the ATP keeps whether invariable. This decline is rapid when the animals are 
convulsing and slower when the systemic effects of anoxia and convulsions are prevented 
by paralysis and oxygenation. 
The hypoglycemia is characterized by low levels of blood glucose. Against the 
hypoglycemia in the individual is involved the release of glucagon, norepinephrine, cortisol, 
epinephrine and growth hormone. These elements are related with limit glucose utilization. 
The main stimulus for increase of glucose production is the glucagon and it is also a 
response to insulin induced hypoglycemia in the normal individual. When individual has 
diabetes its cells are more prone to low blood sugar due the abnormalities in the cell 
response in relation to hypoglycemia. Some studies verified using a conscious catheterized 
dog model that the hypoglycemia increased glucagon´s ability overcame the inhibitory 
effect of insulin on hepatic glucose production. 
The glucagon is main defense against a low blood glucose level. The insulin exerts a great 
effect on glucagon´s action. The some studies have showed that the glucagon can have such 
a prominent role in counterregulation. 
7. Leptospirose interrogans wolffi sorovar 
Adolf Weil in 1882 described the diseases that He observed in two situations involved four 
patients in 1870. The clinical signs were similar and much private at patients. The disease 
was characterized by sudden appearance, high fever, splenomegaly and icterus.   
In 1881 in Praga city, Weiss described the disease called “icterus catarrhalis” that probably 
will be the disease of Weil. Globig in 1890 described the “Badeepidemie” the disease that 
showed a great differ when compared to disease of Weil. In 1891, F. Muller described the 
Schlamfieberepidemie in chleisen the disease with symptoms much similar. Rimpau et al., 
described Feldfieber in which was the name that descrived the Leptospirose not icterus. The 
Lepiospirose was recognized with different names including bilious typhus by Weil others 
authors called it of Weil disease, icterus infectious. 
The agent was isolated by first time, in Japan, in 1915 by Inada & Ito. The researchers 
isolated Leptospira of minas workers called Spirochaeta icterohaemorrhagiae. 
In 1915, Uhlenhut & Fromme, showed the existence of etiologic agent, inoculating the army 
blood suspect of have Weil disease in guineas pigs. The animals inoculated died and 
Leptospira were identified microscopically, being called of Spirochaeta icterohaemorrhagiae. 
Miyajima, Ido, Hoki, Ito & Wani (1917) demonstrated that mouses were carriers of 
leptospira showed that 40% them were renal carriers. 
8. General characteristics 
The cells are flexible helical with 0.1 µm of diameter and 6-20µm of length. They are faintly 
stained by aniline days. The cells not cored are visible by contrast microscopy or by 
darkfield microscopy. The helical conformation is to right side (clock spring) existing in one 
or both extreme typical hook. Two perisplasmatic flagella (fibril axial and endoflagelo) 
occurs in each cell where is inserted in each extreme and rarely whether overrides in central 
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region. When it is liquid medium has characteristics movements with alternated rotation to 
the long of axis and translation in direction from extreme without hook. In viscose medium 
are observed snak movements. They are aerobic its colonies are diffuse and formed surface 
below of medium with 1% of agar and turbid colonies at agar 2%. Optimal temperature is of 
28-30ºC. The genus is chemical organotrophs using fatty acids or fatty alcohol having 15 
carbonic atoms with energy source. Not use carbohydrates with energy source being 
necessary serum and albumin to your growth.     
Leptospirose is a disease caused by bacteria of Leptospiracea family genus Leptospire that 
might to be found in worldwide. The infections by leptospire have been reported in human 
being, cattle, pigs, horses, sheep, dogs, rodents and also severe wilds animal’s species in the 
Brazil and also worldwide. Leptospirose is disease of acute manifestation of third to tenth 
four day after infection. Leptospire enters the host through mucosa and broken skin, 
resulting in bacteremia. The spirochetes multiply in organs, most commonly the central 
nervous system, kidneys, and liver. They are cleared by the immune response from the 
blood and most tissues but persist and multiply for some time in the kidney tubules. 
Infective bacteria are shed in the urine. The mechanism of tissue damage is not known. 
This disease might itself make chronic after this period and, in the last thirty years the pigs 
have been appointed as main domestic animals carriers of Leptospire being accountable by 
epidemics occurrences in the Human and others domestic species. Leptospire could to be 
considered main agent of problems related with reproductive failure in pigs. 
The symptoms of chronic infection are known to induce reproductive failure in farm 
animals, the acute lethal form of leptospirosis is generally observed in animals. There is 
various serogroups of Leptospire and in farm animals; bacterins need to contain five 
serogroups because of variation in local epidemiological condition.  
Pathogenic leptospires infect a variety of animals as has been said, but the naturally 
acquired clinical disease has been documented only in a limited range of mammals. 
Leptospirosis has been reported mainly in sheep and goats are among the domestic species 
which are less susceptible to the pathogenic action of leptospirores. In most cases of 
leptospire infection are asymptomatic, severe outbreaks do occur with a significant loss of 
sheep, goats and pigs. 
The animals considered of high risk to leptospire infection are gravid and young animals be 
infected by any pathogenic serovar depending upon the specific epidemiologic situation.  
The Leptospiroses are divided in further of 200 sorovar grouped in 23 serogroups. In pigs 
the Leptospirose is characterized by occurrence of abortions in the final third of gestation, 
heat repetition, fetal mummification, birth of weak piglets, and low number of piglets, 
vulvae discharge and embryonic death.         
The pigs are might to be definitive hosts especially, pomona, bratislava and tarassoli sorovars 
and still accidental hosts as in cases of infection by icterohaemorrhagie, canicola sorovars. In 
first case there is a hosts parasite adaptation where the Leptospire are kept in urinary tract 
for long period being eliminated by urine in conditions for infect others animals. The signs 
are moderate being detected the infection just in pregnant female. In accidental infection 
when are infected by an adapted sorovar the other specie the signs of diseases are further 
evident but the permanence in urinary tract occurs by low time occurring the elimination of 
lower number of Leptospire in urine.   
Although actually be available a large number of techniques for laboratorial diagnostic of 
routine for Leptospira this techniques still not satisfy some requirement as sensibility, 
specificity and practice. The antibody presence anti-Leptospire in serologic samples 
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collected in animals of slaughterhouse no represents adequate sampling for a study with 
Leptospire in pigs in a region determined. This samples also no reflect the situation grange 
inside. Nevertheless it allows that itself has a general basis of its occurrence and may to 
suggest what are the Leptospire sorovars that has large importance in region of animal origin.  
Other method of detection of Leptospira is the agglutination serum, in which it is employed 
in suspensions of strains.  
The results of serologic test applied to the diagnostic of Leptospira depends of technique 
employed, of antigen collections used and also variations related the farms localization year 
of period into that samples were performed moving of animals. The interference of these 
factors becomes necessary the existence of epidemiologic sanitary systems permanent that 
enables the monitoring of spatial distribution of sorovars of Leptospira present in different 
regions so to rationalize the control using the immunoprophylaxis.   
In pigs the biochemical dosage in blood involved bilirubin, glucose fatty acid and plasma 
proteins in responses the experimental infections by leptospira are scarce in literature. The 
blood dosage may to assist in diagnostic, prognostic and in the treatment of animals. The 
bilirubin determination represent a parameter for detect acute hemolysis. 
The disease caused by Leptospira is characterized by clinical stages with remissions and 
exacerbations. 
Leptospira organisms are very thin, tightly coiled, obligate aerobic spirochetes and also are 
characterized by a unique flexuous type of motility. 
The genus is divided into two species: the free-living leptopire L biflexa and the pathogenic 
leptospiras L interrogans. This leptospira is of serotypes causes of zoonotic disease.  
The Humans may be accidental hosts. However the primary hosts are domestic animals and 
also wild. In Humans this disease may have severity from fatal to subclinical.The first case 
of leptospirosis, in Humans was described in 1886 as a severe icteric illness and was referred 
to as Weil's disease; however, most human cases of leptospirosis are nonicteric and are not 
life-threatening. 
In contrast to the pathogenic leptospiras, serotypes of L biflexa exist in water and soil as 
free-living organisms.  
Although L biflexa has been isolated from mammalian hosts on occasion, no pathology has 
been found. 
The explanation of why the leptopire not occurence of infections at animals of laboratory yet 
not is knowledge. The widespread distribution of L biflexa in fresh water and the 
leptospiras has the capacity to pass through 0.45 to 0.22-μm-pore-size sterilizing filters, they 
have been found as contaminants of filter-sterilized media. 
9. Prophylaxis 
In current days the immunization by vaccination is a practice more important in cattle 
hygienic with results direct and an economic return of activity and warrant of excellent 
sanitary standard of flocks and the opening and maintain of makers. The vaccination 
represents the minor costs of inside of productive process and may be decisive for obtaining 
of good results at animal production.  
10. Experimental infection 
In Brazil occurs a high incidence of Leptospira interrogans wolfii sorovar. This data was 
reported after a serologic survey in pigs with historic of reproductive failure. This same 
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region. When it is liquid medium has characteristics movements with alternated rotation to 
the long of axis and translation in direction from extreme without hook. In viscose medium 
are observed snak movements. They are aerobic its colonies are diffuse and formed surface 
below of medium with 1% of agar and turbid colonies at agar 2%. Optimal temperature is of 
28-30ºC. The genus is chemical organotrophs using fatty acids or fatty alcohol having 15 
carbonic atoms with energy source. Not use carbohydrates with energy source being 
necessary serum and albumin to your growth.     
Leptospirose is a disease caused by bacteria of Leptospiracea family genus Leptospire that 
might to be found in worldwide. The infections by leptospire have been reported in human 
being, cattle, pigs, horses, sheep, dogs, rodents and also severe wilds animal’s species in the 
Brazil and also worldwide. Leptospirose is disease of acute manifestation of third to tenth 
four day after infection. Leptospire enters the host through mucosa and broken skin, 
resulting in bacteremia. The spirochetes multiply in organs, most commonly the central 
nervous system, kidneys, and liver. They are cleared by the immune response from the 
blood and most tissues but persist and multiply for some time in the kidney tubules. 
Infective bacteria are shed in the urine. The mechanism of tissue damage is not known. 
This disease might itself make chronic after this period and, in the last thirty years the pigs 
have been appointed as main domestic animals carriers of Leptospire being accountable by 
epidemics occurrences in the Human and others domestic species. Leptospire could to be 
considered main agent of problems related with reproductive failure in pigs. 
The symptoms of chronic infection are known to induce reproductive failure in farm 
animals, the acute lethal form of leptospirosis is generally observed in animals. There is 
various serogroups of Leptospire and in farm animals; bacterins need to contain five 
serogroups because of variation in local epidemiological condition.  
Pathogenic leptospires infect a variety of animals as has been said, but the naturally 
acquired clinical disease has been documented only in a limited range of mammals. 
Leptospirosis has been reported mainly in sheep and goats are among the domestic species 
which are less susceptible to the pathogenic action of leptospirores. In most cases of 
leptospire infection are asymptomatic, severe outbreaks do occur with a significant loss of 
sheep, goats and pigs. 
The animals considered of high risk to leptospire infection are gravid and young animals be 
infected by any pathogenic serovar depending upon the specific epidemiologic situation.  
The Leptospiroses are divided in further of 200 sorovar grouped in 23 serogroups. In pigs 
the Leptospirose is characterized by occurrence of abortions in the final third of gestation, 
heat repetition, fetal mummification, birth of weak piglets, and low number of piglets, 
vulvae discharge and embryonic death.         
The pigs are might to be definitive hosts especially, pomona, bratislava and tarassoli sorovars 
and still accidental hosts as in cases of infection by icterohaemorrhagie, canicola sorovars. In 
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when are infected by an adapted sorovar the other specie the signs of diseases are further 
evident but the permanence in urinary tract occurs by low time occurring the elimination of 
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Although actually be available a large number of techniques for laboratorial diagnostic of 
routine for Leptospira this techniques still not satisfy some requirement as sensibility, 
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collected in animals of slaughterhouse no represents adequate sampling for a study with 
Leptospire in pigs in a region determined. This samples also no reflect the situation grange 
inside. Nevertheless it allows that itself has a general basis of its occurrence and may to 
suggest what are the Leptospire sorovars that has large importance in region of animal origin.  
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blood dosage may to assist in diagnostic, prognostic and in the treatment of animals. The 
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characterized by a unique flexuous type of motility. 
The genus is divided into two species: the free-living leptopire L biflexa and the pathogenic 
leptospiras L interrogans. This leptospira is of serotypes causes of zoonotic disease.  
The Humans may be accidental hosts. However the primary hosts are domestic animals and 
also wild. In Humans this disease may have severity from fatal to subclinical.The first case 
of leptospirosis, in Humans was described in 1886 as a severe icteric illness and was referred 
to as Weil's disease; however, most human cases of leptospirosis are nonicteric and are not 
life-threatening. 
In contrast to the pathogenic leptospiras, serotypes of L biflexa exist in water and soil as 
free-living organisms.  
Although L biflexa has been isolated from mammalian hosts on occasion, no pathology has 
been found. 
The explanation of why the leptopire not occurence of infections at animals of laboratory yet 
not is knowledge. The widespread distribution of L biflexa in fresh water and the 
leptospiras has the capacity to pass through 0.45 to 0.22-μm-pore-size sterilizing filters, they 
have been found as contaminants of filter-sterilized media. 
9. Prophylaxis 
In current days the immunization by vaccination is a practice more important in cattle 
hygienic with results direct and an economic return of activity and warrant of excellent 
sanitary standard of flocks and the opening and maintain of makers. The vaccination 
represents the minor costs of inside of productive process and may be decisive for obtaining 
of good results at animal production.  
10. Experimental infection 
In Brazil occurs a high incidence of Leptospira interrogans wolfii sorovar. This data was 
reported after a serologic survey in pigs with historic of reproductive failure. This same 
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study showed a possible relation between biochemical results of blood with infection 
induced by this sorovar. That way, the present study was realized with aims of verify itself 
is possible to relate biochemical parameters of blood including glucose fee with occurrence 
of septicemia caused by Leptospira interrogans wolfii sorovar. In our experiment eight, 90 days 
old pigs of the Wessex lineage all castrated male were used experiment divided into two 
groups of four animals. Biochemical alterations in the serum of the animals were analyzed 
in both groups during 36 days. Control  (Group I) received 0.5mL of a 0.9% sterile sodium 
choride inoculated by intracranial vein injection; Group II animals were inoculated by the 
same way with 5.0mL of Brazilian “armadillo”. Three days after inoculation blood was 
collected without anticoagulant; the same process was repeated at 72 hours intervals during 
eighteen days in both, control and experiments groups. Quantitative biochemical 
parameters were direct, indirect and total bilirubin all were observed after six days. Glucose 
fatty acid decreased after the third day inoculation. The increased bilirubin levels could be 
due to acute hemolisys, hypoglycemia, hypolypidemia that could be related to hepatic 
lesions and septicemia. 
In the Group II has been observed an increased of direct bilirubin levels in the third day 
after inoculation which came back the initial values from the sixth day when compared to 
Group I. This increase of direct bilirubin in the third day observed in the pigs of Group II 
may be due the hemolysis which indicates that liver no presented any lesions and suggest 
efficiency in the hepatic conjugation of bilirubin with glucuronic acid. When there is hepatic 
lesions this cause damage in parenchymal hepatic cells difficult the conjugation. 
In values of indirect bilirubin might itself to observe that between start of experiment and 
third day there was a decrease followed of a increase of levels in the sixth day in the 
inoculated animals with wolfii sorovar and that from ninth day has been verified a fall in 
levels that itself kept stables to fifteenth day similar behavior has been observed in control. 
However this bilirubin increased has been discrete when compared to animals inoculated. 
This decreased of levels of bilirubin to third day after the inoculation with serum wolfii 
sorovar has been verified by others authors. After hemolysis the indirect bilirubin is not 
apparent in the first hours. The marked increase of bilirubin seems to indicate a hemolysis 
excessive. Some endotoxins cause changes in carbohydrate metabolism of erythrocytes with 
a consequent decrease of ATP. That would be a possible explanation for loss of motility of 
contractile system of erythrocytes membrane. 
That loss of motility causes changes in the morphology of erythrocytes, passing from 
biconcave disk to spherical shape (spherocytosis). That abnormality would result in the 
detection and removal of spherocytic cells by reticulum macrophage system, spleen, liver 
and bone marrow where would be destroyed with release of hemoglobin that would be 
transformed in bilirubin. 
In the inoculated pigs has been observed a fall of levels of fatty acids while in control Group 
there was the fall then an increase, being the major value detected to twelfth day. The 
decrease of fatty acids in the pigs inoculated with wolfii sorovar caused a secondary 
hypoglycemia and a hypolipidemia. 
The glucose levels presented a decrease to third day after inoculation then of constant 
increase thus to overcome the initials values in the fifteenth. In the control Group also has 
been verified a fall of glucose fee then an increased from third day reaching to the maximum 
value in the ninth day and decreased the lower values than initials between the twelfth and 
fifteenth day. The hypoglycemia observed occurs by increase of consumption of glucose by 
tissues in septicemia case. The plasma protein levels have been unchanged despite to has 
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increased in third day in pigs of Group II after the inoculation with wolfii sorovar. This 
hypoproteinemia in inoculated animals could to be related with a hepatic lesion discrete 
that may have been caused by leptospire infection. In some cases of septicemia may have an 
increase of capillary permeability that allow the leakage of albumin for extracellular 
compartments which possibly could prove the septicemia have started just in the third day 
of experiment. The leptospirose induction model with intravenous inoculation of wolfii 
sorovar showed effective. The blood biochemical variations of pigs inoculated were 
hypoglycemia, suggesting a hepatic lesion and the occurrence of a bacterial septicemia and 
also hyperbilirubinemia, indicating with this that a main cause of toxicity of wolfii sorovar 
showed in this study is grave anemia hemolytic. 
The lost of piglet ranging of 4 to 10% in childbirth, others 20% may die before weaning. The 
causes of die of piglet are many. The hypoglycemia may to be caused by septicemia or to be 
a result of all a complex evolving needs specific temperature interfering in glycogens 
feeding frequency and amount of colostrums that subsequently the milk ingestion.  
11. Conclusion  
Concluding the model of induction of leptospirose caused by intravenous inoculation of 
wolfii sorovar showed itself effective. The biochemical variations in the blood of inoculated 
pigs with wolfii sorovar were: hypoglycemia, hypolipidemia and hypoproteinemia 
suggesting a hepatic lesion and bacterial septicemia. The hyperbilirubinemia might to 
indicate that main cause of toxicity of wolfii sorovar is a severe hemolytic anemia. However 
the low glucose fee has aggravating role in the septicemia in pigs. 
 
 
Fig. 1. Comparative of glucose level in pigs inoculated and uninoculated (control) 
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Group II (pig inoculated) animals were inoculated by the same way with 5.0mL of a cell 
culture containing 1.0x108cells mL-1 of Leptospira interrogans sorovar wolffi, wild strain L-10, 
isolated from a wild species of Brazilian. 
The biochemical changes were analyzed in the serum of the animals in broth Groups during 
36 days. All parameters returned to normal levels after fifteen days, in all animals tested. 
 
 
Fig. 2. Fatty acids levels in pigs inoculated and uninoculated (control). 
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